WO1996010559A1 - Urea derivatives and their use as acat-inhibitors - Google Patents

Urea derivatives and their use as acat-inhibitors Download PDF

Info

Publication number
WO1996010559A1
WO1996010559A1 PCT/JP1995/001982 JP9501982W WO9610559A1 WO 1996010559 A1 WO1996010559 A1 WO 1996010559A1 JP 9501982 W JP9501982 W JP 9501982W WO 9610559 A1 WO9610559 A1 WO 9610559A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
mixture
nmr
apci
mass
Prior art date
Application number
PCT/JP1995/001982
Other languages
French (fr)
Inventor
Takeshi Terasawa
Akira Tanaka
Toshiyuki Chiba
Hisashi Takasugi
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9419970A external-priority patent/GB9419970D0/en
Priority claimed from GBGB9506720.3A external-priority patent/GB9506720D0/en
Priority claimed from GBGB9514021.6A external-priority patent/GB9514021D0/en
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Priority to KR1019970702138A priority Critical patent/KR970706242A/en
Priority to AU35779/95A priority patent/AU3577995A/en
Priority to JP8511616A priority patent/JPH10510512A/en
Priority to EP95932934A priority patent/EP0784612A1/en
Publication of WO1996010559A1 publication Critical patent/WO1996010559A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/38—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/47—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Definitions

  • This invention relates to new urea derivatives and pharmaceutically acceptable salts thereof which are useful as a medicament.
  • acyl-CoA cholesterol acyltransferase enzyme (hereinafter, ACAT) inhibitors, for example, in U.S. Patent Nos. 4,473,579 and 4,623,662, EP Patent Application Publication Nos. 0354994, 0399422 and 0512570 and PCT International Publication Nos. WO 91/13871, WO 93/24458 and WO 94/26738.
  • ACAT cholesterol acyltransferase enzyme
  • This inventios relates to new urea derivatives and pharmaceutically acceptable sales thereof which have an inhibitory activity against ACAT and an advantage of good absorption into blood on oral administration, to processes for the preparation thereof, to a pharmaceutical
  • composition comprising the same and to a method for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby.
  • One object of this invention is to provide new and useful urea derivatives and pharmaceutically acceptable salts which possess an inhibitory activity against ACAT.
  • Another object of this invention is to provide
  • a further object of this invention is to provide a pharmaceutical composition comprising, as an active
  • Still further object of this invention is to provide a therapeutic method for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby in human beings or animals, using said urea derivatives and pharmaceutically acceptable salts thereof.
  • inhibitors are useful for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis of diseases caused thereby such as cardiac insufficiency (e.g. angina pectoris, myocardial infarction, etc.),
  • cardiac insufficiency e.g. angina pectoris, myocardial infarction, etc.
  • the object urea derivatives of this invention are new and can be represented by the following general formula (I):
  • R 1 is a group of the formula :
  • R 4 is aryl which may have suitable substituent (s), or heterocyclic group which may have suitable substituent (s), and
  • Y is bond, lower alkylene, H
  • R 2 is lower alkyl, lower alkoxy (lower) alkyl, cycloalkyl, ar (lower) alkyl which may have suitable substituent (s), heterocyclic group or heterocyclic (lower) alkyl,
  • R 3 is aryl which may have suitable substituent (s) or
  • n 0 or 1.
  • the object compound (I) of the present invention can be prepared by the following processes.
  • R 1 , R 9 , R 3 and n are each as defined above,
  • the starting compound can be prepared by tne following processes.
  • R 1 , R 2 , and R 4 are each as defined above,
  • R 5 is lower alkoxy
  • R 6 is lower alkyl
  • X is a leaving group
  • Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt,
  • a salt with an inorganic base for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt
  • a salt with an organic base for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt,
  • an inorganic acid addition salt e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • an organic carboxylic or sulfonic acid addition salt e.g., formate, acetate, trifluoroacetate, maieate, tartrate, fumarate, citrate, methanesulfonate, benzenesulfonate,
  • toluenesulfonate etc.
  • a salt with a basic or acidic amino acid e.g., arginine, aspartic acid, glutamic acid, etc.
  • lower is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
  • Suitable “lower alkyl” and “lower alkyl moiety” in the terms “ar (lower) alkyl”, “lower alkoxy (lower) alkyl” and “heterocyclic (lower) alkyl” may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, hexyl, and the like, and in which more preferable example may be C 1 -C 4 alkyl.
  • Suitable "lower alkylene” may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene,
  • methvlmethylene, ethylethylene, propylene, and the like in which more preferable example may be C 1 -C 4 alkylene and the most preferable one may be methylene.
  • Suitable "lower alkoxy” and “lower alkoxy moiety" in the term “lower alkoxy (lower) alkyl” may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like.
  • Suitable "cycloalkyl” may include cyclo (C 3 -C 7 ) alkyl (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.) and the like.
  • aromatic (lower) alkyl may include phenyl, naphthyl and the like.
  • Suitable "halogen” may include fluorine, bromine, chlorine and iodine.
  • Suitable “leaving group” may include acid residue, and the like.
  • Suitable "acid residue” may include halogen as
  • Suitable "heterocylic group” and “heterocyclic moiety” in the term “heterocyclic (lower) alkyl” may include
  • thiazolyl isothiazolyl, thiadiazolyl (e.g., 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl,
  • benzothiazolyl benzothiadiazolyl, etc.
  • Suitable "protected amino” may include acylamino or an amino group substituted by a conventional protecting group such as mono (or di or tri i aryl (lower ) alkyl, for example, mono (or di or tri ) phenyl ( lower ) alkyl (e.g., benzyl, trityl, etc.) or the like.
  • a conventional protecting group such as mono (or di or tri i aryl (lower ) alkyl, for example, mono (or di or tri ) phenyl ( lower ) alkyl (e.g., benzyl, trityl, etc.) or the like.
  • protected hydroxy may include acyl, mono (or di or
  • phenyl ( lower) alkyl which may have one or more suitable substituent (s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), et:c.], substituted (lower) alkyl (e.g., methoxymethyl,
  • acylamino may include Carbamoyl; Thiocarbamoyl;
  • Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2, 2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.);
  • alkanoyl e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2, 2-dimethylpropanoy
  • alkoxycarbonyl e.g., methoxycarbonyl, ethoxycarbcnyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.
  • alkylsulfonyl e.g., methylsulfonyl, ethylsulfonyl, etc.
  • lower or higher alkoxysulfonyl e.g., methoxysulfonyl, ethoxysulfonyl, etc.
  • cyclo (lower) alkylcarbonyl e.g., cyclopentylcarbonyl, cyclohexylcarbonyl, etc.
  • alkoxysulfonyl e.g., methoxysulfonyl, ethoxysulfonyl, etc.
  • cyclo (lower) alkylcarbonyl e.g., cyclopentylcarbonyl, cyclohexylcarbonyl, etc.
  • Aromatic acyl such as
  • aroyl e.g., benzoyl, toluoyl, naphthoyl, etc.
  • ar (lower) alkanoyl e.g., phenyl (lower) alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl,
  • phenylisobutanoyl phenylpentanoyl, phenylhexanoyl, etc.
  • naphthyl (lower) alkanoyl e.g., naphthylacetyl
  • ar (lower) alkenoyl e.g., phenyl (lower) alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.),
  • naphthyl (lower) alkenoyl e.g., naphthylpropenoyl
  • ar (lower) alkoxycarbonyl e.g., phenyl (lower) alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.];
  • aryloxycarbonyl e.g., phenoxycarbonyl
  • aryloxy (lower) alkanoyl e.g., phenoxyacetyl
  • arylglyoxyloyl e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.
  • arylsulfonyl e.g., phenylsulfonyl, p-tolylsulfonyl, etc.; or the like.
  • Suitable "substituent” in the terms "aryl which may have suitable substituent (s) " and “ar (lower) alkyl which may have suitable substituent (s) " may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or di or tri) halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above, cyclo (lower) alkyl, cyclo ( lower) alkenyl, halogen as exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl as exemplified above, ar (lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy (lower) alkyl wherein lower alkyl moiety as exemplified above, protected
  • Suitable "substituent” m the term “heterocyclic group whicn may have suitable suostituent (s)” may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or ⁇ i or
  • halogen moiety and lower alkyl moiety are each as exemplified above, cyclo (lower) alkyl, cyclo (lower) alkenyl, halogen as exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, as
  • aryl as exemplified above, mono (or di or tri) ar (lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy (lower) alkyl wherein lower alkyl moiety as exemplified above, protected carboxy (lower) alkyl, nitro, amino, protected amino,
  • di (lower) alkylamino wherein lower alkyl moiety is as exemplified above, amino (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected amino (lower)- alkyl, hydroxy (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected hydroxy (lower) alkyl, cyanc, sulfo, sulfamoyl, carbamoyloxy, mercapto, lower alkylthio wherein lower alkyl moiety is as exemplified above, lower alkylsulfinyl wherein lower alkyl moiety is as exemplified above, acyl as exemplified above, oxo, imino, and the like.
  • isoxazolyl each of which may have suitable substituent (s)" may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or di or tri) halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above,
  • arylthio wherein aryl moiety is as exemplified above, heterocyclic group as exemplified above, ar (lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy (lower) alkyl wherein lower alkyl moiety as exemplified above, protected
  • the compound (I) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (III) or a salt thereof.
  • This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which do not adversely affect the reaction, or the mixture thereof.
  • a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which do not adversely affect the reaction, or the mixture thereof.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
  • the starting compound when in liquid, it can be used also as a solvent.
  • the compound (I) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof and the compound (IV) or a salt thereof to formation reaction of ureido group.
  • This reaction is carried out in the presence of reagent which introduces carbonyl group such as phosgene [e.g. , triphosgene, etc.], haloformate compound [e.g. ethyl chloroformate, trichloromethyl chloroformate, phenyl chloroformate, etc.], N,N'-carbonyldiimidazole, metal carbonyl compounds [a.g. cobalt carbonyl, manganese
  • carbonyl group such as phosgene [e.g. , triphosgene, etc.]
  • haloformate compound e.g. ethyl chloroformate, trichloromethyl chloroformate, phenyl chloroformate, etc.
  • N,N'-carbonyldiimidazole a.g. cobalt carbonyl, manganese
  • carbonyl etc.
  • catalysts such as palladium chloride, etc., or the like.
  • This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N, N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which ⁇ o not adversely affect the reaction, or the mixture thereof.
  • a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N, N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which ⁇ o not adversely affect the reaction, or the mixture thereof.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the reaction is usually carried out in the presence of an organic base such as tri (lower) alkylamine (e.g., tri (lower) alkylamine (e.g., tri (lower) alkylamine (e.g., tri (lower) alkylamine (e.g., tri (lower) alkylamine (e.g., tri (lower) alkylamine (e.g., tri (lower) alkylamine (e.g., tri (lower) alkylamine
  • trimethylamine triethylamine, diisopropylethylamine, etc.), or the like.
  • the compound (lb) or a salt thereof can be prepared by subjecting the compound (la) or a salt thereof to oxidation reaction.
  • Oxidation is carried out in a conventional manner, which is capable or oxidizing a sulfur atom to an oxidized sulfur atom
  • suitable oxidizing reagent may be oxygen acid such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as perbenzoic acid
  • the reaction is usually carried out in a conventional solvent such as water, alcohol, (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
  • a conventional solvent such as water, alcohol, (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
  • dichloromethane ethylene dichloride, chloroform, N,N- dimethylformamide, N, N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction .
  • hydrophilic solvents may be used in a mixture with water.
  • the reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
  • the compound (VII) or a salt thereof can be prepared by reacting the compound (V; with the compound (VI;.
  • the reaction can be carried out m the manner
  • the compound (IXa) or a salt thereof can be prepared DV reacting the compound (VII) or a salt thereof with the compound (VIII) or a salt thereof.
  • reaction can oe carried out m the manner
  • the compound (X) or a salt thereof can oe prepared by subjecting the compoun ⁇ (IX) or a salt thereof to reduction reaction.
  • Reduction is carried out m a conventional manner, including chemical re ⁇ uction and catalytic reduction.
  • Suitable reducing reagents to be used in cnemical reduction and hydrides e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum nydride, sodium borohydride, sodium cyanoborohydride, ⁇ iisooutylaluminum hydride, etc.
  • a metal e.g., tin, zinc, iron, etc.
  • metallic compounc e.g., chromium chloride, chromium acetate, etc.
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum blac ⁇ , colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like.
  • platinum catalysts e.g., platinum plate, spongy platinum, platinum blac ⁇ , colloidal platinum, platinum oxide, platinum wire, etc.
  • palladium catalysts e.g., spongy palladium, pal
  • the reduction is usually carried out in the
  • the reduction is usually carried out in the presence of an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid,
  • an organic acid or an inorganic acid e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid,
  • the compound (Xa) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with the compound (XII) or a salt thereof.
  • the reaction can be carried out in the manner
  • the compound (Xb) or a salt thereof can be prepared by reacting the compound (XIII) or a salt thereof with the compound (XII) or a salt thereof.
  • the reaction can be carried out in the manner disclosed in Preparation 38 or similar manners thereto.
  • the compound (Ila) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XIV) or a salt thereof and then by subjecting the resultant compound to reduction reaction.
  • Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.
  • Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.) or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid,
  • hydrides e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.
  • a metal e.g., tin, zinc, iron, etc.
  • metallic compound e.g., chromium chloride, chromium acetate, etc.
  • Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black,
  • palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc. nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like.
  • nickel catalysts e.g., reduced nickel, nickel oxide, Raney nickel, etc.
  • cobalt catalysts e.g., reduced cobalt, Raney cobalt, etc.
  • iron catalysts e.g., reduced iron, Raney iron, Ullman iron, etc.
  • the reduction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, toluene, dioxane,
  • a conventional solvent such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, toluene, dioxane,
  • Processes (1)-(3) and (A) - (E) can be referred to the ones as exemplified for the compound (I).
  • the compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like.
  • the compound (I) and the other compounds may include one or more stereoisomer (s) such as optical isomer(s) and geometrical isomer(s) due to
  • Preferred embodiments of the object compound (I) are as follows.
  • R 1 is a group of the formula
  • R 4 is phenyl which may have 1 to 3 suitable
  • substituent (s) (more preferably substituent selected from the group consisting of halogen, lower alkyl, di (lower) alkylamino, protected amino (more preferably acylamino;
  • alkoxy (lower) alkoxy; and mono (or di or
  • tetrazolylphenyl (triphenyl (lower)- alkyltetrazolyl) phenyl, trihalo (lower)- alkylphenyl, phenyl having two lower alkyl and hydroxy, or phenyl having two lower alkyl and lower alkoxy (lower) alkoxy]; or heterocyclic group
  • triphenyl (lower alkyl) and oxo) [more preferably thienyl; pyrazolyl which may have lower alkyl or triphenyl (lower) alkyl; imidazolyl;
  • triazolyl which may have one or two
  • substituent (s) selected from the group consisting of lower alkyl and phenyl (lower) alkyl; pyridyl; pyrrolyl; tetrazolyl which may have lower alkyl or triphenyl (lower) alkyl; oxazolyl;
  • Y is bond, lower alkylene
  • acyloxy preferably acyloxy
  • R 2 is lower alkyl, lower alkoxy (lower) alkyl,
  • cyclo (C 3 -C 7 ) alkyl (more preferably cyclopentyl, cyclohexyl or cycloheptyl), phenyl (lower) alkyl which may nave 1 to 3 (more preferably one or two;
  • substituent (s) (more preferably substituent (s) selected from the group consisting of halogen, lower alkoxy and di (lower alkyl) ammo) [more preferably phenyl (lower) alkyl, halophenyl (lower) alkyl, lower alkoxyphenyl (lower) alkyl or ci (lower alkyl) ammophenyl (lower) alkyl],
  • R 3 is phenyl which may have 1 to 3 (more preferably two or three) suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl and halogen) [more preferably di (or tri) (lower alkyl)phenyl or trihalcphenyl];
  • each of whicn may nave 1 to 3 (more preferably two or three) suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl, lower alkylthio, halogen, lower alkoxy, lower alkylsulfinyl and lower
  • alkylsulfonyl [more preferably pyridyl having two lower alkylthio and lower alkyl;
  • alkylthio tri (lower alkyl) pyridyl; pyridyl having two (lower) alkoxy and lower alkyl; pyridyl having lower alkoxy, lower alkylthio and lower alkyl; pyridyl having two lower alkylsulfinyl and lower alkyl;
  • n 0 or 1.
  • acceptable salts thereof possess a strong inhibitory activity against ACAT, and are useful for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby.
  • Test compound (a) is :
  • Acyl-CoA cholesterol acyltransferase (ACAT)
  • ACAT activity was measured by the method of Heider et al. described in Journal of Lipid Research, Vol. 24, page 1127 (1983).
  • the enzyme ACAT was prepared from the mucosal microsome fraction of the small intestine of male, 18-week old Japanese white rabbits which had been fed diet
  • test compound containing 2% cholesterol for 8 weeks.
  • the inhibitory activity of test compound was calculated by measuring the amount of the labeled cholesterol ester produced from
  • Cholesterol ester fraction in the chloroform-methanol extracts was isolated by thin-layer chromatographv and was counted their label.
  • the compound (I) of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral or external
  • compositions may be capsules, tablets, dragees, granules, suppositories, solution, lotion, suspension, emulsion, ointment, gel, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifylng agents, buffers and other commonly used additives.
  • the dosage of the compound (I) will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound (I) may be effective for treating the above-mentioned diseases. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day.
  • the following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.
  • dichlorometha.ne (1 ( ⁇ and anhydrous sodium carbonate (206.8 g) was added a solution of 1-methylpyrazole (80 g) in dichloromethane u00 ml) at 0-5°C. After stirring for one hour under ice-cooling, the mixture was stirred for further one hour at room temperature, then cooled. To the reaction mixture water (1 l) was added thereto. The dichloromethane layer was separated and aqueous layer was extracted twice with dichloromethane. The combined organic layer was washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was distilled in vacuo to afford 4-bromo-1-methylpyrazole
  • IR (Film) 3515, 3265, 3060, 2935, 2875, 1705, 1650, 1615, 1515 cm -1
  • N-bromosuccmimide (5.29 gi m tetrachlorometnane (150 ml) was added benzoyl peroxide (144 mg) and the mixture was refluxed for 6 hours. The mixture was cooled, and the insoluble materials were filtered off. The filtrate was evaporated m vacuo and the residue was purified by column chromatography on silica gel to give crude 3-bromomethyl bipnenyl (6.59 g) as a yellow oil.
  • IR (Film) 3360, 3075, 2835, 2740, 1695, 1600,
  • dichloromethane (30 ml) was added a solution of dimethyl sulfoxide (1.83 ml) in dichloromethane (4 ml) keeping the temperature below -60°C.
  • 4-(oxazol-5- yDbenzyl alcohol 2.5 g
  • dichloromethane 25 ml
  • dimethyl sulfoxide 2 ml
  • triethylamine 8 ml
  • triphenylchloromethane (1.76 g) at 0-5°C. The mixture was stirred for 4 hours at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with dil.
  • IR (Film) 3265, 3150, 3070, 2925, 2850, 1645,
  • N-cycloheptyl-4-(4- benzoyl) benzylamine (1.87 g) in ethylene glycol (10 ml) were added potassium hydroxide (511 mg) and hydrazine monohydrate (1.95 g), and the mixture was stirred at 150°C for 5 hours and at 200°C for 4 hours.
  • the mixture was poured into a mixture of dichloromethane and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo.
  • the residue was purified by column chromatography on silica gel to give N-cycloheptyl-4-(4-benzyl) benzylamine (1.29 g) as an orange oil.
  • N-benzyl-3-(1-tritylpyrazol-3- yl) benzylamine (8.60 g) in anisole (17.2 ml) was added trifluoroacetic acid (34.4 ml) at room temperature and the mixture was stirred at 80°C for 3.5 hours. The mixture was concentrated in vacuo and the residue was pulverized with diisopropyl ether. The powder was collected by filtration, washed with diisopropyl ether and dried in vacuo to give N- benzyl-3-(pyrazol-3-yl) benzylamine bis ( trifluoroacetate) (7.35 g).

Abstract

Urea derivatives of formula (I), wherein R1 is a group of formula (1) (in which R4 is aryl which may have suitable substituent(s), or heterocyclic group which may have suitable substituent(s), and Y is bond, lower alkylene, -S-, -O-, (a), =CH-, -CONH-, (b), (in which R7 is lower alkyl), -NHSO¿2?-, -SO2NH-, -SO2NHCO- or -CONHSO2-); or thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent(s); R?2¿ is lower alkyl, lower alkoxy(lower)alkyl, cycloalkyl, ar(lower)alkyl which may have suitable substituent(s), heterocyclic group or heterocyclic(lower)alkyl, R3 is aryl which may have suitable substituent(s) or heterocyclic group which may have suitable substituent(s), and n is 0 or 1, and a pharmaceutically acceptable salt thereof which are useful as a medicament in the treatment of hypercholesterolemia, hyperlipidemia and atherosclerosis.

Description

DESCRIPTION
UREA DERIVATIVES AND THEIR USEAS ACAT-INHIBITORS TECHNICAL FIELD
This invention relates to new urea derivatives and pharmaceutically acceptable salts thereof which are useful as a medicament. BACKGROUND ART
Some urea derivatives have been known as acyl-CoA : cholesterol acyltransferase enzyme (hereinafter, ACAT) inhibitors, for example, in U.S. Patent Nos. 4,473,579 and 4,623,662, EP Patent Application Publication Nos. 0354994, 0399422 and 0512570 and PCT International Publication Nos. WO 91/13871, WO 93/24458 and WO 94/26738.
DISCLOSURE OF INVENTION
This inventios relates to new urea derivatives and pharmaceutically acceptable sales thereof which have an inhibitory activity against ACAT and an advantage of good absorption into blood on oral administration, to processes for the preparation thereof, to a pharmaceutical
composition comprising the same and to a method for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby.
One object of this invention is to provide new and useful urea derivatives and pharmaceutically acceptable salts which possess an inhibitory activity against ACAT.
Another object of this invention is to provide
processes for preparation of said urea derivatives and salts thereof.
A further object of this invention is to provide a pharmaceutical composition comprising, as an active
ingredient, said urea derivatives and pharmaceutically acceptable salt thereof.
Still further object of this invention is to provide a therapeutic method for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby in human beings or animals, using said urea derivatives and pharmaceutically acceptable salts thereof.
High levels of blood cholesterol and blood lipids are conditions which are involved in the onset of
atherosclerosis.
It is well known that inhibition of ACAT-catalyzed cholesterol esterification could lead to diminish
intestinal absorption of cholesterol as well as a decrease in the intracellular accumulation of cholesterol esters in the intima of the arterial wall. Therefore, ACAT
inhibitors are useful for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis of diseases caused thereby such as cardiac insufficiency (e.g. angina pectoris, myocardial infarction, etc.),
cerebrovascular disturbance (e.g. cerebral infarction, cerebral apoplexy, etc.), arterial aneurism, peripheral vascular disease, xanthomas, restenosis after percutaneous transluminal coronary angioplasty, or the like. The object urea derivatives of this invention are new and can be represented by the following general formula (I):
Figure imgf000004_0001
wherein
R1 is a group of the formula :
Figure imgf000005_0001
(in which
R4 is aryl which may have suitable substituent (s), or heterocyclic group which may have suitable substituent (s), and
Y is bond, lower alkylene,
Figure imgf000005_0002
H
- (in which R7 is lower
Figure imgf000005_0003
alkyl),
-NHSO2-, -SO2NH-, -SO2NKCO- or -CONHSO2-); or
thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent (s);
R2 is lower alkyl, lower alkoxy (lower) alkyl, cycloalkyl, ar (lower) alkyl which may have suitable substituent (s), heterocyclic group or heterocyclic (lower) alkyl,
R3 is aryl which may have suitable substituent (s) or
heterocyclic group which may have suitable
substituent (s), and
n is 0 or 1.
The object compound (I) of the present invention can be prepared by the following processes.
Figure imgf000006_0001
Figure imgf000007_0001
Figure imgf000008_0001
wherein
R1, R9, R3 and n are each as defined above,
is pyridyl having two lower alkylthio and lower alkyl, and
is pyridyl having two lower alkylsulfonyl and lower
Figure imgf000008_0003
alkyl; pyridyl having two lower alkylsulfinyl and lower alkyl; or pyridyl having lower alkylsulfonyl, lower alkylsulfinyl and lower alkyl. The starting compound can be prepared by tne following processes.
Process (A)
Figure imgf000008_0002
Figure imgf000009_0001
Figure imgf000010_0001
Figure imgf000011_0001
Figure imgf000012_0001
wherein R1, R2, and R4 are each as defined above,
R5 is lower alkoxy,
R6 is lower alkyl,
is aryl which may have suitable
Figure imgf000012_0002
substituent (s), and
X is a leaving group.
Suitable pharmaceutically acceptable salts of the object compound (I) are conventional non-toxic salts and may include a salt with a base or an acid addition salt such as a salt with an inorganic base, for example, an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt; a salt with an organic base, for example, an organic amine salt (e.g., triethylamine salt, pyridine salt, picoline salt,
ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.);
an inorganic acid addition salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.); an organic carboxylic or sulfonic acid addition salt (e.g., formate, acetate, trifluoroacetate, maieate, tartrate, fumarate, citrate, methanesulfonate, benzenesulfonate,
toluenesulfonate, etc.); a salt with a basic or acidic amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.). In the above and subsequent descriptions of the present specification, suitable examples and illustration of the various definitions which the present invention intends to include within the scope thereof are explained in detail as follows.
The term "lower" is used to intend a group having 1 to 6, preferably 1 to 4, carbon atom(s), unless otherwise provided.
The term "higher" is used to intend a group having to 20 carbon atoms, unless otherwise provided.
Suitable "lower alkyl" and "lower alkyl moiety" in the terms "ar (lower) alkyl", "lower alkoxy (lower) alkyl" and "heterocyclic (lower) alkyl" may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, tert-pentyl, hexyl, and the like, and in which more preferable example may be C1-C4 alkyl.
Suitable "lower alkylene" may include straight or branched one such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene,
methvlmethylene, ethylethylene, propylene, and the like, in which more preferable example may be C1-C4 alkylene and the most preferable one may be methylene.
Suitable "lower alkoxy" and "lower alkoxy moiety" in the term "lower alkoxy (lower) alkyl" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy and the like.
Suitable "cycloalkyl" may include cyclo (C3-C7) alkyl (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.) and the like.
Suitable "aryl" and "aryl moiety" in the term
"ar (lower) alkyl" may include phenyl, naphthyl and the like.
Suitable "halogen" may include fluorine, bromine, chlorine and iodine.
Suitable "leaving group" may include acid residue, and the like.
Suitable "acid residue" may include halogen as
exemplified above, and the like.
Suitable "heterocylic group" and "heterocyclic moiety" in the term "heterocyclic (lower) alkyl" may include
unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocvclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, dihydropyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 1H-1,2,4-triazolyl, 4H-1,2,4- triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), etc.;
saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocvclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidyl, piperazinyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 4 nitrogen atom(s), for example, indolyl, isoindolyl, indolinyl, indolizinyl, benzimidazolyl, quinolyl,
isoquinolyl, indazolyl, benzotriazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocvclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4- oxadiazolyl, 1,2,5-oxadiazolyl, etc.), etc.;
saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example,
morpholinyl, sydnonyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atcm(s), for example,
thiazolyl, isothiazolyl, thiadiazolyl (e.g., 1,2,3- thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl,
1,2,5-thiadiazolyl, etc.), dihydrothiazinyl, etc.;
saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example,
thiazolidinyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, dihydroaithiinyl,
dihydrodithionyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for
example, benzothiazolyl, benzothiadiazolyl, etc.; unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom, for example, furyl, etc.;
saturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom, for example, 4H-2,3,5,6-tetrahydropyranyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 3 oxygen atom(s), for example, chromanyl, isochromanyl, methylenedioxyphenyl, etc.;
unsaturated 3 to 8-membered (more preferably 5 or 6- membered) heteromonocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example, dihydrooxathiinyl, etc.;
unsaturated condensed heterocyclic group containing 1 to 2 sulfur atom(s), for example, benzothienyl,
benzodithiinyl, etc.;
unsaturated condensed heterocyclic group containing an oxygen atom and 1 to 2 sulfur atom(s), for example,
benzoxathiinyl, etc.; and the like.
Suitable "protected amino" may include acylamino or an amino group substituted by a conventional protecting group such as mono (or di or tri i aryl (lower ) alkyl, for example, mono (or di or tri ) phenyl ( lower ) alkyl (e.g., benzyl, trityl, etc.) or the like.
Suitable "hydroxy protective group" in the term
"protected hydroxy" may include acyl, mono (or di or
tri) phenyl ( lower) alkyl which may have one or more suitable substituent (s) (e.g., benzyl, 4-methoxybenzyl, trityl, etc.), trisubstituted silyl [e.g., tri (lower) alkylsilyl (e.g., trimethylsilyl, t-butyldimethylsilyl, etc.), et:c.], substituted (lower) alkyl (e.g., methoxymethyl,
ethoxymethyl, etc.), tetrahydropyranyl and the like.
Suitable "acyl" and "acyl moiety" in the term
"acylamino" may include Carbamoyl; Thiocarbamoyl;
Aliphatic acyl such as lower or higher alkanoyl (e.g., formyl, acetyl, propanoyl, butanoyl, 2-methylpropanoyl, pentanoyl, 2, 2-dimethylpropanoyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, tridecanoyl, tetradecanoyl, pentadecanoyl, hexadecanoyl, heptadecanoyl, octadecanoyl, nonadecanoyl, icosanoyl, etc.);
lower or higher alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbcnyl, t-butoxycarbonyl, t-pentyloxycarbonyl, heptyloxycarbonyl, etc.);
lower or higher alkylsulfonyl (e.g., methylsulfonyl, ethylsulfonyl, etc.);
lower or higher alkoxysulfonyl (e.g., methoxysulfonyl, ethoxysulfonyl, etc.); cyclo (lower) alkylcarbonyl (e.g., cyclopentylcarbonyl, cyclohexylcarbonyl, etc.); or the like.
Aromatic acyl such as
aroyl (e.g., benzoyl, toluoyl, naphthoyl, etc.);
ar (lower) alkanoyl [e.g., phenyl (lower) alkanoyl (e.g., phenylacetyl, phenylpropanoyl, phenylbutanoyl,
phenylisobutanoyl, phenylpentanoyl, phenylhexanoyl, etc.), naphthyl (lower) alkanoyl (e.g., naphthylacetyl,
naphthylpropanoyl, naphthylbutanoyl, etc.), etc.];
ar (lower) alkenoyl [e.g., phenyl (lower) alkenoyl (e.g., phenylpropenoyl, phenylbutenoyl, phenylmethacryloyl, phenylpentenoyl, phenylhexenoyl, etc.),
naphthyl (lower) alkenoyl (e.g., naphthylpropenoyl,
naphthylbutenoyl, etc.), etc.];
ar (lower) alkoxycarbonyl [e.g., phenyl (lower) alkoxycarbonyl (e.g., benzyloxycarbonyl, etc.), etc.];
aryloxycarbonyl (e.g., phenoxycarbonyl,
naphthyloxycarbonyl, etc.);
aryloxy (lower) alkanoyl (e.g., phenoxyacetyl,
phenoxypropionyl, etc.); arylglyoxyloyl (e.g., phenylglyoxyloyl, naphthylglyoxyloyl, etc.);
arylsulfonyl (e.g., phenylsulfonyl, p-tolylsulfonyl, etc.); or the like.
Suitable "substituent" in the terms "aryl which may have suitable substituent (s) " and "ar (lower) alkyl which may have suitable substituent (s) " may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or di or tri) halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above, cyclo (lower) alkyl, cyclo ( lower) alkenyl, halogen as exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl as exemplified above, ar (lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy (lower) alkyl wherein lower alkyl moiety as exemplified above, protected
carboxy (lower) alkyl, nitro, ammo, protected ammo,
di (lower) alkylammo wnerem lower alκyl moiety is as exemplified above, ammo (lower) alkyl wnerem lower alkyl moiety is as exemplified above, protected
ammo lower) alkyl, hydroxy (lower) alκyl wherein lower alκyl moiety is as exemplified above, protected
hydroxy (lower) alkyl, cyano, sulfc, sulfamoyl, carbamoyloxy, mercapto, lower alkylthio wherein lower alkyl noiety is as exemplified above, immo, protected ammo as exemplified above, heterocyclic group which may have mono (or di or tri) ar ( lower) alkyl wherein heterocyclic group, aryl moiety and lower alkyl moiety are each as exemplifieα above, and the like.
Suitable "substituent" m the term "heterocyclic group whicn may have suitable suostituent (s)" may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or αi or
tri) halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above, cyclo (lower) alkyl, cyclo (lower) alkenyl, halogen as exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, as
exemplified above, aryl as exemplified above, mono (or di or tri) ar (lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy (lower) alkyl wherein lower alkyl moiety as exemplified above, protected carboxy (lower) alkyl, nitro, amino, protected amino,
di (lower) alkylamino wherein lower alkyl moiety is as exemplified above, amino (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected amino (lower)- alkyl, hydroxy (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected hydroxy (lower) alkyl, cyanc, sulfo, sulfamoyl, carbamoyloxy, mercapto, lower alkylthio wherein lower alkyl moiety is as exemplified above, lower alkylsulfinyl wherein lower alkyl moiety is as exemplified above, acyl as exemplified above, oxo, imino, and the like.
Suitable "substituent" in the term "thiazolyl,
imidazolyl, pyrazolyl, pyridyl, thienyl, furyl or
isoxazolyl, each of which may have suitable substituent (s)" may include lower alkyl as exemplified above, lower alkoxy as exemplified above, lower alkenyl, lower alkynyl, mono (or di or tri) halo (lower) alkyl wherein halogen moiety and lower alkyl moiety are each as exemplified above,
cyclo (lower) alkyl, cyclo (lower) alkenyl, halogen as
exemplified above, carboxy, protected carboxy, hydroxy, protected hydroxy, aryl as exemplified above, haloaryl wherein halogen moiety and aryl moiety are each as
exemplified above, arylthio wherein aryl moiety is as exemplified above, heterocyclic group as exemplified above, ar (lower) alkyl wherein aryl moiety and lower alkyl moiety are each as exemplified above, carboxy (lower) alkyl wherein lower alkyl moiety as exemplified above, protected
carboxy (lower) alkyl, nitro, amino, protected amino,
di (lower) alkylamino wherein lower alkyl moiety is as exemplified above, amino (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected
amino (lower) alkyl, hydroxy (lower) alkyl wherein lower alkyl moiety is as exemplified above, protected
hydroxy (lower) alkyl, cyano, sulfo, sulfamoyl, carbamoyloxv, m.ercapto, lower alkylthio wherein lower alkyl moiety is as exemplified above, imino, and the like.
The processes for preparing the object and starting compounds of the present invention are explained in detail in the following.
Process (1)
The compound (I) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof with the compound (III) or a salt thereof.
This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N,N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which do not adversely affect the reaction, or the mixture thereof.
The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.
When the starting compound is in liquid, it can be used also as a solvent.
Process (2)
The compound (I) or a salt thereof can be prepared by subjecting the compound (II) or a salt thereof and the compound (IV) or a salt thereof to formation reaction of ureido group.
This reaction is carried out in the presence of reagent which introduces carbonyl group such as phosgene [e.g. , triphosgene, etc.], haloformate compound [e.g. ethyl chloroformate, trichloromethyl chloroformate, phenyl chloroformate, etc.], N,N'-carbonyldiimidazole, metal carbonyl compounds [a.g. cobalt carbonyl, manganese
carbonyl, etc.], a combination of carbon monoxide and catalysts such as palladium chloride, etc., or the like.
This reaction is usually carried out in a solvent such as water, alcohol (e.g., methanol, ethanol, etc.), benzene, N, N-dimethylformamide, tetrahydrofuran, toluene, methylene chloride, ethylene dichloride, chloroform, dioxane, diethyl ether or any other solvents which άo not adversely affect the reaction, or the mixture thereof.
The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
The reaction is usually carried out in the presence of an organic base such as tri (lower) alkylamine (e.g.,
trimethylamine, triethylamine, diisopropylethylamine, etc.), or the like.
Process (3)
The compound (lb) or a salt thereof can be prepared by subjecting the compound (la) or a salt thereof to oxidation reaction.
Oxidation is carried out in a conventional manner, which is capable or oxidizing a sulfur atom to an oxidized sulfur atom, and suitable oxidizing reagent may be oxygen acid such as periodate (e.g. sodium periodate, potassium periodate, etc.), peroxy acid such as perbenzoic acid
(e.g., perbenzoic acid, m-chloroperbenzoic acid, etc.), and the like.
The reaction is usually carried out in a conventional solvent such as water, alcohol, (e.g., methanol, ethanol, isopropyl alcohol, etc.), tetrahydrofuran, dioxane,
dichloromethane, ethylene dichloride, chloroform, N,N- dimethylformamide, N, N-dimethylacetamide, or any other organic solvent which does not adversely affect the reaction .
Among these solvents, hydrophilic solvents may be used in a mixture with water.
The reaction temperature is not critical and the reaction is usually carried out under cooling to heating.
Process (A) -
Figure imgf000022_0001
The compound (VII) or a salt thereof can be prepared by reacting the compound (V; with the compound (VI;.
The reaction can be carried out m the manner
disclosed in Preparation 2 or similar manners thereto.
Process (A)-
Figure imgf000022_0002
)
The compound (IXa) or a salt thereof can be prepared DV reacting the compound (VII) or a salt thereof with the compound (VIII) or a salt thereof.
The reaction can oe carried out m the manner
disclosed in Preparation 20 or similar manners thereto. Process (B)
The compound (X) or a salt thereof can oe prepared by subjecting the compounα (IX) or a salt thereof to reduction reaction.
Reduction is carried out m a conventional manner, including chemical reαuction and catalytic reduction.
Suitable reducing reagents to be used in cnemical reduction and hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum nydride, sodium borohydride, sodium cyanoborohydride, αiisooutylaluminum hydride, etc.), a metal (e.g., tin, zinc, iron, etc.) or metallic compounc (e.g., chromium chloride, chromium acetate, etc.), and the like.
Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum blacκ, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black, palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like.
The reduction is usually carried out in the
conventional solvent such as water, alcohol (e.g.,
methanol, ethanol, propanol, etc.), tetrahydrofuran, toluene, dichloromethane, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide or any other solvents which do not adversely affect the reaction, or a mixture thereof.
The reduction is usually carried out in the presence of an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid,
p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
Additionally, in case that the above-mentioned acids to be used in chemical reduction are m liquid, they can also be used as a solvent.
Process (C)
The compound (Xa) or a salt thereof can be prepared by reacting the compound (XI) or a salt thereof with the compound (XII) or a salt thereof.
The reaction can be carried out in the manner
disclosed in Preparation 48 or similar manners thereto.
Process (D)
The compound (Xb) or a salt thereof can be prepared by reacting the compound (XIII) or a salt thereof with the compound (XII) or a salt thereof.
The reaction can be carried out in the manner disclosed in Preparation 38 or similar manners thereto.
Process (E)
The compound (Ila) or a salt thereof can be prepared by reacting the compound (X) or a salt thereof with the compound (XIV) or a salt thereof and then by subjecting the resultant compound to reduction reaction.
Reduction is carried out in a conventional manner, including chemical reduction and catalytic reduction.
Suitable reducing reagent to be used in chemical reduction are hydrides (e.g., hydrogen iodide, hydrogen sulfide, lithium aluminum hydride, sodium borohydride, sodium cyanoborohydride, etc.) or a combination of a metal (e.g., tin, zinc, iron, etc.) or metallic compound (e.g., chromium chloride, chromium acetate, etc.) and an organic acid or an inorganic acid (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid,
p-toluenesulfonic acid, hydrochloric acid, hydrobromic acid, etc.).
Suitable catalysts to be used in catalytic reduction are conventional ones such as platinum catalysts (e.g., platinum plate, spongy platinum, platinum black, colloidal platinum, platinum oxide, platinum wire, etc.), palladium catalysts (e.g., spongy palladium, palladium black,
palladium oxide, palladium on carbon, colloidal palladium, palladium on barium sulfate, palladium on barium carbonate, etc.), nickel catalysts (e.g., reduced nickel, nickel oxide, Raney nickel, etc.), cobalt catalysts (e.g., reduced cobalt, Raney cobalt, etc.), iron catalysts (e.g., reduced iron, Raney iron, Ullman iron, etc.), and the like.
The reduction is usually carried out in a conventional solvent such as water, alcohol (e.g., methanol, ethanol, propanol, etc.), tetrahydrofuran, toluene, dioxane,
N,N-dimethylformamide, N, N-dimethylacetamide or any other solvents which do not adversely affect the reaction, or a mixture thereof.
Additionally, in case that the above-mentioned acids to be used in chemical reduction are in liquid, they can also be used as a solvent.
Suitable salts of the object and starting compounds in
Processes (1)-(3) and (A) - (E) can be referred to the ones as exemplified for the compound (I).
The compounds obtained by the above processes can be isolated and purified by a conventional method such as pulverization, recrystallization, column chromatography, reprecipitation, or the like.
It is to be noted that the compound (I) and the other compounds may include one or more stereoisomer (s) such as optical isomer(s) and geometrical isomer(s) due to
asymmetric carbon atom(s) and double bond(s), and all of such isomers and mixture thereof are included within the scope of this invention.
Preferred embodiments of the object compound (I) are as follows.
R1 is a group of the formula
Figure imgf000025_0001
(in which
R4 is phenyl which may have 1 to 3 suitable
substituent (s) (more preferably substituent selected from the group consisting of halogen, lower alkyl, di (lower) alkylamino, protected amino (more preferably acylamino;
most preferably lower alkylsulfonylamino), cyano, heterocyclic group (more preferably tetrazolyl) which may have mono (or di or tri) ar (lower) alkyl
(more preferably mono (or di or
tri)phenyl (lower) alkyl; most preferably
triphenyl (lower) alkyl), hydroxy, protected hydroxy (more preferably lower
alkoxy (lower) alkoxy; and mono (or di or
tri) halo (lower) alkyl (more preferably
trihalo (lower) alkyl)), [more preferably phenyl, halophenyl, lower alkylphenyl,
di (lower) alkylaminophenyl, lower
alkylsulfonylaminophenyl, cyanophenyl,
tetrazolylphenyl, (triphenyl (lower)- alkyltetrazolyl) phenyl, trihalo (lower)- alkylphenyl, phenyl having two lower alkyl and hydroxy, or phenyl having two lower alkyl and lower alkoxy (lower) alkoxy]; or heterocyclic group
(more preferably thienyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrrolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, piperazinyl, thiazolidinyl or methylenedioxyphenyl) which may have 1 to 3 (more preferably one or two) suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl, mono (or di or tri) ar (lower) alkyl (more preferably phenyl (lower) alkyl or
triphenyl (lower alkyl) and oxo) [more preferably thienyl; pyrazolyl which may have lower alkyl or triphenyl (lower) alkyl; imidazolyl;
triazolyl which may have one or two
substituent (s) selected from the group consisting of lower alkyl and phenyl (lower) alkyl; pyridyl; pyrrolyl; tetrazolyl which may have lower alkyl or triphenyl (lower) alkyl; oxazolyl;
lower alkylthiazolyl; lower alkyloxadiazolyl;
lower alkylpiperazinyl; dioxothiazolidinyl; or methylenedioxyphenyl];
Y is bond, lower alkylene,
Figure imgf000027_0001
(in which R7 is lower alkyl),
Figure imgf000027_0002
-NHSO2-, -SO2NH-, -SO2NHCO- or -CONHSO2-); or thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have 1 to 5 suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl, hydroxy, protected hydroxy (more
preferably acyloxy), phenyl, halophenyl, phenylthio and pyrrolyl) [more preferably halophenylthiazclyl, phenylimidazolyl, phenylpyrazolyl, phenylpyridyl, phenylthiopyridyl, pyrrolylpyridyl, phenylthienyl, phenylfuryl, phenylisoxazolyl or chromanyl having 4 lower alkyl and hydroxy];
R2 is lower alkyl, lower alkoxy (lower) alkyl,
cyclo (C3-C7 ) alkyl (more preferably cyclopentyl, cyclohexyl or cycloheptyl), phenyl (lower) alkyl which may nave 1 to 3 (more preferably one or two;
most preferably one) suitable substituent (s) (more preferably substituent (s) selected from the group consisting of halogen, lower alkoxy and di (lower alkyl) ammo) [more preferably phenyl (lower) alkyl, halophenyl (lower) alkyl, lower alkoxyphenyl (lower) alkyl or ci (lower alkyl) ammophenyl (lower) alkyl],
tetrahydropyranyl or furyl (lower) alkyl, and
R3 is phenyl which may have 1 to 3 (more preferably two or three) suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl and halogen) [more preferably di (or tri) (lower alkyl)phenyl or trihalcphenyl];
pyridyl or pyrimidmyl, each of whicn may nave 1 to 3 (more preferably two or three) suitable substituent (s) (more preferably substituent selected from the group consisting of lower alkyl, lower alkylthio, halogen, lower alkoxy, lower alkylsulfinyl and lower
alkylsulfonyl) [more preferably pyridyl having two lower alkylthio and lower alkyl;
pyridyl having halogen, lower alkyl and lower
alkylthio; tri (lower alkyl) pyridyl; pyridyl having two (lower) alkoxy and lower alkyl; pyridyl having lower alkoxy, lower alkylthio and lower alkyl; pyridyl having two lower alkylsulfinyl and lower alkyl;
pyridyl having two lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkoxy and lower alkyl; pyridyl having lower alkylsulfinyl, lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkylsulfonyl and lower alkyl; pyridyl having two halogen and lower alkyl;
di (lower) alkoxypyrimidinyl; or pyrimidinyl having two lower alkylthio and lower alkyl], and
n is 0 or 1.
The object compounds (I) and pharmaceutically
acceptable salts thereof possess a strong inhibitory activity against ACAT, and are useful for the prevention and/or treatment of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby.
In order to illustrate the usefulness of the object compound (I), the pharmacological test data of the
representative compound of the compound (I) are shown in the following.
Test compound (a) :
1-Cycloheptyl-1-(4-phenoxyphenylmethyl)-3-(2,4,6- trifluoroohenyl) urea Test :
Acyl-CoA : cholesterol acyltransferase (ACAT)
inhibitory activity Method :
: ACAT activity was measured by the method of Heider et al. described in Journal of Lipid Research, Vol. 24, page 1127 (1983). The enzyme ACAT was prepared from the mucosal microsome fraction of the small intestine of male, 18-week old Japanese white rabbits which had been fed diet
containing 2% cholesterol for 8 weeks. The inhibitory activity of test compound was calculated by measuring the amount of the labeled cholesterol ester produced from
[14C]oleoyl-CoA and endogenous cholesterol as follows.
[14C] Oleoyl-CoA and microsome were incubated with test compound at 37°C for 5 minutes. The reaction was stopped by the addition of chloroform-methanol (2:1, V/V).
Cholesterol ester fraction in the chloroform-methanol extracts was isolated by thin-layer chromatographv and was counted their label.
Figure imgf000029_0001
For therapeutic purpose, the compound (I) of the present invention can be used in a form of pharmaceutical preparation containing one of said compounds, as an active ingredient, in admixture with a pharmaceutically acceptable carrier such as an organic or inorganic solid or liquid excipient suitable for oral, parenteral or external
(topical) administration, wherein more preferable one is oral administration. The pharmaceutical preparations may be capsules, tablets, dragees, granules, suppositories, solution, lotion, suspension, emulsion, ointment, gel, or the like. If desired, there may be included in these preparations, auxiliary substances, stabilizing agents, wetting or emulsifylng agents, buffers and other commonly used additives.
While the dosage of the compound (I) will vary depending upon the age and condition of the patient, an average single dose of about 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg and 1000 mg of the compound (I) may be effective for treating the above-mentioned diseases. In general, amounts between 0.1 mg/body and about 1,000 mg/body may be administered per day. The following Preparations and Examples are given for the purpose of illustrating the present invention in more detail.
- to be continued en the next page -
Preparation 1
To a solution of acetophenone (20 g) and dimethyl oxalate (23.6 g) in N,N-dimethylformamide (160 ml) was added sodium hydride (60% oil suspension, 8 g) at 0-5°C. The mixture was stirred for one hour at room temperature, then heated for 30 minutes at 50°C. After cooling, to the reaction mixture was added 2.4N-hydrochloric acid (70 ml) and extracted with ethyl acetate. The organic layer was washed with water, brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (700 g, n-hexane - ethyl acetate (4:1 to 1:1)) to give methyl 2,4-dioxo-4-phenylbutyrate (20.32 g).
IR (KBr) : 1732, 1622, 1601, 1574, 1444, 1269 cm-1 NMR (CDCl3, δ) : 3.95 (3H, s), 7.10 (1H, s), 7.45- 7.68 (3H, m), 7.95-8.06 (2H, m), 15.0-15.5 (1H, br)
APCI-MASS (m/z) : 207 (M+H+)
Preparation 2
The mixture of 3-acetylbenzonitrile (43.55 g) and N,N- dimethylformamide dimethyl acetal (107.2 g) was stirred at 90°C for 3 hours under nitrogen. The mixture was
concentrated in vacuo and diisopropyl ether (400 ml) was added thereto. The red-brown precipitates were collected by filtration, washed with diisopropyl ether and dried to give 3- [ (E) -3-dimethylaminoρropenoyl ] benzonitrile (48.62 g).
IR (KBr) : 3070, 2900, 2225, 1645, 1600, 1550 cm-1 NMR (DMSO-d6, δ) : 2.96 (3H, s), 3.17 (3H, s),
5.93 (1H, d, J=12.1Hz), 7.65 (1H, dd, J=7.7,
7.7Hz), 7.72 (1H, d, J=12.1Hz), 7.95 (1H, d, J=7.7Hz), 8.20 (1H, d, J=7.7Hz), 8.34 (1H, s) APCI-MASS (m/z) : 201 (M+H+) Preparation 3
To a solution of N-(3-acetylbenzyl)-acetamide (9.56 g) in 1,2-dimethoxyethane (150 mi) was added dropwise bromine (7.99 g) at room temperature and the mixture was stirred at the same temperature for 1.5 hours. The precipitates were dissolved by addition of ethanol (150 ml) and thioacetamide (4.51 g) was added to the solution. The mixture was refluxed for 2.5 hours and evaporated in vacuo. The residue was extracted by ethyl acetate and the organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-[(2- methylthiazol-4-yl) benzyl]-acetamide (8.24 g).
IR (KBr) : 3295, 3110, 3070, 2930, 1645, 1550 cm-1 NMR (DMSO-d6, δ) : 1.89 (3H, s), 2.72 (3H, s),
4.29 (2H, d, J=5.9Hz), 7.2-7.9 (4H, m), 7.90 (1H, s), 8.40 (1H, t, J=5.9Hz)
APCI-MASS (m/z) : 247 (M+H+) Preparation 4
To a solution of N-[3-(2-methylthiazol-4-yl)benzyl]- acetamide (8.23 g) in ethanol (100 ml) was added cone, hydrochloric acid (13.9 ml) and the mixture was refluxed for 12 hours. The mixture was cooled to 5°C and acetone (100 ml) was added thereto slowly. The precipitates were collected by filtration and washed with acetone, drieα over phosphorus pentoxide to give 3-(2-methylthiazol-4-yl)- benzylamine-hydrochloride (5.14 g).
IR (KBr) : 3090, 2915, 2840, 2635, 1605, 1575,
1510 cm-1
NMR (DMSO-d6, δ) : 2.73 (3H, s), 4.07 (2H, ABq,
J=5.7Hz), 7.47 (2H, d, J=5.1Hz), 7.9-8.0 (1H, m), 7.97 (1H, s), 8.14 (1H, s), 8.57 (2H, br s)
APCI-MASS (m/z) : 205 (M of free compound +H+) Preparation 5
To a suspension of methyl 4-[(E)-3-dimethylamino- propenoyl]benzoate (5.0 g) in methanol (150 ml) was added acetic acid (1.84 ml) and hydrazine monohydrate (1.56 ml). A.fter stirring for 10 hours at room temperature, the solvent was evaporated in vacuo. The residue was dissolved in ethyl acetate, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give methyl 4- (pyrazol-3-yl)benzoate (4.21 g).
IR (KBr) : 2800-3500 (br), 1709, 1610, 1537, 1439,
1414 cm-1
NMR (DMSO-d6, δ) : 3.86 (3H, s), 6.85 (1H, d,
J=2.2Hz), 7.84 (1H, br s), 7.85-8.10 (4H, m), 13.10 (1H, br)
APCI-MASS (m/z) : 203 (M+H+)
Preparation 6
To a solution of methyl 4-[(E)-3-dimethylamino- propenoyl) benzoate (5.23 g) in acetic acid (50 ml) was added methylhydrazine (1.31 ml). The mixture was stirred for 3 hours at room temperature. To the solution was added 5N-sodium hydroxide solution in order to basify under ice cooling and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate
solution, water, brine, dried over magnesium sulfate, evaporated in vacuo. After chromatography on silica gel (eluting with dichloromethane-methanol (120:1)), methyl 4-(1-methylpyrazol-3-yl)benzoate (3.14 g) was isolated and methyl 4-(1-methylpyrazol-5-yl) benzoate (1.63 g) was obtained.
Methyl 4-(1-methylpyrazol-3-yl) benzoate:
IR (KBr) : 3134, 2949, 1705, 1612, 1439, 1344,
1281 cm-1
NMR (CDCl3, δ) : 3.92 (3H, s), 3.97 (3H, s), 6.61
(1H, d, J=2.2Hz), 7.41 (1H, d, J=2.2Hz), 7.82- 7.93 (2H, m), 8.03-8.14 (2H, m)
APCI-MASS (m/z) : 217 (M+H+)
Methyl 4-(1-methylpyrazol-5-yl) benzoate :
IR (KBr) : 3035, 2960, 1718, 1614, 1464, 1425,
1286 cm-1
NMR (CDCl3, δ) : 3.93 (3H, s), 3.96 (3H, s), 6.38
(1H, d, J=2.0Hz), 7.46-7.57 (2H, m), 7.54 (1H, d,
J=2.0Hz), 8.08-8.19 (2H, m)
APCI-MASS (m/ z ) : 217 (M+ H+ )
Preparation 7
To a solution of thiophenol (2.20 g) in methanol (10 ml) was added 28% sodium methoxide-methanol solution (3.86 ml) and the mixture was stirred at room temperature for 15 minutes. To the mixture was added methyl 6- chloronicotinate (3.43 g) and the mixture was refluxed for 6.5 hours under nitrogen. The mixture was evaporated to dryness and the residue was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatographv on silica gel to give methyl 6-(phenylthio) nicotinate (5.13 g) as a crystal.
IR (KBr) : 3070, 2950, 1720, 1585, 1550 cm-1
NMR (CDCI3, δ) : 3.91 (3H, s), 6.86 (1H, dd, J=8.5, 0.8Hz), 7.4-7.5 (3H, m), 7.55-7.7 {2H, m), 8.00 (1H, dd, J=8.5, 2.2Hz), 9.00 (1H, dd, J=2.2, 0.8Hz)
APCI-MASS (m/z) : 246 (M+H+)
Preparation 8
To a solution of aniline (8.20 g) in pyridine (100 ml) was added portionwise 4-carboxybenzenesulfonyl chloride (17.65 g) at 5°C and the mixture was stirred at 90°C for 6 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate (300 ml), ice water (200 ml) and cone, hydrochloric acid (150 ml). The precipitates were formed and collected by filtration and washed with ethyl acetate and diisopropyl ether and dried in vacuo over phosphorus pentoxide tb give 4-(phenylsuifamoyl) benzoic acid (6.87 g) as white crystal. The filtrate was separated and the organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. To the residue was added diisopropyl ether and the second crop (6.57 g) was obtained by filtration.
IR (KBr) : 3265, 2840, 2675, 2560, 1680, 1600,
1575 cm-1
NMR (DMSO-d6, δ) : 7.0-7.2 (3K. m), 7.2-7.35 (2H,
m), 7.85 (2H, d, J=8.4Hz), 8.07 (2H, d, J=8.4Hz),
10.45 (1H, s)
Preparation 9
To a solution of ethyl 4-aminobenzoate (8.26 g) in pyridine (25 ml) was added dropwise benzenesulfonyl
chloride (8.83 g) at 5°C and the mixture was stirred at room temperature for 1 hour under nitrogen. The mixture was poured into a mixture of ethyl acetate (150 ml), ice water (100 ml) and cone, hydrochloric acid (30 ml). The precipitates were formed and collected by filtration, washed with ethyl acetate and diisopropyl ether and dried in vacuo over phosphorus pentoxide to give ethyl 4 - (phenylsulfonylamino) benzoate (10.72 g) as a white crystal. The filtrate was separated and the organic layer was washed with brine, dried over magnesium sulfate and evaporated m vacuo. To the residue was added diisopropyl ether and the second crop (3.83 g) was obtained by filtration.
IR (KBr) : 3230, 3070, 2990, 2940, 2880, 1695,
1610, 1510 cm-1
NMR (DMSO-d6, δ) : 1.27 (3H, t, =7.1Hz), 4.24 (2H, q, J=7.1Hz), 7.22 (2H, d, J=8.8Hz), 7.5-7.7 (3H, m), 7.8-7.9 (4H, m), 10.86 (1H, s)
APCI-MASS (m/z) : 306 (M+H+) Preparation 10
To a stirred mixture of bromine (50.2 ml) in
dichlorometha.ne (1 (} and anhydrous sodium carbonate (206.8 g) was added a solution of 1-methylpyrazole (80 g) in dichloromethane u00 ml) at 0-5°C. After stirring for one hour under ice-cooling, the mixture was stirred for further one hour at room temperature, then cooled. To the reaction mixture water (1 ℓ) was added thereto. The dichloromethane layer was separated and aqueous layer was extracted twice with dichloromethane. The combined organic layer was washed with water and brine, dried over magnesium sulfate and evaporated under reduced pressure. The residue was distilled in vacuo to afford 4-bromo-1-methylpyrazole
(150.6 g).
bp : 82°C (20 mmHg)
IR (Neat) : 3100, 2930 cm-1
NMR (CDCl3, δ) : 3.89 (3H, s), 7.38 (1H, s),
7.44 (1H, s)
APCI-MASS (m/z) : 161, 163 (M+H+ ) Preparation 11
To a solution of methyl 4-formylbenzoate (4.0 g) and tosylmethyl isocyanide (5.0 g) m methanol (40 ml) was added potassium carbonate (3.54 g). The mixture was refluxed for 3.5 hours. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water and brme, dried over magnesium sulfate,
evaporated m vacuo. The residue was chromatograpneα or. silica gel (100 g, elutmg with n-hexane - ethyl acetate (2:1 to 1:1) to give methyl 4- (oxazol-5-yl) benzoate (4.04 g). IR (KEr) : 1726, 1614, 1275, 1109 cm-1
NMR (CDCl3, δ) : 3.94 (3H, s), 7.48 (1H, s),
7.68-7.78 (2H, m), X 97 (1H, s), 8.06-8.16 (2H, m)
APCI-MASS (m/z) : 204 (M+H+)
Preparation 12
A solution of methyl 2,4-dioxo-4-phenylbutyrate (6 g) and hydroxylamine-hydrochloride (6.07 g) in methanol (120 ml) was refluxed for 4 hours. The solvent was removed in vacuo. To the residue was added chloroform. The organic solution was washed with water, brine, dried over magnesium sulfate, evaporated in vacuo. The residue was
chromatographed on silica gel (150 g, n-hexane - ethyl acetate (3:1)) to give 3-methoxycarbonyl-5-phenylisoxazole (5.25 g).
IR (KBr) : 1728, 1570, 1448, 1250 cm-1
NMR (CDCl3, δ) : 4.01 (3H, s), 6.94 (1H, s),
7.45-7.55 (3H, m), 7.75-7.88 (2H, m)
APCI-MASS (m/z) : 204 (M+H+)
Preparation 13
A solution of methyl 2,4-dioxo-4-phenylbutyrate (6 g) and hydrazine, mo.nohydrate (1.42 ml) in ethanol (48 ml) was refluxed for 5 hours. The solvent was removed in vacuo. The resulting solid was collected by filtration, washed with diisopropyl ether to give 5-methoxyIcarbonyl-3- pyenylpyrazole (3.0 g).
IR (KBr) : 2500-3400 (br), 1730, 1491, 1244 cm-1 NMR (DMSO-d6, δ) : 3.83, 3.88 (total 3H, each s),
7.18-7.53 (4H, m), 7.78-7.94 (2H, m), 13.90-14.15 (1H, m)
APCI-MASS (m/z) : 203 (M+H+) Preparation 14
A mixture of methyl 3-cyanobenzoate (8.0 g), sodium a∑ide (19.38 g) and ammonium chloride (15.95 g) in N,N- dimethylformamide (32 ml) was heated for 2.5 hours at 120°C. The mixture was poured into ice water (300 ml) - ethyl acetate (100 ml). Under ice cooling, to the solution was added sodium nitrite (20.5 g) then
6N-hydrochloric acid until pH was adjusted to 1-2. After stirring for 30 minutes at room temperature, the mixture was extracted with ethyl acetate - tetrahydrofuran, washed with water and brine, dried over magnesium sulfate,
evaporated in vacuo to give methyl 3-(1H-tetrazol-5- yl)benzoate (10.01 g).
IR (KBr) : 2300-3500 (br), 1705, 1684, 1618,
1562 cm-1
NMR (DMSO-d6,δ) : 3.93 (3H, s), 7.78 (1H, dd,
J=7.9, 7.9Hz), 8.10-8.20 (1H, m), 8.25-8.38 (1H, m), 8.60-8.70 (1H, m)
APCI-MASS (m/z) : 205 (M+H+)
Preparation 15
To the solution of 4-bromobenzyl alcohol (4.85 g) and 3-tri-n-butylstannylthiophene (11.6 g) was added
tεtrakis (triphenylphosphine) palladium (0) (0.9 g), then the mixture was heated for one hour at 140°C. After cooling, the resulting precipitate was collected by filtration and washed with n-hexane to give 4-(3-thienyl) benzyl alcohol (2.67 g).
IR (KBr) : 3300 (br), 1425, 1200, 1045, 1014,
777 cm-1
NMR (CDCl3, δ) : 1.72 (1H, t, J=5.9Hz), 4.72 (2H, d,
J=5.9Hz), 7.30-7.50 (5H, m), 7.60 (2H, dd, J=6.4, 1.8Hz) Preparation 16
The following compound was obtained according to a similar manner to that of Preparation 15.
4-(2-Thienyl) benzyl alcohol
IR (KBr) : 3300 (br), 1427, 1213, 1047, 806 cm-1
NMR (CDCl3, δ) : 1.70 (1H, t, J=5.9Hz), 4.71 (2H, d, J=5.9Hz), 7.08 (1H, dd, J=5.I, 3.6Hz), 7.22-
7.42 (4H, m), 7.52-7.68 (2H, m)
Preparation 17
A mixture of ethyl 4-acetylbenzoate (10 g) and N,N- dimethylformamide dimethyl acetal (41.8 ml) was heated for 18 hours at 85°C. After cooling, the resulting solid was collected by filtration, washed with diisopropyl ether to give methyl 4-[(E)-3-dimethylaminopropenoyl] benzoate
(10.44 g).
IR (KBr) : 1718, 1637, 1578, 1541, 1425 cm-1
NMR (DMSO-d6, δ) : 2.94 (3H, s), 3.17 (3H, s),
3.88 (3H, s), 5.85 (1H, d, J=12.2Hz), 7.77 (1H, d, J=12.2Hz), 7.90-8.05 (4H, m;
APCI-MASS (m/z) : 234 (M+H+)
Preparation 18
To a suspension of lithium aluminum hydride (569 mg) in tetrahydrofuran (120 ml) was added dropwise a solution of 2-methoxycarbonyl-4-(pyrrol-1-yl) pyridine (3.03 g) at 5°C and the mixture was stirred at room temperature for 3 hours. To the mixture were added sodium fluoride (2.52 g) and water (811 mg) and the mixture was stirred at room temperature for 30 minutes. The insoluble materials were removed by filtration and washed with tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give [4- (pyrrol-1-yl)pyridin-2-yl]methanol (1.14 g). IR (KBr) : 3190, 2955, 2845, 1595, 1575, 1500 cm-1 NMR (DMSO-d6, δ) : 4.58 (2H, d, J=5.8Hz), 5.48 (1H, t, J=5.8Hz), 6.35-6.4 (2H, m), 7.52 (1H, dd, J=5.6, 2.4Hz), 6.55-6.6 (2H, m), 7.62 (1H, d, J=1.9Hz), 8.47 (1H, d, J=5.6Hz)
APCI-MASS (m/z) : 175 (M+H+)
Preparation 19
The following compounds were obtained according to a similar manner to that of Preparation 18.
(1) 3- (Pyrazol-3-yl) benzyl alcohol
IR (Film) : 3245, 2930, 2880 cm-1
NMR (DMSO-d6, δ) : 4.52 (2H, d, J=5.6Hz), 5.29 (1H, t, J=5.6Hz), 6.68 (1H, d, J=2.2Hz), 7.2-7.7 (4H, m), 7.76 (1H, d, J=2.2Hz), 12.9 (1H, br s)
APCI-MASS (m/z) : 175 (M+H+)
(2) ( 6-Phenylpyridin-3-yl) methanol
IR (Film) : 3325, 2865, 1600, 1565, 1475 cm-1
NMR (CDCl3, δ) : 4.74 (2H, s), 7.4-7.55 (3H, m),
7.7-7.85 (2H, m), 7.9-8.05 (2H, m), 8.62 (1H, d, J=1.3Hz)
APCI-MASS (m/z) : 186 (M+H+)
(3) 4-(Benzoylamino) benzyl alcohol
IR (KBr) : 3320, 2840, 1655, 1595, 1545 cm-1
NMR (DMSO-d6, δ) : 4.50 (2H, d, J=5.7Hz), 5.22 (1H, t, J=5.7Hz), 7.05 (1H, d, J=7.6Hz), 7.29 (1H, d, J=7.6Hz), 7.5-7.7 (4H, m), 7.77 (1H, s), 7.96
(2H, dd, J=7.6, 1.5Hz), 10.23 (1H, s) APCI-MASS (m/z) : 228 (M+H+)
(4) 4-(Phenylsulfonylamino) benzyl alcohol
IR (Film) : 3515, 3265, 3060, 2935, 2875, 1705, 1650, 1615, 1515 cm-1
NMR (DMSO-d6, δ) : 4.36 (2H, d, J=5.8Hz), 5.07 (1H, t, J=5.8Hz), 7.02 (2H, d, J=8.6Hz), 7.15 (2H, d, J=8.6Hz), 7.5-7.65 (2H, m), 7.7-7.8 (2H, m), 10.21 (1H, s)
APCI-MASS (m/z) : 264 (M+H+)
(5) (6-Phenylthiopyridin-3-yl) methanol
IR (Film) : 3320, 2865, 1590, 1560 cm-1
NMR (CDCl3, δ) : 2.46 and 2.71 (total 1H, t,
J=5.6Hz), 4.64 and 4.72 (total 2H, d, J=5.6Hz), 6.88 and 7.31 (total 1H, d, J=8.3Hz), 7.4-7.75 (6H, m), 8.3-8.4 (1H, m)
APCI-MASS (m/z) : 218 (M+H+)
(6) 4-(Oxazol-5-yl)benzyl alcohol
IR (KBr) : 3330 (br), 1510, 1491, 1041, 818 cm-1 NMR (CDCI3, δ) : 4.74 (2H, s), 7.34 (1H, s),
7.35-7.50 (2H, m), 7.59-7.72 (2H, m), 7.91 (1H, s)
APCI-MASS (m/z) : 176 (M+H+)
(7) (3-Phenylpyrazol-5-yl) methanol
IR (KBr) : 2500-3500 (br), 1471, 1360, 1030, 1001,
766 cm-1
NMR (DMSO-d6, δ) : 4.38-4.58 (2H, m), 4.95-5.37
(1H, m), 6.52-6.66 (1H, m), 7.20-7.53 (3H, m), 7.68-7.90 (2H, m), 12.68-13.10 (1H, m)
APCI-MASS (m/z) : 175 (M+H+)
(8) 4- (Pyrazol-3-yl) benzyl alcohol
IR (KBr) : 2500-3600 (br), 1522, 1456, 1419, 1032,
841, 762 cm-1
NMR (DMSO-d6, δ) : 4.51 (2H, d, J=5.7Hz), 5.07-5.27 (1H, m), 6.60-6.74 (1H, br s), 7.20-7.85 (5H, m), 12.82, 13.24 (total 1H, each br s)
APCI-MASS (m/z) : 175 (M+H+)
(9) 4-(1-Methylpyrazol-5-yl) benzyl alcohol
IR (KBr) : 2500-3600 (br), 1495, 1460, 1425, 1385,
1273 cm-1
NMR (CDCl3, δ) : 2.12 (1H, t, J=5.7Hz), 3.88 (3H, s), 4.77 (2H, d, J=5.7Hz), 6.30 (1H, d, J=1.9Hz), 7.35-7.52 (4H, m), 7.51 (1H, d, J=1.9Hz) APCI-MASS (m/z) : 189 (M+H+)
(10) 3-(1H-Tetrazol-5-yl)benzoyl alcohol
IR (KBr) : 2100-3600 (br), 1562, 1485, 1419,
1219 cm-1
NMR (DMSO-d6, δ) : 4.61 (2H, s), 5.20-5.60 (1H,
br), 7.48-7.65 (2H, m), 7.85-7.98 (1H, m), 8.05 (1H, s)
APCI-MASS (m/z) : 177 (M÷H+) Preparation 20
To a solution of 3-[(E)-3-dimethylaminopropenoyl]- benzonitrile (48.5 g) in methanol (500 ml) was added acetic acid (21.82 g) followed by slow addition of hydrazine monohvdrate (18.17 g) at room temperature and the mixture was stirred at 17.5 hours at the same temperature. The mixture was evaporated to dryness and the residue was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized and the crystal was collected by filtration, washed with
diisopropyl ether and dried to give 3-(pyrazcl-3- yl) benzonitrile (37.71 g).
IR (KBr) : 3190, 3075, 2840, 2760, 2230, 1560 cm-1 NMR (DMSO-d6, δ) : 6.88 (1H, d, J=2.1Hz), 7.62 (1H, dd, 3=1 . 7 , 7.7Hz), 7.75 (1H, d, J=7.7Hz), 7.83 (1H, br s), 8.16 (1H, d, J=7.7Hz), 8.24 (1H, s), 13.08 (1H, br)
Preparation 21
To a suspension of sodium hydride (2.0 g) in N,N- dimethylformamide (100 ml) was added thiophenol (5.51 g), and the mixture was stirred at room temperature for 15 minutes. To the mixture was added 4-fluorobenzonitrile (6.66 g), and the mixture was stirred at 130°C for 16 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give
4-(phenylthio) benzonitrile (12.24 g) as an oil.
IR (Film) : 3070, 2235, 1595, 1505 cm-1
NMR (CDCl3, δ) : 7.15-7.3 (2H, m), 7.65-7.8 (2H,
m), 7.4-7.6 (5H, m)
APCI-MASS (m/z) 212 (M+H+)
Preparation 22
To a suspension of 4-(phenylsulfamoyl) benzole acid (13.43 g) in 1,2-dichloroethane (130 ml) were added thionyl chloride (11.52 g) and N, N-dimethylformamide (2 drops) and the mixture was stirred at 100°C for 2 hours, under
nitrogen. The resulting solution was evaporated in vacuo and the residue was dissolved in dichloromethane (150 ml). To this solution was added N,O-dimethylhydroxylamine-hydro- chloride (5.19 g), followed by dropwise addition of
triethylamine (9.80 g) at 5°C. The mixture was stirred at room temperature for 4 hours. Water was added thereto and the separated organic layer was washed with brine, dried over magnesium sulfate and evaported in vacuo. The residue was purified by column chromatography on silica gel to give N-methyl-N-methoxy-4-(phenylsulfamoyl) benzamide (11.31 g) as an oil.
IR (KBr) : 3150, 2950, 2905, 2890, 1625, 1600,
1570, 1495 cm-1
NMR (DMSO-d6, δ) : 3.24 (3H, s), 3.48 (3H, s), 7.0- 7.2 (3H, m), 7.2-7.3 (2H, m), 7.7-7.9 (4H, m),
10.38 (1H, s)
Preparation 23
To the solution of 4-fluorobenzonitrile (10 g) and pyrazole (6.74 g) in N, N-dimethylformamide (100 ml) was added potassium carbonate (13.7 g). Then the mixture was heated for 4 hours at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (1 ℓ), washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel (400 g, eluting with n-hexane - ethyl acetate (3:1)) to give 4- (pyrazol-1-yl) benzonitrile (10.54 g).
IR (KBr) : 2226, 1608, 1529, 1394 cm-1
NMR (CDCl3, δ) : 6.54 (1H, dd, J=2.5, 1.8Hz), 7.70- 7.90 (5H, m), 8.00 (1H, d, J=2.5Hz)
APCI-MASS (m/z) : 170 (M+H+)
Preparation 24
To the solution of 4-fluorobenzonitrile (10 g) and imidazole (6.74 g) in N, N-dimethylformamide (200 ml) was added potassium carbonate (13.7 g). Then the mixture was heated for 2 hours at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (2 ℓ), washed with water, brine, dried over magnesium sulfate and evaporated in vacuo to give 4-(imidazol-1-yl) benzonitrile (10.34 g).
IR (KBr) : 2225, 1608, 1520 cm-1
NMR (CDCl3, δ) : 7.27 (1H, s), 7.34 (1H, t,
J=1.2Hz), 7.46-7.60 (2H, m), 7.75-7.89 (2H, m), 7.95 (1H, s)
APCI-MASS (m/z) : 170 (M+H+) Preparation 25
To a solution of methyl 4-(1-methylpyrazol-3- yl) benzoate (2.5 g) in dichloromethane (80 ml) was added dropwise diisobutylaluminum hydride (1.02M toluene
solution, 25.0 ml) at -60 - -50°C. After stirring for 30 minutes at the same temperature, sodium fluoride (4.28 g) and water (1.38 ml) was added thereto. The mixture was warmed to room temperature over 15 minutes and stirred for one hour. Insoluble materials were removed by filtration. The filtrate was evaporated in vacuo to give 4-(l- methylpyrazol-3-yl) benzyl alcohol (1.74 g).
IR (KBr) : 2500-3650 (br), 1508, 1462, 1431, 1360,
1302 cm-1
NMR (CDCl3, δ) : 1.90 (1H, t, J=5.7Hz), 3.95 (3H, s), 4.70 (2H, d, J=5.7Hz), 6.54 (1H, d, J=2.2Hz),
7.33-7.43 (3H, m), 7.74-7.84 (2H, m)
APCI-MASS (m/z) : 189 (M+H+)
Preparation 26
To a solution of 4-bromo-1-methylpyrazole (1 g) in ether (15 ml) was added dropwise n-butyliithium (1.63M in hexane, 4.2 ml) keeping the temperature below -60°C. After stirring for 30 minutes, a solution of tri-n-butyltin chloride (1.85 ml) in ether (1.85 ml) was added thereto. After stirring for one hour, the mixture was warmed to room temperature over 30 minutes and stirred for one hour. The reaction mixture was diluted with ether, washed with water and brine, dried over magnesium sulfate. and evaporated under reduced pressure to give 1-methyl-4-tri-(n- butyl) stannylpyrazole (2.3 g).
IR (Neat) : 2930, 1504, 1460, 1120 cm-1
NMR (CDCl3, δ) : 0.75-1.70 (27H, m), 3.93 (3H, s),
7.23 (1H, s), 7.42 (1H, s) Preparation 27
To a suspension of 5-bromc-2-furancarboxylιc acid (10 g), N,O-dimethylhydroxylamme-hydrochloride (5.1 g) and 1- hydroxybenzotriazole (7.07 g) m dichloromethane (300 ml) was added dropwise a solution of 1-(3-dιmethylammopropyl)- 3-ethylcarbodιιmιde (6.37 g) m dichloromethane (60 ml) at room temperature. The resulting mixture was stirred at room temperature for 18 hours. Water (180 ml) was added thereto and the insoluble materials were removed by
filtration. The organic layer was separated and washed with brme, dried over magnesium sulfate, evaporated m vacuo. The residue was chromatographed on silica gel (350 g, elutmg with ethyl acetate - n-hexane (1:1)) to give 5- bromo-2-(N-methyl-N-methoxycarbamoyl) furan (7.60 g).
IR (Neat) : 2974, 2937, 1649, 1566, 1477 cm-1
NMR (CDCl3, δ) : 3.34 (3H, s), 3.77 (3H, s), 6.45
(1H, d, J=3.5Hz), 7.09 (1H, d, J=3.5Hz) APCI-MASS (m/z) : 234, 236 (M+H+) Preparation 28
To a mixture of 3-methylbιphenyl (5.0 g. and
N-bromosuccmimide (5.29 gi m tetrachlorometnane (150 ml) was added benzoyl peroxide (144 mg) and the mixture was refluxed for 6 hours. The mixture was cooled, and the insoluble materials were filtered off. The filtrate was evaporated m vacuo and the residue was purified by column chromatography on silica gel to give crude 3-bromomethyl bipnenyl (6.59 g) as a yellow oil.
IR (Film) : 3030, 1600, 1575 cm-1
NMR (CDCI3, δ) : 4.56 (2H, s), 7.35-7.7 (9H, m)
Preparation 29
The following compounds were obtained according to a similar manner to that of Preparation 28. (1) 4-Bromomethylbenzophenone
IR (KBr) : 3050, 1650, 1605 cm-1
NMR (CDCl3, δ) : 4.54 (2H, s), 7.4-7.85 (9H, m) (2) 4-(Pyridin-3-yl) benzyl bromide
NMR (DMSO-d6, δ) : 6.10 (2H, s), 7.4-8.4 (6H, m),
8.9-9.3 (2H, m)
(3) 4-(Pyridin-2-yl) benzyl bromide
IR (Film) : 3050, 3010, 2985, 1735, 1585, 1565 cm-1 NMR (CDCI3, δ) : 4.58 (2H, s), 7.2-8.1 (7H, m),
8.7-8.8 (1H, m)
Preparation 30
To a solution of 4-ethoxycarbonyl-2-(4- chlorophenyl) thiazole (2.68 g) in a mixture of
tetrahydrofuran (40 ml) and ethanol (10 ml) was added lithium borohydride (218 mg) at room temperature and the mixture was stired at 50°C for 1.5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue crystalline solid was collected by filtration to give [2-(4-chlorophenyl) thiazol-4-yl] methanoI (1.43 g).
IR (KBr) : 3270, 3080, 2920, 2865, 1595, 1525,
1505 cm-1
NMR (DMSO-d6, δ) : 4.63 (2H, d, J=5.8Hz), 5.40 (1H, t, J=5.8Hz), 7.51 (1H, s), 7.5-7.6 (2H, m), 7.9- 8.0 (2H, m)
APCI-MASS (m/z) : 226 (M+H+)
Preparation 31
To a solution of methyl 6-chloronicotinate (6.86 g) and dihvdroxyphenyl borane (5.85 g) in 1,2-dimethoxyethane (150 ml) was added 2M sodium carbonate aσueous solution (48 ml), followed by tetrakis (triphenylphosphine) palladium (0) (2.31 g) and the mixture was refluxed for 16 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give methyl 6- phenylnicotinate (7.75 g) as a white crystal.
IR (KBr) : 3070, 3030, 2995, 2945, 2845, 1725,
1595, 1560 cm-1
NMR (CDCl3, δ) : 3.98 (3H, s), 7.4-7.6 (3H, m),
7.82 (1H, dd, J=8.3, 0.9Hz), 8.0-8.1 (2H, m), 8.35 (1H, dd, J=8.3, 2.2Hz), 9.28 (1H, dd, J=2.2, 0.9Hz)
Preparation 32
The following compound was obtained according to a similar manner to that of Preparation 31.
N-Methyl-N-methoxy-4-[4-(dimethylamino)phenyl]- benzamide
IR (KBr) : 3255, 3000, 2815, 1605, 1540, 1505 cm-1 NMR (CDCI3, δ) : 3.01 (6H, s), 3.38 (3H, s), 3.60
(3H, s), 6.80 (2H, d, J=8.9Hz), 7.5-7.65 (4H, m),
7.74 (2H, dd, J=6.5, 1.9Hz)
APCI-MASS (m/z) : 285 (M+H+)
Preparation 33
To a suspension of 4- (pyrrol-1-yl) benzoic acid (3.74 g) and N,O-dimethylhydroxylamine-hydrochloride (1.95 g ) in dichloromethane (100 ml) was added dropwise a solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (2.43 g) in dichloromethane (15 ml) at room temperature. The resulting solution was stirred at the same temperature for 18 hours. Water (60 ml) was addeα to tne mixture, and the insoluble materials were removed by filtration. The filtrate was separated, and the organic layer was washed with brine, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give 4-(pyrrol-1-yl)-N-methyl-N-metnoxybenzamide (2.12 g) as a white crystal.
IR (KBr) : 3130, 3045, 2975, 2935, 1640, 1610,
1580, 1525 cm-1
NMP (CDCl3, δ) : 3.39 (3H, s), 3.58 (3H, s),
6.4-6.45 (2H, m), 7.15-7.2 (2H, m), 7.4-7.5 (2H, m), 7.8-7.9 (2H, m)
APCI-MASS (m/z) : 231 (M+H+) Preparation 34
To a suspension of 3-(pyrrol-1-yl) benzoic acid (5.62 g), N,O-dimethylhydroxylamine-hydrochloride (2.93 g) and 1- hydroxybenzotriazole (4.05 g) m dichloromethane (150 ml) was added dropwise a solution of 1-(3-dιmethylamιnopropyl)- 3-etnylcaroodιιmιde (3.65 g) m αichloromethane (30 ml) at room temperature. The resulting solution was stirred at room temperature for 20 hours. Water (100 ml) was added thereto and tne insoluble materials were removed by
filtration. The filtrate was separated and the organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The resiαue was purified oy column chromatography on silica gel to give 3-(pyrrol-1- yl)-N-methyl-N-methoxybenzamide (5.19 g) as a yellow oil.
IR (Film) : 3130, 2935, 1645, 1610, 1585, 1500 cm-1 NMR (CDCI3, δ) : 3.39 (3H, s), 3.57 (3H, s),
6.35-6.4 (2H, m), 7.1-7.15 (2H, m), 7.45-7.6 (3H, m), 8.7-8.75 (1H, m)
APCI-MASS (m/z) : 231 (M+H+) Preparation 35
The following compound was obtained according to a similar manner to that of Preparation 34. [4-(N-Methyl-N-methoxy)carbamoylphenyl]- dihydroxyborane
IR (KBr) : 3380, 1610, 1545, 1510 cm-1
NMR (DMSO-d6, δ) : 3.25 (3H, s), 3.53 (3H, s),
7.5-7.8 (4H, ml
APCI-MASS (m/z) : 210 (M+H+)
Preparation 36
To a suspension of lithium aluminum hydride (348 mg) in tetrahydrofuran (30 ml) was added dropwise a solution of 4-(pyrrol-1-yl)-N-methyl-N-methoxybenzamide (2.11 g) in tetrahydrofuran (40 ml) at 5°C and the mixture was stirred at 5°C for 1.5 hours. To the mixture were added sodium fluoride (1.54 g) and water (495 mg), and the mixture was stirred at room temperature for 30 minutes. The insoluble materials were filtered off and washed with
tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4-(pyrrol-1-yl) benzaldehyde (1.65 g).
IR (KBr) : 3130, 2800, 2745, 1690, 1605, 1520 cm-1 NMR (CDCl3, δ) : 6.35-6.45 (2H, m), 7.15-7.25 (2H, m), 7.5-7.6 (2H, m), 7.9-8.0 (2H, m), 9.99 (1H, s)
APCI-MASS (m/z) : 172 (M+H+) Preparation 37
The following compounds were obtained according to a similar manner to that of Preparation 36.
(I) 3-(Pyrrol-1-yl)benzaldehyde
IR (Film) : 3220, 1700, 1650, 1590, 1540, 1500 cm-1 NMR (CDCI3, δ) : 6.4-6.45 (2H, m), 7.15-7.20 (2H, m), 7.55-7.8 (3H, m), 8.9-8.95 (1H, m), 10.06 (1H, s)
APCI-MASS (m/z) : 172 (M+H+)
(2) 4-(4-Dimethylaminophenyl)benzaldehyde
IR (KBr) : 2895, 2810, 2725, 1695, 1680, 1595,
1540 cm-1
NMR (CDCl3, δ) : 3.03 (6H, s), 6.8-6.9 (2H, m),
7.55-7.65 (2H, m), 7.65-7.75 (2H, m), 7.85-7.95
(2H, m), 10.01 (1H, s)
APCI-MASS (m/z) : 226 (M+H+)
(3) 4-(Phenylsulfamoyl) benzaldehyde
IR (KBr) : 3260, 3055, 2860, 1695, 1595 cm-1
NMR (DMSO-d6, δ) : 7.0-7.15 (3H, m), 7.2-7.3 (2H, m), 7.93 (2H, d, J=8.1Hz), 8.05 (2H, d, J=8.1Hz), 10.04 (1H, s), 10.48 (1H, br s)
APCI-MASS (m/z) : 262 (M+H+) (4) 2-Bromo-5-furaldehyde
IR (KBr) : 1670, 1464, 1377, 1271 cm-1
NMR (CDCl3, δ) : 6.57 (1H, d, J=3.6Hz), 7.19 (1H,
d, J=3.6Hz), 9.54 (1H, s)
Preparation 38
To a suspension of 4-bromobenzaldehyde (1.85 g) and [4-flurophenyl]dihydroxyborane (1.40 g) in toluene (50 ml) was added powdered potassium carbonate (2.07 g), followed by addition of tetrakis (triphenylphosphine) palladium (0) (578 mg) and the mixture was refluxed for 24 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (4- fluorophenyl) benzaldehyde (1.67 g) as a white crystal.
IR (KBr) : 3055, 2855, 2755, 1705, 1600, 1565,
1520 cm-1
NMR (CDCl3, δ) : 7.1-7.25 (2H, m), 7.55-7.7 (2H,
m), 7.71 (2H, d, J=8.2Hz), 7.95 (2H, d, J=8.2Hz), 10.06 (1H, s)
APCI-MASS (m/z) : 201 (M+H+) Preparation 39
To a solution of 2-bromo-5-thiophenecarbaldehyde (2 g) and dihydroxyphenylborane (1.66 g) was added 2M sodium carbonate solution (13.6 ml) and
tetrakis (triphenylphosphine) palladium (0) (605 mg) . The mixture was heated for 5 hours at 80°C. The reaction mixture was poured into water, extracted with
dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (100 g, eluting with n-hexane - ethyl acetate (5:1)) to give 2- phenyl-5-thiophenecarbaldehyde (1.80 g).
IR (KBr) : 1647, 1441, 1232, 754 cm-1
NMR (CDCl3, δ) : 7.33-7.50 (4H, m), 7.60-7.80 (3H, m), 9.90 (1H, s)
APCI-MASS (m/z) : 189 (M+H+)
Preparation 40
The following compounds were obtained according to a similar manner to that of Preparation 39.
(1) 2-Phenyl-5-furaldehyde
IR (Neat) : 1674, 1522, 1475, 1257 cm-1
NMR (CDCI3, δ) : 6.85 (1H, d, J=3.7Hz), 7.33 (1H,
d, J=3.7Hz), 7.37-7.53 (3H, m), 7.80-7.92 (2H, m), 9.66 (1H, s) APCI-MASS (m/z) : 173 (M+H+)
(2) 4-Phenyl-2-thiophenecarbaIdehyde
IR (KBr) : 1676, 1539, 1429, 1173, 760 cm-1
NMR (CDCl3, δ) : 7.30-7.66 (5H, m), 7.82-7.90 (1H, m), 8.00-8.08 (1H, m), 9.93 (1H, d, J=1.2Hz) FAB-MASS (m/z) : 189 (M+H+)
(3) 4-(4-Methylphenyl) benzaldehyde
IR (KBr) : 3095, 3060, 2860, 2765, 1690, 1600,
1575, 1505 cm-1
NMR (CDCl3, δ) : 2.42 (3H, s), 7.29 (2H, d,
J=10.4Hz), 7.55 (2H, dd, J=6.3, 1.8Hz), 7.74 (2H, dd, J=6.6, 1.8Hz), 7.94 (2H, dd, J=6.6, 1.8Hz), 10.05 (1H, s)
APCI-MASS (m/z) : 197 (M+H+)
4-(4-Chlorophenyl) benzaldehyde
IR (KBr) : 3055, 2820, 2720, 1695, 1605 cm-1
NMR (CDCl3, δ) : 7.4-7.5 (2H, m), 7.55-7.65 (2H,
m), 7.7-7.8 (2H, m), 7.9-8.0 (2H, m), 10.06 (1H, s)
APCI-MASS (m/z) : 217 (M+H+) (5) 4-(4-Bromophenyl) benzaldehyde
IR (KBr) : 3050, 2820, 2725, 1705, 1605, 1575,
1555 cm-1
NMR (CDCI3, δ) : 7.45-7.55 (2K, m), 7.55-7.65 (2H, m), 7.65-7.75 (2H, m), 7.95-8.05 (2H, m), 10.06 (1H, s)
APCI-MASS (m/z) : 263, 261 (M+H+)
Preparation 41
To a solution of 4-carboxybenzaldehyde (3.00 g) and triethvlamine (2.23 g) in dichloromethane (50 ml) was added dropwise isobutyl chloroformate (3.01 g) at 5°C and the mixture was stirred at 5°C for 40 minutes. To this
solution was added aniline (2.05 g) and the mixture was stirred at room temperature for 16 hours. Water was added to the mixture, and the separated organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. To the residue was added hexane: ethyl acetate (1:1) and the powder was collected by filtration to give 4- (phenylcarbamoyl) benzaldehyde (2.24 g). The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give the second crop (1.12 g).
IR (KBr) : 3340, 3055, 2820, 2725, 1705, 1650,
1575, 1535 cm-1
NMR (DMSO-d6, δ) : 7.13 (1H, t, J=7.3Hz), 7.3-7.45
(2H, m), 7.79 (2H, d, J=7.5Hz), 8.0-8.2 (4H, m), 10.12 (1H, s), 10.46 (1H, s)
APCI-MASS (m/z) : 226 (M+H+) Preparation 42
To a solution of ethyl 4-ammooenzoate (3.30 g) m pyridme (10 ml) was added αropwise benzoyl chloride
(3.09 g) at 5°C, and the mixture was stirred at room temperature for 1.6 hours. The mixture was poured into a mixture of ethyl acetate, ice water and 6N hydrocnloric acid (40 ml), and the separated organic layer was washed witn water and brme, dried over magnesium sulfate and evaporated in vacuo. The resicue was crystallized from hexane and ethyl acetate (5:1), and the crystal was
collected by filtration to give ethyl 4- (benzoylammo) - benzoate (5.14 g).
IR (KBr) : 3300, 3050, 2980, 1720, 1650, 1530 cm-1 NMR (DMSO-d6, δ) : 1.34 (3H, t, J=7.1Hz), 4.34 (2H, q, J=7.1Hz), 7.5-7.7 (5H, m), 7.95-8.2 (3H, m), 8.45-8.5 (1H, m), 10.48 (1H, s) APCI-MASS (m/z) : 270 (M+H+)
Preparation 43
The following compound was obtained according to a similar manner to that of Preparation 41.
4-(2-Pyridylcarbamoyl) benzaldehyde
IR (KBr) : 3230, 3180, 3115, 3035, 2810, 2725,
1710, 1675, 1585, 1540 cm-1
NMR (DMSO-d6, δ) : 7.20 (1H, dd, J=6.8, 1.5Hz),
7.8-7.9 (1H, m), 8.03 (2H, d, J=8.4Hz), 8.20 (2H, d, J=8.4Hz), 8.15-8.25 (1H, m), 8.4-8.45 (1H, m), 10.12 (1H, s), 11.06 (1H, s)
APCI-MASS (m/z) : 227 (M+H+)
Preparation 44
To a solution of [2-(4-chlorophenyl) thiazol-4- yl]methanol (1.42 g) in chloroform (80 ml) was added activated manganese dioxide (5.48 g) and the mixture was refluxed for 1.8 hours. The mixture was filtered and the filtrate was evaporated in vacuo to give 4-formyl-2-(4- chlorophenyl) thiazole (1.28 g).
IR (KBr) : 3110, 2840, 1695, 1595, 1575, 1500 cm-1
NMR (DMSO-d6, δ) : 7.55-7.65 (2H, m), 8.0-8.1 (2H, m), 8.80 (1H, s), 9.99 (1H, s)
APCI-MASS (m/z) : 224 (M+H+)
Preparation 45
To a solution of (3-phenylpyrazol-5-yl) methanol (1.30 g) in acetone (130 ml) was added activated manganese dioxide (6.5 g) and the mixture was refluxed 1.5 hours.
The mixture was filtered and the filtrate was evaporated in vacuo to give 3-phenyl-5-formylpyrazole (1.16 g).
IR (KBr) : 2400-3500 (br), 1676, 1473, 1282,
1192 cm-1 NMR (DMSO-d6,δ ) : 7.20 7.56 (4H, m) 7.75-7.95
(2H, m), 9.93 (1H, s), 14.05-14.30 (1H, br)
APCI-MASS (m/z) 173 (M+H+ ) Preparation 46
The following compounds were obtained according to similar manners to those of Preparations 44 and 45.
(1) 3-(Pyrazol-3-yl) benzaldehyde
IR (Film) : 3325, 2975, 2920, 2840, 2745, 1700,
1610, 1585 cm-1
NMR (DMSO-d6, δ) : 6.84 (1H, d, J=2.0Hz), 7.6-8.25
(4H, m), 8.36 (1H, s), 10.07 (1H, s), 13.05 (1H, br s)
APCI-MASS (m/z) : 173 (M+H+)
(2) 6-Phenyl-3-formylpyridine
IR (KBr) : 3060, 2835, 2785, 2740, 1695, 1590,
1560 cm-1
NMR (CDCl3, δ) : 7.25-7.4 (4H, m), 7.92 (1H, d,
J=8.3Hz), 8.05-8.15 (2H, m), 8.24 (1H, dd, J=8.3, 2.2Hz), 9.14 (1H, dd, J=2.2, 0.7Hz), 10.14 (1H, s)
APCI-MASS (m/z) : 184 (M+H+)
(3) 2-Formyl-4-(pyrrol-1-yl) pyridine
IR (KBr) : 3110, 2845, 1705, 1595 cm-1
NMR (DMSO-d6, δ) : 6.35-6.4 (2H, m), 7.75-7.8 (2H, m), 7.98 (1H, dd, J=5.2, 2.5Hz), 3.12 (1H, d, J=2.2Hz), 8.80 (1H, d, J=5.5Hz), 10.0 (1H, s)
APCI-MASS (m/z) : 173 (M+H+)
(4) 6-Phenylthio-3-formylpyridine
IR (Film) : 3055, 2840, 2780, 1700, 1585, 1550 cm-1 NMR (CDCl3, δ) : 6.94 and 7.49 (total 1H, d, J=8.4Hz), 7.45-7.65 (6H, m), 7.89 and 8.14 (total 1H, dd, J=8.4, 2.2Hz), 8.82 and 8.87 (total 1H, d, J=2.2Hz), 9.98 and 10.10 (total 1H, s) APCI-MASS (m/z) : 216 (M+H+)
(5) 4-(Benzoylamino) benzaldehyde
IR (KBr) : 3305, 3055, 2840, 2735, 1715, 1660,
1645, 1540 cm-1
NMR (DMSO-d6, δ) : 7.5-7.7 (5H, m), 7.95-8.15 (3H, m), 8.40 (1H, s), 10.02 (1H, s), 10.54 (1H, s)
APCI-MASS (m/z) : 226 (M+H+)
(6) 4-(Phenylsulfonylamino) benzaldehyde
IR (KBr) : 3240, 3060, 2935, 2850, 2765, 1690,
1680, 1580, 1510 cm-1
NMR (DMSO-d6, δ) : 7.29 (2H, d, J=8.6Hz), 7.55-7.7 (3H, m), 7.75-7.9 (4H, m), 9.81 (1H, s), 11.01 (1H, s)
APCI-MASS (m/z) : 262 (M+H+)
(7) 4-(3-Thienyl) benzaldehyde
IR (KBr) : 1689, 1601, 1211, 1167 cm-1
NMR (CDCl3, δ) : 7.41-7.47 (2H, m), 7.62 (1H, t,
J=2.1Hz), 7.70-7.83 (2H, m), 7.85-7.98 (2H, m), 10.02 (1H, s)
APCI-MASS (m/z) : 189 (M+H+)
(8) 4-(2-Thienyl) benzaldehyde
IR (KBr) : 1699, 1601, 1213, 1170 cm-1
NMR (CDCl3, δ) : 7.14 (1H, dd, J=5.1, 3.7Hz), 7.40
(1H, dd, J=5.1, 1.1Hz), 7.47 (1H, dd, J=3.7,
1.1Hz), 7.70-7.82 (2H, m), 7.82-7.96 (2H, m), 10.00 (1H, s)
APCI-MASS : 189 (M+H+) (9) 4-(Pyrazol-3-yl) benzaldehyde
IR (Neat) : 2400-3700 (br), 1697, 1606, 1211, 1171,
837 cm-1
NMR (DMSO-d6, δ) : 6.90 (1H, d, J=2.3Hz), 7.83 (1H, br s), 7.85-8.12 (4H, m), 10.00 (1H, s), 13.13
(1H, br)
APCI-MASS (m/z) : 173 (M+H+)
(10) 4-(1-Methylpyrazol-3-yl) benzaldehyde
IR (KBr) : 1695, 1603, 1566, 1431, 1306 cm-1
NMR (CDCl3, δ) : 3.99 (3H, s), 6.64 (1H, d,
J=2.3Hz), 7.43 (1H, d, J=2.3Hz), 7.86-8.03 (4H, m), 10.01 (1H, s)
APCI-MASS (m/z) : 187 (M+H+)
(11) 4-(1-Methylpyrazol-5-yl) benzaldehyde
IR (KBr) : 1695, 1608, 1568, 1390, 1215, 1184 cm-1 NMR (CDCI3, δ) : 3.95 (3H, s), 6.41 (1H, d,
J=1.9Hz), 7.56 (1H, d, J=1.9Hz), 7.57-7.68 (2H, m), 7.93-8.04 (2H, m), 10.08 (1H, s)
APCI-MASS (m/z) : 187 (M+H+)
(12) 3-(1H-Tetrazol-5-yl)benzaldehyde
IR (KBr) : 2400-3500 (br), 1674, 1612, 1560, 1373,
1207 cm-1
NMR (DMSO-d6, δ) : 7.86 (1H, dd, J=7.7, 7.7Hz),
8.08-8.20 (1H, m), 8.30-8.42 (1H, m), 8.57 (1H, dd, J=1.5, 1.5Hz), 10.13 (1H, s)
APCI-MASS (m/z) : 175 (M+H+)
Preparation 47
To a suspension of 3- (pyrazol-3-yl)benzonitrile (37.70 g) in formic acid (300 ml) was added a suspension of Raney Nickel (Trademark : NDT-90) in water (130 ml) and the mixture was refluxed for 3.5 hours. The mixture was cooled to room temperature and Raney Nickel was removed by filtration and washed with formic acid (150 ml). The filtrate was evaporated to dryness and dichloromethane and ice water were added to the residue. The mixture was adjusted to pH ca. 8.5 by addition of 5N sodium hydroxide aqueous solution. The insoluble materials were removed by celite pad and the filtrate was separated. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3- (pyrazol-3- yl) benzaldehyde (37.17 g).
IR (KBr) : 3190, 2975, 2840, 1690, 1605, 1585 cm-1 NMR (DMSO-d6, δ) : 6.84 (1H, d, J=2.2Hz), 7.65 (1H, dd, J=7.6, 7.6Hz), 7.75-7.85 (2H, m), 7.84 (1H, d, J=7.6Hz), 8.35 (1H, s), 10.07 (1H, s), 13.06
(1H, br s)
Preparation 48
To a solution of 4-fluorobenzaldehyde (2.48 g) and 4- bromophenol (3.46 g) in N,N-dimethylacetamide (20 ml) was added powdered potassium carbonate (2.76 g), and the mixture was refluxed for 17 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(4-bromophenoxy) benzaldehyde (1.51 a) .
IR (KBr) : 3030, 2920, 2840, 2735, 1705, 1600,
1560 cm-1
NMR (CDCl3, δ) : 6.95-7.1 (4H, m), 7.45-7.55 (2H, m), 7.8-7.9 (2H, m), 9.94 (1H, s ) APCI-MASS (m/z) : 279, 277 (M+H+)
Preparation 49
To a solution of 4-bromobenzaldehyde (4.96 g) and 4-fluorophenol (4.48 g) in N,N-dimethylacetamide (25 ml) was added powdered potassium carbonate (5.53 g), and the mixture was refluxed for 6 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(4- fluorophenoxy) benzaldehyde (1.92 g) as an orange oil.
IR (Film) : 3360, 3075, 2835, 2740, 1695, 1600,
1585, 1495 cm-1
NMR (CDCl3, δ) : 6.7-6.3 (1H, m), 6.85-6.95 (1H,
m), 7.0-7.2 (4H, m), 7.8-7.9 (2H, m), 9.92 (1H, s)
APCI-MASS (m/z) : 217 (M+H+)
Preparation 50
To a solution of 4-phenylthiobenzonitrile (12.23 g) in toluene (200 ml) was added dropwise diisobutylaluminum hydride (1.02M toluene solution) (114 ml) at -70°C over 50 minutes and the mixture was stirred at -70°C for 30
minutes. To the mixture were added sodium fluoride (19.45 g) and water (6.26 g), and the mixture was warmed to room temperature. The insoluble materials were removed by filtration and washed with toluene. The filtrate was evaporated in vacuo and the residue was dissolved in tetrahydrofuran (50 ml). To this solution was added 6N hydrochloric acid (19.3 ml) and the mixture was stirred at room temperature for 1 hour. The mixture was extracted with ethyl acetate, and the organic layer was washed with water and brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (phenylthio) benzaldehyde (9.83 g) as a yellow oil.
IR (Film) : 3055, 2830, 2745, 1695, 1595, 1560, 1505 cm- 1
NMR (CDCl3, δ ) : 7 . 15- 7 . 3 ( 4H, m) , 7 . 35-7 . 6 ( 3H,
m), 7 . 65-7 . 75 ( 2H, m) , 9 . 91 ( 1H, s )
APCI-MASS (m/ z ) : 215 (M+H+ )
Preparation 51
To a solution of 4-(pyrazol-1-yl)benzonitrile (5.0 g) in dichloromethane (150 ml) was added dropwise
diisobutylaluminum hydride (1.02M toluene solution, 58 ml) keeping the temperature below -60°C. After stirring for one hour, sodium fluoride (9.95 g) and water (3.2 ml) were added thereto. The reaction mixture was warmed to room temperature over 30 minutes and stirred for 1.5 hours.
Insoluble material was removed by filtration. The filtrate was concentrated by evaporation in vacuo. The residue was dissolved in tetrahydrofuran (25 ml). To he solution was added IN-hydrochloric acid and stirred for one hour at room temperature. To the mixture was added 5N-sodium hydroxide solution (10 ml). The objective compound was extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (100 g, n-hexane - ethyl acetate (1:1)) to give 4-(pyrazol- 1-yl) benzaldehyde (4.36 g).
IR (KBr) : 1695, 1605, 1390, 1200 cm-1
NMR (CDCl3, δ) : 6.54 (1H, dd, J=2.5, 1.8Hz), 7.79 (1H, d, J=1.5Hz), 7.85-8.10 (5H, m), 10.02 (1H, s)
APCI-MASS (m/z) : 173 (M+H+)
Preparation 52
The following compound was obtained according to a similar manner to that of Preparation 51. 4-(Imidazol-1-yl) benzaldehyde IR (KBr) : 1686, 1606, 1522, 1313 cm-1
NMR (CDCl3, δ) : 7.15-8.10 (7H, m), 10.05 (1H, s)
APCI-MASS (m/z) : 173 (M+H+) Preparation 53
To a solution of methyl 5-phenyl-3- isoxazolecarboxylate (4.73 g) in dichloromethane (150 ml) was added dropwise diisobutylaluminum hydride (1.02M toluene solution 45.7 ml) at -70°C -60°C. After stirring for one hour at the same temperature, sodium fluoride (7.83 g) and water (2.52 ml) were added thereto. The mixture was warmed to room temperature over 30 minutes and stirred for one hour. Insoluble materials were removed by filtration. The filtrate was evaporated in vacuo. The residue was chromatographed on silica gel (85 g, n-hexane - ethyl acetate (3:1)) to give 5-phenyl-3-isoxazolecarbaldehyde (1.94 g).
IR (KBr) : 3126, 1713, 1568, 1456, 1184 cm-1
NMR (CDCl3, δ) : 6.90 (1H, s), 7.35-7.68 (3H, m),
7.75-7.92 (2H, m), 10.20 (1H, s)
Preparation 54
To the solution of 4-bromobenzaldehyde (462 mg) and 1- methyl-4-tri-n-butylstannylpyrazole (1.1 g) was added tetrakis (triphenylphosphine) palladium (0) (87 mg). Then the mixture was heated for 3 hours at 140°C. After cooling, the reaction mixture was diluted with toluene (6 ml). An aσueous solution (5 ml) of potassium fluoride (1.74 g) was added to the mixture and stirred for one hour. Insoluble material was removed by filtration. The filtrate was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed on silica gel (40 g, eluting with n-hexane - ethyl acetate (1:2)) to give 4-(1-methylpyrazol-4-yl) benzaldehyde (427.4 mg). IR (KBr) : 1693, 1605, 1169, 831 cm-1
NMR (CDCl3, δ) : 3.98 (3H, s), 7.57-7.67 (2H, m), 7.73 (1H, s), 7.85 (1H, s), 7.80-7.92 (2H, m), 9.98 (1H, s)
APCI-MASS (m/z) : 187 (M+H+)
Preparation 55
To a solution of oxalyl chloride (1.5 ml) in
dichloromethane (30 ml) was added a solution of dimethyl sulfoxide (1.83 ml) in dichloromethane (4 ml) keeping the temperature below -60°C. After 20 minutes, 4-(oxazol-5- yDbenzyl alcohol (2.5 g) in dichloromethane (25 ml) and dimethyl sulfoxide (2 ml) was added dropwise at the same temperature then stirred for one hour. To the mixture was added triethylamine (8 ml) and stirred for 30 minutes. The reaction mixture was warmed to room temperature over 30 minutes. After stirring for one hour, the mixture was diluted with ethyl acetate, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (80 g, elutmg with n-hexane - ethyl acetate (1:1)) to give 4-(cxazol-5- yl) benzaldehyde (2.20 g).
IR (KBr) : 1693, 1610, 1211, 1111, 829 cm-1
NMR (CDCl3, δ) : 7.54 (1H, s), 7.75-8.05 (4H, m),
8.00 (1H, s), 10.03 (1H, s)
APCI-MASS (m/z) : 174 (M+H+)
Preparation 56
To the solution of 3-(1H-tetrazol-5-yl) benzaldehyde (1.0 g) in pyridine (15 ml) was added
triphenylchloromethane (1.76 g) at 0-5°C. The mixture was stirred for 4 hours at room temperature. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with dil.
hydrochloric acid, water, brine, dried over magnesium sulfate, evaporated in vacuo to give 3-(1-trityl-1H- tetrazol-5-yl) benzaldehyde (2.51 g).
IR (KBr) : 1699, 1516, 1491, 1446, 1201 cm-1
NMR (DMSO-d6, δ) : 7.05-7.20 and 7.38-7.53 (15H,
m), 7.80 (1H, dd, 3=7 . 7 , 7.7Hz), 8.05-8.14 (1H, m), 8.30-8.40 (1H, m), 8.50-8.55 (1H, m), 10.12 (1H, s)
Preparation 57
The mixture of 4-formylbiphenyl (3.64 g) and
cycloheptylamine (2.49 g) was heated at 120°C for 6 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (30 ml). To the solution was added carefully sodium borohydride (757 mg), and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated in vacuo and the residue was
extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-(4- biphenylylmethyl) cycloheptylamine (5.24 g) as a yellow oil.
IR (Film) : 3030, 2920, 2850 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.5-2.7 (1H,
m), 3.72 (2H, s), 7.3-7.7 (9H, m)
APCI-MASS (m/z) : 280 (M+H+)
Preparation 58
The suspension of 4-[4-(dimethylamino) phenyl]- benzaldehyde (640 mg) and cycloheptylamine (643 mg) in toluene (3 ml) was stirred at 120°C for 5 hours under nitrogen. The mixture was evaporated to dryness and dissolved in ethanol (20 ml). To this solution was added sodium borohydride (107 mg) and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with brme, dried over
magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give N- cycloheptyl 4-[4-(dimethylammo) phenyl]benzylamine (945 mg) .
IR (KBr) : 3275, 3025, 2920, 2850, 2805, 1610,
1535, 1505 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.65-2.85 (1H,
m), 2.99 (6H, s), 5.79 (2H, s), 6.80 (2H, d, J=8.8Hz), 7.34 (2H, d, J=8.8Hz), 7.45-7.65 (4H, m)
APCI-MASS (m/z) : 323 (M+H+)
Preparation 59
The mixture of 4-phenoxybenzaldehyde (1.98 g) and benzylamine (1.61 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved m ethanol (20 ml). To this solution was added sodium borohydride (378 mg) and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated to dryness and the residue was extracted witn dichloromethane. The organic layer was washed with brme, dried over
magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give N- benzyl-4-phenoxybenzylamme (2.07 g).
IR (Film) : 3035, 2915, 2820, 1680, 1505 cm-1
NMR (CDCl3, δ) : 3.78 (2H, s), 3.82 (2H, s), 6.9-
7.4 (14H, m)
APCI-MASS (m/z) : 290 (M+H+)
Preparation 60
The mixture of 4-phenoxybenzaldehyde (1.98 g) and furfurylamme (1.61 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temparature and dissolved in ethanol (20 ml) To this solution was added sodium borohydride (378 mg) and the mixture was stirred at room temperature for 1 hour. The mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-furfuryl-4-phenoxybenzylamine (2.51 g).
IR (Film) : 3060, 3035, 2920, 2830, 1590, 1505 cm-1 NMR (CDCl3, δ) : 3.76 (2H, s), 3.80 (2H, s),
6.15-6.2 (1H, m), 6.3-6.35 (1H, m), 6.9-7.4 (10H, m)
APCI-MASS (m/z) : 280 (M+H+)
Preparation 61
The following compounds were obtained according to similar manners to those of Preparation 57, 58, 59 and 60.
(1) N-(2-Biphenylylmethyl)-cycloheptylamine
IR (Film) : 3060, 3020, 2935, 2910, 2850, 1460 cm-1 NMR (CDCl3, δ) : 1.2-1.8 (12H, m), 2.4-2.6 (1H, m),
3.71 (2H, s), 7.2-7.5 (9H, m)
APCI-MASS (m/z) : 280 (M+H+)
(2) N-Cycloheptyl-4-phenoxybenzylamine
IR (Film) : 3030, 2920, 2850, 1590, 1505 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.6-2.8 (1H,
m), 3.75 (2H, s), 6.9-7.4 (9H, m) APCI-MASS (m/z) : 296 (M+H+) (3) N-Cyclohexyl-3-phenoxybenzylamine
IR (Film) : 3035, 2925, 2850, 1585 cm-1
NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.6-2.8 (1H, m),
3.75 (2H, s), 6.8-7.4 (9H, m)
APCI-MASS (m/z) : 296 (M+H+) (4) N-Cycloheptyl-[2-(4-chlorophenyl)thiazol-4- yl] methylamine
IR (KBr) : 2930, 2850, 1595 cm-1
NMR (DMSO-d6, δ) : 1.3-2.2 (12H, m), 2.6-2.8 (1H, m), 3.84 (2H, s), 7.49 (1H, s), 7.5-7.6 (2H, m),
7.9-8.0 (2H, m)
APCI-MASS (m/z) : 321 (M+H+)
(5) N-Cycloheptyl-(2-phenylimidazol-5-yl) methylamine
IR (KBr) : 3080, 2925, 2855, 1575 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.6-2.75 (1H, m), 3.62 (2H, br s), 6.82 and 7.06 (total 1H, br s), 7.25-7.45 (3H, m), 7.8-7.95 (2H, m), 12.28 (1H, br)
APCI-MASS (m/z) : 270 (M+H+)
(6) N-Cycloheptyl-4-(pyrrol-1-yl)benzylamine
IR (Film) : 2925, 2850, 1610, 1525 cm-1
NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.6-2.8 (1H, m), 3.79 (2H, s), 6.3-6.4 (2H, m), 7.0-7.1 (2H, m),
7.3-7.45 (4H, m)
APCI-MASS (m/z) : 269 (M+H+)
(7) N-Cycloheptyl-3-(pyrrol-1-yl) benzylamine
IR (Film) : 2925, 2850, 1610, 1595, 1545, 1500 cm-1
NMR (CDCl3, δ) : 1.4-1.95 (12H, m), 2.6-2.8 (1H,
m), 6.30-6.35 (2H, m), 7.10-7.15 (2H, m), 7.15- 7.45 (4H, m)
APCI-MASS (m/z) : 269 (M+H+)
(8) N-Cycloheptyl-[4-(pyrrol-1-yl)pyridin-2-yl]methylamine IR (Film) : 3305, 3135, 3100, 2925, 2855, 1600,
1575 cm-1
NMR (DMSO-d6, δ) : 1.3-2.0 (12H, m), 2.55-2.7 (1H, m), 3.82 (2H, s), 6.35-6.4 (2H, m), 6.5-6.55 (2H, m), 6.55-6.6 (1H, m), 6.65-6.7 (1H, d, J=2.2Hz), 8.47 (1H, d, J=5.6Hz)
APCI-MASS (m/z) : 282 (M+H+) (9) N-Cycloheptyl (6-phenylpyridin-3-yl) methylamine
IR (Film) : 3030, 2910, 2850, 1560 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12K, m), 2.6-2.8 (1H, m), 3.83 (2H, s), 7.3-7.5 (2H, m), 7.65-7.8 (2H, m), 7.95-8.05 (2H, m), 8.61 (1H, s)
APCI-MASS (m/z) : 281 (M+H+)
(10) N-Cycloheptyl-3-(pyrazol-3-yl) benzylamine
IR (Film) : 3210, 2915, 2850, 1610, 1540 cm-1
NMR (DMS0-d6 δ) : 1.3-1.9 (12H, m), 2.5-2.7 (1H,
m), 3.72 (2H, s), 6.68 (1H, d, J=2.1Hz), 7.15-7.8
(5H, m)
APCI-MASS (m/z) : 270 (M+H+)
(11) N-Cycloheptyl-4-(4-fluorophenyl) benzylamine
IR (Film) : 2925, 2855, 1500 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.65-2.85 (1H,
m), 3.81 (2H, s), 7.05-7.2 (2H, m), 7.35-7.6 (6H, m)
APCI-MASS (m/z) : 298 (M+H+)
(12) N-Cycloheptyl-4-(4-chlorophenyl) benzylamine
IR (KBr) : 3030, 2925, 2855, 1485 cm-1
NMR (CDCI3, δ) : 1.35-2.0 (12H, m), 2.6-2.8 (1H,
m), 3.82 (2H, s), 7.4-7.6 (8H, m)
APCI-MASS (m/z) : 314 (M+H+)
(13) N-Cycloheptyl-4-(4-bromophenyl) benzylamine
IR (KBr) : 3035, 2925, 2855, 1480 cm-1
NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.6-2.8 (1H, m), 3.81 (2H, s), 7.35-7.65 (8H, m) APCI-MASS (m/z) : 360, 358 (M+H+)
(14) N-Cycloheptyl-4-(4-methylphenyl) benzylamine
IR (Film) : 3025, 2910, 2855, 1500 cm-1
NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.39 (3H, s), 2.65-2.8 (1H, m), 3.81 (2H, s), 7.24 (2H, d, J=7.6Hz), 7.37 (2H, d, J=8.3Hz), 7.4-7.6 (4H, m) APCI-MASS (m/z) : 294 (M+H+) (15) N-Cycloheptyl-4-(4-bromophenoxy) benzylamine
IR (Film) : 3030, 2925, 2850, 1585, 1505, 1480 cm-1 NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.6-2.8 (1H, m), 3.75 (2H, s), 6.8-7.0 (4H, m), 7.25-7.5 (4H, m) APCI-MASS (m/z) : 376, 374 (M+H+)
(16) N-Cycloheptyl-4-(4-phenylthιo) benzylamine
IR (Film) : 2920, 2850, 1510 cm-1
NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.55-2.75 (1H, m), 3.75 (2H, s), 7.2-7.5 (9H, m)
APCI-MASS (m/z) : 312 (M+H+)
(17) N-Cycloheptyl-(6-phenylthιopyrιdm-3-yl) methylamine IR (Film) : 3305, 2925, 2850, 1700, 1585, 1560 cm-1 NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.55-2.75 (1H, m), 3.71 (2H, s), 6.87 (1H, d, J=8.2Hz), 7.4-7.7
(6H, m), 8.35-8.4 (1H, iX
APCI-MASS (m/z) : 313 (M+HX
(13) N-Cycloheptyl-4-(4-benzoylammo) benzylamine
IR (Film) : 3265, 3150, 3070, 2925, 2850, 1645,
1615, 1595, 1555 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.55-2.7 (1H, m), 3.69 (2H, s), 7.07 (1H, d, J=7.7Hz), 7.27 (1H, t, J=7.7Hz), 7.5-7.8 (5H, m), 7.9-8.0 (2H, m), 10.22 (1H, s) APCI-MASS (m/z) : 323 (M+H+)
(19) N-Cycloheptyl-4-(2-pyridylcarbamoyl) benzylamine
IR (KBr) : 3305, 2925, 2855, 1680, 1610, 1580,
1535, 1505 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.5-2.7 (1H, m), 3.76 (2H, s), 7.17 (1H, dd, J=6.3, 4.9Hz), 7.45 (2H, d, J=8.2Hz), 7.98 (2H, d, J=8.2Hz), 7.8-7.9 (1H, m), 8.19 (1H, d, J=8.4Hz),
8.35-8.4 (1H, m), 10.70 (1H, s)
APCI-MASS (m/z) : 324 (M+H+)
(20) N-Cycloheptyl-4-(4-fluorophenoxy) benzylamine
IR (Film) : 2925, 2855, 1505 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.65-2.8 (1H, m),
3.75 (2H, s), 6.85-7.1 (6H, m), 7.2-7.35 (2H, m) APCI-MASS (m/z) : 314 (M+H+)
(21) N-Cycloheptyl-4-(phenylsulfamoyl) benzylamine
NMR (DMS0-d6, δ) : 1.2-1.8 (12H, m), 2.5-2.6 (1H, m), 3.70 (2H, s), 7.0-7.15 (3H, m), 7.15-7.25 (2H, m), 7.47 (2H, d, J=8.3Hz), 7.68 (2H, d, J=8.3Hz), 10.23 (1H, s)
APCI-MASS (m/z) : 359 (M+H+)
(22) N-Cycloheptyl-4-(3-thienyl) benzylamine
IR (KBr) : 2924, 1458, 1201, 775 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.62-2.78 (1H, m), 3.80 (2H, s), 7.30-7.47 (5H, m), 7.50-7.60 (2H, m)
APCI-MASS (m/z) : 286 (M+H+)
(23) N-Cycloheptyl-4-(2-thιenyl) benzylamine
IR (Neat) : 2924, 1502, 1458, 1101, 810 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.62-2.78 (1H, m), 3.79 (2H, s), 7.07 (1H, dd, J=5.1, 3.6Hz), 7.22-7.40 (4H, m), 7.50-7.65 (2H, m) APCI-MASS (m/z) : 286 (M+H+) (24) N-Cycloheptyl-4-(pyrazol-1-yl) benzylamine
IR (Neat) : 2927, 1610, 1525, 1460, 1394 cm-1
NMR (CDCl3, δ) : 1.30-1.95 (12H, m), 2.60-2.78 (1H, m), 3.81 (2H, s), 6.46 (1H, t, J=2.1Hz), 7.36- 7.46 (2H, m), 7.58-7.68 (2H, m), 7.71 (1H, d, J=1.6Hz), 7.91 (1H, d, J=2.1Hz)
APCI-MASS (m/z) : 270 (M+H+)
(25) N-Cycloheptyl-4-(imidazol-1-yl) benzylamine
IR (Neat) : 2922, 1522, 1303, 1057 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.60-2.80 (1H, m), 3.83 (2H, s), 7.20 (1H, d, J=1.0Hz), 7.27 (1H, d, J=1.0Hz), 7.30-7.50 (4H, m), 7.84 (1H, s) APCI-MASS (m/z) : 270 (M+H+) (26) N-Cycloheptyl-4-(1-methylpyrazol-4-yl) benzylamine
IR (KBr) : 3277, 2924, 1572, 1443, 1194, 802 cm-1 NMR (CDCl3, δ) : 1.30-2.20 (12H, m), 2.62-2.80 (1H, m), 3.78 (2H, s), 3.94 (3H, s), 7.27-7.47 (4H, m), 7.58 (1H, s), 7.74 (1H, s)
APCI-MASS (m/z) : 284 (M+H+)
(27) N-Cycloheptyl-2-(2-phenylthiophen-5-yl) methylamine
IR (Neat) : 2924, 1599, 1462, 754 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.66-2.85 (1H, m), 3.98 (2H, s), 6.87 (1H, d, J=3.6Hz), 7.15
(1H, d, J=3.6Hz), 7.18-7.45 (3H, m), 7.52-7.64 (2H, m)
APCI-MASS (m/z) : 286 (M+H+) (28) N-Cycloheptyl-4-(oxazol-5-yl) benzylamine IR (KBr) : 2924, 1510, 1485, 1103, 822 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.60-2.80 (1H, m), 3.81 (2H, s), 7.33 (1H, s), 7.33-7.46 (2H, m), 7.55-7.69 (2H, m), 7.90 (1H, s)
APCI-MASS (m/z) : 271 (M+H+)
(29) N-Cycloheptyl-(2-phenylfuran-5-yl) methylamine
IR (Neat) : 2924, 1545, 1456, 1020, 760 cm-1
NMR (CDCl3, δ) : 1.30-1.95 (12H, m), 2.64-2.80 (1H, m), 3.84 (2H, s), 6.24 (1H, d, J=3.3Hz), 6.57
(1H, d, J=3.3Hz), 7.17-7.45 (3H, m), 7.58-7.72 (2H, m)
APCI-MASS (m/z) : 270 (M+H+) (30) N-Cycloheptyl-(5-phenylisoxazol-3-yl) methylamine
IR (Neat) : 2926, 2854, 1616, 1574, 1456, 1113,
766 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.65-2.82 (1H, m), 3.90 (2H, s), 6.53 (1H, s), 7.34-7.53 (3H, m), 7.70-7.86 (2H, m)
APCI-MASS (m/z) : 271 (M+H+)
(31) N-Cycloheptyl-(3-phenylpyrazol-5-yl) methylamine
IR (Neat) : 2300-3600 (br), 1570, 1460, 1358,
1026 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.65-2.82 (1H, m), 3.92 (2H, s), 6.46 (1H, s), 7.20-7.50 (3H, m), 7.64-7.80 (2H, m)
APCI-MASS (m/z) : 270 (M+H+)
(32) N-Cycloheptyl-(4-phenylthiophen-2-yl) methylamine
IR (Neat) : 2924, 2852, 1502, 1458, 1367, 841,
735 cm-1
NMR (CDCl3, δ) : 1.32-1.98 (12H, m), 2.70-2.88 (1H, m), 4.01 (2H, s), 7.19-7.62 (7H, m) APCI-MASS (m/z) : 286 (M+H+)
(33) N-Cycloheptyl-4-(pyrazol-3-yl)benzylamine
e IR (Neat) : 2300-3600 (br), 1514, 1456, 1350,
1205 cm-1
NMR (DMSO-d6, δ) : 1.20-1.93 (12H, m), 2.50-2.72
(1H, m), 3.73 (2H, s), 6.67 (1H, d, J=1.9Hz), 7.30-7.90 (5H, m), 12.70-13.40 (1H, br) APCI-MASS (m/z) : 270 (M+H+)
(34) N-Cycloheptyl-4-(1-methylpyrazol-3-yl)benzylamine
IR (KBr) : 2922, 2852, 1510, 1462, 1429, 1358,
1234 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.61-2.78 (1H, m), 3.80 (2H, s), 3.95 (3H, s), 6.52 (1H, d,
J=2.2Hz), 7.29-7.40 (3H, m), 7.70-7.80 (2H, m) APCI-MASS (m/z) : 284 (M+H+)
(35) N-Cycloheptyl-4-(1-methylpyrazol-5-yl)benzylamine
IR (Neat) : 2924, 2854, 1493, 1462, 1385, 1273 cm-1
NMR (CDCI3, δ) : 1.32-1.98 (12H, m), 2.62-2.81 (1H, m), 3.83 (2H, s), 3.89 (3H, s), 6.29 (1H, d, J=1.9Hz), 7.33-7.46 (4H, m), 7.51 (1H, d,
J=1.9Hz)
APCI-MASS (m/z) : 284 (M+H+)
(36) N-Cycloheptyl-3-(l-trityl-1H-tetrazol-5-yl)benzylamine IR (KBr) : 2922, 2852, 1697, 1515, 1452, 750,
698 cm-1
NMR (CDCl3, δ) : 1.30-1.95 (12H, m), 2.62-2.78 (1H, m), 3.83 (2H, s), 7.10-7.50 (17H, m), 7.96-8.12 (2H, m)
FAB-MASS (m/z) : 514 (M+H+) (37) N-Cycloheptyl-4-(phenylcarbamoyl)benzylamine IR (KBr) : 3475, 3345, 3055, 2925, 2850, 1645,
1600, 1525, 1505 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.5-2.65 (1H, m), 3.78 (2H, s), 7.09 (1H, t, J=7.3Hz), 7.35 (2H, s), 7.48 (2H, d, J=8.2Kz), 7.78 (2H, d,
J=7.5Hz), 7.90 (2H, d, J=8.2Hz), 10.20 (1H, s) APCI-MASS (m/z) : 323 (M+H+)
( 38) N-Cycloheptyl-4-(phenylsulfonylamino)benzylamine
IR (KBr) : 3130, 3015, 2930, 2855, 1610, 1570,
1505 cm-1
NMR (DMSO-d6, δ) : 1.2-1.8 (12H, m), 2.5-2.6 (1H, m), 3.58 (2H, s), 6.99 (2H, d, J=8.5Hz), 7.16 (2H, d, J=8.5Hz), 7.45-7.6 (3H, m), 7.65-7.75 (2H, m)
APCI-MASS (m/z) : 359 (M+H+)
Preparation 62
The mixture of 4-formyl-2-(4-chlorophenyl) thiazole (2.24 g) and benzylamine (2.14 g) was stirred at 120°C under nitrogen for 5 hours. The mixture was cooled to roo temperature and dissolved in ethanol (30 ml). To this solution was added sodium borohydride (378 mg) ana the mixture was stirred at room temperature for 1.1 nours. Th mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with brme, dried over magnesium sulfate and
evaporated m vacuo. The residue was purified by column chromatography to give N-benzyl-[2-(4-chlorophenyl)thiazol- 4-yl] methylamine (3.22 g).
IR (Film) : 3060, 3030, 2915, 2835, 1495 cm-1
NMR (DMSO-d6, δ) : 2.64 (1H, br s), 3.67 (2H, s),
3.78 (2H, s), 7.2-7.4 (5K, ml, 7.52 (1H, s), 7.5- 7.6 (2H, m), 7.9-8.0 (2H, m)
APCI-MASS (m/z) : 315 (M+H+) Preparation 63
The mixture of 3-bromomethylbiphenyl (6.58 g) and cycloheptylamine (6.03 g) was stirred at 120°C for 3.5 hours under nitrogen. The mixture was cooled to room temperature, and the mixture of dichloromethane and water were added thereto. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-(3-biphenylylmethyl)- cycloheptylamine (4.49 g) as an orange oil.
IR (Film) : 3060, 3030, 2920, 2850, 1460 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.7-2.85 (1H,
m), 3.85 (2H, s), 7.3-7.7 (9H, m) APCI-MASS (m/z) : 280 (M+H+)
Preparation 64
The following compounds were obtained according to similar manners to those of Preparations 62 and 63. (1) N-Cycloheptyl-4-(pyridin-3-yl) benzylamine
NMR (CDCl3, δ) : 1.3-1.9 (12H, m), 2.9-3.05 (1H,
m), 7.3-7.6 (5H, m), 7.8-7.9 (1H, m), 8.5-8.6 (1H, m), 8.8-8.85 (1H, m)
APCI-MASS (m/z) : 281 (M+H+)
(2) N-Cycloheptyl-4-(pyridin-2-yl) benzylamine
IR (Film) : 3050, 3005, 2920, 2850, 1585, 1565 cm-1 NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.6-2.7 (1H,
m), 3.74 (2H, s), 7.25-7.5 (3H, m), 7.8-8.1 (4H, m), 8.6-8.7 (1H, m)
APCI-MASS (m/z) : 281 (M+H+)
(3) N-Cycloheptyl-4-(4-benzoyl) benzylamine
IR (Film) : 3050, 2925, 2850, 1655, 1605 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.6-2.8 (1H, m), 3.87 (2H, s), 7.4-7.65 (5H, m), 7.75-7.9 (4H, m) APCI-MASS (m/z) : 308 (M+H+)
Preparation 65
To a solution of 3-(2-methylthiazol-4-yl)- benzylamine-hydrochloride (2.41 g) in a mixture of
dichloromethane (30 ml) and water (10 ml) was added 5N sodium hydroxide aqueous solution and adjusted to pH 9-10. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. To the residual oil was added cycloheptanone (1.68 g) and the mixture was stirred at 120°C under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (30 ml) . To this solution was added sodium borohydride (378 mg) and the mixture was stirred at room temperature for 2.5 hours. The mixture was evaporated to dryness and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatogaphy on silica gel to give N-cycloheptyl-3- (2-methylthiazol-4-yl) benzylamine (2.07 g) as a yellow oil.
IR (Film) : 3380, 2915, 2855, 1455 cm-1
NMR (CDCl3, δ) : 1.30-2.0 (12H, m), 2.7-2.85 (1H,
m), 2.76 (3H, s), 3.82 (2H, s), 7.32 (1H, s), 7.25-7.4 (2H, m), 7.75-7.9 (2H, m)
APCI-MASS (m/z) : 301 (M+H+)
Preparation 66
To a suspension of N-cycloheptyl-4-(4- benzoyl) benzylamine (1.87 g) in ethylene glycol (10 ml) were added potassium hydroxide (511 mg) and hydrazine monohydrate (1.95 g), and the mixture was stirred at 150°C for 5 hours and at 200°C for 4 hours. The mixture was poured into a mixture of dichloromethane and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cycloheptyl-4-(4-benzyl) benzylamine (1.29 g) as an orange oil.
IR (Film) : 3025, 2905, 2850, 1510 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.6-2.8 (1H, m),
3.74 (2H, s), 3.96 (2H, s), 7.1-7.4 (9H, m)
APCI-MASS (m/z) : 294 (M+H+) Preparation 67
To a solution of 3-(pyrazol-3-yl) benzaldehyde (4.33 g) in pyridine (20 ml) was added trityl chloride (7.71 g) under ice cooling. The mixture was stirred for 30 minutes, and then warmed to room temperature. After stirring for 3 hours at the same temperature, the reaction mixture was poured into ice aqueous hydrochloric acid, extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (eluting with n-hexane - ethyl acetate (2:1)) to give 3-(1-tritylpyrazol-3-yl) benzaldehyde (9.26 g).
IR (KBr) : 3477, 3060, 3030, 1697, 1601, 1491,
1444 cm-1
NMR (DMSO-d6, δ) : 6.93 (1H, d, J=2.5Hz), 7.1-7.5
(16H, m), 7.63 (1H, dd, J=7.7, 7.7Hz), 7.85 (1H, d, J=7.7Hz), 8.08 (1H, d, J=7.7Hz), 8.25 (1H, s), 10.04 (1H, s)
Preparation 68
The mixture of 3-(1-tritylpyrazol-3-yl) benzaldehyde
(15.31 g) and benzylamine (7.91 g) was stirred at 120°C for 5 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (120 ml). To this solution was added carefully sodium borohydride (1.40 g) at room temperature and the mixture was stirred for 2 hours. The mixture was concentrated in vacuo and to the residue were added dichloromethane and ice water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-benzyl-3- (l-tritylpyrazol-3-yl)benzylamine (12.18 g) as an amorphous solid.
IR (KBr) : 3059, 3028, 1599, 1493 cm-1
NMR (DMSO-d6, δ) : 3.65-3.75 (4H, m), 6.77 (1H, d, J=2.5Hz), 7.05-7.45 (18H, m), 7.55-7.75 (2H, m)
Preparation 69
To a suspension of N-benzyl-3-(1-tritylpyrazol-3- yl) benzylamine (8.60 g) in anisole (17.2 ml) was added trifluoroacetic acid (34.4 ml) at room temperature and the mixture was stirred at 80°C for 3.5 hours. The mixture was concentrated in vacuo and the residue was pulverized with diisopropyl ether. The powder was collected by filtration, washed with diisopropyl ether and dried in vacuo to give N- benzyl-3-(pyrazol-3-yl) benzylamine bis ( trifluoroacetate) (7.35 g).
IR (KBr) : 3059, 3005, 1669, 1510, 1489 cm-1
NMR (DMSO-d6, δ) : 4.2-4.3 (4H, m), 6.70-6.75 (1H, m), 7.1-7.6 (7H, m), 7X5-8.0 (3H, m)
Preparation 70
To a solution of 2,4-dichloro-6-methyl-3-nitropyridine (30.33 g) in acetonitrile (100 ml) was added dropwise sodium methoxide (28% methanol solution) (85.1 ml) at 5°C, and the mixture was stirred at 80°C for 6 hours. The mixture was cooled and poured into a mixture of ethyl acetate and ice water. The separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 2,4-dimethoxy- 6-methyl-3-nitropyridine (28.21 g) as a pale yellow crystal.
IR (KBr) : 3093, 3035, 3005, 2960, 2868, 1601, 1581,
1531 cm-1
NMR (DMSO-d6, δ) : 2.44 (3H, s), 3.92 and 3.94 (6H, s x 2), 6.97 (1H, s)
APCI-MASS (m/z) : 199 (M+H+)
Preparation 71
To a solution of 2,4-dimethoxy-6-methyl-3- nitropyridine (28.1 g) in 1,4-dioxane (200 ml) and methanol (100 ml) was added 101 palladium on carbon (14 g) under nitrogen and the mixture was hydrogenated under atmospheric pressure for 4.5 hours. Palladium on carbon was filtered off and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-amino-2, 4-dimethoxy-6-methylpyridine (23.41 g) as an orange oil.
IR (Film) : 3458, 3373, 2945, 2856, 1605 cm-1
NMR (DMSO-d6, δ) : 2.26 (3H, s), 3.79 and 3.82 (6H, s x 2), 3.96 (2H, br s), 6.52 (1H, s)
APCI-MASS (m/z) : 169 (M+H+)
Preparation 72
To a solution of 3-amino-2,4-bis (methylthio)-6- methylpyridine (7.90 g) in dichloromethane (160 ml) was added N,N-dimethylaniline (5.73 g) at 5°C, followed by dropwise addition of phenyl chloroformate (6.78 g). The mixture was warmed to room temperature and stirred at 4 hours. To the mixture were added ice water (60 ml) and 6N hydrochloric acid (10 ml), and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized, and the crystal was collected by filtration, washed with
diisopropyl ether and dried in vacuo to give 3- phenoxycarbonylamino-2, 4-bis (methylthio)-6-methylpyridine (10.46 g).
IR (KBr) : 3410, 3228, 3196, 3145, 3003, 2926, 1732,
1591, 1556, 1537 cm-1
NMR (DMSO-d6, δ) : 2.45 (6H, s), 2.46 (3H, s), 6.94
(1H, s), 7.0-7.5 (5H, m), 9.48 (1H, br s)
APCI-MASS (m/z) : 321 (M+H+)
Preparation 73
To a solution of 2,4,6-trifluoroaniline (883 mg) and N,N-dimethylaniline (0.91 ml) in methylene chloride (18 ml) was added phenyl chloroformate (0.83 ml) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was washed with IN-hydrochloric acid (three times), water, aqueous sodium bicarbonate, water, and brine. The organic layer was dried over magnesium sulfate and
evaporated in vacuo. The resulting solid was collected an washed with n-hexane to give phenyl N-(2,4,6- trifluorophenyl) carbamate (1.46 g).
IR (KBr) : 3253, 1749, 1722, 1538, 1240, 1200 cm-1
NMR (CDCl3, δ) : 6.26 (1H, br s), 6.70-6.86 (2H, m),
7.10-7.46 (5H, m)
APCI-MASS (m/z) : 268 (M+H+) Preparation 74
To a solution of 3-amino-2,4-dimethoxy-6- methylpyridine (23.40 g) in dichloromethane (200 ml) was added N,N-dimethylaniline (20.23 g), followed by dropwise addition of phenyl chloroformate (23.94 g) at 5°C. The mixture was warmed to room temperature and stirred for 3 hours. The resulting precipitates were collected by filtration, washed with dichloromethane and diisopropyl ether, and dried in vacuo to give 2,4-dimethoxy-6-methyl-3- phenoxycarbonylaminopyridine (21.95 g) as a white crystal.
IR (KBr) : 3408, 3251, 3147, 3064, 2983, 2947, 2860, 1713 , 1593 , 1497 cm- 1
NMR (DMSO-d6 , δ ) : 2 . 38 ( 3H, s ) , 3 . 85 ( 6H, s ) ,
6.72 (1H, s), 7.05-7.3 (3H, m), 7.35-7.45 (2H, m), 8.83 (1H, br)
APCI-MASS (m/z) : 289 (M+H+)
Preparation 75
A mixture of 4-(4-bromophenoxy) benzaldehyde (10.0 g) and benzylamine (5.42 g) was stirred at 120°C for 4 hours. After cooling to room temperature, the resulting solid was suspended in ethanol (150 ml). To the suspension was added carefully sodium borohydride (1.36 g), and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with methylene chloride. The organic layer was washed with water, brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column
chromatography on silica gel (250 g, eluting with methylene chloride - methanol (20: IX to give N-benzyl-4- ( 4- bromophenoxy) benzylamine (11.51 g) as a pale yellow oil.
IR (Neat) : 3061, 3028, 2700-3000 (br), 1608, 1583,
1504, 1481, 1240 cm-1
NMR (CDCl3, δ) : 3.79 (2H, s), 3.82 (2H, s),
6.80-7.00 (4H, m), 7.20-7.5C (9H, m)
APCI-MASS (m/z) : 368, 370 (M+H+ )
Preparation 76
The mixture of 3-(1-trityIpyrazol-3-yl) benzaldehyde (9.18 g) and cycloheptylamine (3.75 g) was stirred at 120°C for 4 hours. The mixture was cooled to room temperature and dissolved in ethanol (120 ml). To this solution was added sodium borohydride (836 mg) and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and extracted with methylene chloride. The organic layer was washed with water and brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel (eluting with methylene chloride - methanol ,40:1 to 10:1)) to give N-cycloheptyl-3-(1-trιtylpyrazol-3-yl) benzylamine (7.92 g).
NMR (DMSO-d6, δ) : 1.20-1.90 (12K, m), 2.50-2.70 (1H, m), 3.69 (2H, s), 6.77 (1H, d, J=2.5Hz), 7.05- 7.50 (12H, m), 7.55-7.65 (1H, m), 7.71 (1H, s) APCI-MASS (m/z) : 512 (M-^H+)
Preparation 77
To a suspension of 3-amιno-2,4,6- trimethylpyndine-hydrochloride (5.18 g) m 1,2- dichloroethane (120 ml; was added dnsopropylethylamine (19.39 g) at room temperature, followed by addition of phenyl chloroformate (7.05 g). The mixture was refluxed for 10 hours under nitrogen. The mixture was cooled and poured into ice water. The separated organic layer was washed with brme, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3- phenoxycarbonylamιno-2,4,6-trιmethyl pyridme as a crude orange oil (3.17 g).
IR (KBr) : 3275, 2924, 1740, 1713, 1605, 1550 cm-1 NMR (DMSO-d6, δ) : 2.22 (3H, s), 2.39 (6H, s), 7.01
(1H, s), 7.2-7.6 (5H, m), 9.42 (1H, brs) APCI-MASS (m/z) : 257 (M+H+)
Preparation 78
To a suspension of 4-chloro-6-methyl-2-methylthιo-3- mtropyridme (16.0 g) in a mixture of 1,4-dιoxane (200 ml and methanol (50 ml) was added Raney-Nickel (NDT-90;
trademark: Kawaken fine chemicals) (ca. 30 g) under
nitrogen, and the mixture was hydrogenated under
atomospheric pressure for 3 hours. Raney-Nickel was filtered off and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-amino-2-chloro-6-methyl-4-methylthiopyridine (12.86 g) as an orange oil.
IR (film) : 3424, 3322, 2922, 1707, 1606, 1570,
1529 cm-1
NMR (DMSO-d6, δ) : 2.29 (3H, s), 2.31 (3H, s), 4.93
(2H, brs), 6.98 (1H, s)
APCI-MASS (m/z) : 191, 189 (M+H+)
Preparation 79
To a solution of 3-amino-4-chloro-6-methyl-2- methylthiopyridine (12.75 g) in dichloromethane (200 ml) was added N,N-dimethylaniline (6.00 g; at 5°C, followed by dropwise addition of phenylchloroformate (7.11 g). The mixture was warmed to room temperature and stirred at the same temperature for 4 hours. The mixture was washed with dilute hydrochloric acid and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was
triturated with diisopropyl ether and collected by
filtration, washed with diisopropyl ether and dried in vacuo under phosphorus pentoxide to give 2-chloro-6-methyl- 4-methylthio-3-phenoxycarbonylaminopyridine (9.58 g).
IR (KBr) : 3194, 2924, 1751, 1579, 1514, 1489 cm-1 NMR (DMSO-d6, δ) : 2.29 (3H, s), 2.50 (3H, s),
6.7-6.85 (3H, m), 6.98 (1H, s), 7.1-7.25 (2H, m), 9.35 (1H, brs)
Preparation 80
To a solution of 3,5-di-tert-butyl-4-hydroxyphenol (9.65 g) and imidazole (3.55 g) in N,N-dimethylformamide (80 ml) was added tert-butyldimethylsilyl chloride (6.54 g) at 5°C, and the mixture was stirred at room temperature for 3 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-tert- butyldimethylsilyloxy-3,5-di-tert-butyl-4-hydroxybenzene (13.91 g) as a white solid.
IR (KBr) : 3651, 2958, 2929, 2858, 1601, 1470 cm-1 NMR (CDCl3, δ) : 0.18 (6H, s), 0.91 (9H, s),
1.41 (18H, s), 6.73 (2H, s)
APCI-MASS (m/z) : 336 (M+)
Preparation 81
To a suspension of sodium hydride (60% oil dispersion) (1.65 g) in N,N-dimethylformamide (100 ml) was added dropwise a solution of 1-tert-butyldimethylsilyloxy-3,5-di- tert-butyl-4-hydroxybenzene (13.89 g) in N,N- dimethylformamide (70 ml) at 5°C, and the mixture was stirred at the same temperature for 1 hour. To the
resulting solution was added chloromethyl methyl ether (4.99 g) at 5°C and the mixture was stirred at room
temperature for 5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- tert-butyldimethylsilyloxy-3,5-di-tert-butyl-4-methoxy methoxybenzene (13.49 g) as a yellow solid.
IR (KBr) : 2962, 2929, 2897, 2860, 1597 cm-1
NMR (CDCl3, δ) : 0.19 (6H, s), 0.9S (9H, s), 1.41
(18H, s), 3.62 (3H, s), 4.86 (2H, s), 6.72 (2H, s)
AFCI-MASS (m/z) : 331 (M+H+)
Preparation 82
To a solution of 1-tert-butyldimethylsilyloxy-3,5-di- tert-butyl-4-methoxymethoxybenzene (13.42 g) in tetrahydrofuran (20 ml) was added 1.0M solution of
tetrabutylammonium fluoride (38.8 ml) at room temperature and the mixture was stirred at the same temperature for 2 hours. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3,5-di-tert- butyl-4-methoxymethoxyphenol (9.43 g) as a yellow crystal.
IR (KBr) : 3369, 3012, 2958, 2910, 2870, 2779, 1610,
1589 cm-1
NMR (CDCl3, δ) : 1.42 (18H, s), 3.63 (3H, s),
4.87 (2H, s), 6.74 (2H, s) Preparation 83
To a solution of 1-(4-fluorophenoxy)-4-nitrobenzene (22.9 g) in ethyl acetate (200 ml) was added 10% palladium- carbon (50% wet) (9.16 g), and the mixture was hydrogenated under atmospheric pressure at room temperature for 3 hours. Palladium on carbon was filtered off and washed with tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4- (4-fluorophenoxy) aniline (18.27 g) as a red powder.
IR (KBr) : 3450, 3395, 3325, 3230, 3070 3045, 3020,
1635, 1490 cm-1
NMR (CDCl3, δ) : 6.65-6.75 (2H, m), 6.8-7.05 (6H, m) APCI-MASS (m/z) : 204 (M+H+) Preparation 84
To a solution of 3-(4-fluorophenoxy) benzyl alcohol (3.97 g) in chloroform (50 ml) was added activated
manganese dioxide (15.82 g) and the mixture was refluxed for 4.5 hours. Manganese dioxide was filtered off and the filtrate was evaporated in vacuo to give crude 3-(4- fluorophenoxy) benzaldehyde (3.81 g) as a yellow oil.
IR (Film) : 3074, 2837, 2819, 2731, 1701, 1585, 1502,
1481, 1450 cm-1
NMR (DMSO-d6, δ) : 7.1-7.45 (6H, m), 7.55-7.75 (2H, m), 9.98 (1H, s)
Preparation 85
To a suspension of lithium aluminum hydride (5.69 g) in tetrahydrofuran (300 ml) was added dropwise a solution of 4- (4-fluorophenoxy) benzonitrile (21.32 g) in
tetrahydrofuran (200 ml) at 5°C, and the mixture was stirred at room temperature for 4 hours. To the mixture was added sodium fluoride (16.80 g), followed by dropwise addition of cold water (5.41 g) and the mixture was stirred at room temperature for 45 minutes. The insoluble
materials were filtered off and washed with
tetrahydrofuran. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4-(4-fluorophenoxy) benzylamine (21.39 g) as a yellow oil.
IR (KBr) : 3352, 3269, 3043, 2864, 1645, 1606,
1495 cm-1
NMR (DMSO-d6, δ) : 3.69 (2H, s), 6.9-7.4 (8H, m)
APCI-MASS (m/z) :201 (M+H+-NH3)
Preparation 86
To a solution of phenyl chloroformate (31.2 g) in 1,2- dichloroethane (250 ml) was added dropwise a solution of 3-amino-2,4,6-trimethylpyridine (22.62 g) in 1,2- dichloroethane (120 ml) at 100°C, and the mixture was refluxed for 1 hour under nitrogen. The mixture was cooled to room temperature and added dropwise a mixture of ethyl acetate (2ℓ ) and tetrahydrofuran (1 ℓ). The precipitates were collected by filtration, washed with ethyl acetate and diisopropyl ether and dried in vacuo over phosphorus pentoxide to give 2,4,6-trimethyl-3- phenoxycarbonylaminopyridine-hydrochloride (48.84 g).
IR (KBr) : 3413, 1741, 1645, 1541, 1483 cm-1
NMR (DMSO-d6, δ) : 2.49 (3H, s), 2.69 (6H, s),
7.2-7.5 (5H, m), 7.65-7.75 (1H, m), 9.63 and
10.20 (total 1H, br s)
APCI-MASS (m/z) : 257 (M+H+-HCl )
Preparation 87
To a solution of 5-amino-4,6-bis (methylthio)-2- methylpyrimidine (4.10 g) in dichloromethane (80 ml) was added N,N-dimethylaniline (2.96 g) at 5°C, followed by dropwise addition of phenyl chloroformate (3.51 g). The mixture was stirred at room temperature for 2 hours under nitrogen. The mixture was washed with dilute hydrochloric acid and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was triturated with diisopropyl ether collected by filtration, washed with diisopropyl ether and dried in vacuo to give 4,6-bis (methylthio)-2- methyl-5-phenoxycarbonylaminopyrimidine (5.74 g).
IR (KBr) : 3217, 3005, 2924, 1711, 1595, 1485 cm-1 NMR (DMSO-d6, δ) : 2.49 (6H, s), 2.59 (3H, s),
7.0-7.5 (5H, m), 9.27 and 9.68 (total 1H, s) APCI-MASS (m/z) : 322 (M+H+)
Preparation 88
To a solution of 2-(3-bromophenyl)-1,3-dioxoiane
(20.42 g) and triisopropoxyborane (25.14 g) in
tetrahydrofuran (350 ml) was added dropwise n-butyllithium (1.70M hexane solution, 78.8 ml) at -72°C over 2-hours under nitrogen. The mixture was warmed to room temperature and stirred for 21 hours. The mixture was poured into a mixture of ethyl acetate and dilute hydrochloric acid and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give crude dihydroxy-(3-formylphenyl)- borane (14.83 g).
IR (KBr) : 3354, 2840, 1678, 1603, 1581 cm-1
NMR (DMSO-d6, δ) : 7.55-7.7 (1H, m), 7.8-8.15 (2H, m), 8.33 (2H, s), 10.03 (1H, s)
Preparation 89
To a suspension of 4-bromo-1-tritylpyrazole (18.96 g) and crude dihydroxy-(3-formylphenyl) borane (14.6 g) in toluene (400 ml) were added powdered potassium carbonate (10.10 g) and tetrakis (triphenylphosphine) palladium (0) (2.81 g), and the mixture was refluxed for 6 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine., dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-(1-tritylpyrazol-4-yl) benzaldehyde (2.65 g) as a yellow solid.
IR (KBr) : 3057, 3024, 2812, 2727, 1699, 1603,
1585 cm-1
NMR (DMSO-d6, δ) : 7.0-7.15 (5H, m), 7.35-7.5 (10H, m), 7.7-7.85 (2H, m), 7.97 (1H, d, J=7.7Hz), 8.13 (1H, d, J=7.7Hz), 8.31 (1H, s), 10.13 (1H, s)
Preparation 90
To a solution of 3-bromobenzaldehyde (1.25 g) and 1-methyl-4-tri-n-butylstanniopyrazole (3.0 g) was added tetrakis (triphenylphosphine) palladium (0) (234 mg). Then the mixture was heated for 4 hours at 140°C. After
cooling, the reaction mixture was diluted with toluene (16 ml). An aqueous solution (14 ml) of potassium fluoride (4.7 g) was added to the mixture and stirred for one hour. Insoluble material was filtered off. The filtrate was washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was chromatographed on silica gel (60 g, eluting with n-hexane - ethyl acetate (1:2)) to give 3-(1-methylpyrazol-4-yl) benzaldehyde (978.1 mg).
IR (Neat) : 2943, 2818, 1686, 1608, 1230, 1174 cm-1 NMR (CDCl3, δ) : 3.98 (3H, s), 7.47-7.58 (1H, m),
7.65-7.78 (3H, m), 7.83 (1H, s), 7.93-7.98 (1H, m), 10.04 (1H, s)
APCI-MASS (m/z) : 187 (M+H+)
Preparation 91
To a solution of 3-[(E)-3-dimethylaminopropenoyl]- benzonitrile (8 g) in acetic acid (80 ml) was added
methylhydrazine (2.23 ml). The mixture was stirred for 3.5 hours at room temperature. To the solution was added 5N- sodium hydroxide aqueous solution in order to basify under ice cooling and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate
solution, water, brine, dried over magnesium sulfate, evaporated in vacuo. After chromatography on silica gel (eluting with dichloromethane-methanol), 3-(1- methylpyrazol-3-yl)benzonitrile (4.45 g) and 3-(1- methylpyrazol-5-yl) benzonitrile (2.09 g) were obtained. 3-(1-Methylpyrazol-3-yl)benzonitrile;
o mp : 97-98°C
IR (KBr) : 3115, 2935, 2220, 1602, 1471, 1352,
1246 cm-1
NMR (CDCl3, δ) : 3.97 (3H, s), 6.56 (1H, d, J=2.3Hz), 7.37-7.60 (3H, m), 7.95-8.10 (2H, m)
APCI-MASS (m/z) : 184 (M+H+)
3-(1-Methylpyrazol-5-yl)benzonitrile;
mp : 95-97°C
IR (KBr) : 3066, 2951, 2231, 1475, 1416, 1335, 1236 cm1
NMR (CDCl3, δ) : 3.92 (3H, s), 6.37 (1H, d, J=1.5Hz),
7.50-7.75 (5H, m)
APCI-MASS (m/z) : 184 (M+H+)
Preparation 92
A mixture of 3-(bromoacetyl) benzonitrile (38.2 g) and formamide (190 ml) was heated for 30 minutes at 185°C and cooled to room temperature. The mixture was poured into saturated sodium bicarbonate solution (400 ml) and
extracted with ethyl acetate (1.8 t) . The organic layer was washed with water and brine, dried over magnesium sulfate. After evaporation to 200 ml, the resulting precipitate was collected by filtration, washed with ethyl acetate - isopropyl ether (2:1) to give 3-(imidazol-4- yl) benzonitrile (13.3 g) .
mp : 190-191°C
IR (KBr) : 2250-3240 (br), 2224, 1606, 1477, 1333,
1070, 970, 824, 789 cm-1
NMR (DMSO-d6, δ) : 7.50-7.68 (2H, m), 7.70-7.87 (2H, m), 8.05-8.20 (2H, m), 12.32 (1H, br) APCI-MASS (m/z) : 170 (M+H+)
Preparation 93
To a solution of methyl 4-formylbenzoate (5.0 g) in ethanol (50 ml) was added sodium borohydride (576 mg) carefully at 0-5°C and stirred for 30 minutes. The mixture was poured into water and extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give methyl 4-hydroxymethylbenzoate (5.06 g).
IR (KBr) : 2750-3670 (br), 1722, 1614, 1437, 1286,
1111, 1047, 1016, 756 cm-1
NMR (CDCl3, δ) : 1.89 (1H, t, J=5.9Hz), 3.92 (3H, s), 4.77 (2H, d, J=5.9Hz), 7.37-7.50 (2H, m), 7.97- 8.10 (2H, m)
APCI-MASS (m/z) : 167 (M+H+)
Preparation 94
To a solution of methyl 4-hydroxymethylbenzoate (5.0 g) and imidazole (4.1 g) in N,N-dimethylformamide (25 ml) was added tert-butyldimethylsilyl chloride (4.77 g) carefully at 0-5°C and stirred for 2 hours at room
temperature. The reaction mixture was poured into 0.1N hydrochloric acid (100 ml) and extracted with ethyl
acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give methyl 4-(tert-butyldimethylsilyloxymethyl) benzoate (8.43 g).
IR (Neat) : 2954, 2859, 1724, 1464, 1281, 1107,
841 cm-1
NMR (CDCl3, δ) : 0.11 (6H, s), 0.95 (9H, s), 3.91
(3H, s), 4.79 (2H, s), 7.34-7.44 (2H, m), 7.95- 8.05 (2H, m)
APCI-MASS (m/z) : 281 (M+H+)
Preparation 95
A mixture of methyl 4-(tert-butyldimethylsilyloxy- methyl) benzoate (1.0 g) and hydrazine monohydrate (0.87 ml) in ethanol (0.8 ml) was refluxed for one hour. After cooling to room temperature, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo to give [4-(tert- butyldimethylsilyloxymethyl) benzoyl] hydrazine (1.0 g).
mp : 83-85°C
IR (KBr) : 3273 (br), 2954, 2858, 1662, 1599, 1539,
1335, 1254, 1093, 841 cm-1
NMR (DMSO-d6, δ) : 0.08 (6H, s), 0.91 (9H, s), 4.47 (2H, s), 4.75 (2H, s), 7.30-7.40 (2H, m), 7.75- 7.85 (2H, m), 9.72 (1H, s)
APCI-MASS (m/z) : 281 (M+H+)
Preparation 96
To a mixture of [4-(tert-butyldimethylsilyloxymethyl)- benzoyl] hydrazine (8.0 g) and ethyl
acetimidate-hydrochloride (4.24 g) in ethanol (160 ml) was added triethylamine (4.8 ml) at room temperature and stirred for 30 minutes. The reaction mixture was
evaporated in vacuo. Then the residue was dissolved in ethyl acetate (120 ml), washed with water and brine. The organic layer was dried over magnesium sulfate, evaporated in vacuo. And the residue was heated for 10 minutes at 200°C, cooled to room temperature, chromatographed on silica gel (200 g, eluting with n-hexane - ethyl acetate (2:1)) to give 2-[4-(tert-butyldimethylsilyloxymethyl)- phenyl]-5-methyl-1,3,4-oxadiazole (6.35 g).
mp : 62-65°C
IR (KBr) : 2956, 2933, 2897, 2860, 1576, 1502, 1257,
1086, 843 cm-1
NMR (DMSO-d6, δ) : 0.10 (6H, s), 0.92 (9H, s), 2.58 (3H, s), 4.80 (2H, s), 7.45-7.55 (2H, m), 7.90- 8.00 (2H, m)
APCI-MASS (m/z) : 305 (M-*-H+)
Preparation 97
To a solution of 2-[4-(tert-butyldimethylsilyloxy- methyl) phenyl]-5-methyl-1,3,4-oxadiazole (2.0 g) in
methanol (20 ml) was added IN hydrochloric acid (13 ml) dropwise at 0-5°C and stirred for one hour. The reaction mixture was recooled to 0-5°C, and sodium bicarbonate (1115 g) was added thereto carefully. The mixture was extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The resulting precipitate was collected by filtration ana washed with n-hexane to give 2-(4-hydroxymethylphenyI)-5-methyl-(1,3,4- oxadiazole (0.75 g).
IR (KBr) : 3323 (br), 2877, 2819, 1614, 1576, 1416,
1257, 1053, 833, 729 cm-1
NMR (DMSO-d6, δ) : 2.58 (3H, s) , 4.59 (2H, d,
J=5.4Hz), 5.39 (1H, t, J=5.4Hz), 7.47-7.57 (2H, m), 7.87-7.97 (2H, m)
APCI-MASS (m/z) : 191 (M+H+) Preparation 98
A mixture of 2-[4-(tert-butyldimethylsilyloxymethyl)- phenyl]-5-methyl-1,3,4-oxadiazole (5.05 g) and benzylamine (18 ml) was heated for 2 drops at 150°C. After cooling to room temperature, the mixture was chromatographed on silica gel (250 g, eluting with dichloromethane-methanol (20:1)) to give 4-benzyl-3-[4-(tert-butyldimethylsilyloxymethyl)- phenyl]-5-methyl-4H-1,2,4-triazole (5.04 g).
mp : 90-91°C
IR (KBr) : 2953, 2929, 2885, 2854, 1524, 1460, 1431,
1255, 1101, 1003, 835 cm-1
NMR (CDCl3, δ) : 0.08 (6H, s), 0.94 (9H, s), 2.37
(3H, s), 4.77 (2H, s), 5.16 (2H, s), 6.90-7.03 (2H, m), 7.27-7.55 (7H, m)
APCI-MASS (m/z) : 394 (M+H+)
Preparation 99
To the solution of N-cycloheptyI-4-(4-benzyl-5-methyl- 4H-1,2,4-triazol-3-yl)benzylamine (500 mg) in methanol (25 ml) was added Palladium Black (500 mg) and formic acid
(1.25 ml). The mixture was stirred for 4.5 hours at the room temperature. Palladium Black was removed by
filtration. The filtrate was basified with 1N sodium hydroxide aqueous solution under ice cooling and evaporated in vacuo to dryness. The residue was diluted with
dichloromethane-methanol (5:1), dried over magnesium sulfate, evaporated in vacuo. After chromatography on silica gel (15 g, eluting with dichloromethane-methanol (4:1)) N-cycloheptyl-4-(5-methyl-4H-I,2,4-triazol-3- yl) benzylamine (219.6 mg) was isolated.
IR (KBr) : 2500-3700 (br), 2926, 2854, 1564, 1458,
1099 cm-1
NMR (CDCl3, δ) : 1.30-2.00 (12H, m), 2.48 (3H, s), 2.65-2.80 (1H, m), 3.83 (2H, s), 4.60-5.15 (2H, br), 7.30-7.40 (2H, m), 7.90-8.00 (2H, m)
APCI-MASS (m/z) : 285 (M+H+)
Preparation 100
To the solution of 3-(1H-tetrazol-5-yl)benzaldehyde ( 600 mg ) in N, N-dimethylformamide ( 6 ml ) was added sodium hydride (60% oil suspension, 138 mg) at 0-5°C. After stirring for 15 minutes, to the mixture was added methyl iodide (0.43 ml). The solution was stirred for 3 hours at room temperature, then stirred for 30 minutes at 40°C. The reaction mixture was poured into water and extracted with ethyl acetate, washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. After
chromatography on silica gel (25 g, eluting with n-hexane - ethyl acetate (1:1), 3-(2-methyl-2H-tetrazol-5- yl) benzaldehyde (510.7 mg) and 3-(1-methyl-1H-tetrazoI-5- yl) benzaldehyde (81.6 mg) was obtained.
3-(2-Methyl-2H-tetrazol-5-yl) benzaldehyde
mp : 98-99°C
IR (KBr) : 3072, 2839, 1691, 1587, 1520, 1443 cm-1 NMR (DMSO-d6, δ) : 4.47 (3H, s), 7.81 (1H, dd, J=7.7,
7.7Hz), 8.05-8.10 (1H, m), 8.33-8.40 (1H, m),
8.55-8.58 (1H, m), 10.14 (1H, s)
APCI-MASS (m/z) : 189 (M+H+) 3-(1-1ethyl-1H-tetrazol-5-yl) benzaldehyde IR (KBr) : 1699, 1608, 1535, 1450, 1394 cm-1
NMR (DMSO-d6, δ) : 4.22 (3H, s), 7.87 (1H, dd, J=7.7, 7.7Hz), 8.13-8.25 (2H, m), 8.38-8.40 (1H, m), 10.14 (1H, s)
APCI-MASS (m/z) : 189 (M+H+ )
Preparation 101
To the solution of 4-fluorobenzaldehyde (3.0 g) and iH-1, 2, 4-trιazole (2.0 g) m N,N-dimethylformamide (30 ml) was added potassium carbonate (4.0 g). Then the mixture was heated for one hour at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water, brme, dried over magnesium sulfate and evaporated m vacuo. The resulting solid was collected and washed with diisopropyl ether to give 4-(1H-1,2,4-triazol- 1-yl) benzaldehyde (1.95 g).
mp : 147-148°C
IR (KBr) : 3130, 2856, 1709, 1603, 1518, 1441,
1275 cm -1
NMR (CDCl3, δ) : 7.88-8.01 (2H, m), 6.01-8.14 (2H, m), 8.16 (1H, s), 8.70 (1H, s), 10.07 (1H, s) APCI-MASS (m/z) : 174 (M+H+)
Preparation 102
To a solution of 4-fluorobenzaldehyde (5.0 g) and 1H- 1,2,3-trιazole (3.33 g) in N,N-dimethylformamide (50 ml) was added potassium carbonate (6.68 g). Then the mixture was heated for one hour at 120°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water, brme, dried over magnesium sulfate ana evaporated to about 50 ml m vacuo. The resulting
precipitate was collected by filtration, washed witn n- hexane to give 4-(1H-1,2,3-trιazol-1-yl) benzaldehyde (3.44 g). The mother liquid was evaporated to about 10 ml in vacuo. The resulting precipitate was also collected in the similar procedure as mentioned above to give 4-(2H-1,2,3- triazol-2-yl) benzaldehyde (297 mg).
4-(1H-1,2,3-Triazol-1-yl)benzaldehyde
IR (KBr) : 3138, 3116, 2845, 1695, 1603, 1516, 1419,
1389 cm-1
NMR (CDCl3, δ) : 7.91 (1H, s), 7.93-8.11 (4H, m),
8.12 (1H, s), 10.09 (1H, s)
APCI-MASS (m/z) : 174 (M+H+)
4-(2H-1,2,3-Trιazol-2-yl)benzaldehyde
IR (KBr) : 3114, 3084, 2715, 1699, 1603, 1508, 1408,
1383 cm-1
NMR (CDCl3, δ) : 7.89 (2H, s), 7.95-8.06 (2H, m),
8.23-8.33 (2H, m), 10.06 (1H, s)
APCI-MASS (m/z) : 174 (M+H+)
Preparation 103
To a solution of 4-fluorobenzaldehyde (6.21 g) in N,N-dimethylformamide (100 ml) were added
11-methylpιperazme (6.01 g) and powdered potassium
carbonate (8.29 g), and the mixture was stirred at 150°C for 4.5 hours under nitrogen. The mixture was poureα into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brme, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (4-methylpιperazm-1-yl) benzaldehyde (5.31 g) as a yellow solid.
IR (KBr) : 2935, 2840, 2790, 2750, 1690, 1600, 1560 ,
1520 cm- 1
NMR (DMSO-d6, δ) : 2.22 (3H, s), 2.4-2.5 (4H, m),
3.35-3.45 (4H, m), 7.04 (2H, d, J=8.8Hz), 7.70 (2H, d, J=8.8Hz), 9.71 (1H, s) Preparation 104
To a solution of 4-bromoaniline (6.88 g) in pyridine (20 ml) was added dropwise methanesulfonyl chloride (4.58 g) at 5°C and the mixture was stirred at 5°C for 1.5 hours and at room temperature for 1.5 hours. The mixture was poured into a mixture of ethyl acetate and dilute
hydrochloric acid and the insoluble materials were filtered off. The filtrate was separated and the organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was crystallized and the crystal was collected by filtration, washed with
diisopropyl ether and dried to give 4-bromo-N- methylsulfonylaniline (8.30 g) .
IR (KBr) : 3290, 1490 cm-1
NMR (DMSO-d6, δ) : 3.00 (3H, s), 7.16 (2H, d,
J=8.7Hz), 7.52 (2H, d, J=8.7Hz), 9.92 (1H, br)
Preparation 105
To a suspension of N-methyl-N-methoxy-4- sulfamoylbenzamide (3.53 g) and benzole acid (1.95 g) in dichloromethane (100 ml) were added 4-dimethylaminopyridine (1.96 g) and 1-(3-dimethylaminopropyl)-3-ethyl
carbodiimide-hydrochloride (3.07 g) at room temperature and the mixture was stirred at the same temperature for 18 hours. The mixture was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-methyl-N-methoxy 4-(N-benzoylsulfamoyl) benzamide (1.35 g).
IR (KBr) : 3072, 2970, 2937, 1649, 1597, 1560,
1544 cm-1
NMR (DMSO-d6, δ) : 3.27 (3H, s), 3.55 (3H, s), 7.35- 7.5 (3H, m), 7.68 (2H, d, J=8.2Hz), 7.85-7.95 (2H, m), 7.96 (2H, d, J=8.2Hz)
APCI-MASS (m/z) : 349 (M+H+) Preparation 106
To a suspension of 4-cyanobenzaldehyde (26.23 g) was added carefully sodium borohydride (3.78 g) at room
temperature, and the mixture was stirred at the same temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over
magnesium sulfate and evaporated in vacuo to give crude 4-cyanobenzyl alcohol (24.97 g) as an oil.
IR (Film) : 3419, 2916, 2875, 2229, 1610 cm-1
NMR (CDCl3, δ) : 2.07 (1H, br), 4.79 (2H, br s), 7.41
(2H, d, J=8.1Hz), 7.65 (2H, d, J=8.1Hz) APCI-MASS (m/z) : 134 (M+H+) Preparation 107
To a solution of 4-cyanobenzyl alcohol (24.96 g) in N, N-dimethylformamide (100 ml) were added imidazole (16.0 g) and tert-butyldimethylsilyl chloride (31.0 g) at room temperature and the mixture was stirred for 2 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(tert- butyldimethylsilyloxymethyl) benzonitrile (40.78 g) as an oil.
IR (Film) : 2954, 2429, 2885, 2858, 2229, 1610 cm-1 NMR (CDCl3, δ) : 0.11 (6H, s), 0.95 (9H, s), 4.79
(2H, s), 7.43 (2H, d, J=8.3Hz), 7.63 (2H, d, J=8.3Hz)
APCI-MASS (m/z) : 248 (M+H+)
Preparation 108
To a solution of n-butyllithium (1.71M hexane
solution, 58.5 ml) in diethyl ether (150 ml) was added dropwise 3-bromopyridine (15.8 g) at 5°C, and the mixture was stirred at 5°C for an hour. The mixture was cooled to -6C°C and a solution of 4-(tert-butyldimethylsiiyl- oxymethyl) benzonitrile (19.79 g) in diethyl ether (80 ml) was added dropwise over 1.2 hours under nitrogen. The mixture was gradually warmed to room temperature and stirred at the same temperature for additional 2 hours. The mixture was poured into a mixture of ethyl acetate and dilute hydrochloric acid, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-[( 4-tert- butyldimethylsilyloxymethyl ) benzoyl ] pyridine ( 4 . 96 g) as a red oil.
IR (Film) : 3034, 2954, 2930, 2835, 2856, 1660, 1608,
1585, 1537 cm-1
NMR (CDCl3, δ) : 0.16 (6H, s), 0.99 (9H, s), 4.87
(2H, s), 7.50 (2H, d, J=7.6Hz), 7.83 (2H, d, J=7.6Hz), 7.4-7.5 (1H, m), 8.1-8.2 (1H, m), 8.6- 8.9 (1H, m), 8.99 (1H, d, J=2.1Hz)
APCI-MASS (m/z) :328 (M+H+)
Preparation 109
To a suspension of 3-[(4-tert-butyldimethylsilyloxy- methyl) benzoyl]pyridine (4.94 g) in ethylene glycol (40 ml) were added potassium hydroxide (1.27 g) and hydrazine hydrate (4.84 g) and the mixture was stirred at 150°C for 2 hours and at 200°C for 4 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(3-pyridylmethyl) benzyl alcohol (1.26 g) as an orange oil.
IR (Film) : 3323, 3030, 2920, 2868, 1579, 1549, 1514 cm-1
NMR (CDCl3, δ) : 1.85 (1H, br), 3.97 (2H, s), 4.67
(2H, s), 7.15-7.5 (6H, m), 8.45-8.55 (2H, m) APCI-MASS (m/z) : 200 (M+H+)
Preparation 110
To a solution of 4-(3-pyridylmethyl) benzyl alcohol (1.26 g) in chloroform (30 ml) was activated manganese dioxide (5.50 g) and the mixture was refluxed for 2 hours. Manganese dioxide was removed off and the filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give 4-(3-pyridylmethyl)- benzaldehyde (1.09 g) as an orange oil.
IR (Film) : 3029, 2989, 2910, 2831, 2738, 1697, 1599,
1510 cm-1
NMR (CDCl3, δ) : 4.07 (2H, s), 7.24 (1H, dd, J=7.8, 4.8Hz), 7.35 (2H, d, J=8.1Hz), 7.47 (1H, dd, J=7.8, 1.4Hz), 7.83 (2H, d, J=8.1Hz), 8.49 (1H, d, J=1.4Hz), 8.51 (1H, s), 9.99 (1H, s) APCI-MASS (m/z) : 198 (M+H+)
Preparation 111
To a solution of 1-ethoxycarbonyl-4-diethylphosphono- 1,4-dihydropyridine (34.71 g) in tetrahydrofuran (200 ml) was added dropwise n-butyllithium (1.71M hexane solution, 70.2 ml) at -60°C over 30 minutes under nitrogen, and the mixture was stirred at -60°C for 40 minutes. To this solution was added dropwise a solution of 4-cyanobenzyI bromide (27.40 g) in tetrahydrofuran (80 ml) at -60°C and the mixture was gradually warmed to room temperature and stirred for 21 hours. The mixture was poured into a mixture of ethyl acetate and dilute hydrochloric acid, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-ethoxycarbonyI-4-(4-cyanobenzyl)-4- diethylphosphono-1,4-dihydropyridine (47.10 g) as a crude red oil.
IR (Film) : 3053, 2891, 2933, 2903, 2227, 1728, 1689,
1626, 1606 cm-1
NMR (CDCl3, δ) : 1.2-1.4 (9H, m), 3.06 (2H, d,
J=7.6Hz), 4.1-4.3 (6H, m), 4.7-4.9 (2H, m),
7.65-7.9 (2H, m), 7.22 (2H, d, J=8.2Hz), 7.55 (2H, d, J=8.2Hz)
APCI-MASS (m/z) : 405 (M+H+)
Preparation 112
To a solution of 1-ethoxycarbonyl-4-(4-cyanobenzyl)-4- diethylphosphono-1,4-dihydropyridine (42.10 g) in
dichloromethane (350 ml) was added dropwise
diisobutylaluminum hydride (1.01M toluene solution, 515 ml) at -60°C over 55 minutes and the mixture was stirred at - 60°C for 1.5 hours. The mixture was gradually warmed to 5°C and stirred at 5°C for 1.5 hours. To the mixture were added sodium fluoride (87.34 g) and water (28.11 g) and tne mixture was stirred at room temperature for an hour. The insoluble materials were filtered off and washed with dichloromethane. The filtrate was evaporated in vacuo and the residue was dissolved in tetrahydrofuran (200 mi). To this solution was added 6N hydrochloric acid (30 ml) and the mixture was stirred at room temperature for 3 hours. The mixture was adjusted to pH ca. 8 by addition of 5N sodium hydroxide and extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(4-pyridylmethyl) benzaldehyde (4.62 g) as a red oil.
IR (Film) : 3381, 3053, 3030, 2924, 2831, 2738, 1697,
1606, 1576 cm-1
NMR (CDCl3, δ) : 4.08 (2H, s), 7.1-7.2 (2H, m), 7 . 3- 7 . 4 5 ( 2H, m) , 7 . 8-7 . 9 ( 2K, m), 8 . 5- 8 . 6 ( 2H, m) , 10 . 00 ( 1H, s )
Preparation 113
To a solution of pyrazole (1.67 g) in
N, N-dimethylformamide (30 ml) was added sodium hydride (60% oil suspension, 950 mg) at 0-5°C. After stirring for 30 minutes, to the mixture was added a solution of
4-bromomethylbenzonitrile (4.0 g) in N,N-dimethylformamide (10 ml) dropwise under ice cooling, and the mixture was stirred for two hours at room temperature. The reaction mixture was diluted with ethyl acetate (240 ml), washed with water and brine, dried over magnesium sulfate,
evaporated in vacuo. The residue was chromatographed on silica gel (100 g, eluting with n-hexane - ethyl acetate
(1:1)) to give 4- (pyrazol-1-ylmethyl) benzonitrile (3.49 g). mp : 80-81°C
IR (KBr) : 3055, 2958, 2229, 1610, 1510, 1446, 1392,
1275 cm-1
NMR (CDCl3, δ) : 5.39 (2H, s), 6.33 (1H, dd, J=2.1,
2.1Hz), 7.18-7.30 (2H, m), 7.44 (1H, d, J=2.1Hz), 7.55-7.70 (3H, m)
APCI-MASS (m/z) : 184 (M+H+) Preparation 114
To a solution of imidazole (1.67 g) in
N, N-dimethylformamide (30 ml) was added sodium hydride (60- oil suspension, 950 mg) at 0-5°C. After stirring for 30 minutes, to the mixture was added a solution of
4-bromomethylbenzonitrile (4.0 g) in N,N-dimethylformamide (10 ml) dropwise under ice cooling, and the mixture was stirred for two hours at room temperature. The reaction mixture was diluted with ethyl acetate (240 ml), washed with water and brine, dried over magnesium sulfate,
evaporated in vacuo. The residue was chromatographed on silica gel (100 g, eluting with dichloromethane - methanol (15:1)) to give 4-(imidazol-1-ylmethyl) benzonitrile (3.26 g).
IR (KBr) : 3095, 3057, 2229, 1608, 1510, 1425, 1236,
1074, 731 cm-1
NMR (CDCl3, δ) : 5.21 (2H, s), 6.90 (1H, s), 7.14
(1H, s), 7.15-7.27 (2H, m), 7.57 (1H, s), 7.60-
7.72 (2H, m)
APCI-MASS (m/z) : 184 (M+H+)
Preparation 115
To a suspension of 3,5-di-tert-butyl-4-hydroxybenzoic acid (10.0 g) in methanol (100 ml) were added sodium hydroxide (1.6 g) and water (6 ml) and the mixture was stirred at room temperature for 35 minutes. The mixture was evaporated in vacuo and dried thoroughly. The sodium salt was suspended in petroleum ether (60 ml), and thionyl Cxhloride (30.93 g) was added thereto and the mixture was stirred at room temperature for 16 hours. The mixture was evaporated in vacuo and the residue was redissolved in petroleum ether (200 ml). The insoluble materials were filtered off and the filtrate was evaporated in vacuo to give 3,5-di-tert-butyl-4-hydroxybenzoyl chloride (9.81 g) as a yellow solid.
IR (KBr) : 3554, 2974, 2956, 1736, 1597, 1574 cm-1
Preparation 116
To a solution of sodium azide (4.61 g) in water (30 ml) was added dropwise a solution of 3,5-di-tert-butyl-4- hydroxybenzoyl chloride (12.72 g) in tetrahydrofuran (60 ml) at 5°C over 30 minutes, and the mixture was stirred at 5°C for 1.5 hours. The mixture was extracted with ethyl acetate, and the organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. To the residue was added n-hexane (60 ml) and the insoluble materials were filtered off. The filtrate was evaporated m vacuo to give 3,5-di-tert-butyl-4-hydroxybenzoyl azide (1.49 g) as a yellow solid.
IR (KBr) : 3593, 2966, 2912, 2873, 2141, 1668,
1599 cm-1
Preparation 117
A suspension of 3,5-di-tert-butyl-4-hydroxybenzoyl azide (1.49 g) in benzene (30 ml) was refluxed for an hour under nitrogen. To tne mixture was added tert-butanol (4.01 g) and the mixture was refluxed for 3 hours. The mixture was evaporated m vacuo and the residue was purified by column chromatography on silica gel to give N-tert-butoxycarbonyl-3, 5-di-tert-butyl-4-hydroxyanιlme (1.17 g) as a white solid.
IR (KBr) : 3647, 3331, 2958, 2913, 2873, 1693, 1606,
1547 cm-1
NMR (DMSO-d6, δ) : 1.34 (18H, s), 1.44 (9H, s), 6.60 (1H, s), 7.22 (2H, s), 8.84 (1H, br s)
Preparation 118
To a solution of N-tert-butoxycarbonyl-3,5-di-tert- butyl-4-hydroxyanιlme (3.97 g) in ethyl acetate (60 ml) and ethanol (15 ml) was added 4N hydrochloric acid in ethyl acetate (30.8 ml) and the mixture was stirred at room temperature for 24 hours. The mixture was evaporateα m vacuo and the residue was triturateα with diisopropyl ether. The powder was collected by filtration, washed with diisopropyl ether and dried in vacuo to give 3,5-dι-tert- butyl-4-hydroxyanιlme-hydrochlorιde (2.85 g).
IR (KBr) : 2966, 2912, 2873, 2590, 1581, 1512 cm-1 NMR (DMSO-d6, δ) : 1.38 (18K, s), 7.12 (2H, s),
7.34 (1H, s), 9.83 (2H, br s) Preparation 119
To a suspension of 4-formylbenzoic acid (1.65 g), 3,5- di-tert-butyl-4-hydroxyaniline-hydrochloride (2.83 g) and 1-hydroxybenzotriazole (1.49 g) in dichloromethane (60 ml) was added 3-(3-dimethylaminopropyl)-1-ethylcarbodiimide
(1.71 g) at room temperature and the resulting solution was stirred at the same temperature for 20 hours. The mixture was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-[(3,5-di- tert-butyl-4-hydroxyphenyl) carbamoyl]benzaldehyde (2.53 g).
IR (KBr) : 3624, 3286, 2958, 2912, 2872, 1703, 1645,
1606, 1547 cm-1
NMR (DMSO-d6, δ) : 1.43 (18H, s), 6.83 (2H, d,
J=5.1Hz), 7.09 (2H, d, J=5.1Hz), 7.12 (2H, s),
10.07 (1H, s), 10.19 (1H, s)
APCI-MASS (m/z) : 354 (M+H+)
Preparation 120
To a suspension of 4-formylbenzoic acid (7.5 g) in dichloromethane (25 ml) were added thionyl chloride (11.9 g) and N,N-dimethylformamide (365 mg) at room temperature, and the mixture was refluxed for 4 hours under nitrogen. The mixture was evaporated in vacuo and dried in vacuo to give crude 4-formylbenzoyl chloride (8.53 g) as a white powder.
IR (KBr) : 3066, 2856, 1745, 1691, 1576, 1504 cm-1
Preparation 121
To a solution of 4-fluoroaniline (5.0 g) and
triethylamine (6.07 g) in dichloromethane (60 ml) was added portionwise 4-formylbenzoyl chloride (8.53 g) at 5°C and the mixture was stirred at room temperature for 2 hours. The mixture was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was crystallized from hexane - ethyl acetate (3:1) and
collected by filtration, washed with hexane - ethyl acetate (3:1) and dried in vacuo to give 4-[N-(4-fluorophenyl)- carbamoyl] benzaldehyde (4.58 g).
IR (KBr) : 3356, 2872, 1703, 1651, 1606, 1537,
1514 cm-1
NMR (DMSO-d6, δ) : 7.15-7.3 (2H, m), 7.8-7.9 (2H, m), 8.06 (2H, d, J=8.4Hz), 8.14 (2H, d, J=8.4Hz), 10.12 (1H, s), 10.53 (1H, br s)
APCI-MASS (m/z) : 244 (M+H+)
Preparation 122
To a suspension of sodium hydride (60% oil dispersion, 464 mg) in N,N-dimethylformamide (50 ml) was added dropwise a solution of 4-[N-(4-fluorophenyl) carbamoyl] benzaldehyde (2.63 g) in N,N-dimethylformamide (40 ml) at 5°C under nitrogen, and the mixture was stirred at room temperature for an hour. To the mixture was added methyl iodide (3.29 g), and the mixture was stirred at room temperature for 3 hours. The mixture was poured into a mixture of ethyl acetate and ice water. The separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-[N-(4- fluorophenyl)-N-methylcarbamoyl]benzaldehyde (2.24 g) as an orange oil.
IR (Film) : 3068, 2981, 2939, 2839, 2737, 1703, 1639,
1608, 1571, 1510 cm-1
NMR (DMSO-d6, δ) : 3.37 (3H, s), 7.05-7.2 (2H, m), 7.25-7.35 (2H, m), 7.46 (2H, d, J=8.1Hz), 7.77
(2H, d, J=8.1Hz), 9.93 (1H, s)
APCI-MASS (m/z) : 258 (M+H+)
Preparation 123
To a solution of 1,4-bis (hydroxymethyl) benzene (25.72 g) in N,N-dimethylformamide (300 ml) were added imidazole (15.21 g) and tert-butyldimethylsilyl chloride (28.06 g) at room temperature, and the mixture was stirred for 10 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(tert- butyldimethylsilyloxymethyl) benzyl alcohol (27.89 g) as an oil.
IR (Film) : 3352, 2954, 2931, 2887, 2858, 1541, 1514,
1466 cm-1
NMR (DMSO-d6, δ) : 0.07 (6H, s), 0.90 (9H, s), 4.47 (2H, d, J=5.7Hz), 4.68 (2H, s), 5.10 (1H, t, J=5.7Hz), 7.2-7.3 (4H, m)
Preparation 124
To a solution of 4-(tert-butyldimethylsilyloxymethyl)- benzyl alcohol (27.86 g) in chloroform (300 ml) was added activated manganese dioxide (47.98 g) and the mixture was refluxed for 3.5 hours. Manganese dioxide was filtered off and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (tert-butyldimethylsilyloxymethyl) benzaldehyde (26.86 g) as a pale yellow oil.
IR (Film) : 2955, 2931, 2889, 2858, 2731, 1703,
1608, 1578, 1541 cm-1
NMR (DMSO-d6, δ) : 0.10 (6H, s), 0.92 (9H, s), 4.82 (2H, s), 7.53 (2H, d, J=8.2Hz), 7.89 (2H, d,
J=8.2Hz), 9.99 (1H, s)
Preparation 125
To a solution of N-cycloheptyl-4-(tert- butyldimethylsilyloxymethyl) benzylamine (53.74 g) in
methanol (250 ml) was added dropwise cone, hydrochloric acid (38.6 ml) at 5°C, and the mixture was stirred at room temperature for 3 hours. The mixture was evaporated in vacuo and the residue was pulverized with tetrahydrofuran and ethyl acetate. The powder was collected by filtration, washed with ethyl acetate and tetrahydrofuran and ethyl acetate (1:1), and dried in vacuo under phosphorus
pentoxide to give N-cycloheptyl-4- hydroxymethylbenzylamine-hydrochloride (37.92 g).
IR (KBr) : 3294, 2927, 2858, 2791, 1578, 1541, 1514,
1456 cm-1
NMR (DMSO-d6, δ) : 1.4-2.2 (12H, m), 3.05-3.25 (1H, m), 4.12 (2H, s), 4.52 (2H, d, J=5.7Hz), 5.27 (1H, t, J=5.7Hz), 7.36 (2H, d, J=8.0Hz), 7.48 (2H, d, J=8.0Hz), 8.7-8.9 (1H, br)
APCI-MASS (m/z) : 234 (M+H+-HCl)
Preparation 126
To a suspension of N-cycloheptyl-4- hydroxymethylbenzylamine-hydrochloride (37.9 g) in
chloroform (400 ml) were added activated manganese dioxiαe (60.86 g) and triethylamine (14.21 g), and the mixture was refluxed for 4 hours. Manganese dioxide was filtered off and the filtrate was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cycloheptyl-4-formylbenzylamme (18.27 g) as a yellow oil.
IR (Film) : 3051, 2924, 2854, 2731, 1701, 1606, 1576,
1468 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.0-2.2 (1H,
br), 2.5-2.7 (1H, m), 3.77 (2H, s), 7.56 (2H, d, J=8.1Hz), 7.85 (2H, d, J=8.1Hz), 9.97 (1H, s) APCI-MASS (m/z) : 232 (M+H+) Preparation 127
To a solution of N-cycloheptyl-4-formylbenzylamine (18.26 g) in ethanol (200 ml) were added thiazolidin 2,4- dione (9.25 g) and piperidine (6.72 g), and the mixture was refluxed for 17 hours. The mixture was cooled to 5°C and the precipitates were collected by filtration, washed with ethanol and diisopropyl ether and dried in vacuo to give N-cycloheptyl-4-[(2,4-dioxothiazolidin-5-ylidene)methyl]- benzylamine (9.61 g) as a yellow crystal. The filtrate was evaporated in vacuo and the residue was purified by column chromatography on silica gel to give the second crop (4.13 g).
IR (KBr) : 3429, 3024, 2929, 2858, 1684, 1622, 1576,
1547, 1458 cm-1
NMR (DMSO-d6, δ) : 1.3-2.2 (12H, m), 3.05-3.25 (1H, m), 4.12 (2H, s), 7.35 (1H, s), 7.52 (2H, d, J=8.5Hz), 7.58 (2H, d, J=8.5Hz)
APCI-MASS (m/z) : 331 (M+H+) Preparation 128
To a suspension of N-cycloheptyl-4-[(2,4- dioxothiazolin-5-ylidene)methyl]benzylamine (13.61 g) in tetrahydrofuran (300 ml) and methanol (300 ml) was added 5% sodium-amalgam (56.8 g), and the mixture was stirred at room temperature for 24 hours. The insoluble materials were removed by filtration on celite and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cycloheptyl-4-[(2,4- dioxothiazolidin-5-yl)methyl] benzylamine (5.84 g) as a yellow solid.
IR (KBr) : 3028, 2933, 2862, 2764, 1674, 1630, 1581,
1460 cm-1
NMR (DMSO-d6, δ) : 1.3-2.2 (12H, m), 2.9-3.1 (1H, m), 2.95 (1H, dd, J=13.8, 9.3Hz), 3.36 (1H, dd,
J=9.3, 4.0Hz), 4.54 (1H, dd, J=9.3, 4.0Hz), 7.25 (1H, d, J=8.1Hz), 7.38 (1H, d, J=8.1Hz)
APCI-MASS (m/z) : 333 (M+H+)
Preparation 129
To a solution of 4-fluorobenzaldehyde (20.11 g) and 4- chlorophenol (25.0 g) in N,N-dimethylformamide (250 ml) was added powdered potassium carbonate (26.81 g), and the mixture was stirred at 150°C under nitrogen for 7 hours. The mixture was cooled and poured into a mixture of ethyl acetate and water. The separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4-(4- chlorophenoxy) benzaldehyde (32.49 g) as a yellow oil.
IR (Film) : 3070, 2985, 2830, 2740, 1735, 1695, 1605,
1580, 1485 cm-1
NMR (CDCl3, δ) : 7.0-7.15 (4H, m), 7.35-7.45 (2H, m),
7.8-7.9 (2H, m), 9.93 (1H, s)
APCI-MASS (m/z) : 235, 233 (M+H+)
Preparation 130
To a solution of 4-fluorobenzaldehyde (5 g) and 3- fluorophenol (5.42 g) in N,N-dimethylformamide (50 mi) was added potassium carbonate (6.68 g). Then the mixture was heated for 3.5 hours at 150°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water, brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was chromatographed on silica gel (200 g, eluting with n-hexane - ethyl acetate (10:1)) to give 4-(3-fluorophenoxy) benzaldehyde (8.67 g).
IR (Neat) : 3072, 2831, 2738, 1697, 1587, 1483 cm-1 NMR (CDCl3, δ) : 6.75-7.00 (3H, m), 7.05-7.18 (2H, m), 7.28-7.42 (1H, m), 7.82-7.95 (2H, m), 9.95 (1H, s)
APCI-MASS (m/z) : 217 (M+H+) Preparation 131
To a solution of 4-fluorobenzaldehyde (3 g) and
4-trifluoromethylphenol (4.7 g) in N,N-dimethylformamide (30 ml) was added potassium carbonate (4.0 g). Then the mixture was heated for 5 hours at 150°C. After cooling, the reaction mixture was diluted with ethyl acetate (300 ml), washed with water, brine, dried over magnesium sulfate and evaporated in vacuo. The residue was chromatographed on silica gel (200 g, eluting with n-hexane - ethyl acetate (15:1)) to give 4-(4-trifluoromethylphenoxy) benzaldehyde (982.1 mg).
IR (Neat) : 3074, 2831, 2738, 1701, 1587, 1502 cm-1 NMR (CDCl3, δ) : 7.05-7.25 (4H, m), 7.60-7.75 (2H, m), 7.85-7.98 (2H, m), 9.96 (1H, s)
FAB-MASS (m/z) : 267 (M+H+)
Preparation 132
To a solution of 4-fluorobenzaldehyde (3 g) and 3,4- methylenedioxyphenol (4 g) in N, N-dimethylformamide (30 ml) was added potassium carbonate (4 g) . Then the mixture was heated for 2 hours at 150°C. After cooling, the reaction mixture was diluted with ethyl acetate (200 ml), washed with water, brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was chromatographed en silica gel (120 g, eluting with n-hexane - ethyl acetate (5:1)) to give 4-(3,4-methylenedioxyphenoxy) benzaldehyde (2.67 g) .
mp : 65-66°C
IR (KBr) : 1691, 1600, 1481, 1227 cm-1
NMR (CDCl3, δ) : 6.02 (2H, s), 6.50-6.65 (2H, m),
6.82 (1H, d, J=8.3Hz), 6.96-7.07 (2H, m), 7.78- 7.89 (2H, m), 9.91 (1H, s)
APCI-MASS (m/z) : 243 (M+HH) Preparation 133
To a solution of 4-fluorobenzaldehyde (2.48 g) and 3,5-di-tert-butyl-4-methoxymethoxyphenol (5.33 g) in N,N- dimethylformamide (40 ml) was added powdered potassium carbonate (2.76 g), and the mixture was stirred at 150°C for 6 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 4- (3,5-di-tert-butyl-4-methoxymethoxyphenoxy) benzaldehyde (4.03 g) as an orange oil.
IR (Film) : 2960, 2872, 2740, 2693, 1581, 1504 cm-1 NMR (CDCl3, δ) : 1.43 (18H, s), 3.66 (3H, s), 4.94 (2H, s), 6.99 (2H, s), 7.02 (2H, d, J=8.8Hz),
7.83 (2H, d, J=8.8Hz), 9.92 (1H, s)
APCI-MASS (m/z) : 371 (M+H+)
Preparation 134
To a solution of 4-fluoronitrobenzene (14.11 g) and 4- fluorophenol (12.33 g) in N,N-dimethylformamide (150 ml) was added powdered potassium carbonate (15.20 g), and the mixture was stirred at 100°C for 4.5 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was crystallized and the crystal was collected by filtration and washed with hexane and dried to give 4- (4-fluorophenoxy) nitrobenzene (22.96 g) as a yellow crystal.
IR (KBr) : 3110, 3075, 2925, 2835, 1585, 1510 cm-1 NMR (CDCl3, δ) : 6.95-7.2 (6H, m), 8.15-8.3 (2H, m) APCI-MASS (m/z) : 234 (M+H+) Preparation 135
To a suspension of 3-hydroxybenzyl alcohol (12.41 g) and 1-chloro-4-fluorobenzene (19.58 g) in 1,3-dimethyl-2- imidazolidinone (40 ml) were added powdered potassium carbonate (8.29 g), cuprous chloride (198 mg) and
8-hydroxyquinoline (290 mg) at room temperature, and the mixture was stirred at 150°C for 8 hours. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-(4-fluorophenoxy) benzyl alcohol (3.98 g) as a yellow oil.
IR (Film) : 3352, 3074, 2931, 2875, 1610, 1585, 1502,
1448 cm-1
NMR (DMSO-d6, δ) : 4.47 (2H, d, J=5.6Hz), 5.22 (1H, t, J=5.6Hz), 6.8-7.4 (8H, m)
Preparation 136
To a solution of 4-fluorobenzonitrile (50.0 g) and 4- fluorophenol (50.93 g) in N, N-dimethylformamide (400 ml) was added powdered potassium carbonate (62.75 g), and the mixture was stirred at 150°C for 6 hours. The mixture was cooled to 5°C and poured into ice water (2.5 ℓ). The precipitates were collected by filtration, washed with water and dried in vacuo to give 4-(4-fluorophenoxy)- benzonitrile (87.56 g).
IR (KBr) : 3188, 3076, 2220, 1649, 1608, 1483 cm-1 NMR (DMSO-d6, δ) : 7.05-7.15 (2H, m), 7.2-7.45 (4H, m), 7.8-7.9 (2H, m)
APCI-MASS (m/z) : 214 (M+H-1-)
Preparation 137
To a stirred suspension of 3-acetylbenzonitrile (25.4 g) m ethyl ether - 1,4-dioxane (10:1, 275 ml) was added bromine (9 ml) dropwise at room temperature. After 40 minutes, to the mixture was added sodium bicarbonate (15 g) in water (200 ml) at 0-5°C, and extracted with ethyl acetate. The organic layer was separated and washed with saturated sodium bicarbonate solution, water and brine, dried over magnesium sulfate, evaporated in vacuo to give 3- (bromoacetyl) benzonitrile (39.2 g).
IR (KBr) : 3103, 3068, 2941, 2229, 1707, 1599,
1429, 1279, 1223, 1149 cm-1
NMR (CDCl3, δ) : 4.42 (2H, s), 7.66 (1H, dd, J=8.1,
8.1Hz), 7.85-7.95 (1H, m), 8.18-8.32 (2H, m)
Preparation 138
A mixture of 3-(pyrazol-3-yl) benzaldehyde (56.0 g) and benzylamine (42.6 ml) in toluene (560 ml) was refluxed for 5 hours. The reaction mixture was cooled to room
temperature, and evaporated in vacuo. The residue was suspended in ethanol (840 ml) and sodium borohydride (12.3 g) was added carefully under ice cooling. Then the mixture was stirred for one hour at 50°C. After additional
stirring for 2 hours at room temperature, the reaction mixture was evaporated in vacuo. To the residue was added water (300 ml), and extracted with dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (1.5 kg, eluting with
dichloromethane - methanol (10:1)) to give N-benzyl-3- (pyrazol-3-yl)benzylamine (71.8 g).
mp : 82-83°C
IR (KBr) : 2290-3310 (br), 1606, 1543, 1441,
1354 cm-1
NMR (DMSO-d6, δ) : 3.71 (2H, s), 3.72 (2H, s), 6.68 (1H, d, J=2.1Hz), 7.15-7.42 (7H, m), 7.50-7.90 (3H, m), 12.85, 13.22 (total 1H, each br)
APCI-MASS (m/z) : 264 (M+H+) Preparation 139
To a solution of 4-(4-fluorophenoxy) aniline (2.03 g) ana cycloheptanone (1.35 g) in ethanol (40 ml) were aαded simultaneously a solution of sodium cyanoborohydride (314 mg) m ethanol (30 ml; and a solution of acetic acid (601 mg) in ethanol [ 10 ml) over 1 hour at room temperature. The mixture was stirreα at room temperature for additional 1.2 hours. The mixture was evaporated in vacuo and the residue was poured into a mixture of ethyl acetate and water and adjusteα to pH 8 by addition of 5N sodium hydroxide aqueous solution. The separated organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give N-cycIoneptyl-4-(4- fluorophenoxy) aniline (2.11 g) as a red oil.
IR (Film) : 3405, 2925, 2855, 1735, 161C, 1495 cm-1 NMR (CDCl3, δ) : 1.4-2.15 (12H, m), 3.3-3.5 (1H, m),
6.4-6.6 (2H, m), 6.75-7.05 (6H, m) APCI-MASS (m/z) : 300 (M+H+)
Preparation 140
The mixture of 4-(4-fluorophenoxy) Penzaiαenyαe (1.73 g) and benzylamine (1.29 g) was stirreα at 120°C for 4 nours under nitrogen. The mixture was cooled to room temperature and dissolved m ethanol ( 40 ml). To this solution was added carefully sodium oorohydride (303 mg) and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted witn dichloromethane. Tne organic layer was washed with brme, dried over magnesium sulfate and
evaporated in vacuo. The residue was purifieα py column chromatography on silica gel to give N-benzyl-14-(4- fluorophenoxy)] benzylamine (1.78 g) as a yellow oil.
IR (Film) : 3062, 3028, 2916, 2821, 1605, 1497 cm-1
NMR (CDCl3, δ) 3.78 (2H, s), 3.82 (2H, 6.9-7.1 (6H, m), 7.2-7.4 (7H, m)
APCI-MASS (m/z) : 308 (M+H+)
Preparation 141
The mixture of 4-(4-fluorophenoxy) benzaldehyde (1.73 g) and pentylamine (1.40 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml). To this solution was added carefully sodium borohydride (303 mg), and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-pentyl-4-(4- fluorophenoxy) benzylamine (1.72 g) as a yellow oil.
IR (Film) : 3051, 2956, 2929, 2858, 2818, 1610,
1498 cm-1
NMR (CDCl3, δ) : 0.89 (3H, t, J=6.4Hz), 1.2-1.4 (4H, m), 1.5-1.7 (2H, m), 2.63 (2H, t, J=7.1Hz), 3.76
(2H, s), 6.9-7.1 (6H, m), 7.28 (2H, d, J=9.1Hz) APCI-MASS (m/z) : 288 (M+H+)
Preparation 142
The mixture of 4-(4-fluorophenoxy) benzaldehyde (2.16 g) and cyclohexylamine (1.49 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml). To this solution was added carefully sodium borohydride (378 mg), and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclohexyl-4-(4- fluorophenoxy) benzylamine (3.06 g) as a yellow oil.
IR (Film) : 3034, 2929, 2852, 1608, 1497 cm-1
NMR (CDCl3, δ) : 1.0-1.4 and 1.5-2.0 (10H, m),
2.4-2.6 (1H, m), 3.78 (2H, s), 6.9-7.1 (6H, m),
7.28 (2H, d, J=8.4Hz)
APCI-MASS (m/z) : 300 (M+H+)
Preparation 143
The mixture of 4-(4-fluorophenoxy) benzaldehyde (2.16 g) and cyclopentylamine (1.28 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml). To this solution was added carefully sodium borohydride (378 mg) and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclopentyl 4-(4- fluorophenoxy) benzylamine (2.67 g) as a yellow oil.
IR (Film) : 3032, 2953, 2868, 2819, 1608, 1500 cm-1 NMR (CDCl3, δ) : 1.3-2.0 (8H, m), 3.05-3.25 (1H, m), 3.74 (2H, s), 6.9-7.1 (6H, m), 7.27 (2H, d,
J=8.4Hz)
APCI-MASS (m/z) : 286 (M+H+)
Preparation 144
The mixture of 4-(4-fluorophenoxy) benzylamine (4.35 g) and 2, 3, 5, 6-tetrahydro-4H-pyran-4-one (2.40 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (80 ml). To this solution was added carefully sodium
borohydride (757 mg) and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brme, dried over
magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N- 2,3,5,6-tetrahydro-4H-pyran-4-yl)-4-(4- fluorophenoxy) benzylamine (5.15 g) as an orange oil.
IR (Film) : 2927, 2845, 1498, 1464 cm-1
NMR (CDCl3, δ) : 1.4-1.7 (4H, m), 3.3-4.0 (4H, m), 3.80 (2H, s), 6.8-7.1 (6H, m), 7.2-7.4 (2H, m) APCI-MASS (m/z) : 302 (M+H+)
Preparation 145
The mixture of 4-(4-fluorophenoxy) benzaldehyde (3.24 g) and phenethylamme (2.73 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in etnanol (60 ml). To this solution was added carefully sodium borohydride (567 mg), and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brme, dried over magnesium sulfate and
evaporated m vacuo. The resiαue was purified oy column chromatography on silica gel to give N-(2-phenethyl)-4-(4- fluorophenoxy) benzylamine (4.73 g) as a yellow oil.
IR (Film) : 3061, 3028, 2927, 2821, 1608, 1497,
1454 cm-1
NMR (CDCl3, δ) : 1.47 (1H, br s), 2.75-3.0 (4H, m),
3.77 (2H, s), 6.85-7.1 (6H, m), 7.15-7.35 (7H, m) APCI-MASS (m/z) : 322 (M+H+)
Preparation 146
The mixture of 4-(4-fluorophenoxy) benzalαehyde (4.32 g) and 2-ethoxyethylamιne (3.57 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (80 ml). To this solution was added carefully sodium borohydride (757 mg), and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-(2-ethoxyethyl)-4- (4-fluorophenoxy) benzylamine (5.50 g) as a yellow oil.
IR (Film) : 3053, 2976, 2929, 2866, 1608, 1498,
1456 cm-1
NMR (CDCl3, δ) : 1.20 (3H, t, J=7.0Hz), 2.8-2.9 (2H, m), 3.45-3.6 (4H, m), 3.78 (2H, s), 6.9-7.1 (6H, m), 7.25-7.35 (2H, m)
APCI-MASS (m/z) : 290 (M+H+)
Preparation 147
The mixture of 3-(pyrazol-3-yl) benzaldehyde (1.27 g) and benzylamine (1.19 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml). To this solution was added carefully sodium borohydride (280 mg), and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated in vacuo and the residue was
extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-benzyl-3-(pyrazol-3- yl) benzylamine (1.22 g) as an oil.
IR (Film) : 3169, 3062, 3026, 2916, 2839, 1606, 1589,
1537, 1495 cm-1
NMR (DMSO-d6, δ) : 3.70 (2H, s), 3.7 (2H, s), 6.69 (1H, d, J=2.1Hz), 7.2-7.5 (7H, m), 7.7-7.9 (3H, s)
APCI-MASS (m/z) : 264 (M+H+) Preparation 148
The mixture of 3-(pyrazol-3-yl) benzaldehyde (1.72 g) and cyclohexylamine (1.49 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (30 ml). To this solution was added carefully sodium borohydride (378 mg) and the mixture was stirred at room temperature for 3 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclohexyl-3- (pyrazol-3-yl) benzylamine (1.15 g).
IR (KBr) : 3246, 3118, 3041, 2924, 2854, 1608,
1558 cm-1
NMR (DMSO-d6, δ) : 1.0-2.0 (10H, m), 2.4-2.6 (1H, m), 3.88 (2H, s), 6.70 (1H, br s), 7.25-7.45 (2H, m), 7.6-7.9 (3H, m), 12.90 (1H, br s)
APCI-MASS (m/z) : 256 (M+H+)
Preparation 149
The mixture of 3-(pyrazol-3-yl) benzaldehyde (1.72 g) and cyclopentylamine (1.70 g) was stirred at 120°C for 4 hours under nitrogen. The mixture was cooled to room temperature and dissolved in ethanol (40 ml). To this solution was added carefully sodium borohydride (378 mg), and the mixture was stirred at room temperature for 3 hours. The mixture was evaporated in vacuo and the residue was extracted with dichloromethane. The organic layer was washed with brine, dried over magnesium sulfate and
evaporated in vacuo. The residue was purified by column chromatography on silica gel to give N-cyclopentyl-3- (pyrazol-3-yl)benzylamine (1.26 g).
IR (Film) : 3265, 1610, 1589 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (8H, m), 3.05-3.25 (1H, m), 3.78 (2H, s), 6.68 (1H, s), 7.2-7.4 (2H, m), 7.6-7.9 (3H, m), 12.88 (1H, br)
APCI-MASS (m/z) : 242 (M+H+) Preparation 150
A mixture of 3-(1-tritylpyrazol-3-yl) benzaldehyde (1.72 g) and 4-fluorobenzylamine (0.57 ml) was stirred at 120°C for 4 hours. The mixture was cooled to room
temperature and dissolved in ethanol (26 ml). To the mixture was added sodium borohydride (158 mg) and the reaction mixture was stirred at 50°C for 2 hours. The mixture was poured into water, extracted with
dichloromethane. The organic layer was washed with water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (50:1)) to give N-(4-fluorobenzyl)-3-(l-tritylpyrazol-3-yl) benzylamine (1.40 g).
IR (Neat) : 3059, 2827, 1603, 1506, 1446, 1219 cm-1 NMR (CDCl3, δ) : 3.79 (2H, s), 3.82 (2H, s), 6.58
(1H, d, J=2.5Hz), 6.90-7.05 (2H, m), 7.10-7.45 (20H, m), 7.65-7.83 (2H, m)
FAB-MASS (m/z) : 524 (M+H+) Preparation 151
A mixture of 3-(pyrazol-3-yl) benzaldehyde (1.0 g) and 4-methoxybenzylamine (0.91 ml) was heated for 3 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml). To the solution was added sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (10:1)) to give N-(4-methoxybenzyl)-3-(pyrazol-3- yl) benzylamine (1.17 g).
IR (Film) : 2370-3680 (br), 1610, 1512, 1248,
1036 cm-1
NMR (CDCl3, δ) : 3.77 (2H, s), 3.79 (3H, s), 3.84 (2H, s), 6.60 (1H, d, J=2.2Hz), 6.80-6.92 (2H, m), 7.17-7.41 (4H, m), 7.54-7.66 (2H, m), 7.85 (1H, s)
APCI-MASS (m/z) : 294 (M+H+)
Preparation 152
A mixture of 3-(pyrazol-3-yl) benzaldehyde (1.0 g) and 4-fluorobenzylamine (0.8 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml). To the solution was added sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (10:1)) to give N-(4-fluorobenzyl)-3-(pyrazol-3- yl) benzylamine (1.28 g).
IR (Film) : 2370-3680 (br), 1605, 1508, 1220,
1095 cm-1
NMR (CDCl3, δ) : 3.79 (2H, s), 3.84 (2H, s), 6.61 (1H, d, J=2.3Hz), 6.90-7.10 (2H, m), 7.18-7.45 (4H, m), 7.52-7.70 (2H, m), 7.75 (1H, s) APCI-MASS (m/z) : 282 (M+H+)
Preparation 153
A mixture of 3-(pyrazol-3-yl) benzaldehyde (1.2 g), 4- (dimethylamino) benzylamine-dihydrochloride (1.87 g) and triethylamine (11.7 ml) in toluene (30 ml) was refluxed for 5 hours. An insoluble material was removed by filtration and evaporated in vacuo. The residue was dissolved in ethanol (18 ml). To the solution was added sodium borohydride (264 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (8:1)) to give N-[ 4-(dimethylamino)benzylJ-3-(pyrazol-3- yl) benzylamine (1.68 g).
IR (Film) : 2330-3700 (br), 1614, 1524, 1446, 1350,
804, 766 cm-1
NMR (CDCl3, δ) : 2.93 (6H, s), 3.75 (2H, s), 3.84 (2H, s), 6.59 (1H, d, J=2.2Hz), 6.65-6.75 (2H, m), 7.15-7.40 (4H, m), 7.55-7.66 (2H, m), 7.76
(1H, s)
Figure imgf000123_0001
Preparation 154
The following compounds were obtained according to a similar manner to that of Preparation 57, 58, 59, 60, 62, 75, 76, 138, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152 or 153.
(1) N-Cycloheptyl-4-(4-chlorophenoxy)benzylamine
IR (Film) : 3035, 2925, 2855, 1610, 1590, 1505,
1485 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.6-2.8 (1H, m),
3.76 (2H, s), 6.9-7.05 (4H, m), 7.25-7.4 (4H, m) APCI-MASS (m/z) : 332, 330 (M+H+)
(2) N-Cycloheptyl-4-(3-fluorophenoxy) benzylamine IR (Neat) : 2926, 2854, 1599, 1483, 1269, 1213 cm-1 NMR (CDCl3, δ) : 1.30-2.10 (12H, m), 2.62-2.80 (1H, m), 3.77 (2H, s), 6.62-6.85 (3H, m), 6.93-7.05 (2H, m), 7.18-7.40 (3H, m)
APCI-MASS (m/z) : 314 (M+H+)
(3) N-Cycloheptyl-4-(4-trifluoromethylphenoxy) benzylamine IR (Neat) : 2926, 2854, 1601, 1504, 1462, 1327 cm-1 NMR (CDCl3, δ) : 1.30-2.00 (12H, m), 2.65-2.80 (1H, m), 3.78 (2H, s), 6.95-7.10 (4H, m), 7.30-7.40
(2H, m), 7.50-7.62 (2H, m)
APCI-MASS (m/z) : 364 (M+H+)
(4) N-Cycloheptyl-4-(3,4-methylenedioxyphenoxy) benzylamine IR (Neat) : 2924, 2854, 1606, 1502, 1481, 1354 cm-1
NMR (CDCl3, δ) : 1.30-1.95 (12H, m), 2.60-2.75 (1H, m), 3.74 (2H, s), 5.97 (2H, s), 6.47 (1H, dd, J=8.4, 2.4Hz), 6.56 (1H, d, J=2.4Hz), 6.75 (1H, d, J=8.4Hz), 6.85-6.96 (2H, m; , 7.20-7.31 (2H, m) APCI-MASS (m/z) : 340 (M+H+)
(5) N-Cycloheptyl-4-(3,5-di-tert-butyl-4- methoxymethoxyphenoxy) benzylamine
IR (Film) : 2920, 2860, 1587 cm-1
NMR (CDCl3, δ) : 1.40 and 1.42 (total 18H, s),
1.4-2.2 (14H, m), 2.8-2.95 (1H, m), 3.62 and 3.64 (total 3H, s), 4.87 and 4.92 (total 2H, s), 6.92 (2H, s), 6.85-6.95 (2H, m), 7.4-7.5 (2H, m)
APCI-MASS (m/z; 468 (M+H+)
(6) N-Cycloheptyl-3-(4-fluorophenoxy) benzylamine
IR (Film) : 3062, 2926, 2854, 1608, 1583, 1502,
1446 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.6-2.8 (1H, m),
3.75 (2H, s), 6.8-7.3 (8H, m) APCI-MASS (m/z) : 314 (M+H+)
(7) N-Cycloheptyl-2-(1-tritylpyrazol-4-yl) benzylamine
NMR (DMSO-d6, δ) : 1.2-1.9 (12H, m), 2.6-2.7 (1H, m), 3.70 (2H, s), 7.1-7.6 (19H, m), 7.76 (1H, s),
8.06 (1H, s)
APCI-MASS (m/z) : 512 (M+H+)
(8) N-Cycloheptyl-3-(1-methylpyrazol-4-yl) benzylamine
IR (Neat) : 2926, 2852, 1610, 1460, 1410, 1230 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.63-2.80 (1H, m), 3.79 (2H, s), 3.94 (3H, s), 7.13-7.48 (4H, m), 7.63 (1H, s), 7.76 (1H, s)
APCI-MASS (m/z) : 284 (M+H+)
(9) N-Cycloheptyl-3-(l-methylpyrazol-3-yl) benzylamine
IR (Neat) : 3400 (br), 2924, 2854, 1610, 1462, 1354,
1242 cm-1
NMR (CDCl3, δ) : 1.30-2.00 (12H, m), 2.64-2.80 (1H, m), 3.83 (2H, s), 3.95 (3H, s), 6.56 (1H, d,
J=2.2Hz), 7.25-7.40 (3H, m), 7.60-7.78 (2H, m) APCI-MASS (m/z) : 284 (M+H+)
(10) N-Cycloheptyl-3-(l-methylpyrazol-5-yl) benzylamine
IR (Neat) : 2924, 2854, 1608, 1462, 1385, 12~5 cm-1 NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.62-2.80 (1H, m), 3.83 (2H, s), 3.90 (3H, s), 6.31 (1H, d, J=1.8Hz), 7.25-7.48 (4H, m), 7.51 (1H, d, J=1.8Hz)
APCI-MASS (m/z) : 284 (M+H+)
(11) N-Cycloheptyl-3-(imidazol-4-yl) benzylamine
IR (Film) : 2300-3600 (br), 2924, 2854, 1610,
1460 cm-1
NMR (DMSO-d6, δ) : 1.20-1.95 (12H, m), 2.55-2.75 (1H, m), 3.73 (2H, s), 7.05-7.80 (6H, m), 12.00-12.25 (1H, br)
APCI-MASS (m/z) : 270 (M+H+) (12) N-Cycloheptyl-4-(5-methyl-1,3,4-oxadiazol-3- yl) benzylamine
IR (KBr) : 3442, 3292, 3211, 2920, 2852, 1689, 1576,
1502, 1450 cm-1
NMR (CDCl3, δ) : 1.30-2.40 (12H, m), 2.61 (3H, s), 2.63-2.80 (1H, m), 3.87 (2H, s), 7.45-7.54 (2H, m), 7.93-8.05 (2H, m)
APCI-MASS (m/z) : 286 (M+H+ )
(13) N-Cycloheptyl-4-(4-benzyl-5-methyl-4H-1,2,4-triazol-3- yl) benzylamine
IR (Neat) : 3298, 2924, 2852, 1612, 1527, 1458,
1358 cm-1
NMR (CDCl3, δ) : 1.30-1.93 (12H, m), 2.38 (3H, s), 2.60-2.77 (1H, m), 3.81 (2H, s), 5.16 (2H, s), 6.90-7.05 (2H, m), 7.27-7.55 (7H, m)
APCI-MASS (m/z) : 375 (M+H+)
(14) N-Cycloheρtyl-3-(2-methyl-2H-tetrazol-5-yl) benzylamine IR (Neat) : 2924, 2854, 1520, 1462, 1365 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.65-2.80 (1H, m), 3.86 (2H, s), 4.40 (3H, s), 7.40-7.48 (2H, m), 7.95-8.05 (1H, m), 8.09 (1H, s)
APCI-MASS (m/z) : 286 (M+H+) (15) N-Cycloheptyl-3-(1-methyl-1H-tetrazol-5-yl) benzylamine IR (Neat) : 2924, 2854, 1533, 1452, 1292 cm-1
NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.65-2.80 (1H, m), 3.88 (2H, s), 4.18 (3H, s), 7.46-7.65 (3H, m), 7.75 (1H, s)
APCI-MASS (m/z) : 286 (M+H+) (16) N-Cycloheptyl-4-(1H-1,2,4-triazoI-1-yl) benzylamine mp : 53-54°C
IR (KBr) : 3101, 2922, 2852, 1518, 1460, 1277, 1147,
984 cm-1
NMR (CDCl3, δ) : 1.30-2.00 (12H, m), 2.60-2.80 (1H, m), 3.84 (2H, s), 7.40-7.55 (2H, m), 7.55-7.70 (2H, m), 8.10 (1H, s), 8.54 (1H, s)
APCI-MASS (m/z) : 271 (M+H+) (17) N-Cycloheptyl-4-(1H-1,2,3-triazol-1-yl) benzylamine mp : 78-79°C
IR (KBr) : 3319, 3124, 2920, 2852, 1520, 1230, 1101,
1041 cm-1
NMR (CDCl3, δ) : 1.30-2.00 (12H, m), 2.63-2.80 (1H, m), 3.87 (2H, s), 7.45-7.57 (2H, m), 7.64-7.76
(2H, m), 7.85 (1H, s), 7.98 (1H, s)
APCI-MASS (m/z) : 271 (M+H+)
(18) N-Cycloheptyl-4-(2H-1,2,3-triazoI-2-yI) benzylamine
IP. (Neat) : 2926, 2854, 1608, 1514, 1460, 1412, 1381,
1259, 951, 824 cm-1
NMR (DMSO-d6, δ) : 1.20-1.90 (12H, m), 2.50-2.70 (1H, m), 3.74 (2H, s), 7.45-7.55 (2H, m), 7.90-8.00 (2H, m), 8.10 (2H, s)
APCI-MASS (m/z) : 271 (M+H+)
(19) N-Cycloheptyl-(4-methylpiperazin-1-yl) benzylamine
IR (Film) : 2925, 2850, 2795, 1615, 1515 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.21 (3H, s), 2.4-2.5 (4H, m), 3.1-3.2 (4H, m), 3.2-3.45 (1H, m), 6.85 (2H, d, J=8.5Hz), 7.15 (2H, d, J=8.5Hz) APCI-MASS (m/z) : 302 (M+H+)
(20) N-Cycloheptyl-4-(4-methylsulfonylaminophenyl)- benzylamine IR (KBr) : 3020, 2930, 2855, 1605, 1495 cm-1
NMR (DMSO-d6, δ) : 1.3-2.0 (12H, m), 2.5-2.7 (1H, m), 3.01 (3H, s), 3.72 (2H, s), 7.27 (2H, d, J=8.5Hz), 7.39 (2H, d, J=8.5Hz), 7.57 (2H, d, J=8.2Hz), 7.63 (2H, d, J=8.2Hz)
APCI-MASS (m/z) : 373(M+H+)
(21) N-Cycloheptyl-4-(N-benzoylsulfamoyl) benzylamine
IR (KBr) : 3477, 3057, 2927, 2858, 1599, 1545 cm-1 NMR (DMSO-d6, δ) : 1.3-2.2 (12H, m), 3.1-3.3 (1H, m),
4.17 (2H, s), 7.2-7.45 (5H, m), 7.4-7.5 (2H, m), 7.75-7.9 (2H, m), 8.4-8.7 (1H, br)
APCI-MASS (m/z) : 387 (M+H+) (22) N-Cycloheptyl-4-(N-phenylsulfonylcarbamoyl) benzylamine IR (KBr) : 3091, 2929, 2858, 1647, 1601, 1537 cm-1 NMR (DMSO-d6, δ) : 1.35-2.2 (12H, m), 3.1-3.3 (1H, m), 4.11 (2H, s), 7.35-7.5 (5H, m), 7.8-7.9 (2H, m), 7.93 (2H, d, J=8.1Hz)
APCI-MASS (m/z) : 387 (M+H+)
(23) N-Cycloheptyl-4-(3-pyridylmethyl) benzylamine
IR (Film) : 3304, 3026, 2924, 2852, 1574, 1512 cm-1 NMR (CDCl3, δ) : 1.4-2.2 (12H, m), 2.6-2.8 (1H, m), 3.75 (2H, s), 3.95 (2H, s), 7.1-7.5 (6H, m), 8.45
(1H, dd, J=4.8, 1.8Hz), 8.49 (1H, d, J=1.8Hz) APCI-MASS (m/z) : 295 (M+H+)
(24) N-Cycloheptyl-4-(4-pyridylmethyl) benzylamine
IR (Film) : 3323, 3022, 2924, 2852, 1599 cm-1
NMR (CDCl3, δ) : 1.3-2.1 (12H, m), 2.6-2.8 (1H, m), 3.77 (2H, s), 3.94 (2H, s), 7.09 (1H, dd, 3=4 . 5 , 1.6Hz), 7.12 (2H, d, J=9.4Hz), 7.29 (1H, d,
J=9.4Hz), 8.48 (2H, dd, J=4.5, 1.6Hz)
APCI-MASS (m/z) : 295 (M+H+) (25) N-Cycloheptyl-4-(pyrazol-1-ylmethyl) benzylamine
IR (Neat) : 2924, 2854, 1514, 1458, 1090, 750 cm-1 NMR (CDCl3, δ) : 1.30-1.98 (12H, m), 2.56-2.77 (1H, m), 3.76 (2H, s), 5.30 (2H, s), 6.27 (1H, dd, J=2.0Hz), 7.10-7.40 (5H, m), 7.54 (1H, d,
J=2.0Hz)
APCI-MASS (m/z) : 284 (M+H+)
(26) N-Cycloheptyl-4-(imidazol-1-ylmethyl) benzylamine
IR (Neat) : 3280 (br), 2924, 2854, 1506, 1458, 1230,
1107, 1076 cm-1
NMR (CDCl3, δ) : 1.20-1.95 (12H, m), 2.60-2.78 (1H, m), 3.76 (2H, s), 5.10 (2H, s), 6.90 (1H, s), 7.00-7.40 (5H, m), 7.54 (1H, s)
APCI-MASS (m/z) : 284 (M+H+)
(27) N-Cycloheptyl-(6-hydroxy-2,5,7,8-tetramethylchroman-2- yl) methylamine
NMR (DMSO-d6, δ) : 1.17 (3H, s), 1.3-1.9 (4H, m),
1.97 (3H, s), 2.01 (3H, s), 2.04 (3H, s), 2.5-2.7
(3H, m), 7.39 (1H, s)
APCI-MASS (m/z) : 332 (M+H+)
(28) N-Cycloheptyl-4-[N-(3,5-di-tert-butyl-4- hydroxyphenyl) carbamoyl ] benzylamine
IR (KBr) : 3639, 3304, 2926, 2858, 1643, 1606, 1547 cm-1 NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 1.39 (18H, s),
2.5-2.7 (1H, m), 3.77 (2H, s), 6.78 (1H, s), 7.45 (2H, d, J=8.2Hz), 7.88 (2H, d, J=8.2Hz), 7.58
(2H, s), 9.87 (1H, s)
APCI-MASS (m/z) : 451 (M+H+)
(29) N-Cycloheptyl-4-[N-(4-fluorophenyl)carbamoyl]- benzylamine
IR (KBr) : 3354, 2927, 2854, 1651, 1612, 1529, 1512 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.5-2.65 (1H, m), 3.77 (2H, s), 7.1-7.3 (2H, m), 7.75-7.85 (2H, m), 7.47 (2H, d, J=8.2Hz), 7.89 (2H, d, J=8.2Hz), 10.22 (1H, s)
APCI-MASS (m/z) : 341 (M+H+)
(30) N-Cycloheptyl-4-[N-(4-fluorophenyl)-N- methylcarbamoyl] benzylamine
IR (KBr) : 3475, 3187, 3120, 3024, 2927, 2853, 1643,
1597, 1541, 1500 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.4-2.6 (1H, m),
3.33 (3H, s), 3.60 (2H, s), 7.05-7.3 (8H, m) APCI-MASS (m/z) : 355 (M+H+)
(31) N-Cycloheptyl-4-(tert-butyldimethylsilyloxymethyl)- benzylamine
IR (Film) : 2927, 2850, 1514, 1464 cm-1
NMR (DMSO-d6, δ) : 0.08 (6H, s), 0.89 (9H, s), 1.3- 1.9 (12H, m), 2.5-2.65 (1H, m), 3.67 (2H, s),
4.67 (2H, s), 7.22 (2H, d, J=8.3Hz), 7.28 (2H, d, J=8.3Hz)
APCI-MASS (m/z) : 348 (M+H+) (32) N-Benzyl-3-phenoxybenzylamine
IR (Film) : 3062, 3030, 2829, 1583, 1487, 1452 cm-1 NMR {DMSO-d6, δ) : 2.63 (1H, br s), 3.64 (2H, s),
3.66 (2H, s), 6.8-7.45 (14H, m) APCI-MASS (m/z) : 290 (M+H+)
(33) N-Benzyl-3-(4-fluorophenoxy) benzylamine
IR (Film) : 3062, 3030, 2916, 2829, 1606, 1584,
1500, 1450 cm-1
NMR (CDCl3, δ) : 3.78 (2H, s), 3.79 (2H, s), 6.8-7.4
(13H, m) APCI-MASS (m/z) : 308 (M+H+) (34) N-Benzyl-3-(l-Methylpyrazol-3-yl) benzylamine
IR (Neat) : 3313, 3028, 2935, 1608, 1498, 1452, 1356,
1242 cm-1
NMR (CDCl3, δ) : 3.83 (2H, s), 3.85 (2H, s), 3.9
(3H, s), 6.55 (1H, d, J=2.3Hz), 7.18-7.42 (8H, m), 7.64-7.73 (1H, m), 7.77(1H, s)
APCI-MASS (m/z) : 278 (M+H+)
(35) N-Benzyl-3-(1-methylpyrazol-5-yl) benzylamine
IR (Neat) : 3310, 3026, 2830, 1606, 1454, 1387,
1275 cm-1
NMR (CDCl3, δ) : 3.84 (2H, s), 3.87 (2H, s), 3.89
(3H, s), 6.31 (1H, d, J=1.9Hz), 7.20-7.45 (9H, m), 7.51 (1H, d, J=1.9Hz)
APCI-MASS (m/z) : 278 (M+H+)
(36) N-Benzyl-4-(1-methylpyrazol-3-yl) benzylamine
IR (Neat) : 3310, 3028, 2937, 2820, 1504, 1454,
1430 cm-1
NMR (CDCl3, δ) : 3.81 (2H, s), 3.83 (2H, s), 3.95
(3H, s), 6.53 (1H, d, J=2.3Hz), 7.18-7.43 (8H, m), 7.70-7.80 (2H, m)
APCI-MASS (m/z) : 278 (M+H+)
(37) N-Benzyl-4-(1-methylpyrazol-5-yl) benzylamine
IR (Neat) : 3305, 3026, 2820, 1493, 1454, 1385,
1275 cm-1
NMR (CDCl3, δ) : 3.85 (2H, s), 3.87 (2H, s), 3.89
(3H, s), 6.30 (1H, d, J=i.9Hz), 7.20-7.50 (9H, m), 7.51 (1H, d, J=1.9Hz)
APCI-MASS (m/z) : 278 (M+H+) (33) N-Benzyl-4-(pyrazol-3-yl) benzylamine IR (Neat) : 2250-3680 (br), 1514, 1495, 1454, 1350 cm-1 NMR (DMSO-d6, δ) : 3.69 (4H, s), 6.67 (1H, d,
J=2.1Hz), 7.15-7.50 (7H, m), 7.60-7.90 (3H, m),
12.81, 13.20 (total 1H, each br)
APCI-MASS (m/z) : 264 (M+H+)
(39) N-Benzyl-4-(l-methylpyrazol-4-yl) benzylamine
mp : 90-91°C
IR (KBr) : 3300, 3020, 2914, 2854, 1570, 1473, 1452,
1194, 1097 cm-1
NMR (CDCl3, δ) : 3.81 (2H, s), 3.82 (2H, s), 3.94
(3H, s), 7.20-7.50 (9H, m), 7.60 (1H, s), 7.75 (1H, s)
APCI-MASS (m/z) : 278 (M+H+)
(40) N-Benzyl-3-(imidazol-4-yl) benzylamine
IR (Neat) : 2200-3560 (br), 1608, 1491, 1454 cm-1
NMR (DMSO-d6, δ) : 3.72 (4H, s), 7.10-7.40 (7H, m),
7.41-7.80 (4H, m)
APCI-MASS (m/z) : 264 (M+H+)
(41) N-Benzyl-3-(2-methyl-2H-tetrazol-5-yl) benzylamine
IR (Neat) : 3028, 2825, 1520, 1452, 1363, 804 cm-1 NMR {CDCI3, δ) : 3.84 (2H, s), 3.89 (2H, s), 4.40
(3H, s), 7.20-7.52 (7H, m), 7.96-8.07 (1H, m),
8.12 (1H, s)
APCI-MASS (m/z) : 280 (M+H+)
(42) N-Benzyl-3-(1-methylpyrazol-4-yl) benzylamine
IR (Neat) : 3305, 3028, 2935, 2827, 1610, 1450, 1363,
1230 cm-1
NMR (CDCl3, δ) : 3.84 (4H, s), 3.94 (3H, s), 7.13- 7.40 (8H, m), 7.45 (1H, s), 7.62 (1H, s), 7.77 (1H, s)
APCI-MASS (m/z) : 278 (M+H+) (43) N-(4-Methoxybenzyl)-4-(4-fluorophenoxy) benzylamine
IR (Neat) : 3001, 2903, 2833, 1610, 1500, 1460, 1248,
1213 cm-1
NMR (CDCl3, δ) : 3.75 (2H, s), 3.76 (2H, s), 3.80
(3H, s), 6.82-7.10 (8H, m), 7.20-7.35 (4H, m)
APCI-MASS (m/z) : 338 (M+H+)
Preparation 155
The following compound was obtained according to a similar manner to that of Preparation 31, 38, 39 or 89.
4-(1-Tritylpyrazol-4-yl) toluene
NMR (DMSO-d6, δ) : 2.27 (3H, s), 7.1-7.5 (19H, m),
7.73 (1H, s), 8.04 (1H, s)
Preparation 156
The following compounds were obtained according to a similar manner to that of Preparation 28. (1) 4-(1-Tritylpyrazol-4-yl)benzyI bromide
NMR (DMSO-d6, δ) : 4.70 and 4.77 (total 2H, s),
7.0-7.8 (21H, m)
(2) 3-3enzoylbenzyl bromide
IR (Film) : 3059, 3028, 1686, 1599 cm-1
NMR (CDCl3, δ) : 4.53 (2H, s), 7.35-7.9 (9H, m)
APCI-MASS (m/z) : 277, 275 (M+H+)
Preparation 157
The following compounds were obtained according to a similar manner to that of Preparation 63.
(1) N-Cycloheptyl-4-(l-tritylpyrazol-4-yl) benzylamine
IR (Film) : 3057, 3028, 2918, 2852, 1641, 1605,
1566 cm-1 NMR (DMSO-d6, δ) : 1.3-2.0 (12H, m), 2.55-2.75 (1H, m), 3.68 and 3.75 (total 2H, s), 7.05-7.25 (5H, m), 7.3-8.1 (16H, m)
APCI-MASS (m/z) : 512 (M+H+)
(2) N-Cycloheptyl-4-(2-cyanophenyl) benzylamine
IR (Film) : 3060, 3030, 2910, 2855, 2225, 1597,
1480 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.65-2.85 (1H, m),
3.85 (2H, s), 7.4-7.8 (8H, m)
APCI-MASS (m/z) : 305 (M+H+)
(3) N-Cycloheptyl-4-[2-(1-trityl-1H-tetrazol-5- yl)phenyl] benzylamine
IR (KBr) : 3058, 3026, 2924, 2854, 1603, 1493,
1446 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.6-2.75 (1H, m), 3.68 (2H, s), 6.8-6.95 (5H, m), 7.01 (2H, d, J=7.9Hz), 7.20 (2H, d, J=7.9Hz), 7.3-7.8 (14H, m) FAB-MASS (m/z) : 590 (M+H+)
(4) N-Cycloheptyl-3-benzoylbenzylamine
IR (Film) : 3059, 2927, 2855, 1653, 1599, 1580 cm-1 NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.6-2.8 (1H, m),
3.85 (2H, s), 7.3-7.8 (9H, m)
APCI-MASS (m/z) : 308 (M+H+)
Preparation 158
The following compounds were obtained according to a similar manner to that of Preparation 50 or 51.
(1) 3-(1-Methylpyrazol-3-yl) benzaldehyde
IR (Neat) : 2941, 2829, 2730, 1695, 1606, 1585, 1439,
1242 cm-1
NMR (CDCl3, δ) : 3.98 (3H, s), 6.62 (1H, d, J=2.2Hz), 7.42 (1H, d, J=2.2Hz), 7.51-7.62 (1H, m), 7.77- 7.86 (1H, m), 8.05-8.13 (1H, m), 8.25-8.32 (1H, m), 10.07 (1H, s)
APCI-MASS (m/z) : 187 (M+H+)
(2) 3-(1-Methylpyrazol-5-yl) benzaldehyde
mp : 72-74°C
IR (KBr) : 3041, 2831, 2733, 1697, 1579, 1462, 1377 cm-1 NMR (CDCl3, δ) : 3.94 (3H, s), 6.39 (1H, d, J=1.4Hz), 7.56 (1H, d, J=1.4Hz), 7.58-7.74 (2H, m), 7.89-
7.97 (2H, m), 10.09 (1H, s)
APCI-MASS (m/z) : 187 (M+H+)
(3) 4-(Pyrazol-1-yl) benzaldehyde
mp : 53-55°C
IR (KBr) : 3109, 2833, 2744, 1693, 1608, 1394, 1213,
760 cm-1
NMR (CDCl3, δ) : 5.43 (2H, s), 6.34 (1H, dd, J=2.1,
2.1Hz), 7.25-7.35 (2H, m), 7.45 (1H, d, J=2.1Hz), 7.59 (1H, d, J=2.1Hz), 7.80-7.90 (2H, m), 9.99
(1H, s)
APCI-MASS (m/z) : 187 (M+H+)
(4) 4-(Imidazol-1-ylmethyl) benzaldehyde
IR (Neat) : 2600-3600 (br), 1695, 1506, 1232, 1076,
818, 737 cm-1
NMR (CDCl3, δ) : 5.22 (2H, s), 6.85-7.95 (7H, m),
10.01 (1H, s)
APCI-MASS (m/z) : 187 (M+H+)
Preparation 159
The following compound was obtained according to a similar manner to that of Preparation 47. 3-(Imidazol-4-yl) benzaldehyde mp : 135-138°C
IR (KBr) : 2080-3390 (br), 1691, 1606, 1479, 1327,
1186, 1066, 978, 781 cm-1
NMR (DMSO-d6, δ) : 7.59 (1H, dd, J=7.6, 7.6Hz), 7.67- 7.80 (3H, m), 8.05-8.15 (1H, m), 8.31 (1H, s),
10.04 (1H, s), 12.30 (1H, br)
APCI-MASS (m/z) : 173 (M+H+)
Preparation 160
The following compounds were obtained according to a similar manner to that of Preparation 44, 45, 84, 110, 124 or 126.
(1) 4-(5-Methyl-1,3,4-oxadiazol-2-yl) benzaldehyde
IR (KBr) : 2829, 1701, 1610, 1590, 1550, 1421 cm-1
NMR (CDCl3, δ) : 2.66 (3H, s), 7.96-8.07 (2H, m),
8.15-8.26 (2H, m), 10.10 (1H, s) APCI-MASS (m/z) : 189 (M+H+) (2) 4-(4-Benzyl-5-methyl-4H-1,2,4-triazol-3- yl) benzaldehyde
IR (KBr) : 3450 (br), 1689, 1608, 1572, 1531,
1207 cm-1
NMR (CDCl3, δ) : 2.44 (3H, s), 5.22 (2H, s), 6.93- 7.07 (2H, m), 7.30-7.47 (3H, m), 7.70-7.80 (2H, m), 7.90-8.00 (2H, m), 10.05 (1H, s)
APCI-MASS (m/z) : 278 (M+H+)
Preparation 161
The following compound was obtained according to a similar manner to that of Preparation 97.
4-Benzyl-2-(4-hydroxymethyl) phenyl-5-methyl-4H-1,2,4- triazole
mp : 118-121°C IR (KBr) : 2600-3650 (br), 1535, 1487, 1425, 1363,
1039, 854, 739 cm-1
NMR (CDCl3, δ) : 2.36 (3H, s), 3.10-3.25 (1H, m),
4.65-4.77 (2H, m), 5.14 (2H, s), 6.90-7.03 (2H, m), 7.25-7.50 (7H, m)
APCI-MASS (m/z) : 280 (M+H+)
Preparation 162
The following compound was obtained according to a similar manner to that of Preparation 31.
N-Methyl-N-methoxy-4-[4-(methylsulfonylamino)phenyl]- benzamide
IR (KBr) : 3210, 2935, 1630, 1608, 1525 cm-1
NMR (DMSO-d6, δ) : 3.04 (3H, s), 3.28 (3H, s), 3.58
(3H, s), 7.32 (2H, d, J=8.6Hz), 7.6-7.8 (6H, m), 9.91 (1H, s)
Preparation 163
The following compounds were obtained according to a similar manner to that of Preparation 36.
(1) 4-(4-Methylsulfonylaminophenyl) benzaldehyde
IR (KBr) : 3290, 2995, 2840, 2745, 1695, 1600, 1525,
1500 cm-1
NMR (DMSO-d6, δ) : 3.06 (3H, s), 7.33 (2H, d,
J=8.5Hz), 7.78 (2H, d, J=8.5Hz), 7.89 (2H, d, J=8.2Hz), 7.98 (2H, d, J=8.2Hz), 9.98 (1H, br s), 10.04 (1H, s)
APCI-MASS (m/z) : 276 (M+H+)
(2) 4-(N-Benzoylsulfamoyl) benzaldehyde
IR (KBr) : 3381, 3057, 2883, 1697, 1599, 1560 cm-1 NMR (DMSO-d6, δ) : 7.3-7.5 (3H, m), 7.9-8.0 (2H, m), 7.44 (2H, d, J=8.3Hz), 8.00 (2H, d, J=8.3Hz), 10.03 (1H, s)
APCI-MASS (m/z) : 290 (M+H+)
Preparation 164
The following compounds were obtained according to a similar manner to that of Preparation 33 or 34.
(1) 4-(N-Methyl-N-methoxysulfamoyl) benzamide
IR (KBr) : 3292, 3201, 3111, 2979, 2943, 1605, 1562,
1504 cm-1
NMR (DMSO-d6, δ) : 3.28 (3H, s), 3.54 (3H, s), 7.49 (2H, br s), 7.74 (2H, d, J=8.4Hz), 7.88 (2H, d, J=8.4Hz)
APCI-MASS (m/z) : 245 (M+H+)
(2) N-Methyl-N-methoxy-6-hydroxy-2,5,7,8- tetramethylchroman-2-carboxamide
IR (KBr) : 3479, 2983, 2935, 2870, 1655 cm-1
NMR (DMSO-d6, δ) : 1.49 (3H, s), 1.97 (3H, s), 2.05 (6H, s), 1.6-1.75 (1H, m), 2.4-2.6 (3H, m), 3.34
(3H, s), 3.57 (3H, s), 7.48 (1H, s)
APCI-MASS (m/z) : 294 (M+H+)
Preparation 165
The following compound was obtained according to a similar manner to that of Preparation 105.
4-(N-Phenylsulfonylcarbamoyl) benzaldehyde
IR (KBr) : 3185, 3155, 3105, 2935, 2850, 1740, 1695,
1645, 1605, 1565, 1550 cm-1
NMR (DMSO-d6, δ) : 6.95 (2H, d, J=7.5Hz), 7.35-7.45
(2H, m), 7.75-7.9 (3H, m), 8.20 (2H, d, J=7.5Hz), 10.02 (1H, s)
APCI-MASS (m/z) : 290 (M+H+) Preparation 166
The following compound was obtained according to a similar manner to that of Preparation 66.
N-Cycloheptyl-3-benzylbenzylamine
IR (Film) : 3059, 3026, 2926, 2852, 1601, 1495 cm-1
NMR (CDCl3, δ) : 1.3-2.0 (12H, m), 2.6-2.8 (1H, m),
3.74 (2H, s), 3.97 (2H, s), 7.0-7.5 (9H, m) APCI-MASS (m/z) : 294 (M+H+)
Preparation 167
The following compound was obtained according to a similar manner to that of Preparation 36. 2-Formyl-6-hydroxy-2,5,7,8-tetramethylchromane
IR (KBr) : 3541, 2981, 2933, 2872, 2833, 2727,
1732 cm-1
NMR (DMSO-d6, δ) : 1.66 (3H, s), 1.7-1.9 (1H, m), 2.2-2.65 (3H, m), 1.97 (3H, s), 2.07 (3H, s), 2.08 (3H, s), 7.55 (1H, s), 9.53 (1H, s)
APCI-MASS (m/z) : 244 (M+H+)
Preparation 168
To a solution of 2-chloro-6-methyl-4-methylthio-3- nitropvridine (13.25 g) in methanol (150 ml) was added 28% sodium methoxide in methanol (23.4 ml), and the mixture was refluxed for 7 hours under nitrogen. The mixture was cooled and the precipitates were collected by filtration, washed with methanol and diisopropyl ether and dried under phosphorus pentoxide to give 2-methoxy-6-methyl-4- methylthio-3-nitropyridine (10.29 g) as a yellow powder.
IR (KBr) : 3024, 2997, 2951, 2924, 2856, 1587, 1541,
1495, 1452 cm-1
NMR (DMSO-d6, δ) : 2.46 (3H, s), 2.57 (3H, s),
3.94 (3H, s), 7.07 (1H, s) APCI-MASS (m/z) : 215 (M+H+)
Preparation 169
To a solution of 2,4-dιchlhro-6-methyl-3-nιtropyrιdme (41.40 g) in methanol (400 ml) was added dropwise a 28 solution of sodium methoxide in methanol (38.6 ml), and the mixture was stirred at 60°C for an hour under nitrogen.
The mixture was evaporated in vacuo and the residue was extracted with ethyl acetate. The organic layer was washed with brme, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 2-chloro-4-methoxy-6-methyl-3- nitropyridme (30.43 g) as a pale yellow crystal.
IR (KBr) : 3088, 2987, 2953, 2883, 1601, 1552, 1524,
1471 cm-1
NMR (DMSO-d6, δ) : 2.51 (3H, s), 4.01 (3H, s),
7.42 (1H, s)
Preparation 170
To a solution of 2-chloro-4-methoxy-6-methyl-3- nitropyridme (30.42 g) in methanol (300 ml) was added dropwise a solution of sodium methanethiolate (12.63 g) m methanol (200 ml) at room temperature and the mixture was stirred at 50°C for 4 hours under nitrogen. The mixture was evaporated in vacuo and the residue was extracted with ethyl acetate. The organic layer was washed with brme, dried over magnesium sulfate and evaporated m vacuo. The residue was purified by column chromatography on silica gel to give 4-methoxy-2-methylthιo-6-methyl-3-nιtropyrιdme (30.23 g) as a yellow powder.
IR (KBr) : 3066, 2997, 2956, 2933, 2858, 1585, 1549,
1514, 1466 cm-1
NMR (DMSO-d6, δ) : 2.51 (3H, s), 2.53 (3H, s),
3.95 (3H, s), 7.11 (1H, s)
APCI-MASS (m/z) : 215 (M+H+) Preparation 171
To a suspension of 4-methoxy-2-methylthio-6-methyl-3- nitropyridine (30.15 g) in ethanol (300 ml) was added cone. hydrochloric acid (58.6 ml), and the mixture was refluxed for 10 hours . The mixture was cooled to 5°C and the precipitates were collected by filtration, washed with ethanol and diisopropyl ether, and dried in vacuo under phosphorus pentoxide to give 4-hydroxy-2-methylthio-6- methyl-3-nitropyridine (19.79 g) as a yellow powder.
IR (KBr) : 2989, 2920, 2783, 1551, 1518 cm-1
NMR (DMSO-d6, δ) : 2.39 (3H, s), 2.50 (3H, s),
6.62 (1H, s)
Preparation 172
To a suspension of 4-hydroxy-2-methylthio-6-methyl-3- nitropyridine (30.65 g) in phosphorus oxychloride (140.8 g) was stirred at 100°C for 10 hours. The mixture was poured into a mixture of ethyl acetate and water, and neutralized by addition of 5N sodium hydroxide aqueous solution. The insoluble materials were filtered off, and the filtrate was separated. The organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The
residue was purified by column chromatography on silica gel to give 4-chloro-2-methylthio-6-methyl-3-nitropyridine
(11.87 g) as a yellow powder.
IR (KBr) : 3103, 3053, 2933, 1560, 1518 cm-1
NMR (DMSO-d6, δ) : 2.55 (3H, s), 2.59 (3H, s),
7.55 (1H, s)
APCI-MASS (m/z) : 221, 219 (M+H+)
Preparation 173
To a solution of 2,4-dichloro-6-methyl-3-nitropyridine (4.14 g) in 1,4-dioxane (50 ml) and methanol (50 ml) was added Raney Nickel (NDT-90, purchased from Kawaken Fine Chemicals) (ca. 2 g), and the mixture was hydrogenated for 4 hours under atmospheric pressure. Raney Nickel was filtered off and washed with methanol, and the filtrate was evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 3-ammo-2, 4-dιchloro- 6-methylpyrιdιne (3.53 g) as a yellow oil.
IR (Film) : 3479, 3385, 3221, 3188, 2924, 1616, 1576,
1543, 1471 cm-1
NMR (DMSO-d6, δ) : 2.28 (3H, s), 5.52 (2H, or s),
7.23 (1H, si
APCI-MASS (m/z) : 181, 179, 177 (M+H+)
Preparation 174
To a solution of 3-amιno-2,4-dιchloro-6-methylpyridme (3.51 g) m dichloromethane (50 mil was added N,N- dimethylanilme (2.88 g) at 5°C, followed by dropwise addition of phenyl chloroformate (3.41 g), and the mixture was stirred at room temperature for 3.5 hours. The mixture was washed with dilute hydrochloric acid and brme, dried over magnesium sulfate and evaporated m vacuo. The residue was crystallized from diisopropyl ether and the crystal was collected oy filtration, washed with
diisopropyl ether and dried m vacuo to give 2,4-dιchloro- 6-methyl-3-phenoxycarbonylammopyrιdιne (1.96 g).
IR (KBr) : 3282, 3244, 3184, 3013, 1718, 1637, 1608,
1524, 1491 cm-1
NMR (DMSO-d6, δ) : 2.27 (3H, s), 7.1-7.5 (5H, m),
7.65 (1H, s), 10.10 (1H, br s) APCI-MASS (m/z) : 301, 299, 297 (M+H+) Preparation 175
A mixture of 3-(pyrazol-3-yl) benzaldehyde (1.0 g) and 2-methoxybenzylamme (0.91 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml). To the solution was added sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (10:1)) to give N-(2-methoxybenzyl)-3-(pyrazol-3- yl) benzylamine (1.06 g).
IR (Film) : 2400-3600 (br), 1603, 1493, 1462,
1244 cm-1
NMR (CDCl3, δ) : 3.81 (3H, s), 3.84 (2H, s), 3.85
(2H, s), 6.59 (1H, d, J=2.2Hz), 6.80-6.98 (2H, m), 7.17-7.50 (4H, m), 7.53-7.67 (2H, m), 7.79 (1H, s)
APCI-MASS (m/z) : 294 (M+H+)
Preparation 176
A mixture of 3-(pyrazol-3-yl) benzaldehyde (1.0 g) and 3-methoxybenzylamine (0.91 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (20 ml). To the solution was added sodium borohydride (220 mg), and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed en silica gel (50 g, eluting with dichloromethane - methanol (15:1); to give N-(3-methoxybenzyl)-3-(pyrazol-3- yl) benzylamine (1.24 g).
IR (Neat) : 2370-3680 (br), 1603, 1487, 1439, 1263,
1157, 1045 cm-1
NMR (CDCl3, δ) : 3.80 (3H, s), 3.81 (2H, s), 3.85
(2H, s), 6.61 (1H, d, J=2.2Hz), 6.75-6.85 (1H, m), 6.86-6.97 (2H, m), 7.19-7.43 (3H, m), 7.55- 7.68 (2H, m), 7.76 (1H, s)
APCI-MASS (m/z) : 294 (M+H+) Preparation 177
A mixture of 4-(4-fluorophenoxy) benzaldehyde (1.5 g) and 3-phenylpropylamine (1.19 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (30 ml). To the solution was added sodium borohydride (262 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (15:1)) to give N-(3-phenylpropyl)-4-(4-fluorophenoxy)- benzylamine (1.92 g).
IR (Neat) : 3028, 2929, 2856, 2818, 1606, 1497, 1454,
1250, 1211 cm-1
NMR (CDCl3, δ) : 1.85 (2H, qn, J=7.4Hz), 2.55-2.75 (4H, m), 3.75 (2H, s), 6.83-7.10 (6H, m), 7.10- 7.36 (7H, m)
APCI-MASS (m/z) : 336 (M+H+)
Preparation 178
A mixture of 3-(pyrazol-3-yl) benzaldehyde (1.0 g) and phenethylamine (0.875 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was
dissolved in ethanol (20 ml). To the solution was added sodium borohydride (220 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with dichloromethane - methanol (15:1 to 10:1)) to give N-(2-phenylethyl)-3-(pyrazol-3- yl) benzylamine (1.27 g).
IR (Neat) : 2300-3700 (br), 1606, 1495, 1452, 1354,
1097 cm-1 NMR (CDCl3, δ) : 2.76-3.00 (4H, m), 3.86 (2H, s),
6.59 (1H, d, J=2.2Hz), 7.10-7.43 (7H, m), 7.53- 7.68 (2H, m), 7.86 (1H, s)
APCI-MASS (m/z) : 278 (M+H+)
Preparation 179
A mixture of 4-(4-fluorophenoxy) benzaldehyde (1.5 g) and (S)-1-phenylethylamine (1.08 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (30 ml). To the solution was added sodium borohydride (262 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with n-hexane - ethyl acetate (4:1 to 2:1) to give N-[(S)-1-phenylethyl]-4-(4- fluorophenoxy) benzylamine (2.23 g).
IR (Neat) : 3028, 2966, 2831, 1606, 1498, 1452, 1250,
1213 cm-1
NMR (CDCl3, δ) : 1.38 (3H, d, J=6.6Hz), 3.56 (1H, d, J=13.1Hz), 3.63 (1H, d, J=13.1Hz), 3.82 (1H, q, J=6.6Hz), 6.83-7.12 (6H, m), 7.15-7.43 (7H, m) APCI-MASS (m/z) : 322 (M+H+)
: -31.2° (C=1.05, CHCl3)
Figure imgf000145_0001
Preparation 180
A mixture of 4-(4-fluorophenoxy) benzaldehyde (1.5 g) and (R)-1-phenylethylamine (1.08 ml) was heated for 4 hours at 120°C. After cooling to room temperature, the mixture was dissolved in ethanol (30 ml). To the solution was added sodium borohydride (262 mg) and stirred for two hours at ambient temperature. The reaction mixture was poured into water and extracted with dichloromethane, washed with water and brine, dried over magnesium sulfate. The solvent was removed in vacuo and the residue was chromatographed on silica gel (50 g, eluting with n-hexane - ethyl acetate (4:1 to 2:1) to give N-[(R)-1-phenylethyl]-4-(4- fluorophenoxy) benzylamine (2.12 g).
IR (Neat) : 3028, 2966, 2831, 1606, 1498, 1452, 1250,
1213 cm-1
NMR (CDCl3, δ) : 1.37 (3H, d, J=6.6Hz), 3.56 (1H,d, J=13.1Hz), 3.63 (1H, d, J=13.1Hz), 3.81 (1H, q, J=6.6Hz), 6.83-7.12 (6H, m), 7.15-7.42 (7H, m) APCI-MASS (m/z) : 322 (M+H+ )
: +31.7° (C=1.02, CHCl3)
Figure imgf000146_0001
Preparation 181
The following compounds were obtained according to a similar manner to that of Preparation 71, 78 or 173.
(1) 3-Amino-2-methoxy-6-methyl-6-methylthiopyridine
IR (Film) : 3444, 3352, 2984, 2947, 2922, 2860, 1585,
1559, 1462 cm-1
NMR (DMSO-d6, δ) : 2.26 (3H, s), 2.43 (3H, s), 3.84
(3H, s), 4.39 (2H, br s), 6.64 (1H, s)
APCI-MASS (m/z) : 185 (M+H+)
(2) 3-Amino-4-chloro-2-methylthio-6-methylpyridine
IR (KBr) : 3417, 3300, 3207, 2922, 1618, 1558 cm-1
NMR (DMSO-d6, δ) : 2.31 (3H, s), 2.51 (3H, s), 4.96
(2H, br s), 6.96 (1H, s)
APCI-MASS (m/z) : 191, 189 (M+H+) Preparation 182
The following compounds were obtained according to a similar manner to that of Preparation 74 or 79.
(1) 2-Methoxy-6-methyl-4-methylthio-3- phenoxycarbonylaminopyridine IR (KBr) : 3217, 1740, 1700, 1649, 1541, 1518 cm-1 NMR (DMSO-d6, δ) : 2.39 (3H, s), 2.45 (3H, s), 3.86 (3H, s), 6.81 (1H, s), 7.0-7.5 (5H, m), 8.76 and 9.17 (total 1H, br s)
APCI-MASS (m/z) : 305 (M+H+)
(2) 4-Chloro-2-methylthio-6-methyl-3- phenoxycarbonyliminopyridine
IR (KBr) : 3207, 3026, 3001, 2926, 1724, 1597, 1554,
1524, 1489 cm-1
NMR (DMSO-d6, δ) : 2.48 (3H, s), 2.51 (3H, s), 7.0-
7.5 (6H, m), 9.37 and 9.77 (total 1H, br s) APCI-MASS (m/z) : 311, 309 (M+H+) Preparation 183
The following compound was obtained according to a similar manner to that of Example 7, 8, 9, 10, 13, 14, 15, 16 or 17. 1-[4-(4-FIuorophenoxy)benzyl]-3-[2,4-bis(methylthio)- 6-methylpyridin-3-yl] urea
IR (KBr) : 3305, 3107, 2924, 1633, 1574, 1498 cm-1 NMR (DMSO-d6, δ) : 2.39 (6H, s), 2.44 (3H, s), 4.22 (2H, d, J=5.8Hz), 6.53-6.7 (1H, br), 6.86 (1H, s), 6.9-7.4 (8H, m), 7.54 (1H, br s)
APCI-MASS (m/z) : 444 (M+H+) Example 1
To a solution of N-(4-biphenylylmethyl)- cycloheptylamine (559 mg) in dichloromethane (10 ml) was added 2,4,6-trimethylphenylisocyanate (322 mg), and the mixture was stirred at room temperature for 1.3 hours under nitrogen. The mixture was evaporated in vacuo and the crystalline compound was collected by filtration using hexane: ethyl acetate (5:1) to give 1-(4-biphenylylmethyl)- l-cycloheptyl-3- (2,4,6-trιmethylphenyl) urea (710 mg).
IR (KBr) : 3320, 2920, 2855, 1625, 1505 cm-1
NMR (DMSO-d6, δ) : 1.5-1.8 (12H, m), 2.00 (6H, s), 2.20 (3H, s), 4.4-4.55 (1H, m), 4.55 (2H, s), 5.48 (1H, s), 6.79 (2H, s), 7.3-7.65 (9H, m) APCI-MASS (m/z) : 441 (M+H+ )
Example 2
To a solution of N-(4-biphenylylmethyl)- cycloheptylamine (559 mg) in dichloromethane (10 ml) was added 2, 6-dιisopropylphenylιsocyanate (406 mg), and the mixture was stirred at room temperature for 1.1 hours. The mixture was evaporated in vacuo and the residue was
purified by column chromatography on silica gel to give 1-(4-bιphenylylmethyl)-1-cycloheptyl-3-(2,6- dnsopropylphenyl) urea (885 mg) as a crystal.
IR (KBr) : 3415, 3340, 3060, 3030, 2960, 2930,
2865, 1625, 1500 cm-1
NMR (CDCl3, δ) : 0.9-1.3 (10H, m), 1.5-1.8 (12H,
m), 1.95-2.1 (2H, m), 2.8-3.0 (2H, m), 4.4-4.6 (1H, m), 4.56 (2H, s), 5.47 (1H, s), 7.0-7.65 (12H, m)
APCI -MASS (m/ z ) : 483 (M+ H+ )
Example 3
To a solution of 2-ammo-4 , 6-dιmethoxypynmιdme ( 465 mg ) and triphosgene ( 297 mg ) in 1 , 2-dιchloroethane ( 20 ml ) was added triethylamine (304 mg) and the mixture was refluxed for 1.8 hours. The mixture was cooled to room temperature and a solution of N-(4-biphenylylmethyl)- cycloheptylamine (559 mg) in 1,2-dichloroethane (10 ml) was added thereto. After being stirred at room temperature for 3.1 hours, the mixture was poured into water and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- (4-biphenylylmethyl)-1-cycloheptyl-3-(4,6- dimethoxypyrimidin-2-yl) urea (205 mg).
IR (KBr) : 3390, 3225, 2925, 2855, 1685, 1600,
1525 cm-1
NMR (CDCl3, δ) : 1.4-2.1 (12H, m), 3.86 (6H, s),
4.25-4.45 (1H, m), 4.58 (2H, s), 6.88 (1H, s),
7.3-7.6 (9H, m)
APCI-MASS (m/z) : 461 (M+H+)
Example 4
To a solution of 2,4,6-trifluoroaniline (441 mg) and triphosgene (297 mg) in dichloromethane (10 ml) was added triethylamine (304 mg) at 5°C and the mixture was refluxed for 2 hours under nitrogen. The mixture was cooled to room temperature and a solution of N-(4-biphenylylmethyl)- cycloheptylamine (559 mg) in dichloromethane (3 ml) was added. The mixture was stirred at room temperature for 1.2 hours and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-(4- biphenylylmethyl)-1-cycloheptyl-3-(2,4,6- trimethylphenyl) urea (752 mg).
IR (KBr) : 3285, 2930, 2860, 1635, 1520 cm-1
NMR (CDCl3, δ) : 1.45-2.15 (12H, m), 4.3-4.45 (1H, m), 4.59 (2H, s), 5.56 (1H, s), 6.55-6.7 (2H, m), 7.3-7.65 (9H, m)
APCI-MASS (m/z) : 453 (M+H+) Example 5
The following compounds were obtained according to similar manners to those of Examples 1, 2, 3 and 4. (1) 1-Cycloheptyl-1-(4-phenoxyphenylmethyl)-3-(2,6- diisopropylphenyl) urea
IR (KBr) : 3415, 3360, 2960, 2925, 2865, 1645,
1590 cm-1
NMR (CDCl3, δ) : 0.9-1.35 (12H, m), 1.4-2.1 (12H, m), 2.8-3.0 (2H, m), 4.35-4.5 (1H, m), 4.50 (2H, s), 5.46 (1H, s), 6.95-7.45 (12H, m)
APCI-MASS (m/z) : 499 (M+H+)
(2) 1-(3-Biphenylylmethyl)-1-cycloheptyl-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3325, 2925, 2855, 1625, 1505 cm-1
NMR (CDCl3, δ) : 1.4-2.1 (12H, m), 1.97 (6H, s),
2.20 (3H, s), 4.2-4.4 (1H, m), 4.57 (2H, s), 5.49 (1H, s), 6.78 (2H, s), 7.3-7.7 (9H, m) APCI-MASS (m/z) : 441 (M+H+)
(3) 1-(2-Bιphenylylmethyl)-1-cycloheptyl-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3285, 2970, 2930, 2860, 1635, 1520 cm-1 NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 1.96 (6H, s),
2.21 (3H, s), 4.25-4.4 (1H, m), 4.37 (2H, s), 5.30 (1H, s), 6.80 (2H, s), 7.2-7.7 (9H, m)
APCI-MASS (m/z) : 441 (M+H+) (4) 1-Cycloheptyl-1-(4-phenoxyphenylmethyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3295, 2920, 2855, 1620, 1590, 1510,
1490 cm-1
NMR (CDCl3, δ) : 1.4-1.8 (12H, m), 2.00 (6H, s),
2.22 (3H, s), 4.35-4.5 (1H, m), 4.48 (2H, s), 5.47 (1H, s), 6.81 2H, s), 7.0-7.4 (9H, m) APCI-MASS (m/z) : 457 (M+H
(5) 1-Cycloheptyl-1-(3-phenoxyphenylmethyI)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3310, 2925, 2855, 1625, 1605, 1585,
1510 cm-1
NMR (CDCl3, δ) : 1.4-1.8 (12H, m), 2.00 (6H, s),
2.21 (3H, s), 4.25-4.45 (1H, m), 4.47 (2H, s), 5.44 (1H, s), 6.80 (2H, s), 6.85-7.4 (9H, m)
APCI-MASS (m/z) : 457 (M+H+)
(6) 1-Cycloheptyl-1-[4-(pyridin-2-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3410, 3320, 2920, 2855, 1625, 1585,
1560, 1505 cm-1
NMR (CDCl3, δ) : 1.4-1.8 (12H, m), 2.03 (6H, s),
2.20 (3H, s), 4.3-4.5 (1H, m), 4.58 (2H, s), 5.49 (1H, s), 6.80 (2H, s), 7.2-7.3 (1H, m), 7.51 (2H, d, J=8.3Hz), 7.7-7.85 (2H, m), 8.02 (2H, d,
J=8.3Hz), 8.7-8.75 (1H, m)
APCI-MASS (m/z) : 442 (M+H+)
(7) 1-Cycloheptyl-1-[4-(pyridin-3-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3315, 2920, 2855, 1645, 1510 cm-1
NMR (CDCl3, δ) : 1.4-1.9 (12H, m), 2.02 (6H, s),
2.21 (3H, s), 4.35-4.5 (1H,m), 4.58 (2H, s), 5.48 (1H, s), 6.80 (2H, s), 7.39 (1H, dd, J=7.9,
4.9Hz), 7.3-7.7 (4H, m), 7.86 (1H, dt, J=8.2,
1.8Hz), 8.60 (1H, d, J=3.6Hz),
8.83 (1H, s)
APCI-MASS (m/z) : 442 (M+H+) (8) 1-Cycloheptyl-1-[[2-(4-chlorophenyl)thiazol-4- yl]methyl]-3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3300, 2920, 2855, 1645, 1610, 1495 cm-1
NMR (CDCl3, δ) : 1.5-2.0 (12H, m), 2.13 (6H, s),
2.24 (3H, s), 4.2-4.4 (1H, m), 4.61 (2H, s), 6.85 (2H, s), 7.18 (1H, s), 7.24 (1H, s),
7.35-7.45 (2H, m), 7.8-7.9 (2H, m)
APCI-MASS (m/z) : 483 (M+H+)
(9) 1-Cycloheptyl-1-[(2-phenylimidazol-5-yl) methyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3100, 2925, 2855, 1620, 1570 cm-1
NMR (DMSO-d6, δ) : 1.35-1.8 (12H, m), 2.06 (6H, s), 2.21 (3H, s), 4.05-4.2 (1H, m), 4.36 (2H, s), 6.83 (2H, s), 7.23 (1H, s), 7.3-7.5 (3H, m), 7.8- 7.9 (2H, m), 8.68 (1H, s), 12.55 (1H, s)
APCI-MASS (m/z) : 431 (M+H+)
(10) 1-Cycloheptyl-1-[4-(pyrrol-1-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3310, 2920, 2855, 1625, 1525, 1510 cm-1
NMR (CDCl3, δ) : 1.4-2.05 (12H, m), 2.01 (6H, s),
2.21 (3H, s), 4.3-4.5 (1H, m), 4.53 (2H, s), 5.46 (1H, s), 6.3-6.4 (2H, m), 6.80 (2H, s), 7.05-7.15 (2H, m), 7.35-7.5 (4H, m)
APCI-MASS (m/z) : 430 (M+H+)
(11) 1-Cycloheptyl-1-[3-(pyrrol-1-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3320, 2920, 2855, 1625, 1610, 1505 cm-1 NMR (CDCl3, δ) : 1.45-2.05 (12H, m), 2.01 (6H, s),
2.21 (3H, s), 4.3-4.5 (1H, m), 4.56 (2H, s), 5.47 (1H, s), 6.35-6.4 (2H, m), 6.80 (2H, s), 7.05- 7.10 (2H, m), 7.25-7.5 (4H, m)
APCI-MASS (m/z) : 430 (M+H+) (12) 1-Cycloheptyl-1-[[ 4-(pyrrcl-1-yl)pyridin-2-yl]methyl]-
3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3220, 2920, 1645, 1605, 1575, 1500 cm-1
NMR (DMSO-d6, δ) : 1.4-1.8 (12H, m), 2.13 (6H, s), 2.21 (3H, s), 4.1-4.3 (1H, m), 4.56 (2H, s), 6.35-6.4 (2H, m), 6.84 (2H, s), 6.5-6.55 (2H, m), 6.55-6.65 (2H, m), 8.50 (1H, br s), 8.51 (1H, d, J=5.6Hz)
APCI-MASS (m/z) : 431 (M+H+)
(13) 1-Cycloheptyl-1-[(6-phenylpyridin-3-yl)methyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3315, 2920, 2855, 1630, 1560, 1515 cm-1 NMR (CDCl3, δ) : 1.4-2.05 (12H, m), 2.09 (6H, s),
2.23 (3H, s), 4.1-4.3 (1H, m), 4.60 (2H, s), 5.53
(1H, s), 6.83 (2H, s), 7.35-7.55 (3H, m), 7.7-7.9 (2H, m), 7.95-8.05 (2H, m), 8.70 (1H, s) APCI-MASS (m/z) : 442 (M+H+) (14) 1-Cycloheptyl-1-[3-(2-methylthiazol-4-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KEr) : 3360, 2925, 2855, 1620, 1505 cm-1
NMR (CDCl3, δ) : 1.4-2.05 (12H, m), 1.98 (6H, s),
2.20 (3H, s), 2.78 (3H, s), 4.4-4.55 (1H, m), 4.57 (2H, s), 5.49 (1H, s), 6.78 (2H, s), 7.33
(1H, s), 7.35-7.5 (2H, m), 7.79 (1H, d, J=7.1Hz), 7.93 (1H, s)
APCI-MASS (m/z) : 462 (M+H+) (15) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3405, 3210, 2925, 2855, 1640, 1610,
1500 cm-1
NMR (CDCl3, δ) : 1.4-1.9 (12H, m), 2.08 (6H, s),
2 20 (3H s) 4 1-4 25 (1H m) 4 54 (2H, s), 6.63 (1H, s), 6.82 (2H, s), 7.2-7.6 (6H, m), 12.86 (1H, s)
APCI-MASS (m/z) : 431 (M+H+) (16) 1-Benzyl-1-(4-phenoxybenzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3310, 3030, 2915, 1630, 1590, 1505 cm-1 NMR (CDCl3, δ) : 2.01 (6H, s), 2.22 (3H, s), 4.63 (2H, s), 5.64 (1H, s), 6.82 (2H, s), 7.0-7.4 (14H, m)
APCI-MASS (m/z) : 451 (M+H+)
(17) 1-Furfuryl-1-(4-phenoxybenzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3280, 3030, 2975, 2915, 1625, 1595,
1530, 1505 cm-1
NMR (CDCl3, δ) : 2.10 (6H, s), 2.25 (3H, s), 4.55 (2H, s), 4.61 (2H, s), 6.03 (1H, s), 6.25-6.3 (1H, m), 6.35-6.4 (1H, m), 6.86 (2H, s), 6.95- 7.45 (10H, m)
APCI-MASS (m/z) : 441 (M+H+)
(18) 1-Cycloheptyl-1-[4-(4-chloropnenyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3400, 3300, 2925, 2855, 1655, 1625,
1505 cm-1
NMR (CDCl3, δ) : 1.5-2.05 (12H, m), 2.01 (6H, s),
2.21 (3H, s), 4.3-4.5 (1H, m), 4.55 (2H, s), 5.46 (1H, s), 6.80 (2H, s), 7.4-7.65 (8H, m) APCI-MASS (m/z) : 476 (M+H+)
(19) 1-Cycloheptyl-1-[4-(4-fluorophenyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3400, 3300, 2925, 2855, 1655, 1625,
1490 cm-1 NMR (CDCl3, δ) : 1.5-2.15 (12H, m), 2.01 (6H, s),
2.21 (3H, s), 4.4-4.6 (1H, m), 4.55 (2H, s), 5.47 (1H, s), 6.80 (2H, s,X 7.05-7.2 (2H, m), 7.45-7.6 (6H, m)
APCI-MASS (m/z) : 459 (M+H+)
(20) 1-Cycloheptyl-1-[4-(4-bromophenyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3400, 3300, 2920, 2855, 1655, 1625,
1505 cm-1
NMR (CDCl3, δ) : 1.5-2.05 (12H, m), 2.01 (6H, s),
2.21 (3H, s), 4.35-4.55 (2H, s), 5.46 (1H, s), 6.80 (2H, s), 7.45-7.6 (8H, m)
APCI-MASS (m/z) 521 (M+H+)
(21) 1-Cycloheptyl-1-[4-(4-methylphenyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3400, 3310, 3020, 2920, 2855, 1660,
1625, 1500 cm-1
NMR (CDCl3, δ) : 1.4-2.1 (12H, m), 1.99 (6H, s),
2.20 (3H, s), 2.40 (3H, s), 4.35-4.55 (1H, m), 4.54 (2H, s), 5.48 (1H, s), 6.79 (2H, s), 7.25 (2H, d, J=7.9Hz), 7.4-7.5 (4H, m), 7.59 (2H, d, J=8.3Hz)
APCI-MASS (m/z) : 455 (M+H+)
(22) 1-Cycloheptyl-1-[4-(4-dimethylaminophenyl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3405, 3325, 2920, 2855, 2805, 1650,
1610, 1535, 1500 cm-1
NMR (CDCl3, δ) : 1.5-2.2 (12H, m), 1.98 (6H, s),
2.20 (3H, s), 3.00 (6H, s), 4.4-4.6 (1H, m), 4.52 (2H, s), 5.50 (1H, s), 7.4-7.65 (8H, m)
APCI-MASS (m/z) 484 (M+H+) (23) 1-Cycloheptyl-1-[4-(4-bromophenoxy)benzyl]-3-(2,4,6- trimethylphenyl ) urea
IR (KBr) : 3410, 3325, 2920, 2855, 1635, 1585,
1505 cm-1
NMR (CDCl3, δ) : 1.5-2.1 (12H, m), 2.01 (6H, s),
2.22 (3H, s), 4.35-4.55 (1H, m), 4.49 (2H, s), 5.46 (1H, s), 6.81 (2H, s), 6.85-7.05 (4H, m), 7.3-7.5 (4H, m)
APCI-MASS (m/z) : 537 (M+H+)
(24) 1-Cycloheptyl-1-(4-benzoylbenzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3325, 2920, 2855, 1655, 1605, 1505 cm-1 NMR (CDCl3, δ) : 1.4-2.05 (12H, m), 2.06 (6H, s), 2.22 (3H, s), 4.2-4.4 (1H, m), 4.61 (2H, s), 5.45
(1H, s), 6.82 (2H, s), 7.5-7.7 (5H, m), 7.75-7.9 (4H, m)
APCI-MASS (m/z) : 469 (M+H+) (25) 1-Cycloheptyl-1-(4-benzylbenzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3305, 3025, 2920, 2855, 1625, 1505 cm-1 NMR (CDCl3, δ) : 1.5-2.05 (12H, m), 1.93 (6H, s),
2.21 (3H, s), 3.97 (2H, s), 4.35-4.55 (1H, m), 4.46 (2H, s), 5.42 (1H, s), 6.78 (2H, s), 7.1-7.4
(9H, m)
APCI-MASS (m/z) : 455 (M+H+)
(26) 1-Cycloheptyl-1-(4-phenylthiobenzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3315, 2920, 1630, 1610, 1505 cm-1
NMR (CDCl3, δ) : 1.4-2.05 (12H, m), 2.00 (6H, s),
2.22 (3H, s), 4.3-4.5 (1H, m), 4.48 (2H, s), 5.42 (1H, s), 6.81 (2H, s), 7.07 (1H, t, J=8.6Hz), 7.25-7.45 (8H, m) APCI-MASS (m/z) : 473 (M+H+:
(27) 1-Cycloheptyl-1-[(6-phenylthiopyridin-3-yl)methyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3310, 2925, 2855, 1630, 1585, 1510 cm-1 NMR (CDCl3, δ) : 1.5-2.05 (12H, m), 2.05 (6H, s), 2.23 (3H, s), 4.05-4.2 (1H, m), 4.47 (2H, s), 5.49 (1H, s), 6.84 (2H, s), 6.90 (1H, d, J=8.3Hz), 7.4-7.65 (6H, my, 8.43 (1H, d, J=1.8Hz) APCI-MASS (m/z) : 474 (M+H+)
(28) 1-Cycloheptyl-1-(4-benzoylaminobenzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3350, 3055, 2920, 2855, 1655, 1610,
1550 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.06 (6H, s),
2.19 (3H, 5), 4.1-4.3 (1H, m), 4.51 (2H, s), 6.81 (2H, s), 7.05 (1H, d, J=7.7Hz), 7.29 (1H, d, J=7.7Hz), 7.40 (1H, s), 7.5-7.7 (4H, m), 7.77 (1H, s), 7.9-8.0 (2H, m), 10.26 (1H, s)
APCI-MASS (m/z) : 484 (M+H+)
(29) 1-Cycloheptyl-1-[4-(phenylcarbamoyl)benzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3425, 3300, 2920, 2860, 1670, 1635,
1600, 1540 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.11 (6H, s),
2.21 (3H, s), 4.1-4.3 (1H, m), 4.58 (2H, s), 6.85 (2H, s), 7.13 (1H, t, J=7.3Hz), 7.3-7.5 (4H, m), 7.65 (1H, s), 7.77 (2H, d, J=7.6Hz), 7.93 (2H, d,
J=8.2Hz), 10.17 (1H, s)
APCI-MASS (m/z) : 484 (M+H+)
(30) 1-Cycloheptyl-1-[4-(2-pyridylcarbamoyl)benzyl]-3- (2,4,6-trιmethylphenyl) urea IR (KBr) : 3335, 2920, 2855, 1675, 1635, 1610,
1580, 1525, 1505 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.10 (6H, s),
2.21 (3H, s), 4.1-4.3 (1H, m), 4.57 (2H, s), 6.84 (2H, s), 7.16 (1H, dd, J=6.8, 5.8Hz), 7.42 (2H, d, J=8.2Hz), 7.63 (1H, br s), 7.8-7.9 (1H, m), 8.00 (2H, d, J=8.2Hz), 8.19 (1H, d, J=8.4Hz), 8.35-8.45 (1H, m), 10.71 (1H, s)
APCI-MASS (m/z) : 485 (M+H+)
(31) 1-Cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3305, 2920, 2855, 1630, 1500 cm-1
NMR (CDCl3, δ) : 1.5-2.1 (12H, m), 2.00 (6H, s),
2.22 (3H, s), 4.3-4.5 (1H, m), 4.76 (2H, s), 5.47
(1H, s), 6.82 (2H, s), 6.9-7.1 (6H, m), 7.36 (2H, d, J=8.5Hz)
APCI-MASS (m/z) : 475 (M+H+) (32) 1-Cycloheptyl-1-[4-(phenylsulfamoyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3395, 3130, 2925, 2860, 1635, 1600,
1500 cm-1
NMR (DMSO-d6, δ) : 1.3-1.8 (12H, m), 2.01 (6H, s), 2.20 (3H, s), 4.05-4.25 (1H, m), 4.5C (2H, s),
6.81 (2H, s), 7.0-7.15 (3H, m), 7.15-7.3 (2H, m), 7.42 (2H, d, J=8.3Hz), 7.57 (1H, br s), 7.70 (2H, d, J=8.3Hz), 10.23 (1H, s)
APCI-MASS (m/z) : 520 (M+H+)
(33) 1-Cycloheptyl-1-[4-(phenylsulfonylamino)oenzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3410, 3110, 2925, 2860, 1630, 1510 cm-1 NMR (DMSO-d6, δ) : 1.3-1.8 (12H, m), 1.99 (6H, s), 2.20 (3H, s), 4.0-4.2 (1H, m), 4.37 (2H, s), 6.81 (2H, s), 7.01 (2H, d, J=8.3Hz), 7.15 (2H, d, J=8.3Hz), 7.37 (1H, br s), 7.5-7.65 (3H, m), 7.7- 7.8 (2H, m), 10.22 (1H, br s)
APCI-MASS (m/z) : 520 (M+H+)
(34) 1-Cycloheptyl-1-[4-(3-thienyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3320, 2920, 1624, 1504, 1252, 775 cm-1 NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.00 (6H, s), 2.20 (3H, s), 4.35-4.55 (1H, m), 4.53 (2H, s),
5.47 (1H, s), 6.79 (2H, s), 7.34-7.50 (5H, m), 7.55-7.66 (2H, m)
APCI-MASS (m/z) : 447 (M+H+) (35) 1-Cycloheptyl-1-[4-(2-thienyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3319, 2922, 1624, 1504, 1253, 849 cm-1 NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.01 (6H, s),
2.20 (3H, s), 4.35-4.55 (1H, m), 4.52 (2H, s), 5.46 (1H, s), 6.79 (2H, s), 7.09 (1H, dd, J=5.1,
3.6Hz), 7.25-7.35 (2H, m), 7.36-7.46 (2H, m), 7.58-7.68 (2H, m)
APCI-MASS (m/z) : 447 (M+H+) (36) 1-Cycloheptyl-1-[4-(pyrazol-1-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3325, 2922, 1628, 1504, 1394 cm-1
NMR (CDCl3, δ) : 1.40-2.08 (12H, m), 2.04 (6H, s),
2.21 (3H, s), 4.28-4.48 (1H, m), 4.55 (2H, s), 5.48 (1H, s), 6.48 (1H, t, J=2.3Hz), 6.81 (2H, s), 7.42-7.54 (2H, m), 7.65-7.78 (3H, m), 7.92 (1H, d, J=2.3Hz)
APCI-MASS (m/z) : 431 (M+H+) (37) 1-Cycloheptyl-1-[4-(imidazol-1-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3310, 2922, 1637, 1520, 1305 cm-1
NMR (CDCl3, δ) : 1.38-2.10 (12H, m), 2.05 (6H, s),
2.22 (3H, s), 4.20-4.40 (1H, m), 4.57 (2H, s), 5.47 (1H, s), 6.83 (2H, s), 7.21 (1H, s), 7.28
(1H, s), 7.33-7.44 (2H, m), 7.45-7.57 (2H, m),
7.85 (1H, s)
APCI-MASS (m/z) : 431 (M+H+) (38) 1-Cycloheptyl-1-[4-(l-methylpyrazol-4-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3321, 2922, 1628, 1504, 1209, 955 cm-1 NMR (CDCl3, δ) : 1.38-2.08 (12H, m), 1.99 (6H, s),
2.20 (3H, s), 3.95 (3H, s), 4.35-4.55 (1H, m), 4.50 (2H, s), 5.47 (1H, s), 6.79 (2H, s), 7.32-
7.53 (4H, m), 7.61 (1H, s), 7.75 (1H, s)
APCI-MASS (m/z) : 445 (M+H+)
(39) 1-Cycloheptyl-1-[(2-phenylthiophen-5-yl)methyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3329, 2922, 1624, 1510, 758 cm-1
NMR (CDCl3, δ) : 1.42-2.15 (12H, m), 2.04 (6H, s),
2.22 (3H, s), 4.25-4.43 (1H, m), 4.63 (2H, s),
5.82 (1H, s), 6.81 (2H, s), 7.02 (1H, d,
J=3.6Hz), 7.16 (1H, d, J=3.6Hz), 7.22-7.43 (3H, m), 7.50-7.61 (2H, m)
APCI-MASS (m/z) : 447 (M+H+)
(40) 1-Cycloheptyl-1-[4-(oxazol-5-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3302, 2922, 1624, 1506, 1105, 941 cm-1 NMR (CDCl3, δ) : 1.38-2.08 (12H, m), 2.03 (6H, s),
2.21 (3H, s), 4.30-4.50 (1H, m), 4.55 (2H, s), 5.45 (1H, s), 6.81 (2H, s), 7.36 (1H, s), 7.42- 7.53 (2H, m), 7.63-7.74 (2H, m), 7.92 (1H, s) APCI-MASS (m/z) : 432 (M+H+)
(41) 1-Cycloheptyl-1-[(2-phenylfuran-5-yl)methyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3340, 2920, 1628, 1508, 762 cm-1
NMR (CDCl3, δ) : 1.40-2.15 (12H, m), 2.09 (6H, s),
2.23 (3H, s), 4.22-4.41 (1H, m), 4.53 (2H, s), 5.93 (1H, s), 6.41 (1H, d, J=3.3Hz), 6.62 (1H, d, J=3.3Hz), 6.83 (2H, s), 7.20-7.43 (3H, m), 7.57- 7.67 (2H, m)
APCI-MASS (m/z) : 431 (M+H+)
(42) 1-Cycloheptyl-1-[(5-phenylisoxazol-3-yl)methyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3326, 2924, 1630, 1512, 766 cm-1
NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.14 (6H, s),
2.24 (3H, s), 4.05-4.25 (1H, m), 4.56 (2H, s), 6.14 (1H, s), 6.63 (1H, s), 6.86 (2H, s), 7.40- 7.53 (3H, m), 7.70-7.82 (2H, m)
APCI-MASS (m/z) : 432 (M+H+)
(43) 1-Cycloheptyl-1-[(3-phenylpyrazol-5-yl)methyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 2700-3600 (br), 2924, 1633, 1508, 1250,
1201 cm-1
NMR (CDCl3, δ) : 1.35-2.10 (12H, m), 2.12 (6H, s),
2.23 (3H, s), 3.92-4.12 (1H, m), 4.47 (2H, s),
6.24 (1H, br s), 6.50 (1H, s), 6.84 (2H, s), 7.25-7.46 (3H, m), 7.62-7.75 (2H, m)
APCI-MASS (m/z) : 431 (M+H+)
(44) 1-Cycloheptyl-1-[(4-phenylthiophen-2-yl)methyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3315, 2922, 2854, 1628, 1508, 1377,
1308 cm-1 NMR (CDCl3, δ) : 1.40-2.13 (12H, m), 2.03 (6H, s), 2.21 (3H, s), 4.26-4.45 (1H, m), 4.66 (2H, s), 5.82 (1H, s), 6.81 (2H, s), 7.21-7.45 (5H, m), 7.50-7.60 (2H, m)
APCI-MASS (m/z) : 447 (M+H+)
(45) 1-Cycloheptyl-1-[4-(pyrazoi-3-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 2800-3500 (br), 2924, 2856, 1645, 1504,
1240 cm-1
NMR (CDCl3, δ) : 1.38-2.10 (12H, m), 2.00 (6H, s), 2.19 (3H, s), 4.35-4.55 (1H, m), 4.54 (2H, s), 5.51 (1H, s), 6.60 (1H, d, J=2.3Hz), 6.78 (2H, s), 7.42-7.53 (2H, m), 7.55 (1H, d, J=2.3Hz), 7.73-7.83 (2H, m)
APCI-MASS (m/z) : 431 (M+H+)
(46) 1-Cycloheptyl-1-[4-(l-methylpyrazoI-3-yI)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3406, 3331, 2924, 2856, 1647, 1502,
1236, 849, 758 cm-1
NMR (CDCl3, δ) : 1.38-2.08 (12H, m), 2.00 (6H, s), 2.20 (3H, s), 3.96 (3H, s), 4.35-4.55 (1H, m), 4.52 (2H, s), 5.50 (1H, s), 6.54 (1H, d, J=2.3Hz), 6.78 (2H, s), 7.35-7.47 (3H, m), 7.77-7.87 (2H, m)
APCI-MASS (m/z) : 445 (M+KX
(47) 1-Cycloheptyl-1-[4-(l-methylpyrazoI-5-yl)benzyl]-3- (2,4, 6-trimethylphenyl) urea
IR (KBr) : 3296, 2922, 2854, 1628, 1506, 1385 cm-1
NMR (CDCl3, δ) : 1.38-2.10 (12H, ml, 2.02 (6H, s), 2.21 (3H, s), 3.89 (3H, s), 4.32-4.50 (1H, m), 4.57 (2H, s), 5.45 (1H, s), 6.30 (1H, d,
J=1.9Hz), 6.81 (2H, s), 7.39-7.56 (5H, m), APCI-MASS (m/z) : 445 (M+H+) (48) 1-Cycloheptyl-1-[3-(1-trityl-1H-tetrazol-5-yl)benzyl]-
3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3340, 2924, 2856, 1649, 1495, 1448,
1240 cm-1
NMR (CDCl3, δ) : 1.38-2.10 (12H, m), 1.96 (6H, s),
2.20 (3H, s), 4.30-4.50 (1H, m), 4.57 (2H, s),
5.42 (1H, s), 6.77 (2H, s), 7.08-7.57 (17H, m),
8.05-8.18 (2H, m) (49) 1-Cycloheptyl-1-[4-phenoxybenzyl-3-(4,6- dimethoxypyrimidin-2-yl) ] urea
IR (KBr) : 3390, 2925, 2860, 1685, 1595 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 3.87 (6H, s),
4.2-4.4 (1H, m), 4.51 (2H, s), 5.66 (1H, s), 6.87 (1H, s), 6.95-7.4 (9H, m)
APCI-MASS (m/z) : 477 (M+H+)
(50) 1-Cycloheptyl-l-(4-phenyIbenzyl)-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3360, 2925, 2855, 1660, 1565 cm-1
NMR (CDCI3, δ) : 1.45-2.1 (12H, m), 2.36 (3H, s),
2.45 (3H, s), 2.46 (3H, s;, 4.3-4.5 (1H, m), 4.62 (2H, s), 5.52 (1H, s), 6.59 (1H, s), 7.3-7.7 (9H, m)
APCI-MASS (m/z) : 506 (M+H+)
(51) 1-(3-Phenylbenzyl)-1-cycloheptyl-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3285, 2925, 2860, 1635, 1610, 1520 cm-1 NMR (CDCl3, δ) : 1.4-2.05 (12H, m), 4.3-4.5 (1H,
m), 4.62 (2H, s), 5.60 (1H, s), 6.55-6.7 (2H, m), 7.3-7.65 (9H, m)
APCI-MASS (m/z) : 453 (M+H+) (52) 1-(2-Phenylbenzyl)-1-cycloheptyl-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3415, 3320, 3060, 3020, 2920, 2855,
1625, 1575 cm-1
NMR (CDCI3, δ) : 1.4-2.0 (12H, m), 4.2-4.35 (1H,
m), 4.40 (2H, s), 5.50 (1H, s), 6.55-6.75 (2H, m), 7.25-7.6 (9H, m)
APCI-MASS (m/z) : 453 (M+H+)
(53) 1-Cycloheptyl-1-(4-phenoxybenzyl)-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3285, 2925, 2860, 1635,. 1590, 1520 cm-1 NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 4.2-4.4 (1H, m), 4.51 (2H, s), 5.58 (1H, s), 6.6-6.75 (2H, m), 7.0-7.4 (9H, m)
APCI-MASS (m/z) : 469 (M+H+)
(54) 1-Cycloheptyl-1-(3-phenoxybenzyl)-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3280, 2930, 2860, 1635, 1615, 1585,
1520 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 4.2-4.4 (1H, m), 4.50 (2H, s), 5.55 (1H, s), 6.6-6.75 (2H, m), 6.9-7.4 (9H, m)
APCI-MASS (m/z) : 469 (M+H+)
(55) 1-Cycloheptyl-1-[4-(pyridin-2-yl)benzyl]-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3285, 2925, 2860, 1635, 1610, 1520 cm-1 NMR (CDCl3, δ) : 1.4-2.1 (12H, m), 4.25-4.4 (1H,
m), 4.61 (2H, s), 5.59 (1H, s), 6.6-6.75 (2H, m),
7.2-7.3 (1H, m), 7.47 (2H, d, J=8.4Hz), 7.7-7.8 (2H, m), 8.02 (2H, d, J=8.4Hz), 8.65-8.75 (1H, m) APCI-MASS (m/z) : 454 (M+H+) (56) 1-Benzyl-1-[[2-(4-chlorophenyl)thiazol-4-yl]methyl]-3- (2,4,6-trifluorophenyl) urea
IR (KBr) : 3270, 3090, 1665, 1640, 1615, 1520 cm-1
NMR (CDCl3, δ) : 4.54 (2H, s), 4.64 (2H, s),
6.65-6.8 (2H, m), 7.3-7.4 (5H, m), 7.34 (1H, s), 7.4-7.5 (2H, m), 7.85-7.95 (2H, m)
APCI-MASS (m/z) : 488 (M+H+)
(57) 1-(Cycloheptyl-1-[4-(pyrrol-1-yl)benzyl]-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3285, 2925, 2860, 1635, 1610, 1520 cm-1
NMR (CDCl3, δ) : 1.4-2.05 (12H, m), 4.2-4.4 (1H,
m), 4.56 (2H, s), 5.57 (1H, s), 6.3-6.4 (2H, m), 6.55-6.7 (2H, m), 7.05-7.15 (2H, m), 7.41 (4H, s) APCI-MASS (m/z) : 442 (M+H+)
(58) 1-Cycloheptyl-1-[4-(3-thienyl)benzyl]-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3300, 2927, 1637, 1518, 1120, 777 cm-1 NMR (CDCl3, δ) : 1.40-2.08 (12H, m), 4.27-4.47 (1H, m), 4.56 (2H, s), 5.58 (1H, s), 6.58-6.73 (2H, m), 7.30-7.50 (5H, m), 7.57-7.70 (2H, m) APCI-MASS (m/z) : 459 (M+H+)
(59) 1-Cycloheptyl-1-.4-(2-thienyl)benzyl]-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3300, 2930, 1635, 1520, 1120 cm-1
NMR (CDCl3, δ) : 1.38-2.08 (12H, m), 4.25-4.45 (1H, m), 4.55 (2H, s), 5.57 (1H, s), 6.55-6.72 (2H, m), 7.09 (1H, dd, J=5.1, 3.6Hz), 7.22-7.42 (4H, m), 7.57-7.70 (2H, m)
APCI-MASS (m/z) : 459 (M+H+)
Example 6
To a stirred suspension of 1-cycloheptyl-1-[3-(1- trityl-1H-tetrazol-5-yl)benzyI]-3-(2,4,6- trimethylphenyl) urea (1.46 g) in methanol (14 ml) was added cone, hydrochloric acid (0.722 ml). The mixture was stirred for one hour at room temperature. Insoluble white solid was collected by filtration, washed with methanol (x2), water (x3) to give 1-cycloheptyl-1-[3-(1H-tetrazol-5- yDbenzyl]-3-(2,4,6-trimethylphenyl) urea (0.79 g).
IR (KBr) : 3359, 2400-3300 (br), 1595, 1512, 1456,
1257 cm-1
NMR (DMSO-d6, δ) : 1.35-1.90 (12H, m), 2.06 (6H,
s), 2.20 (3H, s), 4.14-4.34 (1H, m), 4.59 (2H, s), 6.82 (2H, s), 7.46-7.66 (2H, m), 7.80-7.90 (1H, m), 8.00-8.08 (1H, m)
APCI-MASS (m/z) : 433 (M+H+) Example 7
To a solution of N-cycloheptyl-4-(4- fluorophenoxy) benzylamine (2.51 g) in toluene (100 ml) were added 3-phenoxycarbonylamino-2,4-bis (methylthio)-6- methylpyridine (2.56 g) and triethylamine (2.43 g) and the mixture was refluxed for 4 hours under nitrogen. The mixture was cooled and poured into a mixture of ethyl acetate and water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-1-[4-(4- fluorophenoxy)benzyl]-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl] urea (3.89 g).
IR (KBr) : 3379, 3080, 3055, 2924, 2856, 1651, 1568,
1529, 1497 cm-1
NMR (DMSO-d6, δ) : 1.4-2.0 (12H, m), 2.39 (6H, s),
2.44 (3H, s), 4.0-4.2 (1H, m), 4.45 (2H, s), 6.86 (1H, s), 6.93 (2H, d, J=8.5Hz), 7.0-7.1 (2H, m), 7.15-7.3 (2H, m), 7.36 (2H, d, J=8.5Hz), 7.83 (1H, br s)
APCI-MASS (m/z) : 540 (M+H+) Example 8
To a solution of N-cycloheptyl-4-(4- fluorophenoxy) benzylamine (1.57 g) in toluene (150 ml) were added 2, 4-dimethoxy-6-methyl-3-phenoxycarbonylaminopyridine (1.44 g) and triethylamine (1.52 g), and the mixture was refluxed for 3 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4- dimethoxy-6-methylpyridin-3-yl) urea (1.83 g).
IR (KBr) : 3388, 3062, 2927, 2856, 1668, 1599,
1498 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.35 (3H, s),
3.67 and 3.77 (6H, s x 2), 4.0-4.2 (1H, m), 4.43 (2H, s), 6.63 (1H, s), 6.95-7.4 (8H, m) APCI-MASS (m/z) : 496 (M+H+) Example 9
To a suspension of N-benzyl-3-(pyrazol-3- yl) benzylamine bis (trifluoroacetate) (2.46 g) in toluene (80 ml) were added 2,4-bis (methylthio)-6-methyl-3- phenoxycarbonylaminopyridine (1.60 g) and triethylamine (2.53 g), and the mixture was refluxed for 4.5 hours under nitrogen. The mixture was cooled and poured into a mixture of ethyl acetate and ice water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-benzyl-1-[3- (pyrazol-3-yl)benzyl]-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl] urea (831 mg).
IR (KBr) : 3238, 3061, 3028, 2959, 2924, 2870, 1641,
1564, 1495 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, s), 2.46 (3H, s), 4.49 (4H, br s), 6.6-6.7 (1H, m), 6.90 (1H, s), 7.2- 7.8 (10H, m), 8.29 (1H, br s), 12.88 (1H, br s) APCI-MASS (m/z) : 490 (M+H+) Example 10
The mixture of N-cycloheptyl-3-(l-tritylpyrazol-3-yl)- benzylamine (14.63 g) and phenyl N-(2,4,6- trifluorophenyl) carbamate (7.64 g) and triethylamine (20 ml) in toluene (360 ml) was stirred at 100°C for one hour. After cooling to room temperature, the reaction mixture was washed with water, aqueous sodium bicarbonate, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by column chromatography on silica gel (700 g, eluting with n-hexane - ethyl acetate (4:1 to 3:1)) to give 1-cycloheptyl-1-[3-(1-tritylpyrazol- 3-yl)benzyl]-3-(2,4,6-trifluorophenyl) urea (19.6 g).
IR (KBr) : 2900-3600 (br), 2927, 2858, 1635, 1607,
1520, 1446 cm-1
NMR (CDCl3, δ) : 1.35-2.10 (12H, m), 4.26-4.48 (1H, m), 4.55 (2H, s), 5.57 (1H, s), 6.52-6.70 (3H, m), 6.75-6.97 (2H, ml, 7.10-7.45 (16H, m),
7.68-7.80 (2H, m)
Example 11
The following compounds were obtained according to similar manners to those of Examples 7, 8, 9 and 10.
(1) 1-Cyclohexyl-1-[4-(4-fluorophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3377, 3084, 3057, 2927, 2856, 1653, 1566,
1533, 1497 cm-1
NMR (DMSO-d6, δ) : 1.3-1.8 (10H, m), 2.39 (6H, s), 2.45 (3H, s), 3.85-4.05 (1H, m), 4.47 (2H, s), 6.86 (1H, s), 6.93 (2H, d, J=8.5Hz), 6.95-7.05 (2H, m), 7.35 (2H, d, J=8.5Hz), 7.88 (1H, s) APCI-MASS (m/z) : 526 (M+H+)
(2) 1-Benzyl-1-[4-(4-fluorophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl) urea
IR (KBr) : 3307, 3062, 3029, 2999, 2922, 1735, 1660,
1564, 1497 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, s), 2.46 (3H, s), 4.43 (2H, s), 4.46 (2H, s), 6.89 (1H, s), 6.9-7.4 (13H, m), 8.26 (1H, s)
APCI-MASS (m/z) : 526 (M+H+)
(3) 1-Cycloheptyl-1-(4-phenoxybenzyl)-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3371, 2922, 2856, 1653, 1485, 1219 cm-1 NMR (CDCl3, δ) : 1.35-2.10 (12H, m), 2.36 (3H, s),
2.45 (3H, s), 2.46 (3H, s), 4.22-4.42 (1H, m), 4.55 (2H, s), 5.49 (1H, s), 6.59 (1H, s), 6.95- 7.15 (5H, m), 7.24-7.46 (4H, m)
APCI-MASS (m/z) : 522 (M+H+)
(4) 1-Cycloheptyl-1-[4-(4-bromophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3377, 2924, 2852, 1668, 1481, 1238 cm-1
NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.37 (3H, s), 2.46 (3H, s), 2.47 (3H, s), 4.25-4.40 (1H, m),
4.55 (2H, s), 5.47 (1H, s), 6.60 (1H, s), 6.80- 7.08 (4H, m), 7.35-7.50 (4H, m)
APCI-MASS (m/z) : 600, 602 (M+H+) (5) 1-Benzyl-1-[4-(4-bromophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3200-3700 (br), 2922, 1662, 1564, 1481,
1236 cm-1
NMR (CDCl3, δ) : 2.39 (3H, s), 2.47 (3H, s), 2.49
(3H, s), 4.61 (2H, s), 4.63 (2H, s), 5.68 (1H, s), 6.62 (1H, s), 6.82-7.05 (4H, ml, 7.25-7.50 (9H, m)
APCI-MASS (m/z) : 594, 596 (M+H+) (6) 1-Cycloheptyl-1-[4-(4-bromophenoxy)benzyl]-3-[2,4- dimethoxy-6-methylpyridin-3-yl] urea
IR (KBr) : 3100-3700 (br), 2926, 2856, 1668, 1597,
1504, 1481, 1240 cm-1
NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.38 (3H, s), 3.79 (3H, s), 3.83 (3H, s), 4.25-4.40 (1H, m),
4.52 (2H, s), 5.43 (1H, s), 6.36 (1H, s), 6.82- 7.06 (4H, m), 7.32-7.50 (4H, m)
APCI-MASS (m/z) : 568, 570 (M+H+) (7) 1-Benzyl-1-[4-(4-bromophenoxy)benzyl]-3-[2,4- dimethoxy-6-methylpyridin-3-yl] urea
IR (KBr) : 3200-3400 (br), 2997, 1637, 1595, 1506,
1365 cm-1
NMR (CDCl3, δ) : 2.39 (3H, s), 3.80 (3H, s), 3.85 (3H, s), 4.60 (4H, s), 5.64 (1H, s), 6.38 (1H, s), 6.80-7.05 (4H, m), 7.22-7.50 (8H, m) APCI-MASS (m/z) : 562, 564 (M+H+)
Example 12
To a mixture of 1-cycloheptyl-1-[3-(l-tritylpyrazol-3- yl)benzyl]-3-(2,4,6-trifluorophenyl) urea (17.6 g) and anisole (35 ml) was added trifluoroacetic acid (70 ml). The mixture was stirred at 60°C for 3 hours and cooled to room temperature. The excess trifluoroacetic acid was removed in vacuo. To the residue was added water and ethyl acetate. The mixture was basified with 5N-sodium hydroxide under ice cooling and extracted with ethyl acetate. The organic layer was washed with water, and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel (530 g, eluting with n-hexane - ethyl acetate (2:1 to 1:2)) to give 1-cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trifluorophenyl) urea (10.71 g).
IR (KBr) : 3500-2600 (br), 2927, 2858, 1635, 1520,
1448, 1248, 1120 cm-1
NMR (CDCl3, δ) : 1.30-2.10 (12H, m), 4.26-4.46 (1H, m), 4.59 (2H, s), 5.63 (1H, s), 6.53-6.73 (3H, m), 7.30-7.50 (2H, m), 7.63 (1H, d, J=2.3Hz), 7.65-7.80 (2H, m)
APCI-MASS (m/z) : 443 (M+H+)
Examle 13
To a solution of N-cycloheptyl-4-(4-fluorophenoxy)- benzylamine (1.57 g) in toluene (100 ml) were added 3- phenoxycarbonylamino-2, 4,6-trimethylpyridine (2.56 g) and triethylamine (1.52 g), and the mixture was refluxed for 3 hours under nitrogen. The mixture was cooled and poured into a mixture of ethyl acetate and water. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylpyridin-3-yl) urea (1.83 g).
IR (KBr) : 3313, 2924, 2856, 1630, 1603, 1497 cm-1 NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.06 (3H, s),
2.24 (3H, s), 4.05-4.25 (1H, m), 4.48 (2H, s), 6.98 (1H, s), 6.9-7.1 (4H, m), 7.2-7.4 (4H, m), 7.66 (1H, s)
APCI-MASS (m/z) : 476 (M+H+)
Example 14
To a solution of N-cycloheptyl-4-(4-fluorophenoxy)- benzylamine (2.51 g) in toluene (120 ml) were added 4- chloro-6-methyl-2-methylthio-3-phenoxycarbonylaminopyridine (2.47 g) and triethylamine (2.43 g) at room temperature and the mixture was refluxed for 2.5 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-1-[4-(4-fluorophenoxy)- benzyl]-3-(2-chloro-6-methyl-4-methylthiopyridin-3-yl) urea (2.76 g).
IR (KBr) : 3371, 3299, 2924, 2852, 1655, 1576,
1500 cm-1
NMR (DMSO-d6, δ) : 1.3-1.8 (12H, m), 2.43 (6H, s), 4.0-4.2 (1H, m), 4.46 (2H, s), 6.9-7.5 (9H, m), 8.07 (1H, br s) Example 15
To a solution of N-benzyl-3-(pyrazol-3-yl) benzylamine (54.0 g) and triethylamine (143 ml) in toluene (1.35 l) was added 2,4-bis (methylthio)-3-phenoxycarbonylamino-6- methylpyridine (62.4 g) at room temperature and stirred for 24 hours. The resulting precipitate was collected by filtration and recrystallized from dichloromethane - methanol - n-hexane to give 1-benzyl-1-[3-(pyrazol-3- yl) benzyl]-3-[2,4-bis(methylthio)-6-methylpyridin-3-yl] urea (51.0 g).
mp : 209-210°C
IR (KBr) : 3392, 3246, 2918, 1649, 1489, 1228,
1093 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, s), 2.47 (3H, s), 4.49
(4H, s), 6.66 (1H, br s), 6.90 (1H, s), 7.18-7.90 (10H, m), 8.30 (1H, s), 12.89, 13.30 (total 1H, each br)
APCI-MASS (m/z) : 490 (M+H+)
Example 16
To a solution of N-benzyl-[4-(4-bromophenoxy)benzyl]- amine (1.84 g) and 2,4,6-trimethylphenyl-3- phenoxycarbonylaminopyridine (2.20 g) in N,N- dimethylformamide (50 ml) was added triethylamine (2.53 g), and the mixture was stirred at 150°C for 3 hours under nitrogen. The mixture was cooled and ethyl acetate (150 ml) was added thereto. The insoluble materials were filtered off, and the filtrate was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-benzyl-1-[4-(4-bromophenoxy)- benzyl]-3-(2,4,6-trimethylpyridin-3-yl) urea (2.51 g).
IR (KBr) : 3406, 3313, 2929, 2856, 1714, 1632, 1572,
1495 cm-1
NMR (DMSO-d6, δ) : 2.08 (3H, s), 2.26 (3H, s), 2.35 (3H, s), 4.53 (2H, s), 4.57 (2H, s), 6.95-7.15
(5H, m), 7.3-7.6 (9H, m), 8.05 (1H, br s)
APCI-MASS (m/z) : 531 (M+H+)
Sxample 17
To a solution of N-cycloheptyl-4-(4-fluorophenoxy)- benzylamine (1.25 g) in toluene (80 ml) were added 4,6- bis (methylthio)-2-methyl-5-phenoxycarbonylaminopyrimidine (1.29 g) and triethylamine (1.21 g), and the mixture was refluxed for 2 hours under nitrogen. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-[4,6- is (methylthio) -2-methylpyrimidin-5-yl] urea (1.33 g).
IR (KBr) : 3255, 2926, 2856, 1653, 1522, 1497 cm-1 NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.43 (6H, s), 2.56 (3H, s), 3.95-4.1 (1H, m), 4.46 (2H, s), 6.9-7.4 (8H, m), 8.00 (1H, br s)
APCI-MASS (m/z) : 529 (M+H+) Example 18
To a solution of 1-cycloheptyl-1-[4-(3,5-di-tert- butyl-4-methoxymethoxyphenoxy)]benzyl-3-(2,4,6- trimethylphenyl) urea (860 mg) in methanol (8.6 ml) was added cone, hydrochloric acid (0.91 ml), and the mixture was stirred at room temperature for 2 hours and at 40°C for 3.5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and neutralized by addition of saturated sodium bicarbonate aqueous solution. The
separated organic layer was washed with water and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloheptyl-1-[4-(3,5-di-tert-butyl-4- hydroxyphenoxy)benzyl]-3-(2,4,6-trimethylphenyl) urea (495 mg).
IR (KBr) : 3639, 3404, 3323, 2956, 2923, 2860, 1651,
1593, 1504 cm-1
NMR (CDCl3, δ) : 1.41 (18K, s), 1.5-2.1 (12H, m),
1.98 (6H, s), 2.22 (3H, s), 4.25-4.4 (1H, m), 4.45 (2H, s), 5.03 (1H, s), 6.80 (2H, s), 6.86
(2H, s), 6.93 (2H, d, J=8.5Hz), 7.35 (2H, d, J=8.5Hz)
APCI-MASS (m/z) : 585 (M+H+) Example 19
To a solution of 1-cycloheptyl-1-[4-(4- fluorophenoxy) benzyl]-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl] urea (22.11 g) in dichloromethane (150 ml) was added dropwise a solution of m-chloroperbenzoic acid (26.51 g) in dichloromethane (600 mg) at room
temperature over 2 hours. The mixture was stirred at room temperature for 23 hours. The precipitates were removed by filtration and the filtrate was washed with dilute sodium bicarbonate aqueous solution and brine, dried over
magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-[2,4- bis (methylsulfonyl)-6-methylpyridin-3-yl] urea (20.42 g).
IR (KBr) : 3361, 3074, 3041, 3016, 2927, 2860, 1740,
1664, 1500, 1325, 1159, 1128 cm-1
NMR (CDCl3, δ) : 1.5-2.2 (12H, m), 2.66 (3H, s), 3.19 (3H, s), 3.30 (3H, s), 4.55 (2H, s), 6.95-7.05 (6H, m), 7.34 (2H, d, J=8.6Hz) 7.26 (1H, s), 7.85 (1H, s)
APCI-MASS (m/z) : 604 (M+H+)
Example 20
To a solution of 1-cycloheptyl-1-[4-(4- fluorophenoxy) benzyl]-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl] urea (4.75 g) in dichloromethane (50 ml) was added dropwise a solution of m-chloroperbenzoic acid (3.96 g) in dichloromethane (80 ml) at room temperature. The mixture was stirred at room temperature for 20 hours. The mixture was washed with dilute sodium bicarbonate aqueous solution and brme, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1-cycloneptyl- 1-[4-(4-fluorophenoxy)benzyl]-3-[2,4-bis(methylsulfmyl;-6- methylpyridin-3-yl] urea (2.15 g).
IR (KBr) : 3251, 2927, 2858, 1738, 1651, 1496, 1055,
1036 cm-1
NMR (CDCl3, δ) : 1.4-2.0 (12H, m), 2.59 (3H, s), 2.82 and 2.94 (total 3H, s), 2.98 (3H, s), 4.0-4.2 (2H, m), 4.51 (2H, br s), 6.9-7.1 (7H, m), 7.25- 7.35 (2H, m), 7.77-7.79 (total 1H, s)
APCI-MASS (m/z) : 572 (M+H+)
Example 21
To a suspension of 1-cycloheptyl- 1- [ 3- ( 1- tritylpyrazol-4 -yl ) benzyl ] -3- (2 , 4 , 6-trιmethylphenyI ) urea (800 mg) in anisole (2 ml) was added trifluoroacetic acid (6 ml) and the mixture was stirred at 100°C for 2 hours. The mixture was evaporated in vacuo and poured into a mixture of ethyl acetate and water and adjusted to pH ca. 9 by addition of sodium hydroxide aqueous solution. The separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1-[3-(pyrazol-4-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea (102 mg).
IR (KBr) : 3400, 3207, 2926, 2856, 1635, 1608,
1510 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.08 (6H, s),
2.20 (3H, s), 4.1-4.3 (1H, ml, 4.51 (2H, s), 6.83 (2H, s), 7.1-7.5 (5H, m), 7.84 (1H, s), 8.11 (1H, s), 12.95 (1H, br s)
APCI-MASS (m/z) : 431 (M+H+)
Example 22
The following compounds were obtained according to a similar manner to that of Example 1, 2, 3 or 4.
(1) 1-Cycloheptyl-1-[4-(4-chlorophenoxy)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3410, 2920, 2850, 1660, 1590, 1505,
1485 cm-1
NMR (CDCl3, δ) : 1.5-2.1 (12H, m), 2.00 (6H, s), 2.22 (3H, s), 4.3-4.45 (1H, m), 4.48 (2H, s), 5.6-5.8 (1H, br), 6.81 (2H, s), 6.92 (2H, d, J=8.5Hz), 7.00 (2H, d, J=8.5Hz), 7.28 (2H, d, J=8.4Hz),
7.38 (2H, d, J=8.4Hz)
(2) 1-Cycloheptyl-1-[4-(3-fluorophenoxy)benzyl]-3-(2,4,6- trimethylphenyl) urea
mp : 127-128°C IR (KBr) : 2924, 2856, 1624, 1605, 1506, 1485 cm-1 NMR (CDCl3, δ) : 1.35-2.10 (12H, m), 2.01 (6H, s), 2.22 (3H, s), 4.30-4.50 (1H, m), 4.50 (2H, s), 5.46 (1H, s), 6.60-6.88 (3H, m), 6.79 (2H, s), 7.00-7.10 (2H, m), 7.20-7.35 (1H, m), 7.36-7.47
(2H, m)
APCI-MASS (m/z) : 475 (M+H+)
(3) 1-Cycloheptyl-1-[4-(4-trifluoromethylphenoxy)benzyl]- 3-(2,4,6-trimethylphenyl) urea
mp : 146-147°C
IR (KBr) : 2924, 2856, 1628, 1504, 1327, 1246 cm-1
NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.03 (6H, s),
2.23 (3H, s), 4.30-4.50 (1H, m), 4.51 (2H, s), 5.47 (1H, s), 6.83 (2H, s), 6.95-7.13 (4H, m),
7.35-7.50 (2H, m), 7.53-7.65 (2H, m)
APCI-MASS (m/z) : 525 (M+H+)
(4) 1-Cycloheptyl-1-[4-(3,4-methylenedioxyphenoxy)benzyl] 3-(2,4,6-trimethylphenyl) urea
mp : 125-126°C
IR (KBr) : 3323, 2922, 2854, 1628, 1506, 1481 cm-1 NMR (CDCl3, δ) : 1.38-2.10 (12H, m), 1.99 (6H, s), 2.22 (3H, s), 4.33-4.50 (1H, m), 4.46 (2H, s), 5.46 (1H, s), 5.98 (2H, s), 6.47 (1H, dd, J=8.3,
2.4Hz), 6.56 (1H, d, J=2.4Hz), 6.76 (1H, d, J=8.3Hz), 6.81 (2H, s), 6.90-7.00 (2H, m), 7.26- 7.38 (2H, m)
APCI-MASS (m/z) : 501 (M+H+)
(5) 1-Cycloheptyl-1-[4-(3,5-di-tert-butyI-4- methoxymethoxyphenoxy)]benzyl-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3406, 3323, 2956, 2924, 2862, 1641, 1589,
1504 cm-1 NMR (CDCl3, δ) : 1.41 (18H, s), 1.4-2.2 (14H, m),
1.99 (6H, s), 2.22 (3H, s), 3.62 and 3.65 (total 3H, s), 4.3-4.5 (1H, m), 4.46 (2H, s), 4.86 and 4.92 (total 2H, s), 6.80 (2H, s), 6.95-7.1 (4H, m), 7.4-7.5 (2H, m)
(6) 1-Cycloheptyl-1-[4-(4-fluorophenoxy)phenyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3425, 2925, 2860, 1670, 1610, 1500 cm-1 NMR (CDCl3, δ) : 1.3-1.7 and 1.9-2.1 (12H, m), 2.12
(6H, s), 2.22 (3H, s), 4.45-4.65 (1H, m), 5.30 (1H, br s), 6.82 (2H, s), 7.0-7.3 (8H, m) APCI-MASS (m/z) : 461 (M+H+) (7) 1-Benzyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3307, 3062, 3030, 2918, 1633, 1608, 1510,
1497 cm-1
NMR (CDCl3, δ) : 2.00 (6H, s), 2.22 (3H, s), 4.62
(4H, s), 5.68 (1H, s), 6.82 (2H, s), 6.9-7.1 (6H, m), 7.3-7.45 (7H, m)
APCI-MASS (m/z) : 469 (M+H+)
(8) 1-Pentyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3292, 2958, 2920, 2856, 1632, 1608,
1498 cm-1
NMR (CDCl3, δ) : 0.90 (3H, t, J=6.3Hz), 1.25-1.45
(4H, m), 1.6-1.8 (2H, m), 2.09 (6H, s), 2.30 (3H, s), 3.39 (2H, t, J=7.4Hz), 4.55 (2H, s), 5.74 (1H, br s), 6.84 (2H, s), 6.9-7.1 (6H, m), 7.30 (2H, d, J=8.4Hz)
APCI-MASS (m/z) : 449 (M+H+) (9) 1-Cyclohexyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3296, 2958, 2922, 2890, 1624, 1520,
1487 cm-1
NMR (CDCl3, δ) : 1.3-2.0 (10H, m), 1.99 (6H, s), 2.22 (3H, s), 4.25-4.45 (1H, m), 4.47 (2H, s), 5.54
(1H, br s), 6.81 (2H, s), 6.9-7.1 (6H, m), 7.35 (2H, d, J=8.5Hz)
APCI-MASS (m/z) : 461 (M+H+) (10) 1-Cyclopentyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3400, 3304, 3074, 2933, 2850, 1657, 1608,
1495 cm-1
NMR (CDCl3, δ) : 1.5-1.8 and 2.0-2.15 (8H, m), 2.00 (6H, s), 2.22 (3H, s), 4.47 (2H, s), 4.7-4.9 (1H, m), 5.35 (1H, br s), 6.82 (2H, s), 6.9-7.1 (6H, m), 7.33 (2H, d, J=8.5Hz)
APCI-MASS (m/z) : 447 (M+H+) (11) 1-Cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3284, 2929, 2858, 1633, 1612, 1516,
1497 cm-1
NMR (CDCl3, δ) : 1.4-2.1 (12H, m), 4.25-4.45 (1H,
m), 4.50 (2H, s), 5.58 (1H, s), 6.55-6.7 (2H, m),
6.9-7.1 (6H, m), 7.25-7.4 (2H, m)
APCI-MASS (m/z) : 487 (M+H+)
(12) 1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3404, 3207, 3060, 3029, 2967, 2918, 2858,
1635, 1608, 1510 cm-1
NMR (DMSO-d6, δ) : 2.09 (6H, s), 2.21 (3H, s;, 4.57 (2H, s), 6.0-6.05 (1H, m), 6.84 (2H, s), 7.2-7.5 (7H, m), 7.65-7.8 (3H, m), 7.87 (1H, s), 12.89 (1H, br)
APCI-MASS (m/z) : 425 (M+H+)
(13) 1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3246, 1637, 1522 cm-1
NMR (DMSO-d6, δ) : 4.54 (4H, s), 6.65 (1H, br s), 7.2-7.5 (4H, m), 7.7-7.9 (3H, m), 8.47 (1H, br s), 12.90 and 13.34 (total 1H, br s)
APCI-MASS (m/z) : 437 (M+H+)
(14) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trifluorophenyl) urea
IR (KBr) : 3226, 3062, 2927, 2858, 1635, 1612,
1518 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 4.0-4.2 (1H, m), 4.55 (2H, s), 6.63 (1H, d, J=1.9Hz), 7.15-7.5 (4H, m), 7.6-7.8 (3H, m), 8.10 (1H, br s)
APCI-MASS (m/z) : 444 (M+H+)
(15) 1-Cyclohexyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3226, 2929, 2856, 1635, 1608, 1510 cm-1 NMR (DMSO-d6, δ) : 1.3-1.8 (10H, m), 2.08 (6H, s), 2.20 (3H, s), 4.0-4.2 (1H, m), 4.57 (2H, s), 6.62
(1H, br s), 6.83 (2H, s), 7.2-7.45 (2H, m), 7.55- 7.85 (3H, m), 12.86 (1H, br s)
APCI-MASS (m/z) : 417 (M+H+) (16) 1-Cyclopentyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3188, 2956, 2870, 1635, 1608, 1510 cm-1 NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.08 (6H, s), 2.20 (3H, s), 4.45-4.6 (1H, m), 4.56 (2H, s), 6.63 (1H, br s), 6.83 (2H, s), 7.15-7.45 (2H, m), 7.55-7.85 (5H, m), 12.87 (1H, br s) APCI-MASS (m/z) : 403 (M+H+)
(17) 1-Cycloheptyl-1-[3-(1-tritylpyrazol-4-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3408, 3323, 3059, 3030, 2924, 2856, 1645,
1608, 1562 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.00 (6H, s),
2.20 (3H, s), 4.0-4.2 (1H, m), 4.48 (2H, s), 6.80 (2H, s), 7.1-7.5 (19H, m), 7.70 (1H, s), 8.02 (1H, s)
APCI-MASS (m/z) : 673 (M+H+)
(18) 1-Cycloheptyl-1-[4-(1-tritylpyrazol-4-yl)benzyl]-3- (2,4,6-trimethylphenyl) u rea
IR (KBr)
3406, 3323, 3057, 3030, 2924, 2854, 1640, 1568 cm-1
NMR (DMSO-d6, δ) : 1.40-2.0 (12H, m), 2.08 (6H, s), 2.20 (3H, s), 4.05-4.25 (1H, m), 4.47 (2H, s), 6.83 (2H, s) , 7.05-7.15 (5H, m), 7.25 (2H, d, J=8.2Kz), 7.3-7.4 (11H, m), 7.49 (2H, d, J=8.2Hz), 7.78 (1H, s), 8.07 (1H, s)
APCI-MASS (m/z) : 673 (M+H+)
19;
1-Cycloheptyl-1-[3-(1-methylpyrazol-4-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3408, 2924, 2856, 1637, 1610, 1497,
1234 cm-1
NMR (CDCl3, δ) : 1.38-2.10 (12H, m), 1.98 (6H, s),
2.20 ( 3H, s), 3.95 (3H, s), 4.36-4.56 (1H, m), 4.52 (2H, s), 5.48 (1H, s), 6.73 (2H, s), 7.20- 7.52 (4H, m), 7.62 (1H, s), 7.75 (1H, s) APCI-MASS (m/z) : 445 (M+H+) (20)
1-Cycloheptyl-1-[3-(1-methylpyrazol-3-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
mp : 142-143°C
IR (KBr) : 3346, 2924, 2854, 1630, 1502, 1246 cm-1
NMR (CDCl3, δ) : 1.35-2.10 (12H, m), 1.97 (6H, s),
2.19 (3H, s), 3.95 (3H, s), 4.38-4.58 (1H, m), 4.55 (2H, s), 5.49 (1H, s), 6.53 (1H, d, J=2.2Hz), 6.77 (2H, s), 7.30-7.50 (3H, m), 7.65- 7.88 (2H, m)
APCI-MASS (m/z) : 445 (M+H+)
(21) 1-Cycloheptyl-1-[3-(l-methylpyrazol-5-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
mp : 171-172°C
IR (KBr) : 3307, 2924, 2856, 1626, 1506, 1254 cm-1 NMR (CDCl3, δ) : 1.38-2.10 (12H, m), 2.00 (6H, s),
2.21 (3H, s), 3.89 (3H, s), 4.30-4.50 (1H, m), 4.57 (2H, s), 5.46 (1H, s), 6.29 (1H, d, J=1.9Hz), 6.80 (2H, s), 7.25-7.56 (5H, m)
APCI-MASS (m/z! 445 (M+H+)
(22) 1-Cycloheptyl-1-[3-(imidazol-4-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3140 (br), 2924, 2856, 1635, 1608, 1497 cm-1 NMR (DMSO-d6, δ) : 1.25-1.90 (12H, m), 2.07 (6H, s), 2.20 (3H, s), 4.07-4.27 (1H, m), 4.52 (2H, s),
6.82 (2H, s), 7.08-7.80 (7H, m), 12.13, 12.53
(total 1H, each br)
APCI-MASS (m/z) : 431 (M+H+) (23) 1-Cycloheptyl-1-[4-(5-methyl-1,3,4-oxadiazol-2- yl)benzyl]-3-(2,4,6-trimethylphenyl) urea
mp : 123-124°C
IR (KBr) : 3319, 2924, 2856, 1622, 1500, 1243 cm-1 NMR (CDCl3, δ) : 1.35-2.10 (12H, m), 2.04 (6H, s),
2.22 (3H, s), 2.62 (3H, s), 4.20-4.40 (1H, m), 4.58 (2H, s), 5.58 (1H, s), 6.81 (2H, s), 7.49-
7.59 (2H, m), 7.98-8.08 (2H, m)
APCI-MASS (m/z) : 447 (M+H+) (24) 1-Cycloheptyl-1-[4-(5-methyl-4H-1,2,4-triazol-3- yl)benzyl]-3-(2,4,6-trimethylphenyl) urea
mp : 142-145°C
IR (KBr) : 2600-3700 (br), 2924, 2856, 1633, 1608,
1558, 1504, 1238 cm-1
NMR (CDCl3, δ) : 1.38-2.15 (12H, m), 1.90 (6H, s),
2.27 (3H, s), 2.16 (3H, s), 4.37-4.57 (1H, m), 4.58 (2H, s), 5.59 (1H, s), 6.71 (2H, s), 7.45- 7.57 (2H, m), 8.05-8.17 (2H, m)
APCI-MASS (m/z) : 446 (M+H+)
(25) 1-Cycloheptyl-1-[4-(4-benzyl-5-methyl-4H-1,2,4- triazol-3-yl)benzyl]-3-(2,4,6-trimethylphenyl) urea mp : 193-194°C
IR (KBr) : 3296, 2924, 2856, 1626, 1506, 1252,
847 cm-1
NMR (CDCl3, δ) : 1.35-2.05 (12H, m), 2.00 (6H, s), 2.21 (3H, s), 2.39 (3H, s), 4.20-4.40 (1H, m), 4.55 (2H, s), 5.15 (2H, s), 5.43 (1H, s), 6.80 (2H, s), 6.90-7.05 (2H, m), 7.30-7.60 (7H, m) APCI-MASS (m/z) : 536 (M+H+)
(26) 1-Cycloheptyl-1-[3-(2-methyI-2H-tetrazol-5-yl)benzyl]- 3-(2,4,6-trimethylphenyl) urea
mp : 175-176°C
IR (KBr) : 3327, 2922, 2856, 1628, 1500, 1255 cm-1
NMR (DMSO-d6, δ) : 1.30-1.90 (12H, m), 2.09 (6H, s), 2.20 (3H, s), 4.12-4.30 (1H, m), 4.42 (3H, s), 4.59 (2H, s), 6.83 (2H, s), 7.40-7.65 (3H, m), 7.85-7.95 (1H, m), 8.06 (1H, s)
APCI-MASS (m/z) : 447 (M+H+) (27) 1-Cycloheptyl-1-[3-(l-methyl-1H-tetrazol-5-yl)benzyl] 3-(2,4,6-trimethylphenyl) urea
mp : 171-173°C
IR (KBr) : 3323, 2924, 2854, 1626, 1502, 1444,
1254 cm-1
NMR (DMSO-d6, δ) : 1.40-1.90 (12H, m), 2.06 (6H, s), 2.20 (3H, s), 4.16 (3H, s), 4.10-4.28 (1H, m), 4.59 (2H, s), 6.83 (2H, s), 7.54-7.80 (5H, m)
APCI-MASS (m/z) : 447 (M+H-
(28) 1-Cycloheptyl-1-[4-(1,2,4-1H-triazol-1-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3310, 2924, 2856, 1639, 1518, 1277,
1147 cm-1
NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.07 (6H, s),
2.22 (3H, s), 4.20-4.40 (1H, m), 4.58 (2H, s), 5.49 (1H, s), 6.82 (2H, s), 7.50-7.60 (2H, m), 7.64-7.74 (2H, m), 8.11 (1H, s), 8.55 (1H, s) APCI-MASS (m/z) : 432 (M+H+)
(29) 1-Cycloheptyl-1-[4-(1,2,3-1H-triazol-1-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3331, 2924, 2856, 1637, 1498, 1319, 1234,
1034 cm-1
NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.07 (6H, s),
2.22 (3H, s), 4.20-4.38 (1H, m), 4.60 (2H, s), 5.55 (1H, s), 6.83 (2H, s), 7.52-7.61 (2H, m), 7.70-7.80 (2H, m), 7.86 (1H, s), 8.00 (1H, s) APCI-MASS (m/z) : 432 (M+H+)
(30) 1-Cycloheptyl-1-[4-(2H-1,2,3-triazol-2-yl)benzyl]-3- (2,4,6-trimethylphenyl) urea
mp : 157-158°C
IR (KBr) : 3311, 2924, 2856, 1626, 1512, 1255, 955,
847 cm-1 NMR (CDCl3, δ) : 1.40-2.10 (12H, m), 2.04 (6H, s), 2.21 (3H, s), 4.25-4.45 (1H, m), 4.57 (2H, s), 5.51 (1H, s), 6.81 (2H, s), 7.48-7.58 (2H, m), 7.82 (2H, s), 8.04-8.14 (2H, m)
APCI-MASS (m/z) : 432 (M+H+)
(31) 1-Cycloheptyl-1-[4-(4-methylpiperazin-1-yl)benzyl]-3- (2, 4, 6-trimethylphenyl) urea
IR (KBr) : 3390, 3335, 2925, 2855, 2795, 2360, 1645,
1610, 1515 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.05 (6H, s),
2.20 (6H, s), 2.4-2.5 (4H, m), 3.05-3.15 (4H, m), 4.0-4.2 (1H, m), 4.39 (2H, s), 6.82 (2H, s), 6.88 (2H, d, J=8.5Hz), 7.16 (2H, d, J=8.5Hz), 7.34 (1H, br s)
APCI-MASS (m/z) : 463 (M+H+)
(32) 1-Cycloheptyl-1-[4-(4-methylsulfonylaminophenyl)- benzyl]-3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3400, 3340, 2975, 2925, 2860, 1640,
1500 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.08 (6H, s),
2.20 (3H, s), 3.01 (3H, s), 4.1-4.3 (1H, m), 4.53 (2H, s), 6.83 (2H, s), 7.27 (2H, d, J=8.4Hz), 7.37 (2H, d, J=8.4Hz), 7.53 (1H, br s), 7.55-7.7
(4H, m), 9.82 (1H, s)
APCI-MASS (m/z) : 534 (M+H+)
(33) 1-Cycloheptyl-1-[4-[2-(l-trityl-1H-tetrazol-5- yl)phenyl]benzyl]-3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3407, 3058, 3026, 2924, 2856, 1647, 1608,
1493 cm-1
NMR (DMSO-d6, δ) : 1.4-1.8 (12H, m), 2.04 (6H, s), 2.20 (3H, s), 4.05-4.25 (1H, m), 4.48 (2H, s), 6.83 (2H, s), 7.04 (2H, d, J=7.9Hz), 7.23 (2H, d, J=7.9Hz), 7.5-7.8 (5H, m)
FAB-MASS (m/z) : 751 (M+H+)
(34) 1-Cycloheptyl-1-[4-(N-benzoylsulfamoyl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3415, 3361, 2924, 2858, 1632, 1593,
1549 cm-1
NMR (DMSO-d6, δ) : 1.4-2.0 (12H, m), 2.07 (6H, s),
2.20 (3H, s), 4.1-4.3 (1H, m), 4.51 (2H, s), 6.81 (2H, s), 7.2-7.4 (5H, m), 7.53 (1H, br s), 7.76
(2H, d, J=8.0Hz), 7.88 (2H, d, J=8.0Hz) APCI-MASS (m/z) : 548 (M+H+)
(35) 1-Cycloheptyl-1-[4-(N-phenylsulfonylcarbamoyl)benzyl]- 3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3380, 3290, 3055, 2920, 2855*, 1690, 1625,
1610, 1505 cm-1
NMR (DMSO-d6, δ) : 1.3-1.8 (12H, m), 2.07 (6H, s),
2.21 (3H, s), 4.1-4.25 (1H, m), 4.53 (2H, s), 6.83 (2H, s), 7.38 (2H, d, J=8.2Hz), 7.65-7.8
(4H, m), 7.82 (2H, d, J=8.2Hz), 8.00 (2H, d, J=6.7Hz)
APCI-MASS (m/z) : 548 (M+H+) (36) 1-Cycloheptyl-1-[4-(3-pyridylmethyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3412, 3304, 3028, 2920, 2854, 1626,
1502 cm-1
NMR (CDCl3, δ) : 1.4-2.1 (12H, m), 1.95 (6H, s), 2.21 (3H, s), 3.98 (2H, s), 4.35-4.55 (1H, m), 4.48
(2H, s), 5.42 (1H, s), 6.79 (2H, s), 7.19 (2H, d, J=7.7Hz), 7.15-7.25 (1H, m), 7.35 (2H, d, J=7.7Hz), 7.4-7.5 (1H, m), 8.4-8.5 (2H, m)
APCI-MASS (m/z) : 456 (M+H+) (37) 1-Cycloheptyl-1-[4-(4-pyridylmethyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3408, 3304, 3024, 2922, 2856, 1632, 1605,
1512 cm-1
NMR (CDCl3, δ) : 1.4-2.1 (12H, m), 1.95 (6H, s), 2.21
(3H, s), 3.96 (2H, s), 4.35-4.5 (1H, m), 4.48 (2H, s), 5.42 (1H, s ) , 6X9 (2H, s), 7.09 (2H, dd, J=6.0, 1.6Hz), 7.20 (2H, d, J=8.1Hz), 7.37 (2H, d, J=8.1Kz), 8.49 (2H, dd, J=6.0, 1.6Hz) APCI-MASS (m/z) : 456 (M+H+)
(38) 1-Cycloheptyl-1-(3-benzyIbenzyl)-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3223, 3025, 2922, 2854, 1626, 1506 cm-1 NMR (CDCl3, δ) : 1.4-2.C (12H, m), 1.95 (6H, s), 2.21
(3H, s), 3.97 (2H, s), 4.46 (2H, s), 4.3-4.5 (1H, m), 5.42 (1H, s), 6.79 (2H, s), 7.1-7.35 (9H, m)
APCI-MASS (m/z) : 455 (M+H+) (39) 1-Cycloheptyl-1-[4-(pyrazol-1-ylmethyl)benzyl]-3- (2,4,6-trimethylphenyl) urea
mp : 150-151°C
IR (KBr) : 3307, 2922, 2856, 1628, 1508, 1250,
750 cm-1
NMR (CDCl3, δ) : 1.38-2.05 (12H, m), 1.97 (6H, s),
2.21 (3H, s), 4.30-4.45 (1H, m), 4.49 (2H, s), 5.32 (2H, s), 5.39 (1H, s), 6.28 (1H, dd, J=2.0, 2.0Hz), 6.79 (2H, s), 7.15-7.28 (2H, m), 7.32- 7.42 (3H, m), 7.55 (1H, d, J=2.0Hz)
APCI-MASS (m/z) : 445 (M+H+)
(40) 1-Cycloheptyl-1-[4-(imidazol-1-ylmethyl)benzyl]-3- (2,4,6-trimethylphenyl) urea
IR (KBr) : 3329 (br), 2924, 2856, 1637, 1504, 1234,
849, 735 cm-1 NMR (CDCl3, δ) : 1.35-2.05 (12H, m), 1.99 (6H, s),
2.21 (3H, s), 4.25-4.45 (1H, m), 4.51 (2H, s),
5.12 (2H, s), 5.40 (1H, s), 6.80 (2H, s), 6.89
(1H, s), 7.10 (1H, s), 7.13-7.23 (2H, m), 7.35- 7.45 (2H, m), 7.61 (1H, s)
APCI-MASS (m/z) : 445 (M+H+)
(41) 1-Cycloheptyl-1-[(6-hydroxy-2,5,7,8-tetramethyl- chroman-2-yl)methyl]-3-(2,4,6-trimethylphenyl) urea IR (KBr) : 3313, 2924, 2858, 1740, 1643, 1610,
1510 cm-1
NMR (DMSO-d6, δ) : 1.15 (3H, s), 1.3-2.1 (16H, m), 2.55-2.65 (1H, m), 1.92 (3H, s), 1.99 (3H, s), 2.02 (6H, s), 2.03 (3H, s), 2.21 (3H, s), 3.53 (2H, br s), 6.83 (2H, s), 7.44 (1H, br s)
APCI-MASS (m/z) : 493 (M+H+)
(42) 1-Cycloheptyl-1-[4-[N-(3,5-di-tert-butyl-4- hydroxyphenyl)carbamoyl]benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3639, 3417, 3321, 2951, 2924, 2860, 1643,
1610, 1502 cm-1
NMR (DMSO-d6, δ) : 1.39 (18H, s), 1.4-1.9 (12H, m),
2.10 (6H, s), 2.21 (3H, s), 4.1-4.3 (1H, m), 4.57 (2H, s), 6.78 (1H, s), 6.85 (2H, s), 7.41 (2H, d,
J=8.3Hz), 7.90 (2H, d, J=8.3Hz), 7.44 (2H, s), 7.59 (1H, br s), 9.87 (1H, br s)
APCI-MASS (m/z) : 612 (M+H+) (43) 1-Cycloheptyl-1-[4-[N-(4-fluorophenyl)carbamoyl]- benzyl]-3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3280, 2926, 2856, 1643, 1610, 1549,
1508 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.11 (6H, s), 2.21 (3H, s), 4.1-4.3 (1H, m), 4.57 (2H, s), 6.85 (2H, s), 7.15-7.3 (2H, m), 7.43 (2H, d, J=8.2Hz), 7.64 (1H, br s), 7.75-7.85 (2H, m), 7.90 (2H, d, J=8.2Hz), 10.22 (1H, s)
APCI-MASS (m/z) : 502 (M+H+)
(44) 1-Cycloheptyl-1-[4-[N-(4-fluorophenyl)-N- methylcarbamoyl]benzyl]-3-(2,4,6-trimethylphenyl) urea IR (KBr) : 3321, 2951, 2923, 2860, 1638, 1606 cm-1 NMR (DMSO-d6, δ) : 1.4-1.8 (12H, m), 2.01 (6H, s), 2.20 (3H, s), 3.30 (3H, s), 4.0-4.2 (1H, m), 4.42
(2H, s), 6.82 (2H, s), 7.05-7.3 (8H, m), 7.47 (1H, br s)
APCI-MASS (m/z) : 516 (M+H+) (45) 1-Cycloheptyl-1-[4-[(2,4-dioxothiazolidin-5- yl)methyl]benzyl]-3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 2931, 2858, 2765, 1753, 1709, 1689, 1606,
1632, 1564, 1535, 1502, 1481 cm-1
NMR (DMSO-d6, δ) : 1.4-2.1 (12H, m),2.05 (6H, s),
2.20 (3H, s), 3.0-3.2 (1H, m), 3.3-3.45 (1H, m),
4.0-4.2 (1H, m), 4.47 (2H, s), 4.85-5.0 (1H, m), 6.82 (2H, s), 7.19 (2H, d, J=8.2Hz), 7.25 (2H, d, J=8.2Hz), 7.44 (1H, br s), 12.3 (1H, br) APCI-MASS (m/z) : 494 (M+H+)
(46) 1-Cycloheptyl-1-[4-[(2,4-dιoxothiazolidin-5- ylidene)methyl]benzyl]-3-(2,4,6-trimethylphenyl) urea IR (KBr) : 3410, 3122, 2924, 2958, 2758, 1743, 1707,
1603, 1504 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.08 (6H, s),
2.21 (3H, s), 4.1-4.3 (1H, m), 4.54 (2H, s), 6.84 (2H, s), 7.44 (2H, d, J=8.3Hz), 7.56 (2H, d,
J=8.3Hz), 7.61 (1H, br s), 7.77 (1H, s), 12.60 (1H, br)
APCI-MASS (m/z) : 492 (M+H+) (47) 1-Cycloheptyl-1-[4-(2-cyanophenyl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3410, 3330, 2925, 2855, 2225, 1640, 1610,
1500 cm-1
NMR (CDCl3, δ) : 1.5-1.8 (12H, m), 2.02 (6H, s), 2.21
(3H, s), 4.35-4.55 (1H, m), 4.58 (2H, s), 5.49 (1H, s), 6.80 (2H, s), 7.4-7.3 (8H, m) APCI-MASS (m/z) : 466 (M+H+) Example 23
The following compounds were obtained according to a similar manner to that of Example 7, 8, 9, 10, 13, 14, 15, 16 or 17. (1) 1-Cycloheptyl-1-[4-(4'-chlorophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3371, 2924, 2856, 1662, 1589, 1564, 1506,
1485 cm-1
NMR (DMSO-d6, δ) : 1.35-1.9 (12H, m), 2.39 (6H, s), 2.44 (3H, s), 4.0-4.2 (1H, m), 4.46 (2H, s), 6.86 (1H, s), 6.95-7.1 (4H, m), 7.35-7.5 (4K, m), 7.84 (1H, br s)
APCI-MASS (m/z) : 556 (M+H+) (2) 1-Cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3313, 2955, 2924, 2872, 1655, 1564,
1497 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (8H, m), 2.39 (6H, s),
2.44 (3H, s), 4.3-4.5 (1H, m), 4.47 (2H, s), 6.86
(1H, s), 6.9-7.1 (4H, m), 7.15-7.35 (4H, m), 7.87 (1H, s)
APCI-MASS (m/z) : 512 (M+H+) (3) 1-Cycloheptyl-1-(3-phenoxybenzyl)-3-[ 2 ,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3294, 2924, 2854, 1740, 1635, 1562,
1483 cm-1
NMR (DMSO-d6, δ) : 1.3-2.0 (12H, m), 2.32 (6H, s), 2.43 (3H, s), 4.0-4.2 (1H, m), 4.47 (2H, s), 6.83 (1H, s), 6.9-7.45 (9H, m), 7.84 (1H, br s;
APCI-MASS (m/z) : 522 (M+H+)
(4) 1-Cycloheptyl-1-[3-(4-fluorophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3332, 3066, 2926, 2856, 1664, 1608, 1564,
1497 cm-1
NMR (CDCl3, δ) : 1.45-2.05 (12H, m), 2.34 (3H, s), 2.45 (6H, s), 4.15-4.4 (1H, m), 4.54 (2H, s), 5.46 (1H, s), 6.58 (1H, s), 6.85-7.4 (8H, m)
(5) 1-(4-Dimethylaminobenzyl)-1-[3-(pyrazol-3-yl)benzyl]- 3-(2,4,6-trifluorophenyl) urea
IR (KBr) : 2600-3650 (br), 1635, 1614, 1522, 1448,
1352 cm-1
NMR (DMSO-d6, δ) : 2.83 (6H, s), 4.38 (2H, s), 4.47 (2H, s), 6.55-6.77 (3H, m), 7.08-7.83 (9H, m), 8.39 (1H, s), 12.89, 13.33 (total 1H, each br) APCI-MASS (m/z) : 480 (M+H+)
(6) 1-(2,3,5,6-Tetrahydro-4H-pyran-4-yl)-1-[4-(4- fluorophenoxy)benzyl]-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl] urea
IR (KBr) : 3294, 3064, 2956, 2926, 2848, 1655, 1562,
1497 cm-1
NMR (DMSO-d6, δ) : 1.55-1.85 (4H, m), 2.40 (6H, s), 2.45 (3H, s), 3.3-3.5 (2H, m), 3.8-3.9 (2H, m), 4.1-4.3 (1H, m), 4.51 (2H, s), 6.87 (1H, s), 6.9- 7.4 (8H, m), 7.98 (1H, br s) (7) 1-(2-Phenylethyl)-1-[4-(4-fluorophenoxy)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3294, 3062, 3026, 2924, 1655, 1562,
1497 cm-1
NMR (CDCl3, δ) : 2.40 (3H, s), 2.48 (3H, s), 2.51 (3H, s), 3.01 (2H, t, J=7.8Hz), 3.61 (2H, t, J=7.8Hz), 4.43 (2H, s), 5.65 (1H, br s), 6.64 (1H, s), 6.9-7.1 (6H, m), 7.2-7.35 (7H, m)
APCI-MASS (m/z) : 548 (M+H+)
(8) 1-(2-Ethoxyethyl)-1-[4-(4-fluorophenoxy)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3298, 3063, 2976, 2926, 2881, 2856, 1664,
1562, 1495 cm-1
NMR (DMSO-d6, δ) : 1.12 (3H, t, J=6.9Hz), 2.40 (6H, s), 2.45 (3H, s), 3.46 (2H, q, J=6.9Hz), 3.4-3.65 (4H, m), 4.54 (2H, s), 6.87 (1H, s), 6.93-7.4 (8H, m), 7.9 (1H, br s)
APCI-MASS (m/z) : 516 (M+H+)
(9) 1-Benzyl-1-(3-phenoxybenzyl)-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl] urea
IR (KBr) : 3404, 3032, 2997, 2922, 1668, 1610, 1562,
1500, 1452 cm-1
NMR (DMSO-d6, δ) : 2.35 (6H, s), 2.43 (3H, s), 4.44
(2H, s), 4.47 (2H, s), 6.86 (1H, s), 6.9-7.45 (14H, m), 8.24 (1H, br s)
APCI-MASS (m/z) : 516 (M+H+) (10) 1-Benzyl-1-[3-(4-fluorophenoxy)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3298, 3062, 3028, 2922, 1662, 1564,
1498 cm-1
NMR (CDCl3, δ) : 2.36 (3H, s), 2.46 (6H, s), 4.61
(2H, s), 4.62 (2H, s), 5.66 (1H, s), 6.85-7.4 (13H, m)
APCI-MASS (m/z) : 534 (M+H+)
(11) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3211, 3061, 2924, 2856, 1643, 1564, 1531,
1485 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.39 (6H, s),
2.45 (3H, s), 4.0-4.2 (1H, m), 4.52 (2H, s), 6.6- 6.7 (1H, m), 6.86 (1H, s), 7.2-7.9 (6H, m), 12.85
(1H, br s)
APCI-MASS (m/z) : 496 (M+H+)
(12) 1-Benzyl-1-[3-(l-methylpyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
mp : 165-166°C
IR (KBr) : 3280, 2922, 1643, 1562, 1500, 1435 cm-1
NMR (CDCl3, δ) : 2.36 (3H, s), 2.46 (6H, s), 3.95
(3H, s), 4.66 (4H, s), 5.70 (1H, s), 6.57 (1H, d, J=2.3Hz), 6.61 (1H, s), 7.22-7.45 (8H, m), 7.72-
7.80 (2H, m)
FAB-MASS (m/z) : 504 (M+H+)
(13) 1-Benzyl-1-[3-(l-methylpyrazol-5-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3280, 2922, 1649, 1562, 1500, 1431,
1390 cm-1
NMR (CDCl3, δ) : 2.35 (3H, s), 2.45 (3H, s), 2.46
(3H, s), 3.88 (3H, s), 4.64 (2H, s), 4.71 (2H, s), 5.70 (1H, s), 6.32 (1H, d, J=1.9Hz), 6.61
(1H, s), 7.20-7.55 (10H, m)
FAB-MASS (m/z) : 504 (M+H+)
(14) 1-Benzyl-1-[4-(l-methylpyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea IR (KBr) : 3305, 2922, 1659, 1564, 1489, 1338,
1227 cm-1
NMR (CDCl3, δ) : 2.38 (3H, s), 2.47 (3H, s), 2.49 (3H, s), 3.96 (3H, s), 4.63 (4H, s), 5.71 (1H, s), 6.54 (1H, d, J=2.3Hz), 6.62 (1H, s), 7.25-
7.47 (8H, m), 7.75-7.85 (2H, m)
APCI-MASS (m/z) : 504 (M+H+)
(15) 1-Benzyl-1-[4-(l-methylpyrazol-5-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3286, 2922, 1657, 1562, 1495, 1389 cm-1 NMR (CDCl3, δ) : 2.40 (3H, s), 2.47 (3H, s), 2.49 (3H, s), 3.90 (3H, s), 4.66 (2H, s), 4.69 (2H, s), 5.71 (1H, s), 6.31 (1H, d, J=1.9Hz), 6.63 (1H, s), 7.25-7.51 (9H, m), 7.52 (1H, d, J=1.9Hz)
APCI-MASS (m/z) : 504 (M+H+)
(16) 1-Benzyl-1-[4-(pyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
mp : 150-152°C
IR (KBr) : 3400, 3215, 2922, 1649, 1560, 1487,
1228 cm-1
NMR (DMSO-d6, δ) : 2.44 (6H, s), 2.47 (3H, s), 4.46 (4H, s), 6.72 (1H, s), 6.90 (1H, s), 7.22-7.90 (10H, m), 8.30 (1H, s), 12.87, 13.27 (total 1H, each br)
APCI-MASS (m/z) : 490 (M+H+)
(17) 1-Cycloheptyl-1-[4-(pyrazoi-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
mp : 174-175°C
IR (KBr) : 2690-3700 (br), 2924, 2856, 1637,
1564, 1484, 1340, 1207, 804 cm-1
NMR (DMSO-d6, δ) : 1.30-1.90 (12H, m), 2.41 ( 6H, s), 2.45 (3H, s), 3.95-4.15 (1H, m), 4.49 (2H, s), 6.67 (1H, br s), 6.86 (1H, s), 7.32-7.93 (6H, m), 12.80, 13.19 (total 1H, each br)
APCI-MASS (m/z) : 496 (M+H+) (18) 1-(4-Methoxybenzyl)-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
mp : 170-173°C
IR (KBr) : 3394, 3250, 3101, 2920, 1664, 1562, 1483,
1223 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, s), .2.47 (3H, s), 3.75
(3H, s), 4.41 (2H, s), 4.45 (2H, s), 6.67 (1H, br s), 6.88-7.03 (3H, m), 7.13-7.90 (7H, m), 8.27 (1H, s), 12.89, 13.30 (total 1H, each br)
APCI-MASS (m/z) : 520 (M+H+)
(19) 1-(4-Fluorobenzyl)-1-[3-(pyrazol-3-yl)benzyl]-3-[2 , 4 - bis (methylthio)-6-methylpyridin-3-yl] urea
mp : 166-168°C
IR (KBr) : 3390, 3257, 2920, 1653, 1562, 1489,
1227 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, s), 2.46 (3H, s), 4.47 (2H, s), 4.49 (2H, s), 6.66 (1H, d, J=2.0Hz), 6.90 (1H, s), 7.12-7.45 (6H, m), 7.60-7.90 (3H, m), 8.30 (1H, s), 12.89, 13.30 (total 1H, each br)
APCI-MASS (m/z) : 508 (M+H+)
(20) 1-(4-Dimethylaminobenzyl)-1-[3-(pyrazol-3-yl)benzyl]- 3-[2,4-bis(methylthio)-6-methylpyridin-3-yl] urea mp : 185-188°C
IR (KBr) : 3236, 2922, 1633, 1612, 1524, 1487, 1338,
1219 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, S), 2.47 (3H, s), 2.89 (6H, s), 4.35 (2H, br s), 4.42 (2H, br s), 6.60- 6.76 (3H, m), 6.90 (1H, s), 7.10-7.90 (7H, m), 8.23 (1H, s), 12.89, 13.30 (total 1H, each br) APCI-MASS (m/z) : 533 (M+H+)
(21) 1-Benzyl-1-[4-(l-methylpyrazol-4-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
mp : 224-225°C
IR (KBr) : 3217, 2922, 1655, 1566, 1498, 1456, 1228,
806 cm-1
NMR (DMSO-d6, δ) : 2.43 (6H, s), 2.47 (3H, s), 3.86 (3H, s), 4.30-4.50 (4H, m), 6.90 (1H, s), 7.20-
7.40 (7H, m), 7.50-7.60 (2H, m), 7.86 (1H, s), 8.13 (1H, s), 8.28 (1H, s)
APCI-MASS (m/z) : 504 (M+H+) (22) 1-Cycloheptyl-1-[4-(l-methylpyrazol-4-yl)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridin-3-yl] urea mp : 247-248°C
IR (KBr) : 3188, 2922, 2854, 1641, 1564, 1491,
1213 cm-1
NMR (DMSO-d6, δ) : 1.30-1.90 (12H, m), 2.40 (6H, s),
2.45 (3H, s), 3.85 (3H, s), 3.90-4.15 (1H, m), 4.45 (2H, s), 6.86 (1H, s), 7.28-7.38 (2H, m), 7.43-7.54 (2H, m), 7.83 (1H, s), 7.85 (1H, br s), 8.10 (1H, s)
APCI-MASS (m/z) : 510 (M+H+)
(23) 1-Benzyl-1-[3-(imidazol-4-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
mp : 134-136°C
IR (KBr): 2690-3700 (br), 1637, 1562, 1490, 1228 cm-1
NMR (DMSO-d6, δ) : 2.43 (6H, s), 2.47 (3H, s), 4.47 (4H, s), 6.90 (1H, s), 7.10-7.75 (11H, m), 8.28 (1H, s), 12.17, 12.55 (total 1H, each br)
APCI-MASS (m/z) : 490 (M+H+) (24) 1-Benzyl-1-[3-(2-methyl-2H-tetrazol-5-yl)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3290, 2922, 1655, 1562, 1493, 1227, 970,
806 cm-1
NMR (CDCl3, δ) : 2.39 (3H, s), 2.47 (3H, s), 2.48 (3H, s), 4.40 (3H, s), 4.67 (2H, s), 4.72 (2H, s), 5.72 (1H, s), 6.62 (1H, s), 7.25-7.58 (7H, m), 8.01-8.18 (2H, m)
APCI-MASS (m/z) : 506 (M+H+)
(25) 1-Cycloheptyl-1-[4-[(2,4-dioxothiazolidin-5- yl)methyl]benzyl]-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl ] urea
IR (KBr) : 2924, 2860, 2769, 1753, 1701, 1603,
1506 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.40 (6H, s),
2.45 (3H, s), 3.07 (1H, dd, J=14.0, 9.4Hz), 3.35 (1H, dd, J=14.0, 4.3Hz), 3.95-4.15 (1H, m), 4.45 (2H, s), 4.90 (1H, dd, J=9.4, 4.3Hz), 6.86 (1H, s), 7.17 (2H, d, J=8.1Hz), 7.30 (2H, d, J=8.1Hz),
7.86 (1H, br s), 12.04 (1H, br)
APCI-MASS (m/z) : 559 (M+H+)
(26) 1-Cycloheptyl-1-[4-[(2,4-dioxothiazolidin-5- ylidene)methyl]benzyl]-3-[2,4-bis(methylthio)-6- methylpyridin-3-yl] urea
IR (KBr) : 3406, 3124, 2926, 2856, 2765, 1757, 1711,
1635, 1599, 1487 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.40 (6H, s), 2.45 (3H, s), 4.0-4.2 (1H, m), 4.52 (2H, br s),
6.86 (1H, s), 7.48 (2H, d, J=8.6Hz), 7.54 (2H, d, J=8.6Hz), 7.77 (1H, s), 7.96 (1H, br s), 12.59 (1H, br)
APCI-MASS (m/z) : 557 (M+H+) (27) 1-Benzyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylpyridin-3-yl) urea
IR (KBr) : 3294, 3030, 2922, 1632, 1605, 1498 cm-1 NMR (DMSO-d6, δ) : 2.08 (3H, s), 2.26 (3H, s), 2.35 (3H, s), 4.52 (2H, s), 4.56 (2H, s), 6.95-7.45
(14H, m), 8.02 (1H, br s)
APCI-MASS (m/z) : 476 (M+H+)
(28) 1-Cyclohexyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylpyridin-3-yl) urea
IR (KBr) : 3406, 3313, 2929, 2856, 1714, 1632, 1605,
1572, 1495 cm-1
NMR (DMSO-d6, δ) : 1.0-1.9 (10H, m), 2.07 (3H, s), 2.24 (3H, s), 2.34 (3H, s), 3.95-4.15 (1H, m), 4.51 (2H, s), 6.95-7.4 (6H, m), 7.70 (1H, s)
APCI-MASS (m/z) : 462 (M+H+)
(29) 1-Cycloheptyl-1-[4-(4-bromophenoxy)benzyl]-3-(2,4,6- trimethylpyridin-3-yl) urea
IR (KBr) : 3310, 1632, 1504, 1483, 1238 cm-1
NMR (CDCl3, δ) : 1.38-2.05 (12H, m), 2.04 (3H, s), 2.20 (3H, s), 2.42 (3H, s), 4.30-4.50 (1H, m), 4.50 (2H, s), 5.49 (1H, s), 6.82 (1H, s), 6.83- 6.93 (2H, m), 6.98-7.08 (2H, m), 7.32-7.46 (4H, m)
APCI-MASS (m/z) : 536, 538 (M+H+)
(30) 1-Benzyl-1-[3-(pyrazol-3-yl)benzyl1-3-(2,4,6- trimethylpyridin-3-yl) urea
IR (KBr) : 3236, 2924, 1645, 1564, 1493 cm-1
NMR (DMSO-d6, δ) : 2.10 (3H, s), 2.28 (3H, s), 2.35
(3H, s), 4.59 (4H, s), 6.6-6.7 (1H, m), 6.94 (1H, s), 7.2-7.8 (10H, m), 8.07 (1H, br s), 12.89 (1H, br)
APCI-MASS (m/z) : 426 (M+H+) (31) 1-Cycloheptyl-1-[3-(l-tritylpyrazol-3-yl)benzyl]-3- (2,4,6-trimethylpyridin-3-yl) urea
IR (KBr) : 3404, 3313, 3059, 3028, 2924, 2856, 1720,
1650, 1605, 1500, 1481 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 1.96 (3H, s),
2.19 (3H, s), 2.33 (3H, s), 4.1-4.3 (1H, m), 4.54 (2H, s), 6.71 (1H, d, J=2.5Hz), 6.85 (1H, s), 7.1-7.8 (20H, m)
FAB-MASS (m/z) : 674 (M+H+)
(32) 1-Benzyl-1-[4-(4-fluorophenoxy)benzyl]-3-[4,6- bis (methylthio)-2-methylpyridin-5-yl] urea
IR (KBr) : 3275, 3062, 3030, 2926, 1637, 1535,
1479 cm-1
NMR (DMSO-d6, δ) : 2.46 (6H, s), 2.58 (3H, s), 4.44
(2H, s), 4.48 (2H, s), 6.95-7.4 (13H, m), 8.39 (1H, br s)
APCI-MASS (m/z) : 535 (M+H+) (33) 1-Cycloheptyl-1-[4-(4-bromophenoxy)benzyl]-3-[4,6- bis (methylthio)-2-methylpyrimidin-5-yl] urea
mp : 173-175°C
IR (KBr) : 3375, 2926, 2852, 1668, 1583, 1479, 1238,
810 cm-1
NMR (CDCl3, δ) : 1.38-2.10 (12H, m), 2.48 ( 6H, s),
2.59 (3H, s), 4.20-4.42 (1H, m), 4.54 (2H, s), 5.40 (1H, s), 6.85-6.93 (2H, m), 7.00-7.10 (2H, m), 7.34-7.50 (4H, m)
APCI-MASS (m/z) : 601, 603 (M+H+)
(34) 1-Benzyl-1-[3-(4-fluorophenoxy)benzyl]-3-[4,6- bis (methylthio)-2-methylpyrimidin-5-yl] urea
IR (KBr) : 3271, 3059, 3030, 2926, 2789, 2735, 2605,
1639, 1585, 1533, 1508 cm-1
NMR (CDCl3, δ) : 2.46 (6H, s), 2.58 (3H, s), 4.61 (4H, br s), 5.58 (1H, s), 6.8-7.4 (13H, m) APCI-MASS (m/z) : 535 (M+H+)
(35) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-[4,6- bis(methylthio)-2-methylpyrimidin-5-yl] urea
mp : 164-165°C
IR (KBr) : 3194, 2926, 2856, 1633, 1518, 1419, 1296,
812 cm-1
NMR (DMSO-d6, δ) : 1.30-1.90 (12H, m), 2.43 (6H, s), 2.57 (3H, s), 3.95-4.15 (1H, m), 4.53 (2H, s),
6.65 (1H, s), 7.15-7.90 (5H, m), 8.07 (1H, s), 12.86, 13.30 (total 1H, each br)
APCI-MASS (m/z) : 497 (M+H+) (36) 1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[4,6- bis(methylthio)-2-methylpyrimidin-5-yl] urea
mp : 212-213°C
IR (KBr) : 3388, 3265, 2924, 1653, 1524, 1487, 1390,
1356, 1298, 1228 cm-1
NMR (DMSO-d6, δ) : 2.46 (6H, s), 2.58 (3H, s), 4.50
(4H, s), 6.60-6.70 (1H, m), 7.15-7.85 (10H, m), 8.45 (1H, s), 12.89, 13.32 (total 1H, each br s) APCI-MASS (m/z) : 491 (M+H+) (37) 1-Benzyl-1-[4-(4'-fluorophenoxy)benzyl]-3-[2,4- dimethoxy-6-methylpyridm-3-yl] urea
IR (KBr) : 3394, 3315, 3062, 2945, 2858, 1660, 1597,
1497 cm-1
NMR (DMSO-d6, δ) : 1.99 (3H, s), 3.80 (3H, s), 3.81 (3H, s), 4.41 (2H, s), 4.45 (2H, s), 6.67 (1H, s), 6.95-7.45 (13H, m)
APCI-MASS (m/z) : 502 (M+H+)
(38) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- dιmethoxy-6-methylpyridin-3-yl] urea IR (KBr) : 3379, 3207, 3055, 2926, 2856, 1651, 1597,
1502 cm-1
NMR (DMSO-d6, δ) : 1.3-1.9 (12H, m), 2.35 (3H, s),
3.75 (3H, s), 3.76 (6H, s), 4.0-4.2 (1H, m), 4 .50 (2H, s), 6.55 (1H, s), 6 . 6- 6 . 65 (1H, m), 7.1-7.8
(5H, m), 12.85 (1H, br s)
APCI-MASS (m/z) : 464 (M+H+)
(39) 1-Benzyl-1-[3-(1-tritylpyrazoI-3-yl)benzyl]-3-(2,4- dimethoxy-6-methylpyridin-3-yI) urea
IR (KBr) : 3990, 3066, 3032, 293C, 2923, 1678, 1637,
1512, 1497 cm-1
NMR (DMSO-d6, δ) : 2.36 (3H, s), 3.72 (3H, s), 3.74
(3H, s), 4.46 (4H, br s), 6.64 (1H, s), 6.73 (1H, d, J=2.5Hz), 7.1-7.7 (24H, m)
(40) 1-(4-Fluorobenzyl)-1-[3-(1-tritylpyrazol-3-yl)benzyl]- 3-(2,4,6-trifluorophenyl;urea
IR (KBr) : 3294, 1637, 1608, 1518, 1446, 1225 cm-1 NMR (CDCl3, δ) : 4.58 (2H, s), 4.60 (2H, s), 5.75
(1H, s), 6.54 (1H, d, J=2.5Kz;, 6.57-7.10 (6H, m), 7.13-7.43 (18K, ml, 7.65-7.80 (2H, m)
(41) 1-Cycloheptyl-1-(4-phenylbenzyl)-3-(2,4,6- trimethylpyridin-3-yI) urea
IR (KBr) : 3402, 3023, 2924, 2854, 1728, 1660, 1603,
1566, 1493 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.09 (3H, s), 2.27 (3H, s), 2.34 (3H, s), 4.05-4.25 (1H, m), 4.55 (2H, s), 6.93 (1H, s), 7.3-7.8 (9H, m)
APCI-MASS (m/z) : 442 (M+H+)
Example 24
The following compounds were obtained according to a similar manner to that of Example 6, 12 or 21.
(1) 1-Cycloheptyl-1-[4-(pyrazol-4-yl)benzyl]-3-(2,4,6- trimethylphenyl) urea
IR (KBr) : 3184, 2926, 2856, 1630, 1650, 1510 cm-1 NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.09 (6H, s), 2.21 (3H, s), 4.05-4.25 (1H, m), 4.48 (2H, s), 6.83 (2H, s), 7.28 (2H, d, J=8.2Hz), 7.50 (1H, br S), 7.56 (2H, d, J=8.2Hz), 7.87 (2H, s)
(2) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- dimethoxy-6-methylpyridin-3-yl) urea
IR (KBr) : 3406, 3228, 3062, 3026, 2974, 1676, 1653,
1597, 1508 cm-1
NMR (DMSO-d6, δ) : 2.37 (3H, s), 3.79 (3H, s), 3.80
(3H, s), 4.47 (4H, s), 6.65 (1H, d, J=2.7Hz), 6.66 (1H, s), 7.2-7.5 (7H, m), 7.65-7.8 (4H, m) APCI-MASS (m/z) : 458 (M+H+) (3) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-(2,4,6- trimethylpyridin-3-yl) urea
IR (KBr) : 3400, 3224, 3055, 2929, 2856, 1714, 1633,
1568, 1500 cm-1
NMR (DMSO-d6, δ) : 1.4-1.9 (12H, m), 2.09 (3H, s), 2.26 (3H, s), 2.34 (3H, s), 4.05-4.25 (1H, m),
4.56 (2H, s), 6.6-6.7 (1H, m), 6.91 (1H, s), 7.2- 7.5 (2H, m), 7.6-7.9 (3H, m), 12.85 (1H, br s) APCI-MASS (m/z) : 432 (M+H+) (4) 1-(4-Fluorobenzyl)-1-[3-(pyrazol-3-yl)benzyl]-3- (2,4,6-trifluorophenyl) urea
mp : 204-206°C
IR (KBr) : 3413, 3066, 1664, 1610, 1520, 1223 cm-1 NMR (DMSO-d6, δ) : 4.51 (2H, s), 4.55 (2H, s), 6.65 (1H, d, J=2.3Hz), 7.10-7.50 (9H, m), 7.55-7.90 (2H, m), 8.46 (1H, s), 12.89, 13.30 (total 1H, each br)
APCI-MASS (m/z) : 455 (M+H+) (5) 1-Cycloheptyl-1-[4-[2-(1H-tetrazol-5- yl)phenyl]benzyl]-3-(2,4,6-trimethylphenyl) urea
IR (KBr) : 3408, 3310, 2924, 2856, 1620, 1605,
1506 cm-1
NMR (DMSO-d6, δ) : 1.4-1.8 (12H, m), 2.04 (6H, s), 2.20 (3H, s), 4.05-4.25 (1H, m), 4.48 (2H, s),
6.83 (2H, s), 7.04 (2H, d, J=7.9Hz), 7.23 (2H, d, J=7.9Hz), 7.5-7.8 (5H, m)
F.AB-MASS (m/z) : 509 (M+H+) Example 25
To a solution of 1-cycloheptyl-1-[4-(4- fluorophenoxy)benzyl]-3-[2,4-bis(methylsulfonyl)-6- methylpyridin-3-yl] urea (3.04 g) in methanol (100 ml) was added sodium methanethiolate (315 mg) and the mixture was stirred at 50°C for an hour under nitrogen. The mixture was cooled to 5°C and the precipitates were collected by filtration, washed with methanol and diisopropyl ether and dried in vacuo to give 1-cycloheptyl-1-[4-(4- fluorophenoxy)benzyl]-3-(2-methylsulfonyl-4-methylthio-6- methylpyridin-3-yl) urea (1.35 g) as a crystal.
IR (KBr) : 3377, 3072, 2926, 2858, 1657, 1572, 1498,
1473 cm-1
NMR (CDCl3, δ) : 1.5-2.1 (12H, m), 2.44 (3H, s), 2.54 (3H, s), 3.23 (3H, s), 4.1-4.3 (1H, m), 4.55 (2H, s), 6.98 (1H, s), 6.9-7.1 (6H, m), 7.35 (1H, d,
J=8.6Hz)
Example 26
To a stirred solution of 1-benzyl-1-[3-(pyrazol-3- yl)benzyl]-3-[2,4-bis(methylthio)-6-methylpyridin-3-yl] urea (1 g) in dichloromethane (8 ml) was added a solution of m- chloroperbenzoic acid (1.32 g) in dichloromethane (26 ml) at 0-5°C. After stirring for one hour at room temperature, the mixture was washed with saturated sodium bicarbonate aqueous solution, water and brine, dried over magnesium sulfate, evaporated in vacuo. The residue was
chromatographed on silica gel to give 1-benzyl-1-[3- (pyrazol-3-yl)benzyl]-3-[2,4-bis(methylsulfonyl)-6- methylpyridin-3-yl] urea (183.0 mg) and 1-benzyl-1-[3- (pyrazol-3-yl)benzyl]-3-[2,4-bis(methylsulfinyl)-6- methylpyridin-3-yl] urea (235.6 mg).
1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis(methylsulfonyl)-6-methylpyridin-3-yl] urea
IR (KBr) : 3344, 2924, 1655, 1493, 1313, 1238,
1136 cm-1
NMR (DMSO-d6, δ) : 2.70 (3H, s), 3.32 (6H, s), 4.52 (4H, br s), 6.75 (1H, br s), 7.20-7.85 (10H, m), 8.13 (1H, s), 8.66 (1H, s), 12.87, 13.22 (total 1H, each br)
APCI-MASS (m/z) : 554 (M+H+)
1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis(methylsulfinyl)-6-methylρyridin-3-yl] urea
IR (KBr) : 3217, 2922, 1651, 1495, 1236, 1038,
960 cm-1
NMR (DMSO-d6, δ) : 2.60-2.80 (9H, m), 4.42-4.75 (4H, m), 6.71 (1H, br s), 7.15-7.85 (11H, m), 8.84, 8.96 (total 1H, each s), 12.93, 13.35 (total 1H, each br)
APCI-MASS (m/z) : 522 (M+H+)
Example 27
To a solution of N-cycloheptyl-4-(4- fluorophenoxy) benzylamine (1.57 g) in toluene (40 ml) were added 2,4-dichloro-6-methyl-3-phenoxycarbonylaminopyridine (1.49 g) and triethylamine (1.52 g), and the mixture was stirred at 100°C for 3.5 hours. The mixture was poured into a mixture of ethyl acetate and ice water, and the separated organic layer was washed with brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by column chromatography on silica gel to give 1- cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4-dichloro- 6-methylpyridin-3-yl) urea (916 mg).
IR (KBr) : 3365, 3275, 3062, 2927, 2858, 1653, 1581,
1543, 1497 cm-1
NMR (CDCl3, δ) : 1.5-2.1 (12H, m), 2.47 (3H, s), 4.2- 4.4 (1H, m), 4.53 (2H, s), 5.89 (1H, s), 6.9-7.1 (6H, m), 7.14 (1H, s), 7.36 (2H, d, J=8.7Hz) APCI-MASS (m/z) : 520, 518, 517 (M+H+)
Example 28
The following compounds were obtained according to a similar manner to that of Example 7, 8, 9, 10, 13, 14, 15, 16, 17 or 27.
(1) 1-Cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-[(2- methoxy-4-methylthio-6-methyl)pyridin-3-yl] urea
IR (KBr) : 3371, 3064, 2926, 2856, 1666, 1585,
1498 cm-1
NMR (CDCl3, δ) : 1.5-2.1 (12H, m), 2.38 (6H, s), 3.79 (3H, s), 4.2-4.4 (1H, m), 4.52 (2H, s), 5.66 (1H, br s), 6.53 (1H, s), 6.9-7.1 (6H, m), 7.35 (1H, d, J=8.7Hz)
APCI-MASS (m/z) : 524 (M+H+)
(2) 1-Benzyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2-chloro-4- methylthio-6-methylpyridin-3-yl) urea
IR (KBr) : 3294, 3061, 3030, 2924, 1651, 1576,
1497 cm-1 NMR (CDCl3, δ) : 2.42 (3H, s), 2.47 (3H, s), 4.61 (2H, s), 4.63 (2H, s), 5.96 (1H, s), 6.82 (1H, s), 6.9-7.1 (6H, m), 7.25-7.45 (7H, m) (3) 1-Benzyl-1-[3-(1-methylpyrazol-4-yl)benzyl]-3-[2,4- bis(methylthio)-6-methylpyridin-3-yl] urea
mp : 137-138°C
IR (KBr) : 3255, 2922, 1651, 1562, 1493, 1228,
982 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, s), 2.47 (3H, s), 3.87
(3H, s), 4.66 (2H, br s), 4.48 (2H, br s), 6.90 (1H, s), 7.13 (1H, d, J=7.4Hz), 7.20-7.56 (8H, m), 7.81 (1H, s), 8.06 (1H, s), 8.29 (1H, s) APCI-MASS (m/z) : 504 (M+H+)
(4) 1-Cycloheptyl-1-[3-(l-methylpyrazol-4-yl)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridm-3-yl] urea mp : 197-198°C
IR (KBr) : 3290, 2924, 2854, 1653, 1485, 1227 cm-1 NMR (DMSO-d6, δ) : 1.25-1.90 (12H, m), 2.40 (6H, s),
2.45 (3H, s), 3.87 (3H, s), 3.98-4.17 (1H, m), 4.48 (2H, br s), 6.87 (1H, s), 7.15 (1H, d, J=7.5Hz), 7.27 (1H, dd, J=7.5, 7.5Hz), 7.38 (1H, d, J=7.5Hz), 7.52 (1H, s), 7.80 (1H, s), 7.90 (1H, br s), 8.04 (1H, s)
APCI-MASS (m/z) : 510 (M+H+)
(5) 1-(2-Methoxybenzyl)-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis(methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3220, 2922, 1649, 1562, 1491, 1240 cm-1
NMR (DMSO-d6, δ) : 2.41 (6H, s), 2.46 (3H, s), 3.73 (3H, s), 4.44 (2H, br s), 4.53 (2H, br s), 6.67 (1H, br s), 6.88 (1H, s), 6.90-7.05 (2H, m), 7.15-7.90 (7H, m), 8.19 (1H, br s), 12.89, 13.30 (total 1H, each br) APCI-MASS (m/z) : 520 (M+H+)
(6) 1-(3-Methoxybenzyl)-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis(methylthio)-6-methylpyridin-3-yl] urea
mp : 165-166°C
IR (KBr) : 3400, 3248, 3099, 2926, 1664, 1483, 1225,
1049 cm-1
NMR (DMSO-d6, δ) : 2.41 (6H, s), 2.46 (3H, s), 3.75 (3H, s), 4.46 (2H, br s), 4.50 (2H, br s), 6.58- 6.72 (1H, m), 6.74-6.95 (4H, m), 7.15-7.85 (6H, m), 8.28 (1H, s), 12.87, 13.29 (total 1H, each br)
APCI-MASS (m/z) : 520 (M+H+) (7) 1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2-chloro-4- methylthio-6-methylpyridin-3-yl] urea
IR (KBr) : 3230, 2922, 1647, 1576, 1497, 1338, 1279,
1232 cm-1
NMR (DMSO-d6, δ) : 2.45 (6H, s), 4.51 (4H, br s),
6.57-6.70 (1H, m), 7.16 (1H, s), 7.17-7.85 (10H, m), 8.52 (1H, s), 12.89, 13.31 (total 1H, each br)
APCI-MASS (m/z) : 478, 480 (M+H+) (8) 1-(4-Methoxybenzyl)-1-[4-(4-fluorophenoxy)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridm-3-yl] urea
mp : 130-131°C
IR (KBr) : 3404, 2995, 2924, 2833, 1674, 1610, 1562,
1493, 1250, 1211 cm-1
NMR (CDCl3, δ) : 2.39 (3H, s), 2.49 (3H, s), 2.51
(3H, s), 3.81 (3H, s), 4.56 (2H, s), 4.58 (2H, s), 5.72 (1H, s), 6.64 (1H, s), 6.85-7.12 (8H, m), 7.20-7.38 (4H, m)
APCI-MASS (m/z) 564 (M+H+) (9) 1-Benzyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4- dichloro-6-methylpyridin-3-yl) urea
IR (KBr) : 3302, 3066, 3032, 2924, 1639, 1581, 154
1497 cm-1
NMR (CDCl3, δ) : 2.48 (3H, s), 4.63 (2H, s), 4.64
(2H, s), 6.05 (1H, br s), 6.9-7.4 (14H, m), APCI-MASS (m/z) : 514, 512, 510 (M+H+)
(10) 1-(3-Phenylpropyl)-1-[4-(4-fluorophenoxy)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3290, 2922, 1649, 1562, 1497, 1211,
1093 cm-1
NMR (CDCl3, δ) : 1.92-2.13 (2H, m), 2.38 (3H, s), 2.48 (3H, s), 2.49 (3H, s), 2.68 (2H, t, J=7.7Hz), 3.39 (2H, t, J=7.6Hz), 4.57 (2H, s),
5.57 (1H, s), 6.63 (1H, s), 6.87-7.10 (6H, m), 7.10-7.37 (7H, m)
APCI-MASS (m/z) : 562 (M+H+) (11) 1-(2-Phenylethyl)-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3209 (br), 2922, 1647, 1562, 1491, 1338,
1238 cm-1
NMR (DMSO-d6, δ) : 2.42 (6H, s), 2.47 (3H, s), 2.80- 2.98 (2H, m), 3.35-3.54 (2H, m), 4.44 (2H, s),
6.65 (1H, br s), 6.90 (1H, s), 7.10-7.45 (7H, m), 7.45-7.83 (3H, m), 8.13 (1H, s), 12.87, 13.30 (total 1H, each br)
APCI-MASS (m/z; 504 (M+H+)
(12) 1-[(S)-1-Phenylethyl]-1-[4-(4-fluorophenoxy)benzyl]-3- [2,4-bis(methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3373, 3310, 2978, 2924, 1660, 1562, 1497,
1246, 1211 cm-1
NMR (CDCl3, δ) : 1.63 (3H, d, J=7.1Hz), 2.37 (3H, s), 2.46 (3H, s), 2.47 (3H, s), 4. 27 (1H, d,
J=17.2Hz), 4.50 (1H, d, J=17.2Hz), 5.53 (1H, s), 5.75-5.92 (1H, m), 6.60 (1H, s), 6.83-7.10 (6H, m), 7.22-7.50 (7H, m)
APCI-MASS (m/z) : 546 (M-H+)
: -61.0° (C =1.02, CHCl3)
Figure imgf000209_0001
(13) 1-[(R)-1-Phenylethyl]-1-[4-(4-fluorophenoxy)benzyl]-3- [ 2,4-bis (methylthio)-6-methylpyridin-3-yl] urea
IR (KBr) : 3369, 3309, 2978, 2924, 1659, 1562, 1497,
1246, 1211 cm-1
NMR (CDCl3, δ) : 1.63 (3H, d, J=7.1Hz), 2.37 (3H, s), 2.46 (3H, s), 2.47 (3H, s), 4.27 (1H, d, J=17.2Hz), 4.50 (1H, d, J=17.2Hz), 5.52 (1H, s), 5.75-5.92 (1H, m), 6.60 (1H, s), 6.88-7.10 (6H, m), 7.22-7.50 (7H, m)
APCI-MASS (m/z) : 548 (M+H+)
]α]§9 : + 62.2° (C =1.02, CHCl3)
Figure imgf000209_0002
(14) 1-Cycloheptyl-1-[ 4 -(4-fluorophenoxy)benzyl]-3-( 4- chloro-2-methylthio-6-methyIpyridin-3-yl) urea
IR (KBr) : 3371, 3275, 3062, 2926, 2856, 1653, 1560,
1498 cm-1
NMR (CDCl3, δ) : 1.4-2.1 (I2H, m), 2.44 (3H, s), 2.47 (3H, s), 4.25-4.45 (1H, m), 5.61 (2H, s), 6.89
(1H, s), 6.9-7.1 (6H, m), 7.37 (2H, d, J=8.6Hz) APCI-MASS (m/z) : 530, 528 (M+H+)
(15) 1-3enzyl-1-[4-(4-fluorophenoxy)benzyl]-3-(4-chloro-2- methylthio-6-methylpyridin-3-yl) urea
IR (KBr) : 3275, 3062, 3030, 2924, 1645, 1560,
1497 cm-1
NMR (CDCl3, δ) : 2.46 (3H, s), 2.49 (3H, s), 4.61
(2H, s), 4.63 (2H, s), 5.80 (1H, br s), 6.9-7.1 (7H, m), 7.25-7.4 (7H, m) APCI-MASS (m/z) : 524, 522 (M+H+)
(16) 1-Cycloheptyl-1-[4-(4-bromophenoxy)benzyl]-3-[2- chloro-4-methylthio-6-methylpyridin-3-yl] urea
mp : 105-107°C
IR (KBr) : 3379, 2926, 2854, 1668, 1579, 1483,
1238 cm-1
NMR (CDCl3, δ) : 1.38-2.08 (12H, m), 2.41 (3H, s), 2.48 (3H, s), 4.20-4.40 (1H, m), 4.54 (2H, s), 5.76 (1H, s), 6.82 (1H, s), 6.82-6.93 (2H, m), 6.95-7.08 (2H, m), 7.32-7.50 (4H, m)
APCI-MASS (m/z) : 588, 590, 592 (M+H+)
(17) 1-3enzyl-1-[4-(4-bromophenoxy)benzyl]-3-[2-chloro-4- methylthio-6-methylpyridin-3-yl] urea
IR (KBr) : 3280, 3030, 2920, 1651, 1578, 1504, 1435,
1236, 804 cm-1
NMR (CDCl3, δ) : 2.43 (3H, s), 2.49 (3H, s), 4.63 (2H, s), 4.64 (2H, s), 5.93 (1H, s), 6.84 (1H, s), 6.84-6.94 (2H, m), 6.94-7.07 (2H, m), 7.22- 7.50 (9H, m)
APCI-MASS (m/z) : 582, 584, 566 (M+H+)
(18) 1-Cycloheptyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2-chloro- 4-methylthio-6-methylpyridin-3-yl] urea
mp : 165-166°C
IR (KBr) : 3205, 2926, 2856, 1624, 1572, 1491,
804 cm-1
NMR (DMSO-d6, δ) : 1.30-1.90 (12H, m), 2.43 (6H, s),
4.00-4.18 (1H, m), 4.53 (2H, br s), 6.55-6.67 (1H, m), 7.12 (1H, s), 7.20-7.83 (5H, m), 8.11
(1H, br s), 12.85, 13.28 (total 1H, each br s)
APCI-MASS (m/z) : 484, 486 (M+H+)
Example 29
The following compound can be obtained by treating 1- benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4-bis (methylthio)-6- methylpyridin-3-yl] urea with hydrochloric acid or
hydrochloride in a conventional manner.
1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea-hydrochloride
Example 30
The following compound can be obtained by treating 1- benzyl-1-[3-(pyrazol-3-yl)benzylj-3-[2,4-bis (methylthio)-6- methylpyridin-3-yl] urea with sulfuric acid in a
conventional manner.
1-Benzyl-1-[3-(pyrazol-3-yl)benzyl]-3-[2,4- bis (methylthio)-6-methylpyridin-3-yl] urea·sulfate
Example 31
The following compound was obtained according to a similar manner to that of Example 19.
1-Benzyl-1-[4-(4-fluorophenoxy)benzyl]-3-[2,4- bis (methylsulfonyl)-6-methylpyridin-3-yl] urea
IR (KBr) : 3348, 3066, 3030, 2927, 1734, 1668, 1610,
1583, 1497 cm-1
NMR (CDCl3, δ) : 2.67 (3H, s), 3.20 (3H, s), 3.32
(3H, s), 4.6-4.7 (4H, m), 6.9-7.1 (6H, m), 7.3- 7.5 (2H, m), 7.62 (1H, br s), 7.88 (1H, s)
APCI-MASS (m/z) : 598 (M+H+)
Example 32
The following compound was obtained according to a similar manner to that of Example 29.
1-Cycloheptyl-1-[4-(4-fluorophenoxy)benzyl]-3-(2,4,6- trimethylpyridin-3-yl) urea hydrochloride
mp: 176-178°C
NMR (DMSO-d6, δ) : 1.35-1.9 (12H, m), 2.32 (3H, s), 2.52(3H, s), 2.65 (3H, s), 4.1-4.3 (1H, m; , 4.53 (2H, s), 6.95-7.4 (8H, m), 7.61 (1H, s), 8.30 (1H, br s)

Claims

C L A I M S 1. A compound of the formula
Figure imgf000212_0001
wnerem
R1 is a group of the formula :
Figure imgf000212_0002
(in which
R4 is aryl which may have suitable
substituent (s), or heterocyclic group which may have suitable substituent (s), and
Y is bond, lower alkylene,
Figure imgf000212_0003
(in which R7 is lower
Figure imgf000212_0004
alkyl),
-NHSO2-, -SO2NH-, -SO2NHCO- or -CONHSO2-); or
thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent (s); R2 is lower alkyl, lower alkoxy (lower) alkyl,
cycloalkyl, ar (lower) alkyl which may have suitable substituent (s), heterocyclic group or heterocyclic (lower) alkyl,
R3 is aryl which may have suitable substituent (s) or heterocyclic group which may have suitable substituent (s), and
n is 0 or 1,
and a pharmaceutically acceptable salt thereof
2. A compound of claim 1, wherein
R1 is a group of the formula :
Figure imgf000213_0001
(in which
R4 is phenyl which may have 1 to 3 substituent (s) selected from the group consisting of halogen, lower alkyl, di (lower) alkylamino, protected amino, cyano, heterocyclic group which may have mono (or di or tri)- ar (lower) alkyl, hydroxy, protected hydroxy and mono (or di or tri) halo (lower) alkyl;
or thienyl, pyrazolyl, imidazolyl,
triazolyl, pyridyl, pyrrolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl,
piperazinyl, thiazolidinyl or
methylenedioxyphenyl, each of which may have 1 to 3 substituent (s) selected from the group consisting of lower alkyl, mono (or di or tri) ar (lower) alkyl and oxo;
Y is bond, lower alkylene,
Figure imgf000213_0002
(in which R7 is lower alkvl),
Figure imgf000213_0003
-NHSO2-, -SO9NH-, -SO2NHCO- or -CONHSO2-); or
thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have 1 to 5 substituent (s) selected from the group consisting of lower alkyl, hydroxy, protected hydroxy, phenyl, halophenyl, phenylthio and pyrrolyl;
R2 is lower alkyl; lower alkoxy (lower) alkyl;
cyclo (C3-C7) alkyl; phenyl (lower) alkyl which may have 1 to 3 substituent (s) selected from the group consisting of halogen, lower alkoxy and di (lower alkyDamino; tetrahydropyranyl; or furyl (lower) alkyl;
R3 is phenyl which may have 1 to 3 substituent (s)
selected from the group consisting of lower alkyl and halogen; pyridyl or pyrimidinyl, each of which may have 1 to 3 substituent (s) selected from the group consisting of lower alkyl, lower alkylthio, halogen, lower alkoxy, lower alkylsulfinyl and lower alkylsulfonyl.
3. A compound of claim 2, wherein
R1 is a group of the formula :
Figure imgf000214_0001
(in which
R4 is phenyl which may have 1 to 3 substituent ( s ) selected from the group consisting of halogen, lower alkyl, di (lower) alkylamino, acylamino, cyano, tetrazolyl which may have mono (or di or tri) phenyl (lower ) alkyl, hydroxy, lower alkoxy (lower) alkoxy and mono (or di or tri) halo (lower) alkyl; or thienyl, pyrazolyl, imidazolyl, triazolyl, pyridyl, pyrrolyl, tetrazo-lyl, oxazolyl, thiazolyl, oxadiazolyl, piperazinyl, thiazolidinyl or methylenedioxyphenyl, each of which may have one or two substituent (s) selected from the group consisting of lower alkyl, phenyl (lower) alkyl, triphenyl (lower)- alkyl and oxo;
Y is bond, lower alkylene,
Figure imgf000215_0001
- (in which R7 is lower alkyl),
Figure imgf000215_0002
-NHSO2-, -SO2NH-, -SO2NHCO- or -CONHSO2-); or
thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have 1 to 5 substituent (s) selected from the group consisting of lower alkyl,
hydroxy, acyloxy, phenyl, halophenyl, phenylthio and pyrrolyl;
R2 is lower alkyl; lower alkoxy (lower) alkyl;
cyclo (C3-C7) alkyl; phenyl (lower) alkyl which may have one or two substituent (s) selected from the group consisting of halogen, lower alkoxy and di (lower alkyl) amino; tetrahydropyranyl; or furyl (lower) alkyl; and
R3 is phenyl which may have two or three
substituents selected from the group consisting of lower alkyl and halogen; pyridyl or
pyrimidinyl, each of which may have two or three substituents selected from the group consisting of lower alkyl, lower alkylthio, halogen, lower alkoxy, lower alkylsulfinyl and lower
alkylsulfonyl.
4. A compound of claim 3, wherein
R1 is a group of the formula :
Figure imgf000216_0001
(in which
R4 is phenyl; halopheny; lower alkylphenyl;
di (lower) alkylaminophenyl; lower
alkylsulfonylaminophenyl; cyanophenyl;
tetrazolylphenyl; (triphenyl (lower)- alkyltetrazolyl) phenyl; trihalo (lower)- alkylphenyl; phenyl having two lower alkyl and hydroxy; phenyl having two lower alkyl and lower alkoxy (lower) alkoxy; thienyl;
pyrazolyl which may have lower alkyl or triphenyl (lower) alkyl; imidazolyl; triazolyl which may have one or two substituent (s) selected from the group consisting of lower alkyl and phenyl (lower) alkyl; pyridyl;
pyrrolyl; tetrazolyl which may have lower alkyl or triphenyl (lower) alkyl; oxazolyl; lower alkylthiazolyl; lower alkyloxa- diazolyl; lower alkylpiperazinyl;
dioxothiazolidinyl; or
methylenedioxyphenyl]; and
Y is bond, lower alkylene,
Figure imgf000216_0002
(in which R7 is lower alkyl),
Figure imgf000216_0003
-NHSO2-, -SO2NH-, -SO2NHCO- or -CONHSO2-); halophenylthiazolyl; phenylimidazolyl;
phenylpyrazolyl; phenylpyridyl; phenylthiopyridyl; pyrrolylpyridyl;
phenylthienyl; phenylfuryl; phenylisoxazolyl; or chromanyl having 4 lower alkyl and hydroxy;
R2 is lower alkyl, lower alkoxy (lower) alkyl,
cyclo (C3-C7 ) alkyl, phenyl (lower) alkyl, halophenyl (lower) alkyl, lower
alkoxyphenyl (lower) alkyl, di.dower
alkyl) aminophenyl (lower) alkyl, tetrahydropyranyl or furyl (lower) alkyl, and
R3 is pyridyl having two lower alkylthio and lower alkyl; pyridyl having halogen, lower alkyl and lower alkylthio; tri (lower alkyl) pyridyl; pyridyl having two lower alkoxy and lower alkyl; pyridyl having lower alkoxy, lower alkylthio and lower alkyl; pyridyl having two lower alkylsulfinyl and lower alkyl; pyridyl having two lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkoxy and lower alkyl; pyridyl having lower alkylsulfinyl, lower alkylsulfonyl and lower alkyl; pyridyl having lower alkylthio, lower alkylsulfonyl and lower alkyl; pyridyl having two halogen and lower alkyl; di (lower) alkoxypyrimidinyl; or pyrimidinyl having two lower alkylthio and lower alkyl.
5. A compound of claim 4, wherein
R1 is a group of the formula :
Figure imgf000217_0001
(in which R4 is phenyl or halophenyl, and
Y is -O-), R2 is cyclo (C3-C7) alkyl or phenyl (lower) alkyl,
R3 is phenyl having two lower alkylthio and lower
alkyl; tri (lower alkyl) pyridyl; pyridyl having two halogen and lower alkyl; pyridyl having halogen, lower alkyl and lower alkylthio; pyridyl having lower alkylthio, lower alkoxy and lower alkyl; pyridyl having lower alkylthio, lower alkylsulfonyl and lower alkyl; pyridyl having two lower alkylsulfonyl and lower alkyl; or pyrimidinyl having two lower alkylthio and lower alkyl; and
n is 1.
6. A compound of claim 5, wherein
R1 is a group of the formula :
Figure imgf000218_0001
(in which R4 is halophenyl, and
Y is -O-),
R2 is cyclo (C3-C7) alkyl, and
R3 is tri (lower alkyl) pyridyl; or
pyridyl having two lower alkylsulfonyl and lower alkyl.
7. A compound of claim 4, wherein
R1 is a group of the formula :
Figure imgf000218_0002
(in which R4 is pyrazolyl and
Y is bond), R2 is phenyl (lower) alkyl, lower
alkoxyphenyl (lower) alkyl, halophenyl (lower) alkyl, di (lower) alkylaminophenyl (lower) alkyl or
cyclo (C3-C7) alkyl,
R3 is pyridyl having two lower alkylthio and lower alkyl; pyridyl having halogen, lower alkyl and lower alkylthio; or pyrimidinyl having two lower alkylthio and lower alkyl; and
n is 1.
8. A compound of claim 7, wherein
R1 is a group of the formula :
Figure imgf000219_0001
(in which R4 is pyrazolyl, and
Y is bond),
R2 is phenyl (lower) alkyl, and
R3 is pyridyl having two lower alkylthio and lower
alkyl.
9 . A process for preparing a compound of the formula :
Figure imgf000219_0002
wherein
R1 is a group of the formula :
Figure imgf000220_0001
( in which
R4 i s aryl which may have suitable
substituent (s), or heterocyclic group which mav have suitable substituent ( s ), and
Y is bond, lower alkylene,
Figure imgf000220_0002
(in which R7 is lower
Figure imgf000220_0003
alkyl),
-NHSO2-, -SO2NH-, -SO2NHCO- or -CONHSO2X; or
thiazolyl, imidazolyl, pyrazolyl, pyridyl, thienyl, furyl, isoxazolyl or chromanyl, each of which may have suitable substituent (s);
R2 is lower alkyl, lower alkoxy (lower) alkyl,
cycloalkyl, ar (lower) alkyl which may have suitable substituent (s), heterocyclic group or heterocyclic (lower) alkyl,
R3 is aryl which may have suitable substituent (s) or heterocyclic group which may have suitable substituent (s), and
n is 0 or 1,
or a salt thereof,
which comprises
(1) reacting a compound of the formula :
Figure imgf000220_0004
wherein R1, R2 and n are each as defined .above, or a salt thereof with a compound of the formula
O=C=N-R3 wherein R3 is as defined above,
or a salt thereof to give a compound of the formula
R
Figure imgf000221_0001
wherein R1, R2, R3 and n are each as defined above, or a salt thereof,
or (2 ) subjecting a compound of the formula
Figure imgf000221_0002
wherein R1, R2 and n are each as defined above, or a salt thereof and a compound of the formula :
H2N-R wherein R3 is as defined above, or a salt thereof to formation of ureido group to give a compound of the formula :
Figure imgf000222_0001
wherein R1 , R2 , R3 and n are each as defined above, or a sal t thereof ,
or
(3) subjecting a compound of the formula :
Figure imgf000222_0002
wherein R1 , R2 and n are each as defined above, and is pyridyl having two lower alkylthio and
Figure imgf000222_0004
lower alkyl,
or a salt thereof to oxidation reaction to give a compound of the formula :
Figure imgf000222_0003
wherein R1, R2 and n are each as defined above, and is pyridyl having two lower alkylsulfonyl
Figure imgf000222_0005
and lower alkyl; pyridyl having two
lower alkylsulfinyl and lower alkyl; or pyridyl having lower alkylsulfonyl, lower alkylsulfinyl and lower alkyl; or a salt thereof.
10. A pharmaceutical composition comprising a compound of claim 1, as an active ingredient, in association with a pharmaceutically acceptable, substantially non-toxic carrier or excipient.
11. A compound of claim 1 for use as a medicament.
12. A method of therapeutic treatment and/or prevention of hypercholesterolemia, hyperlipidemia, atherosclerosis or diseases caused thereby which comprises
administering an effective amount of a compound of claim 1 to human beings or animals.
13. Use of a compound of claim 1 for the manufacture of a medicament for treating and/or preventing
hypercholesterolemia, hyperlipidemia, atherosclerosis of diseases caused thereby in human beings or animals.
PCT/JP1995/001982 1994-10-04 1995-09-29 Urea derivatives and their use as acat-inhibitors WO1996010559A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019970702138A KR970706242A (en) 1994-10-04 1995-09-29 Urea derivatives and their use as ACAT-inhibitors (Urea derivatives and their use as ACAT-inhibitors)
AU35779/95A AU3577995A (en) 1994-10-04 1995-09-29 Urea derivatives and their use as acat-inhibitors
JP8511616A JPH10510512A (en) 1994-10-04 1995-09-29 Urea derivatives and their use as ACAT inhibitors
EP95932934A EP0784612A1 (en) 1994-10-04 1995-09-29 Urea derivatives and their use as acat-inhibitors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9419970A GB9419970D0 (en) 1994-10-04 1994-10-04 Urea derivatives
GBGB9506720.3A GB9506720D0 (en) 1995-03-31 1995-03-31 Urea derivatives
GB9514021.6 1995-07-10
GBGB9514021.6A GB9514021D0 (en) 1995-07-10 1995-07-10 Urea derivatives
GB9419970.0 1995-07-10
GB9506720.3 1995-07-10

Publications (1)

Publication Number Publication Date
WO1996010559A1 true WO1996010559A1 (en) 1996-04-11

Family

ID=27267408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/001982 WO1996010559A1 (en) 1994-10-04 1995-09-29 Urea derivatives and their use as acat-inhibitors

Country Status (8)

Country Link
EP (1) EP0784612A1 (en)
JP (1) JPH10510512A (en)
KR (1) KR970706242A (en)
AU (1) AU3577995A (en)
CA (1) CA2200981A1 (en)
IL (1) IL115483A0 (en)
TR (1) TR199501209A2 (en)
WO (1) WO1996010559A1 (en)

Cited By (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016744A1 (en) * 1997-09-29 1999-04-08 Aventis Cropscience Gmbh Acylsulfamoyl benzoic acid amides, plant protection agents containing said acylsulfamoyl benzoic acid amides, and method for producing the same
EP0976744A1 (en) * 1998-07-31 2000-02-02 Eli Lilly And Company Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity
EP1024138A1 (en) * 1997-10-13 2000-08-02 Yamanouchi Pharmaceutical Co. Ltd. Pyrazole derivatives
US6300500B1 (en) 1998-02-25 2001-10-09 Sumitomo Pharmaceuticals Company, Limited Preparation of pyridone derivatives using phthalimido containing starting material
WO2002009648A2 (en) * 2000-08-01 2002-02-07 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
EP1354871A1 (en) * 2000-12-26 2003-10-22 Pola Chemical Industries, Inc. Biphenyl derivatives
US6730671B2 (en) 1999-03-02 2004-05-04 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathespin S
WO2004052861A1 (en) * 2002-12-12 2004-06-24 Kowa Co., Ltd. Hydroxyalkylated cyclic diamine compound
US6756372B2 (en) 1999-09-13 2004-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US7135586B2 (en) 2000-11-21 2006-11-14 Janssen Pharmaceutica, Nv Biphenylcarboxamides useful as lipid lowering agents
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
CN100360507C (en) * 1997-12-22 2008-01-09 拜尔有限公司 Inhibition of raf kinase using substituted heterocyclic ureas
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
CN100390150C (en) * 2006-06-05 2008-05-28 吴汝林 Method for preparing imidazophenylurea hydrochloride
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US7439362B2 (en) 2002-03-28 2008-10-21 Novartis Ag Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
US7507753B2 (en) 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7618960B2 (en) 2005-11-24 2009-11-17 Eisai R&D Management Co., Ltd. Morpholine type cinnamide compound
US7642378B2 (en) 2001-04-06 2010-01-05 Janssen Pharmaceutica Nv Lipid lowering biphenylcarboxamides
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
US7700637B2 (en) 2003-09-17 2010-04-20 Novartis Ag Organic compounds
US7713993B2 (en) 2006-03-09 2010-05-11 Eisai R&D Management Co., Ltd. Multi-cycle cinnamide derivatives
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2010097465A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
WO2010097464A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Novel n-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
WO2010097469A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
WO2010097468A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, pharmaceutical and cosmetic compositions containing them
US7812176B2 (en) 2004-03-23 2010-10-12 Arena Pharmaceuticals, Inc. Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US7884101B2 (en) 2004-11-19 2011-02-08 Arena Pharmaceuticals, Inc. 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US7923563B2 (en) 2004-10-26 2011-04-12 Eisai R&D Management Co., Ltd. Amorphous object of cinnamide compound
US7923573B2 (en) 2004-10-27 2011-04-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US8008293B2 (en) 2007-02-28 2011-08-30 Eisai R&D Management Co., Ltd. Bicyclic oxomorpholine derivative
US8048878B2 (en) 2005-11-24 2011-11-01 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8148418B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8148417B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8258304B2 (en) 2002-08-12 2012-09-04 Janssen Pharmaceutica N.V. N-aryl piperidine substituted biphenylcarboxamides
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
US8354402B2 (en) 2000-09-04 2013-01-15 Janssen Pharmaceutica N.V. Polyarylcarboxamides useful as lipid lowering agents
US8445495B2 (en) 2005-12-15 2013-05-21 Cytokinetics, Inc. Certain Chemical entities, compositions and methods
US8481535B2 (en) 2006-05-18 2013-07-09 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2014032755A3 (en) * 2012-08-29 2014-07-17 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9034911B2 (en) 2008-10-28 2015-05-19 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
EP2858501A4 (en) * 2012-05-22 2015-12-09 Merck Sharp & Dohme TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
US9434692B2 (en) 2006-10-03 2016-09-06 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9453000B2 (en) 2007-08-31 2016-09-27 Eisai R&D Management Co., Ltd. Polycyclic compound
US9556149B2 (en) 2008-04-02 2017-01-31 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor
US9561231B2 (en) 2012-06-12 2017-02-07 Abbvie Inc. Pyridinone and pyridazinone derivatives
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
US10034859B2 (en) 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2128165C1 (en) * 1995-09-18 1999-03-27 Санкио Компани Лимитед Amide derivatives, and composition having acat-inhibiting activity
EP1491527A1 (en) * 2003-06-25 2004-12-29 Bayer CropScience GmbH Process for preparing acylsulfamoylbenzamides
CA2651396A1 (en) * 2006-05-19 2007-11-29 Eisai R&D Management Co., Ltd. Urea type cinnamide derivative
TW200840566A (en) * 2006-12-22 2008-10-16 Esteve Labor Dr Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments
CA2886831A1 (en) * 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
JP6562898B2 (en) * 2013-03-14 2019-08-21 セルタクシス，インコーポレイテッド Inhibitor of leukotriene A4 hydrolase

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2132431A1 (en) * 1971-06-30 1973-01-11 Riedel De Haen Ag PHARMACEUTICAL PREPARATIONS CONTAINING 4-PHENYL-THIAZOLE DERIVATIVES
GB1598900A (en) * 1978-05-23 1981-09-23 Lilly Industries Ltd Heterocyclic amino derivatives
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
EP0370740A1 (en) * 1988-11-21 1990-05-30 The Wellcome Foundation Limited Anti-atherosclerotic diaryl compounds
EP0399422A1 (en) * 1989-05-25 1990-11-28 Takeda Chemical Industries, Ltd. Benzocycloalkane derivatives and production thereof
FR2661676A1 (en) * 1990-05-02 1991-11-08 Lipha Aminobenzocycloalkane derivatives, preparation processes and medicaments containing them
US5169844A (en) * 1991-12-20 1992-12-08 American Home Products Corporation 4-substituted piperidinecarboxylic acid esters: inhibition of cholesterol absorption
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
EP0576357A1 (en) * 1992-06-23 1993-12-29 Sanofi Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH06211814A (en) * 1993-01-14 1994-08-02 Ono Pharmaceut Co Ltd @(3754/24)thio)urea derivative

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2132431A1 (en) * 1971-06-30 1973-01-11 Riedel De Haen Ag PHARMACEUTICAL PREPARATIONS CONTAINING 4-PHENYL-THIAZOLE DERIVATIVES
GB1598900A (en) * 1978-05-23 1981-09-23 Lilly Industries Ltd Heterocyclic amino derivatives
US4623662A (en) * 1985-05-23 1986-11-18 American Cyanamid Company Antiatherosclerotic ureas and thioureas
EP0370740A1 (en) * 1988-11-21 1990-05-30 The Wellcome Foundation Limited Anti-atherosclerotic diaryl compounds
EP0399422A1 (en) * 1989-05-25 1990-11-28 Takeda Chemical Industries, Ltd. Benzocycloalkane derivatives and production thereof
FR2661676A1 (en) * 1990-05-02 1991-11-08 Lipha Aminobenzocycloalkane derivatives, preparation processes and medicaments containing them
US5169844A (en) * 1991-12-20 1992-12-08 American Home Products Corporation 4-substituted piperidinecarboxylic acid esters: inhibition of cholesterol absorption
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
EP0576357A1 (en) * 1992-06-23 1993-12-29 Sanofi Pyrazole derivatives, process for their preparation and pharmaceutical compositions containing them
JPH06211814A (en) * 1993-01-14 1994-08-02 Ono Pharmaceut Co Ltd @(3754/24)thio)urea derivative

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIORG. MED. CHEM. LETT., vol. 4, no. 18, pages 2229 - 2234 *
CHEMICAL ABSTRACTS, vol. 121, no. 25, 19 December 1994, Columbus, Ohio, US; abstract no. 292008, R. E. OLSON ET AL. *
PATENT ABSTRACTS OF JAPAN vol. 018, no. 575 (C - 1268) 4 November 1994 (1994-11-04) *

Cited By (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251827B1 (en) 1997-09-29 2001-06-26 Hoechst Schering Agrevo Gmbh Acylsulfamoylbenzamides, crop protection compositions comprising them, and processes for their preparation
CZ298290B6 (en) * 1997-09-29 2007-08-15 Aventis Cropscience Gmbh Acyl sulfamoylbenzoic acid amides, preparations for protection of culture plants in which these substances are comprised and process of their preparation
WO1999016744A1 (en) * 1997-09-29 1999-04-08 Aventis Cropscience Gmbh Acylsulfamoyl benzoic acid amides, plant protection agents containing said acylsulfamoyl benzoic acid amides, and method for producing the same
US6958339B2 (en) 1997-10-13 2005-10-25 Astellas Pharma Inc. Pyrazole derivative
EP1024138A1 (en) * 1997-10-13 2000-08-02 Yamanouchi Pharmaceutical Co. Ltd. Pyrazole derivatives
EP1024138A4 (en) * 1997-10-13 2002-02-06 Yamanouchi Pharma Co Ltd Pyrazole derivatives
US7285554B2 (en) 1997-10-13 2007-10-23 Astellas Pharma Inc. Pyrazole derivative
US7247635B2 (en) 1997-10-13 2007-07-24 Astellas Pharma Inc. Pyrazole derivative
CN100360507C (en) * 1997-12-22 2008-01-09 拜尔有限公司 Inhibition of raf kinase using substituted heterocyclic ureas
US6300500B1 (en) 1998-02-25 2001-10-09 Sumitomo Pharmaceuticals Company, Limited Preparation of pyridone derivatives using phthalimido containing starting material
US6452008B2 (en) 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
US6617351B1 (en) 1998-07-31 2003-09-09 Eli Lilly And Company Amide, carbamate, and urea derivatives
EP0976744A1 (en) * 1998-07-31 2000-02-02 Eli Lilly And Company Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7897623B2 (en) 1999-01-13 2011-03-01 Bayer Healthcare Llc ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
US8841330B2 (en) 1999-01-13 2014-09-23 Bayer Healthcare Llc Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6730671B2 (en) 1999-03-02 2004-05-04 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathespin S
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6875760B2 (en) 1999-05-17 2005-04-05 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6756372B2 (en) 1999-09-13 2004-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cysteine proteases
US6849660B1 (en) 2000-08-01 2005-02-01 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
US7432264B2 (en) 2000-08-01 2008-10-07 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
WO2002009648A2 (en) * 2000-08-01 2002-02-07 Isis Pharmaceuticals, Inc. Antimicrobial biaryl compounds
WO2002009648A3 (en) * 2000-08-01 2002-06-27 Isis Pharmaceuticals Inc Antimicrobial biaryl compounds
US8354402B2 (en) 2000-09-04 2013-01-15 Janssen Pharmaceutica N.V. Polyarylcarboxamides useful as lipid lowering agents
US7135586B2 (en) 2000-11-21 2006-11-14 Janssen Pharmaceutica, Nv Biphenylcarboxamides useful as lipid lowering agents
US7244848B2 (en) 2000-11-21 2007-07-17 Janssen Pharmaceutica N.V. Biphenylcarboxamides useful as lipid lowering agents
US7538124B2 (en) 2000-11-21 2009-05-26 Janssen Pharmaceutica N.V. Biphenylcarboxamides useful as lipid lowering agents
US7405307B2 (en) 2000-11-21 2008-07-29 Janssen Pharmaceutica N.V. Biphenylcarboxamides useful as lipid lowering agents
US7531576B2 (en) 2000-12-26 2009-05-12 Pola Chemical Industries, Inc. Biphenyl derivatives
EP1354871A1 (en) * 2000-12-26 2003-10-22 Pola Chemical Industries, Inc. Biphenyl derivatives
EP1354871A4 (en) * 2000-12-26 2005-10-26 Pola Chem Ind Inc Biphenyl derivatives
US7642378B2 (en) 2001-04-06 2010-01-05 Janssen Pharmaceutica Nv Lipid lowering biphenylcarboxamides
US7507753B2 (en) 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
US8242147B2 (en) 2002-02-11 2012-08-14 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
US9181188B2 (en) 2002-02-11 2015-11-10 Bayer Healthcare Llc Aryl ureas as kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
US8618141B2 (en) 2002-02-11 2013-12-31 Bayer Healthcare Llc Aryl ureas with angiogenesis inhibiting activity
US7439362B2 (en) 2002-03-28 2008-10-21 Novartis Ag Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
US20090042899A1 (en) * 2002-03-28 2009-02-12 Philipp Lehr Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
US8258304B2 (en) 2002-08-12 2012-09-04 Janssen Pharmaceutica N.V. N-aryl piperidine substituted biphenylcarboxamides
US7332514B2 (en) 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
US7807701B2 (en) 2002-08-30 2010-10-05 Japan Tobacco Inc. Dibenzylamine compounds and pharmaceutical use thereof
WO2004052861A1 (en) * 2002-12-12 2004-06-24 Kowa Co., Ltd. Hydroxyalkylated cyclic diamine compound
US7491826B2 (en) 2003-01-14 2009-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
US9273035B2 (en) 2003-07-22 2016-03-01 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8871797B2 (en) 2003-07-22 2014-10-28 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US9775829B2 (en) 2003-07-22 2017-10-03 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
US7700637B2 (en) 2003-09-17 2010-04-20 Novartis Ag Organic compounds
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7812176B2 (en) 2004-03-23 2010-10-12 Arena Pharmaceuticals, Inc. Processes for preparing substituted N-aryl-N′-[3-(1H-pyrazol-5-YL) phenyl] ureas and intermediates thereof
US7687640B2 (en) 2004-05-26 2010-03-30 Eisai R&D Management Co., Ltd. Cinnamide compound
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
US7880009B2 (en) 2004-05-26 2011-02-01 Eisai R&D Management Co., Ltd. Cinnamide compound
US8110595B2 (en) 2004-06-17 2012-02-07 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US10385023B2 (en) 2004-06-17 2019-08-20 Cytokinetics, Inc. Compounds, compositions and methods
US8513257B2 (en) 2004-06-17 2013-08-20 Cytokinetics, Incorporated Ureas and their use in the treatment of heart failure
US8871769B2 (en) 2004-06-17 2014-10-28 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US10975034B2 (en) 2004-06-17 2021-04-13 Cytokinetics, Inc. Compounds, compositions and methods
US10035770B2 (en) 2004-06-17 2018-07-31 Cytokinetics, Incorporated Compounds, compositions and methods
US8101617B2 (en) 2004-06-17 2012-01-24 Amgen, Inc. Disubstituted ureas and uses thereof in treating heart failure
US9643925B2 (en) 2004-06-17 2017-05-09 Cytokinetics, Incorporated Compounds, compositions and methods
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
US9150564B2 (en) 2004-06-17 2015-10-06 Cytokinetics, Inc. Compounds, compositions and methods
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
US7923563B2 (en) 2004-10-26 2011-04-12 Eisai R&D Management Co., Ltd. Amorphous object of cinnamide compound
US7923573B2 (en) 2004-10-27 2011-04-12 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
US8785441B2 (en) 2004-11-19 2014-07-22 Arena Pharmaceuticals, Inc. 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US10781180B2 (en) 2004-11-19 2020-09-22 Arena Pharmaceuticals, Inc. 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US7884101B2 (en) 2004-11-19 2011-02-08 Arena Pharmaceuticals, Inc. 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP2332526A2 (en) 2005-10-21 2011-06-15 Novartis AG Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
US7618960B2 (en) 2005-11-24 2009-11-17 Eisai R&D Management Co., Ltd. Morpholine type cinnamide compound
US8048878B2 (en) 2005-11-24 2011-11-01 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US8871768B2 (en) 2005-12-15 2014-10-28 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US8445495B2 (en) 2005-12-15 2013-05-21 Cytokinetics, Inc. Certain Chemical entities, compositions and methods
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
US8410108B2 (en) 2005-12-16 2013-04-02 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US8653081B2 (en) 2005-12-16 2014-02-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7989455B2 (en) 2005-12-19 2011-08-02 Cytokinetics, Inc. Compounds, compositions and methods
US7713993B2 (en) 2006-03-09 2010-05-11 Eisai R&D Management Co., Ltd. Multi-cycle cinnamide derivatives
US7897632B2 (en) 2006-03-09 2011-03-01 Eisai R&D Management Co., Ltd. Multi-cyclic cinnamide derivatives
US7973033B2 (en) 2006-03-09 2011-07-05 Eisai R&D Management Co., Ltd. Multi-cyclic cinnamide derivatives
US9328107B2 (en) 2006-05-18 2016-05-03 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9199940B2 (en) 2006-05-18 2015-12-01 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
USRE45337E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8481535B2 (en) 2006-05-18 2013-07-09 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
US8664258B2 (en) 2006-05-18 2014-03-04 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8680119B2 (en) 2006-05-18 2014-03-25 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9221755B2 (en) 2006-05-18 2015-12-29 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9987252B2 (en) 2006-05-18 2018-06-05 Arena Pharmaceuticals, Inc. Primary amines and derivitves thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US10450276B2 (en) 2006-05-18 2019-10-22 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9783502B2 (en) 2006-05-18 2017-10-10 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
USRE45336E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8148417B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US8148418B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
CN100390150C (en) * 2006-06-05 2008-05-28 吴汝林 Method for preparing imidazophenylurea hydrochloride
US7737141B2 (en) 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
US9732039B2 (en) 2006-10-03 2017-08-15 Arena Pharmeceuticals, Inc. Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US10351531B2 (en) 2006-10-03 2019-07-16 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9434692B2 (en) 2006-10-03 2016-09-06 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US8008293B2 (en) 2007-02-28 2011-08-30 Eisai R&D Management Co., Ltd. Bicyclic oxomorpholine derivative
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US10058549B2 (en) 2007-08-15 2018-08-28 Arena Pharmaceuticals, Inc. Imidazo[1,2-α]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
US9453000B2 (en) 2007-08-31 2016-09-27 Eisai R&D Management Co., Ltd. Polycyclic compound
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US10787437B2 (en) 2008-04-02 2020-09-29 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor
US9556149B2 (en) 2008-04-02 2017-01-31 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-HT2A serotonin receptor
EP3025727A1 (en) 2008-10-02 2016-06-01 The J. David Gladstone Institutes Methods of treating liver disease
US10583122B2 (en) 2008-10-28 2020-03-10 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US10117851B2 (en) 2008-10-28 2018-11-06 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US9353064B2 (en) 2008-10-28 2016-05-31 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US10071075B2 (en) 2008-10-28 2018-09-11 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US9801856B2 (en) 2008-10-28 2017-10-31 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US10543193B2 (en) 2008-10-28 2020-01-28 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
US9034911B2 (en) 2008-10-28 2015-05-19 Arena Pharmaceuticals, Inc. Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto
US9745270B2 (en) 2008-10-28 2017-08-29 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8445523B2 (en) 2009-02-26 2013-05-21 Galderma Research & Development Dioxo-imidazolidine derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them
WO2010097465A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
WO2010097464A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Novel n-phenylacetamide derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
US8420682B2 (en) 2009-02-26 2013-04-16 Galderma Research & Development N-phenylacetamide derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them
US8420681B2 (en) 2009-02-26 2013-04-16 Galderma Research & Development Dioxo-imidazolidine derivatives, which inhibit the enzyme SOAT-1, and pharmaceutical and cosmetic compositions containing them
WO2010097469A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, and pharmaceutical and cosmetic compositions containing them
WO2010097468A1 (en) 2009-02-26 2010-09-02 Galderma Research & Development Novel dioxo-imidazolidine derivatives, which inhibit the enzyme soat-1, pharmaceutical and cosmetic compositions containing them
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
WO2011145022A1 (en) 2010-05-21 2011-11-24 Pfizer Inc. 2-phenyl benzoylamides
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2012120414A2 (en) 2011-03-04 2012-09-13 Pfizer Inc. Edn3-like peptides and uses thereof
EP2858501A4 (en) * 2012-05-22 2015-12-09 Merck Sharp & Dohme TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9561231B2 (en) 2012-06-12 2017-02-07 Abbvie Inc. Pyridinone and pyridazinone derivatives
WO2014032755A3 (en) * 2012-08-29 2014-07-17 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US10752581B2 (en) 2013-10-10 2020-08-25 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US11274077B2 (en) 2013-10-10 2022-03-15 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
US10034859B2 (en) 2015-07-15 2018-07-31 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US11304932B2 (en) 2015-07-15 2022-04-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof

Also Published As

Publication number Publication date
KR970706242A (en) 1997-11-03
CA2200981A1 (en) 1996-04-11
EP0784612A1 (en) 1997-07-23
JPH10510512A (en) 1998-10-13
IL115483A0 (en) 1996-01-19
TR199501209A2 (en) 1996-06-21
AU3577995A (en) 1996-04-26

Similar Documents

Publication Publication Date Title
WO1996010559A1 (en) Urea derivatives and their use as acat-inhibitors
EP0770079B1 (en) Heterobicyclic derivatives
US20010044445A1 (en) Azole inhibitors of cytokine production
AU686115B2 (en) Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation
AU685457B2 (en) Guanidine derivatives as inhibitors of Na+/H+ exchange in cells
CA2122236C (en) Quinolines and their analogs
AU2002359376B8 (en) N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives
EP1068187A1 (en) Pyrazole inhibitors of cytokine production
KR20040082425A (en) Nicotinamide derivates useful as p38 inhibitors
JP3473023B2 (en) Benzoylguanidine derivatives as pharmaceuticals
JPH11505524A (en) Imidazo 1,2-A pyridine and imidazo 1,2-A pyrididine derivatives and their use as bone resorption inhibitors
JPH07504411A (en) Quinolylbenzofuran derivatives as leukotriene antagonists
US5574042A (en) Imidazo [1,2-a] pyridines and their pharmaceutical use
JPH11349572A (en) New amide derivative and salt thereof
US6083961A (en) Benzimidazole compounds as bradykinin antagonists
US6812237B2 (en) N-substituted peptidyl nitriles as cysteine cathepsin inhibitors
JPH09507222A (en) Furylthiazole and their use as H 2 receptor antagonists and antimicrobial agents
JPH08208632A (en) New sulfonamide derivative, salt thereof and hypotensor containing the same
AU697748C (en) Benzoylguanidine derivatives as medicaments
MXPA00009837A (en) Pyrazole inhibitors of cytokine production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN HU JP KR MX RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995932934

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2200981

Country of ref document: CA

Ref country code: CA

Ref document number: 2200981

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1019970702138

Country of ref document: KR

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 809598

Date of ref document: 19970521

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995932934

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019970702138

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1995932934

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019970702138

Country of ref document: KR